{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "ALTA_DataCreation.ipynb",
      "provenance": [],
      "collapsed_sections": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "ISknODf7L2ow"
      },
      "source": [
        "nikhil3198"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mG7n6c97Lx9G",
        "outputId": "49863398-df53-4663-8daf-a29b7f195d04"
      },
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JeB-ly1EjhIT",
        "outputId": "dada82a6-cbea-47d7-becc-217a395502db"
      },
      "source": [
        "!unzip /content/testset_data.zip"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Archive:  /content/testset_data.zip\n",
            "  inflating: testset.zip             \n",
            "  inflating: testset_nolabels.txt    \n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "HK05eo4ajnOd",
        "outputId": "1d9b8e10-51fb-4b27-d607-bf0cf3aec333"
      },
      "source": [
        "!unzip /content/testset.zip\n"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Archive:  /content/testset.zip\n",
            "   creating: testset/\n",
            "  inflating: testset/10028120.xml    \n",
            "  inflating: testset/10030325.xml    \n",
            "  inflating: testset/10048703.xml    \n",
            "  inflating: testset/10050644.xml    \n",
            "  inflating: testset/10101345.xml    \n",
            "  inflating: testset/10192751.xml    \n",
            "  inflating: testset/10194662.xml    \n",
            "  inflating: testset/10204712.xml    \n",
            "  inflating: testset/10217079.xml    \n",
            "  inflating: testset/10325291.xml    \n",
            "  inflating: testset/10378621.xml    \n",
            "  inflating: testset/10426254.xml    \n",
            "  inflating: testset/10469378.xml    \n",
            "  inflating: testset/10533947.xml    \n",
            "  inflating: testset/10547172.xml    \n",
            "  inflating: testset/10591385.xml    \n",
            "  inflating: testset/10621922.xml    \n",
            "  inflating: testset/10654964.xml    \n",
            "  inflating: testset/10675071.xml    \n",
            "  inflating: testset/10681281.xml    \n",
            "  inflating: testset/10706194.xml    \n",
            "  inflating: testset/10709835.xml    \n",
            "  inflating: testset/10720605.xml    \n",
            "  inflating: testset/10786346.xml    \n",
            "  inflating: testset/10796356.xml    \n",
            "  inflating: testset/10796429.xml    \n",
            "  inflating: testset/10796760.xml    \n",
            "  inflating: testset/10818057.xml    \n",
            "  inflating: testset/10857517.xml    \n",
            "  inflating: testset/10872548.xml    \n",
            "  inflating: testset/10886135.xml    \n",
            "  inflating: testset/10902835.xml    \n",
            "  inflating: testset/10906651.xml    \n",
            "  inflating: testset/10936125.xml    \n",
            "  inflating: testset/10937475.xml    \n",
            "  inflating: testset/10940092.xml    \n",
            "  inflating: testset/10960901.xml    \n",
            "  inflating: testset/10971664.xml    \n",
            "  inflating: testset/10973843.xml    \n",
            "  inflating: testset/10979055.xml    \n",
            "  inflating: testset/10990583.xml    \n",
            "  inflating: testset/10999775.xml    \n",
            "  inflating: testset/11009518.xml    \n",
            "  inflating: testset/11035351.xml    \n",
            "  inflating: testset/11059707.xml    \n",
            "  inflating: testset/11066214.xml    \n",
            "  inflating: testset/11087186.xml    \n",
            "  inflating: testset/11109029.xml    \n",
            "  inflating: testset/11114103.xml    \n",
            "  inflating: testset/11128824.xml    \n",
            "  inflating: testset/11136953.xml    \n",
            "  inflating: testset/11147989.xml    \n",
            "  inflating: testset/11166969.xml    \n",
            "  inflating: testset/11174482.xml    \n",
            "  inflating: testset/11189684.xml    \n",
            "  inflating: testset/11204585.xml    \n",
            "  inflating: testset/11211366.xml    \n",
            "  inflating: testset/11211367.xml    \n",
            "  inflating: testset/11218151.xml    \n",
            "  inflating: testset/11219226.xml    \n",
            "  inflating: testset/11230671.xml    \n",
            "  inflating: testset/11231700.xml    \n",
            "  inflating: testset/11238494.xml    \n",
            "  inflating: testset/11239327.xml    \n",
            "  inflating: testset/11252459.xml    \n",
            "  inflating: testset/11265954.xml    \n",
            "  inflating: testset/11297595.xml    \n",
            "  inflating: testset/11298538.xml    \n",
            "  inflating: testset/11336416.xml    \n",
            "  inflating: testset/11345978.xml    \n",
            "  inflating: testset/11354851.xml    \n",
            "  inflating: testset/11383577.xml    \n",
            "  inflating: testset/11386927.xml    \n",
            "  inflating: testset/11394602.xml    \n",
            "  inflating: testset/11405956.xml    \n",
            "  inflating: testset/11446557.xml    \n",
            "  inflating: testset/11448661.xml    \n",
            "  inflating: testset/11466120.xml    \n",
            "  inflating: testset/11473087.xml    \n",
            "  inflating: testset/11485707.xml    \n",
            "  inflating: testset/11495618.xml    \n",
            "  inflating: testset/11502313.xml    \n",
            "  inflating: testset/11509158.xml    \n",
            "  inflating: testset/11582950.xml    \n",
            "  inflating: testset/11585368.xml    \n",
            "  inflating: testset/11587008.xml    \n",
            "  inflating: testset/11641030.xml    \n",
            "  inflating: testset/11667937.xml    \n",
            "  inflating: testset/11669346.xml    \n",
            "  inflating: testset/11673343.xml    \n",
            "  inflating: testset/11703280.xml    \n",
            "  inflating: testset/11753159.xml    \n",
            "  inflating: testset/11754714.xml    \n",
            "  inflating: testset/11772963.xml    \n",
            "  inflating: testset/11784215.xml    \n",
            "  inflating: testset/11787578.xml    \n",
            "  inflating: testset/11814494.xml    \n",
            "  inflating: testset/11815495.xml    \n",
            "  inflating: testset/11845946.xml    \n",
            "  inflating: testset/11854642.xml    \n",
            "  inflating: testset/11869581.xml    \n",
            "  inflating: testset/11869657.xml    \n",
            "  inflating: testset/11871930.xml    \n",
            "  inflating: testset/11882771.xml    \n",
            "  inflating: testset/11898004.xml    \n",
            "  inflating: testset/11898005.xml    \n",
            "  inflating: testset/11904108.xml    \n",
            "  inflating: testset/11927718.xml    \n",
            "  inflating: testset/11932277.xml    \n",
            "  inflating: testset/11937178.xml    \n",
            "  inflating: testset/11939810.xml    \n",
            "  inflating: testset/11950733.xml    \n",
            "  inflating: testset/1199907.xml     \n",
            "  inflating: testset/12010667.xml    \n",
            "  inflating: testset/12020304.xml    \n",
            "  inflating: testset/12020306.xml    \n",
            "  inflating: testset/12021091.xml    \n",
            "  inflating: testset/12052606.xml    \n",
            "  inflating: testset/12063772.xml    \n",
            "  inflating: testset/12069641.xml    \n",
            "  inflating: testset/12069980.xml    \n",
            "  inflating: testset/12093648.xml    \n",
            "  inflating: testset/12114036.xml    \n",
            "  inflating: testset/12115160.xml    \n",
            "  inflating: testset/12117397.xml    \n",
            "  inflating: testset/12117400.xml    \n",
            "  inflating: testset/12118964.xml    \n",
            "  inflating: testset/12118972.xml    \n",
            "  inflating: testset/12138072.xml    \n",
            "  inflating: testset/12167135.xml    \n",
            "  inflating: testset/12168911.xml    \n",
            "  inflating: testset/12200073.xml    \n",
            "  inflating: testset/12202325.xml    \n",
            "  inflating: testset/12225294.xml    \n",
            "  inflating: testset/12240903.xml    \n",
            "  inflating: testset/12322776.xml    \n",
            "  inflating: testset/12361440.xml    \n",
            "  inflating: testset/12373695.xml    \n",
            "  inflating: testset/12390647.xml    \n",
            "  inflating: testset/12425329.xml    \n",
            "  inflating: testset/12435255.xml    \n",
            "  inflating: testset/12458990.xml    \n",
            "  inflating: testset/12468197.xml    \n",
            "  inflating: testset/12473877.xml    \n",
            "  inflating: testset/12477919.xml    \n",
            "  inflating: testset/12479763.xml    \n",
            "  inflating: testset/12515986.xml    \n",
            "  inflating: testset/12519582.xml    \n",
            "  inflating: testset/12569376.xml    \n",
            "  inflating: testset/12593999.xml    \n",
            "  inflating: testset/12597676.xml    \n",
            "  inflating: testset/12604544.xml    \n",
            "  inflating: testset/12620440.xml    \n",
            "  inflating: testset/12639199.xml    \n",
            "  inflating: testset/12671151.xml    \n",
            "  inflating: testset/12686036.xml    \n",
            "  inflating: testset/12728155.xml    \n",
            "  inflating: testset/12759325.xml    \n",
            "  inflating: testset/12788588.xml    \n",
            "  inflating: testset/12800963.xml    \n",
            "  inflating: testset/12804417.xml    \n",
            "  inflating: testset/12804438.xml    \n",
            "  inflating: testset/12804508.xml    \n",
            "  inflating: testset/12823497.xml    \n",
            "  inflating: testset/12834520.xml    \n",
            "  inflating: testset/12885680.xml    \n",
            "  inflating: testset/12893694.xml    \n",
            "  inflating: testset/12917913.xml    \n",
            "  inflating: testset/12917943.xml    \n",
            "  inflating: testset/12942235.xml    \n",
            "  inflating: testset/12963897.xml    \n",
            "  inflating: testset/12970637.xml    \n",
            "  inflating: testset/1434928.xml     \n",
            "  inflating: testset/1445513.xml     \n",
            "  inflating: testset/14502372.xml    \n",
            "  inflating: testset/14576245.xml    \n",
            "  inflating: testset/14624092.xml    \n",
            "  inflating: testset/14625332.xml    \n",
            "  inflating: testset/14656957.xml    \n",
            "  inflating: testset/14672486.xml    \n",
            "  inflating: testset/14679419.xml    \n",
            "  inflating: testset/14704724.xml    \n",
            "  inflating: testset/14716790.xml    \n",
            "  inflating: testset/14754723.xml    \n",
            "  inflating: testset/14968141.xml    \n",
            "  inflating: testset/14970960.xml    \n",
            "  inflating: testset/15007496.xml    \n",
            "  inflating: testset/15016485.xml    \n",
            "  inflating: testset/15030341.xml    \n",
            "  inflating: testset/15042359.xml    \n",
            "  inflating: testset/15055095.xml    \n",
            "  inflating: testset/15113460.xml    \n",
            "  inflating: testset/15131789.xml    \n",
            "  inflating: testset/15153824.xml    \n",
            "  inflating: testset/15173497.xml    \n",
            "  inflating: testset/15204150.xml    \n",
            "  inflating: testset/15207952.xml    \n",
            "  inflating: testset/15209619.xml    \n",
            "  inflating: testset/15231616.xml    \n",
            "  inflating: testset/15235689.xml    \n",
            "  inflating: testset/15277432.xml    \n",
            "  inflating: testset/15292314.xml    \n",
            "  inflating: testset/15300570.xml    \n",
            "  inflating: testset/15304471.xml    \n",
            "  inflating: testset/15333967.xml    \n",
            "  inflating: testset/15351331.xml    \n",
            "  inflating: testset/15354280.xml    \n",
            "  inflating: testset/15356306.xml    \n",
            "  inflating: testset/15358717.xml    \n",
            "  inflating: testset/15380802.xml    \n",
            "  inflating: testset/15495090.xml    \n",
            "  inflating: testset/15496998.xml    \n",
            "  inflating: testset/15507951.xml    \n",
            "  inflating: testset/15530629.xml    \n",
            "  inflating: testset/15542510.xml    \n",
            "  inflating: testset/15547519.xml    \n",
            "  inflating: testset/15577775.xml    \n",
            "  inflating: testset/15591600.xml    \n",
            "  inflating: testset/15598960.xml    \n",
            "  inflating: testset/15654705.xml    \n",
            "  inflating: testset/15657155.xml    \n",
            "  inflating: testset/15667494.xml    \n",
            "  inflating: testset/15674889.xml    \n",
            "  inflating: testset/15711421.xml    \n",
            "  inflating: testset/15757807.xml    \n",
            "  inflating: testset/15765034.xml    \n",
            "  inflating: testset/15824412.xml    \n",
            "  inflating: testset/15846679.xml    \n",
            "  inflating: testset/15858471.xml    \n",
            "  inflating: testset/15867028.xml    \n",
            "  inflating: testset/15878052.xml    \n",
            "  inflating: testset/15888839.xml    \n",
            "  inflating: testset/15917737.xml    \n",
            "  inflating: testset/16105793.xml    \n",
            "  inflating: testset/16127954.xml    \n",
            "  inflating: testset/16213659.xml    \n",
            "  inflating: testset/16222881.xml    \n",
            "  inflating: testset/16235327.xml    \n",
            "  inflating: testset/16257341.xml    \n",
            "  inflating: testset/16308411.xml    \n",
            "  inflating: testset/16352624.xml    \n",
            "  inflating: testset/16418528.xml    \n",
            "  inflating: testset/16531143.xml    \n",
            "  inflating: testset/16536797.xml    \n",
            "  inflating: testset/16574042.xml    \n",
            "  inflating: testset/16603881.xml    \n",
            "  inflating: testset/16625635.xml    \n",
            "  inflating: testset/16641776.xml    \n",
            "  inflating: testset/16754904.xml    \n",
            "  inflating: testset/1682683.xml     \n",
            "  inflating: testset/16848101.xml    \n",
            "  inflating: testset/1696799.xml     \n",
            "  inflating: testset/17053529.xml    \n",
            "  inflating: testset/17065896.xml    \n",
            "  inflating: testset/17121867.xml    \n",
            "  inflating: testset/17186396.xml    \n",
            "  inflating: testset/17191050.xml    \n",
            "  inflating: testset/17197574.xml    \n",
            "  inflating: testset/1728471.xml     \n",
            "  inflating: testset/17307888.xml    \n",
            "  inflating: testset/17332726.xml    \n",
            "  inflating: testset/17636675.xml    \n",
            "  inflating: testset/17666608.xml    \n",
            "  inflating: testset/18078406.xml    \n",
            "  inflating: testset/18212134.xml    \n",
            "  inflating: testset/1834868.xml     \n",
            "  inflating: testset/18492531.xml    \n",
            "  inflating: testset/2004476.xml     \n",
            "  inflating: testset/2007745.xml     \n",
            "  inflating: testset/2040866.xml     \n",
            "  inflating: testset/2046107.xml     \n",
            "  inflating: testset/2098372.xml     \n",
            "  inflating: testset/2153735.xml     \n",
            "  inflating: testset/2177507.xml     \n",
            "  inflating: testset/2179111.xml     \n",
            "  inflating: testset/2191938.xml     \n",
            "  inflating: testset/2568506.xml     \n",
            "  inflating: testset/2596940.xml     \n",
            "  inflating: testset/2611126.xml     \n",
            "  inflating: testset/2661788.xml     \n",
            "  inflating: testset/2669155.xml     \n",
            "  inflating: testset/2861907.xml     \n",
            "  inflating: testset/2865614.xml     \n",
            "  inflating: testset/2936244.xml     \n",
            "  inflating: testset/2952685.xml     \n",
            "  inflating: testset/2967893.xml     \n",
            "  inflating: testset/3073880.xml     \n",
            "  inflating: testset/3147087.xml     \n",
            "  inflating: testset/3282670.xml     \n",
            "  inflating: testset/3313041.xml     \n",
            "  inflating: testset/3323028.xml     \n",
            "  inflating: testset/3358567.xml     \n",
            "  inflating: testset/3407650.xml     \n",
            "  inflating: testset/3517206.xml     \n",
            "  inflating: testset/3534506.xml     \n",
            "  inflating: testset/3773199.xml     \n",
            "  inflating: testset/3806287.xml     \n",
            "  inflating: testset/3822681.xml     \n",
            "  inflating: testset/3914014.xml     \n",
            "  inflating: testset/3936774.xml     \n",
            "  inflating: testset/4817186.xml     \n",
            "  inflating: testset/510127.xml      \n",
            "  inflating: testset/51664.xml       \n",
            "  inflating: testset/576962.xml      \n",
            "  inflating: testset/6120755.xml     \n",
            "  inflating: testset/6147641.xml     \n",
            "  inflating: testset/630325.xml      \n",
            "  inflating: testset/6428290.xml     \n",
            "  inflating: testset/6809102.xml     \n",
            "  inflating: testset/707689.xml      \n",
            "  inflating: testset/7370875.xml     \n",
            "  inflating: testset/7388366.xml     \n",
            "  inflating: testset/7393077.xml     \n",
            "  inflating: testset/7487259.xml     \n",
            "  inflating: testset/7509325.xml     \n",
            "  inflating: testset/7543434.xml     \n",
            "  inflating: testset/7566020.xml     \n",
            "  inflating: testset/7605150.xml     \n",
            "  inflating: testset/7641412.xml     \n",
            "  inflating: testset/7798064.xml     \n",
            "  inflating: testset/7835809.xml     \n",
            "  inflating: testset/7846138.xml     \n",
            "  inflating: testset/7847013.xml     \n",
            "  inflating: testset/7869190.xml     \n",
            "  inflating: testset/7924541.xml     \n",
            "  inflating: testset/7932969.xml     \n",
            "  inflating: testset/7935033.xml     \n",
            "  inflating: testset/7980747.xml     \n",
            "  inflating: testset/7995639.xml     \n",
            "  inflating: testset/8045728.xml     \n",
            "  inflating: testset/8088297.xml     \n",
            "  inflating: testset/8100060.xml     \n",
            "  inflating: testset/8108758.xml     \n",
            "  inflating: testset/8150942.xml     \n",
            "  inflating: testset/8238175.xml     \n",
            "  inflating: testset/8256008.xml     \n",
            "  inflating: testset/8353407.xml     \n",
            "  inflating: testset/8413456.xml     \n",
            "  inflating: testset/8481068.xml     \n",
            "  inflating: testset/8487449.xml     \n",
            "  inflating: testset/8582464.xml     \n",
            "  inflating: testset/8664395.xml     \n",
            "  inflating: testset/8677076.xml     \n",
            "  inflating: testset/8703167.xml     \n",
            "  inflating: testset/8745894.xml     \n",
            "  inflating: testset/8751018.xml     \n",
            "  inflating: testset/8759093.xml     \n",
            "  inflating: testset/8759176.xml     \n",
            "  inflating: testset/8804449.xml     \n",
            "  inflating: testset/8885584.xml     \n",
            "  inflating: testset/8902478.xml     \n",
            "  inflating: testset/8902660.xml     \n",
            "  inflating: testset/8921129.xml     \n",
            "  inflating: testset/8954028.xml     \n",
            "  inflating: testset/9016421.xml     \n",
            "  inflating: testset/9050765.xml     \n",
            "  inflating: testset/9099655.xml     \n",
            "  inflating: testset/9112711.xml     \n",
            "  inflating: testset/9126243.xml     \n",
            "  inflating: testset/9215014.xml     \n",
            "  inflating: testset/9215280.xml     \n",
            "  inflating: testset/9222303.xml     \n",
            "  inflating: testset/9255748.xml     \n",
            "  inflating: testset/9282704.xml     \n",
            "  inflating: testset/9394980.xml     \n",
            "  inflating: testset/9400035.xml     \n",
            "  inflating: testset/9400360.xml     \n",
            "  inflating: testset/9405014.xml     \n",
            "  inflating: testset/9405900.xml     \n",
            "  inflating: testset/9439491.xml     \n",
            "  inflating: testset/9461053.xml     \n",
            "  inflating: testset/9486993.xml     \n",
            "  inflating: testset/9493849.xml     \n",
            "  inflating: testset/9515998.xml     \n",
            "  inflating: testset/9571349.xml     \n",
            "  inflating: testset/9606614.xml     \n",
            "  inflating: testset/9613910.xml     \n",
            "  inflating: testset/9635947.xml     \n",
            "  inflating: testset/9646215.xml     \n",
            "  inflating: testset/9713397.xml     \n",
            "  inflating: testset/9732338.xml     \n",
            "  inflating: testset/9794949.xml     \n",
            "  inflating: testset/9799210.xml     \n",
            "  inflating: testset/9807989.xml     \n",
            "  inflating: testset/9809732.xml     \n",
            "  inflating: testset/9819446.xml     \n",
            "  inflating: testset/9853761.xml     \n",
            "  inflating: testset/9972386.xml     \n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NT92v5m0Lyhb",
        "outputId": "1b3828e3-c12a-4995-f5ee-9724cab863d0"
      },
      "source": [
        "!unzip /content/drive/MyDrive/ALTA/public_dat/trainset.zip"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "unzip:  cannot find or open /content/drive/MyDrive/ALTA/public_dat/devset.zip, /content/drive/MyDrive/ALTA/public_dat/devset.zip.zip or /content/drive/MyDrive/ALTA/public_dat/devset.zip.ZIP.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "bs2jV_7y6HUI",
        "outputId": "14b12e2b-487a-4b4f-bca5-7f9d74857a8b"
      },
      "source": [
        "!unzip /content/drive/MyDrive/ALTA/public_dat/devtestset.zip"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Archive:  /content/drive/MyDrive/ALTA/public_dat/devtestset.zip\n",
            "   creating: devtestset/\n",
            "  inflating: devtestset/10023943.xml  \n",
            "  inflating: devtestset/10052444.xml  \n",
            "  inflating: devtestset/10065311.xml  \n",
            "  inflating: devtestset/10083953.xml  \n",
            "  inflating: devtestset/10193252.xml  \n",
            "  inflating: devtestset/10218746.xml  \n",
            "  inflating: devtestset/10227593.xml  \n",
            "  inflating: devtestset/10376614.xml  \n",
            "  inflating: devtestset/10380441.xml  \n",
            "  inflating: devtestset/10380450.xml  \n",
            "  inflating: devtestset/10383500.xml  \n",
            "  inflating: devtestset/10438259.xml  \n",
            "  inflating: devtestset/10449550.xml  \n",
            "  inflating: devtestset/10465168.xml  \n",
            "  inflating: devtestset/10475183.xml  \n",
            "  inflating: devtestset/10505584.xml  \n",
            "  inflating: devtestset/10513500.xml  \n",
            "  inflating: devtestset/10582925.xml  \n",
            "  inflating: devtestset/10589881.xml  \n",
            "  inflating: devtestset/10591433.xml  \n",
            "  inflating: devtestset/10602535.xml  \n",
            "  inflating: devtestset/10637680.xml  \n",
            "  inflating: devtestset/10639540.xml  \n",
            "  inflating: devtestset/10675071.xml  \n",
            "  inflating: devtestset/10736891.xml  \n",
            "  inflating: devtestset/10792124.xml  \n",
            "  inflating: devtestset/10796458.xml  \n",
            "  inflating: devtestset/10819705.xml  \n",
            "  inflating: devtestset/10836730.xml  \n",
            "  inflating: devtestset/10862644.xml  \n",
            "  inflating: devtestset/10865273.xml  \n",
            "  inflating: devtestset/10875955.xml  \n",
            "  inflating: devtestset/10880410.xml  \n",
            "  inflating: devtestset/10888978.xml  \n",
            "  inflating: devtestset/10894991.xml  \n",
            "  inflating: devtestset/10908538.xml  \n",
            "  inflating: devtestset/10920067.xml  \n",
            "  inflating: devtestset/10923571.xml  \n",
            "  inflating: devtestset/10930181.xml  \n",
            "  inflating: devtestset/1093481.xml  \n",
            "  inflating: devtestset/10954007.xml  \n",
            "  inflating: devtestset/10961470.xml  \n",
            "  inflating: devtestset/10965007.xml  \n",
            "  inflating: devtestset/10969225.xml  \n",
            "  inflating: devtestset/10987614.xml  \n",
            "  inflating: devtestset/10995804.xml  \n",
            "  inflating: devtestset/11005775.xml  \n",
            "  inflating: devtestset/11035889.xml  \n",
            "  inflating: devtestset/11072258.xml  \n",
            "  inflating: devtestset/11110735.xml  \n",
            "  inflating: devtestset/11113718.xml  \n",
            "  inflating: devtestset/11136304.xml  \n",
            "  inflating: devtestset/11144703.xml  \n",
            "  inflating: devtestset/11158037.xml  \n",
            "  inflating: devtestset/11174474.xml  \n",
            "  inflating: devtestset/11181776.xml  \n",
            "  inflating: devtestset/11210884.xml  \n",
            "  inflating: devtestset/11225739.xml  \n",
            "  inflating: devtestset/11236719.xml  \n",
            "  inflating: devtestset/11242425.xml  \n",
            "  inflating: devtestset/11251560.xml  \n",
            "  inflating: devtestset/11270304.xml  \n",
            "  inflating: devtestset/11289345.xml  \n",
            "  inflating: devtestset/11328254.xml  \n",
            "  inflating: devtestset/11330653.xml  \n",
            "  inflating: devtestset/11331711.xml  \n",
            "  inflating: devtestset/11333990.xml  \n",
            "  inflating: devtestset/11339934.xml  \n",
            "  inflating: devtestset/11355039.xml  \n",
            "  inflating: devtestset/11370690.xml  \n",
            "  inflating: devtestset/11380322.xml  \n",
            "  inflating: devtestset/11386263.xml  \n",
            "  inflating: devtestset/11406072.xml  \n",
            "  inflating: devtestset/11406076.xml  \n",
            "  inflating: devtestset/11415950.xml  \n",
            "  inflating: devtestset/11416690.xml  \n",
            "  inflating: devtestset/11417373.xml  \n",
            "  inflating: devtestset/11419777.xml  \n",
            "  inflating: devtestset/11486289.xml  \n",
            "  inflating: devtestset/11518884.xml  \n",
            "  inflating: devtestset/11565517.xml  \n",
            "  inflating: devtestset/11565518.xml  \n",
            "  inflating: devtestset/11565519.xml  \n",
            "  inflating: devtestset/11583049.xml  \n",
            "  inflating: devtestset/11676116.xml  \n",
            "  inflating: devtestset/11696804.xml  \n",
            "  inflating: devtestset/11702616.xml  \n",
            "  inflating: devtestset/11706112.xml  \n",
            "  inflating: devtestset/11713157.xml  \n",
            "  inflating: devtestset/11754850.xml  \n",
            "  inflating: devtestset/11757504.xml  \n",
            "  inflating: devtestset/11759645.xml  \n",
            "  inflating: devtestset/11762571.xml  \n",
            "  inflating: devtestset/11790216.xml  \n",
            "  inflating: devtestset/11802748.xml  \n",
            "  inflating: devtestset/11822926.xml  \n",
            "  inflating: devtestset/11832527.xml  \n",
            "  inflating: devtestset/11833633.xml  \n",
            "  inflating: devtestset/11904599.xml  \n",
            "  inflating: devtestset/11907366.xml  \n",
            "  inflating: devtestset/11907922.xml  \n",
            "  inflating: devtestset/11914253.xml  \n",
            "  inflating: devtestset/11930092.xml  \n",
            "  inflating: devtestset/11930093.xml  \n",
            "  inflating: devtestset/11937179.xml  \n",
            "  inflating: devtestset/11985936.xml  \n",
            "  inflating: devtestset/11988059.xml  \n",
            "  inflating: devtestset/11995901.xml  \n",
            "  inflating: devtestset/12022321.xml  \n",
            "  inflating: devtestset/12025432.xml  \n",
            "  inflating: devtestset/12039088.xml  \n",
            "  inflating: devtestset/12041718.xml  \n",
            "  inflating: devtestset/12076493.xml  \n",
            "  inflating: devtestset/12086760.xml  \n",
            "  inflating: devtestset/12091045.xml  \n",
            "  inflating: devtestset/12097535.xml  \n",
            "  inflating: devtestset/12114037.xml  \n",
            "  inflating: devtestset/12135217.xml  \n",
            "  inflating: devtestset/12137645.xml  \n",
            "  inflating: devtestset/12137713.xml  \n",
            "  inflating: devtestset/12137880.xml  \n",
            "  inflating: devtestset/12196473.xml  \n",
            "  inflating: devtestset/12204020.xml  \n",
            "  inflating: devtestset/12213943.xml  \n",
            "  inflating: devtestset/12396679.xml  \n",
            "  inflating: devtestset/12415081.xml  \n",
            "  inflating: devtestset/12472618.xml  \n",
            "  inflating: devtestset/12506950.xml  \n",
            "  inflating: devtestset/12514443.xml  \n",
            "  inflating: devtestset/12525800.xml  \n",
            "  inflating: devtestset/12531578.xml  \n",
            "  inflating: devtestset/12535435.xml  \n",
            "  inflating: devtestset/12537734.xml  \n",
            "  inflating: devtestset/12571256.xml  \n",
            "  inflating: devtestset/12588275.xml  \n",
            "  inflating: devtestset/12597752.xml  \n",
            "  inflating: devtestset/12662389.xml  \n",
            "  inflating: devtestset/12679432.xml  \n",
            "  inflating: devtestset/12689976.xml  \n",
            "  inflating: devtestset/12728140.xml  \n",
            "  inflating: devtestset/12777590.xml  \n",
            "  inflating: devtestset/12780419.xml  \n",
            "  inflating: devtestset/12804462.xml  \n",
            "  inflating: devtestset/12821233.xml  \n",
            "  inflating: devtestset/12821354.xml  \n",
            "  inflating: devtestset/12899587.xml  \n",
            "  inflating: devtestset/12900480.xml  \n",
            "  inflating: devtestset/12911018.xml  \n",
            "  inflating: devtestset/12931367.xml  \n",
            "  inflating: devtestset/12944058.xml  \n",
            "  inflating: devtestset/12949310.xml  \n",
            "  inflating: devtestset/12968085.xml  \n",
            "  inflating: devtestset/12975222.xml  \n",
            "  inflating: devtestset/13678869.xml  \n",
            "  inflating: devtestset/13679527.xml  \n",
            "  inflating: devtestset/14523141.xml  \n",
            "  inflating: devtestset/14567259.xml  \n",
            "  inflating: devtestset/14573734.xml  \n",
            "  inflating: devtestset/14583920.xml  \n",
            "  inflating: devtestset/14583954.xml  \n",
            "  inflating: devtestset/14584015.xml  \n",
            "  inflating: devtestset/14610160.xml  \n",
            "  inflating: devtestset/14625699.xml  \n",
            "  inflating: devtestset/14634843.xml  \n",
            "  inflating: devtestset/14670769.xml  \n",
            "  inflating: devtestset/14678916.xml  \n",
            "  inflating: devtestset/14702015.xml  \n",
            "  inflating: devtestset/14702017.xml  \n",
            "  inflating: devtestset/14707320.xml  \n",
            "  inflating: devtestset/14716181.xml  \n",
            "  inflating: devtestset/14718017.xml  \n",
            "  inflating: devtestset/14724869.xml  \n",
            "  inflating: devtestset/14738790.xml  \n",
            "  inflating: devtestset/14961051.xml  \n",
            "  inflating: devtestset/14973991.xml  \n",
            "  inflating: devtestset/14973999.xml  \n",
            "  inflating: devtestset/14974003.xml  \n",
            "  inflating: devtestset/14978607.xml  \n",
            "  inflating: devtestset/15029914.xml  \n",
            "  inflating: devtestset/15095535.xml  \n",
            "  inflating: devtestset/15130571.xml  \n",
            "  inflating: devtestset/15138245.xml  \n",
            "  inflating: devtestset/15142155.xml  \n",
            "  inflating: devtestset/15150204.xml  \n",
            "  inflating: devtestset/15164315.xml  \n",
            "  inflating: devtestset/15234289.xml  \n",
            "  inflating: devtestset/15240584.xml  \n",
            "  inflating: devtestset/15260010.xml  \n",
            "  inflating: devtestset/15384567.xml  \n",
            "  inflating: devtestset/15450632.xml  \n",
            "  inflating: devtestset/15470832.xml  \n",
            "  inflating: devtestset/15477411.xml  \n",
            "  inflating: devtestset/15505131.xml  \n",
            "  inflating: devtestset/15555974.xml  \n",
            "  inflating: devtestset/15571825.xml  \n",
            "  inflating: devtestset/15572515.xml  \n",
            "  inflating: devtestset/1557997.xml  \n",
            "  inflating: devtestset/15617591.xml  \n",
            "  inflating: devtestset/15623698.xml  \n",
            "  inflating: devtestset/15638939.xml  \n",
            "  inflating: devtestset/15644481.xml  \n",
            "  inflating: devtestset/15685694.xml  \n",
            "  inflating: devtestset/15687461.xml  \n",
            "  inflating: devtestset/15716561.xml  \n",
            "  inflating: devtestset/15722066.xml  \n",
            "  inflating: devtestset/15755947.xml  \n",
            "  inflating: devtestset/15784043.xml  \n",
            "  inflating: devtestset/15788927.xml  \n",
            "  inflating: devtestset/15800988.xml  \n",
            "  inflating: devtestset/15829527.xml  \n",
            "  inflating: devtestset/15846673.xml  \n",
            "  inflating: devtestset/15869575.xml  \n",
            "  inflating: devtestset/15967905.xml  \n",
            "  inflating: devtestset/16026361.xml  \n",
            "  inflating: devtestset/16027691.xml  \n",
            "  inflating: devtestset/16034897.xml  \n",
            "  inflating: devtestset/16034957.xml  \n",
            "  inflating: devtestset/16043733.xml  \n",
            "  inflating: devtestset/16076830.xml  \n",
            "  inflating: devtestset/16080084.xml  \n",
            "  inflating: devtestset/16102549.xml  \n",
            "  inflating: devtestset/16185098.xml  \n",
            "  inflating: devtestset/16186441.xml  \n",
            "  inflating: devtestset/16188764.xml  \n",
            "  inflating: devtestset/16193071.xml  \n",
            "  inflating: devtestset/16249822.xml  \n",
            "  inflating: devtestset/1626996.xml  \n",
            "  inflating: devtestset/16274376.xml  \n",
            "  inflating: devtestset/16291385.xml  \n",
            "  inflating: devtestset/1634662.xml  \n",
            "  inflating: devtestset/16352884.xml  \n",
            "  inflating: devtestset/16413844.xml  \n",
            "  inflating: devtestset/16418463.xml  \n",
            "  inflating: devtestset/16422868.xml  \n",
            "  inflating: devtestset/16424116.xml  \n",
            "  inflating: devtestset/16452102.xml  \n",
            "  inflating: devtestset/16461091.xml  \n",
            "  inflating: devtestset/16472560.xml  \n",
            "  inflating: devtestset/16476868.xml  \n",
            "  inflating: devtestset/16498075.xml  \n",
            "  inflating: devtestset/16505744.xml  \n",
            "  inflating: devtestset/16531939.xml  \n",
            "  inflating: devtestset/16543212.xml  \n",
            "  inflating: devtestset/16594812.xml  \n",
            "  inflating: devtestset/16595758.xml  \n",
            "  inflating: devtestset/16717171.xml  \n",
            "  inflating: devtestset/16808770.xml  \n",
            "  inflating: devtestset/16858177.xml  \n",
            "  inflating: devtestset/16875507.xml  \n",
            "  inflating: devtestset/16877132.xml  \n",
            "  inflating: devtestset/16879663.xml  \n",
            "  inflating: devtestset/16888612.xml  \n",
            "  inflating: devtestset/16895873.xml  \n",
            "  inflating: devtestset/16941030.xml  \n",
            "  inflating: devtestset/16948968.xml  \n",
            "  inflating: devtestset/16968832.xml  \n",
            "  inflating: devtestset/16988643.xml  \n",
            "  inflating: devtestset/17015497.xml  \n",
            "  inflating: devtestset/17085773.xml  \n",
            "  inflating: devtestset/17133159.xml  \n",
            "  inflating: devtestset/17182816.xml  \n",
            "  inflating: devtestset/17237298.xml  \n",
            "  inflating: devtestset/17253530.xml  \n",
            "  inflating: devtestset/17267834.xml  \n",
            "  inflating: devtestset/1736162.xml  \n",
            "  inflating: devtestset/17524711.xml  \n",
            "  inflating: devtestset/17592905.xml  \n",
            "  inflating: devtestset/17592920.xml  \n",
            "  inflating: devtestset/17616342.xml  \n",
            "  inflating: devtestset/17636672.xml  \n",
            "  inflating: devtestset/17689623.xml  \n",
            "  inflating: devtestset/18029834.xml  \n",
            "  inflating: devtestset/18204101.xml  \n",
            "  inflating: devtestset/1827154.xml  \n",
            "  inflating: devtestset/1834190.xml  \n",
            "  inflating: devtestset/18685076.xml  \n",
            "  inflating: devtestset/18697868.xml  \n",
            "  inflating: devtestset/18728264.xml  \n",
            "  inflating: devtestset/19362799.xml  \n",
            "  inflating: devtestset/19454119.xml  \n",
            "  inflating: devtestset/1958976.xml  \n",
            "  inflating: devtestset/1972071.xml  \n",
            "  inflating: devtestset/2144249.xml  \n",
            "  inflating: devtestset/2254504.xml  \n",
            "  inflating: devtestset/2397973.xml  \n",
            "  inflating: devtestset/2401622.xml  \n",
            "  inflating: devtestset/2569550.xml  \n",
            "  inflating: devtestset/2589384.xml  \n",
            "  inflating: devtestset/2729383.xml  \n",
            "  inflating: devtestset/2765809.xml  \n",
            "  inflating: devtestset/2797972.xml  \n",
            "  inflating: devtestset/2927639.xml  \n",
            "  inflating: devtestset/2946314.xml  \n",
            "  inflating: devtestset/2995463.xml  \n",
            "  inflating: devtestset/3129947.xml  \n",
            "  inflating: devtestset/3201166.xml  \n",
            "  inflating: devtestset/3279083.xml  \n",
            "  inflating: devtestset/3339302.xml  \n",
            "  inflating: devtestset/3530834.xml  \n",
            "  inflating: devtestset/3536151.xml  \n",
            "  inflating: devtestset/3564971.xml  \n",
            "  inflating: devtestset/3585263.xml  \n",
            "  inflating: devtestset/3773200.xml  \n",
            "  inflating: devtestset/3783255.xml  \n",
            "  inflating: devtestset/6268713.xml  \n",
            "  inflating: devtestset/6446157.xml  \n",
            "  inflating: devtestset/6462823.xml  \n",
            "  inflating: devtestset/6726967.xml  \n",
            "  inflating: devtestset/6992760.xml  \n",
            "  inflating: devtestset/7441727.xml  \n",
            "  inflating: devtestset/7464862.xml  \n",
            "  inflating: devtestset/7484689.xml  \n",
            "  inflating: devtestset/7503102.xml  \n",
            "  inflating: devtestset/7556315.xml  \n",
            "  inflating: devtestset/7606610.xml  \n",
            "  inflating: devtestset/7636666.xml  \n",
            "  inflating: devtestset/7637478.xml  \n",
            "  inflating: devtestset/7650803.xml  \n",
            "  inflating: devtestset/7668955.xml  \n",
            "  inflating: devtestset/7718463.xml  \n",
            "  inflating: devtestset/7751991.xml  \n",
            "  inflating: devtestset/7755226.xml  \n",
            "  inflating: devtestset/7790794.xml  \n",
            "  inflating: devtestset/7924745.xml  \n",
            "  inflating: devtestset/7947191.xml  \n",
            "  inflating: devtestset/7998591.xml  \n",
            "  inflating: devtestset/8035399.xml  \n",
            "  inflating: devtestset/8067497.xml  \n",
            "  inflating: devtestset/8257885.xml  \n",
            "  inflating: devtestset/8308945.xml  \n",
            "  inflating: devtestset/8343705.xml  \n",
            "  inflating: devtestset/8388353.xml  \n",
            "  inflating: devtestset/8404570.xml  \n",
            "  inflating: devtestset/8411526.xml  \n",
            "  inflating: devtestset/8414854.xml  \n",
            "  inflating: devtestset/8417384.xml  \n",
            "  inflating: devtestset/8424029.xml  \n",
            "  inflating: devtestset/8504041.xml  \n",
            "  inflating: devtestset/8511292.xml  \n",
            "  inflating: devtestset/8531589.xml  \n",
            "  inflating: devtestset/8555803.xml  \n",
            "  inflating: devtestset/8572664.xml  \n",
            "  inflating: devtestset/8600478.xml  \n",
            "  inflating: devtestset/8614419.xml  \n",
            "  inflating: devtestset/8622332.xml  \n",
            "  inflating: devtestset/8723400.xml  \n",
            "  inflating: devtestset/8740106.xml  \n",
            "  inflating: devtestset/8792761.xml  \n",
            "  inflating: devtestset/8805732.xml  \n",
            "  inflating: devtestset/8869670.xml  \n",
            "  inflating: devtestset/8951257.xml  \n",
            "  inflating: devtestset/8953819.xml  \n",
            "  inflating: devtestset/8989331.xml  \n",
            "  inflating: devtestset/9002122.xml  \n",
            "  inflating: devtestset/9039201.xml  \n",
            "  inflating: devtestset/9058407.xml  \n",
            "  inflating: devtestset/9076817.xml  \n",
            "  inflating: devtestset/9099150.xml  \n",
            "  inflating: devtestset/9142003.xml  \n",
            "  inflating: devtestset/9154395.xml  \n",
            "  inflating: devtestset/9161648.xml  \n",
            "  inflating: devtestset/9164801.xml  \n",
            "  inflating: devtestset/9169398.xml  \n",
            "  inflating: devtestset/9193380.xml  \n",
            "  inflating: devtestset/9229283.xml  \n",
            "  inflating: devtestset/9230162.xml  \n",
            "  inflating: devtestset/9279298.xml  \n",
            "  inflating: devtestset/9315764.xml  \n",
            "  inflating: devtestset/9346984.xml  \n",
            "  inflating: devtestset/9358138.xml  \n",
            "  inflating: devtestset/9402381.xml  \n",
            "  inflating: devtestset/9519336.xml  \n",
            "  inflating: devtestset/9565411.xml  \n",
            "  inflating: devtestset/9576405.xml  \n",
            "  inflating: devtestset/9583926.xml  \n",
            "  inflating: devtestset/9625682.xml  \n",
            "  inflating: devtestset/9645824.xml  \n",
            "  inflating: devtestset/9649104.xml  \n",
            "  inflating: devtestset/9651416.xml  \n",
            "  inflating: devtestset/9672436.xml  \n",
            "  inflating: devtestset/9679792.xml  \n",
            "  inflating: devtestset/9707055.xml  \n",
            "  inflating: devtestset/9723629.xml  \n",
            "  inflating: devtestset/9734940.xml  \n",
            "  inflating: devtestset/9737262.xml  \n",
            "  inflating: devtestset/9742977.xml  \n",
            "  inflating: devtestset/9748034.xml  \n",
            "  inflating: devtestset/9758073.xml  \n",
            "  inflating: devtestset/9782811.xml  \n",
            "  inflating: devtestset/9798179.xml  \n",
            "  inflating: devtestset/9829011.xml  \n",
            "  inflating: devtestset/9856427.xml  \n",
            "  inflating: devtestset/9862624.xml  \n",
            "  inflating: devtestset/9866667.xml  \n",
            "  inflating: devtestset/9867550.xml  \n",
            "  inflating: devtestset/9918479.xml  \n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "f0Hksct0hXHv"
      },
      "source": [
        "\n",
        "from bs4 import BeautifulSoup\n",
        " \n",
        "# Reading data from the xml file\n",
        "with open('/content/trainset/10024120.xml', 'r') as f:\n",
        "    data = f.read()\n",
        " \n",
        "# Passing the data of the xml\n",
        "# file to the xml parser of\n",
        "# beautifulsoup\n",
        "bs_data = BeautifulSoup(data, 'xml')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "IGLwVaQfhdcs",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "6115bfc1-b26f-40b6-e1bc-3ea95944ae91"
      },
      "source": [
        "bs_data"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<?xml version=\"1.0\" encoding=\"utf-8\"?>\n",
              "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2011//EN\" \"http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd\">\n",
              "<pubmedarticleset>\n",
              "<pubmedarticle>\n",
              "<medlinecitation owner=\"NLM\" status=\"MEDLINE\">\n",
              "<pmid version=\"1\">\n",
              "    10024120\n",
              "   </pmid>\n",
              "<datecreated>\n",
              "<year>\n",
              "     1999\n",
              "    </year>\n",
              "<month>\n",
              "     03\n",
              "    </month>\n",
              "<day>\n",
              "     01\n",
              "    </day>\n",
              "</datecreated>\n",
              "<datecompleted>\n",
              "<year>\n",
              "     1999\n",
              "    </year>\n",
              "<month>\n",
              "     03\n",
              "    </month>\n",
              "<day>\n",
              "     01\n",
              "    </day>\n",
              "</datecompleted>\n",
              "<daterevised>\n",
              "<year>\n",
              "     2007\n",
              "    </year>\n",
              "<month>\n",
              "     11\n",
              "    </month>\n",
              "<day>\n",
              "     15\n",
              "    </day>\n",
              "</daterevised>\n",
              "<article pubmodel=\"Print\">\n",
              "<journal>\n",
              "<issn issntype=\"Print\">\n",
              "      0025-7079\n",
              "     </issn>\n",
              "<journalissue citedmedium=\"Print\">\n",
              "<volume>\n",
              "       37\n",
              "      </volume>\n",
              "<issue>\n",
              "       2\n",
              "      </issue>\n",
              "<pubdate>\n",
              "<year>\n",
              "        1999\n",
              "       </year>\n",
              "<month>\n",
              "        Feb\n",
              "       </month>\n",
              "</pubdate>\n",
              "</journalissue>\n",
              "<title>\n",
              "      Medical care\n",
              "     </title>\n",
              "<isoabbreviation>\n",
              "      Med Care\n",
              "     </isoabbreviation>\n",
              "</journal>\n",
              "<articletitle>\n",
              "     Recurrence and care seeking after acute back pain: results of a long-term follow-up study. North Carolina Back Pain Project.\n",
              "    </articletitle>\n",
              "<pagination>\n",
              "<medlinepgn>\n",
              "      157-64\n",
              "     </medlinepgn>\n",
              "</pagination>\n",
              "<abstract>\n",
              "<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
              "      To explore the relationship between type of initial care as well as the likelihood of recurrence and consequent care seeking behavior.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"RESEARCH DESIGN\" nlmcategory=\"METHODS\">\n",
              "      Prospective observational cohort recruited from 208 randomly selected North Carolina practices. Cohort study examined the recurrence of low back pain among patients free of back pain 3 months after their index visit to a practitioner for that problem. The following four practitioner strata were examined: primary care providers, chiropractors, orthopedic surgeons, and practitioners in a group model HMO. Patients were interviewed by telephone at 6 and 22 months after the initial visit.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
              "      Rates of disabling and non-disabling low back pain; functional status using the Roland back disability scale; and care seeking.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
              "      Rates of recurrence were substantial; functionally disabling recurrence rates varied between 8% and 14% between 3 to 6 months, and 20% to 35% between 6 to 22 months. Differences in rates among practitioner strata were statistically significant only between 6 to 22 months with higher recurrence rates for HMO patients. Functional status, number of bed days, and time off work were very similar among the practitioner strata. Care seeking, however, was greater among those patients who had initially seen a chiropractor for their back pain. Patients with recurrence saw the same practitioner type they had seen for the index episode 88% of the time. Satisfaction was slightly greater for patients who saw chiropractors when compared with patients seeing allopathic physicians.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
              "      The recurrence of low back pain is common. Severe disability is rare. Patients who had sought care from chiropractors are more likely to return for recurrences than patients who had initially sought care from MDs.\n",
              "     </abstracttext>\n",
              "</abstract>\n",
              "<affiliation>\n",
              "     Department of Medicine, University of North Carolina at Chapel Hill, 27599-7590, USA. carey@med.unc.edu\n",
              "    </affiliation>\n",
              "<authorlist completeyn=\"Y\">\n",
              "<author validyn=\"Y\">\n",
              "<lastname>\n",
              "       Carey\n",
              "      </lastname>\n",
              "<forename>\n",
              "       T S\n",
              "      </forename>\n",
              "<initials>\n",
              "       TS\n",
              "      </initials>\n",
              "</author>\n",
              "<author validyn=\"Y\">\n",
              "<lastname>\n",
              "       Garrett\n",
              "      </lastname>\n",
              "<forename>\n",
              "       J M\n",
              "      </forename>\n",
              "<initials>\n",
              "       JM\n",
              "      </initials>\n",
              "</author>\n",
              "<author validyn=\"Y\">\n",
              "<lastname>\n",
              "       Jackman\n",
              "      </lastname>\n",
              "<forename>\n",
              "       A\n",
              "      </forename>\n",
              "<initials>\n",
              "       A\n",
              "      </initials>\n",
              "</author>\n",
              "<author validyn=\"Y\">\n",
              "<lastname>\n",
              "       Hadler\n",
              "      </lastname>\n",
              "<forename>\n",
              "       N\n",
              "      </forename>\n",
              "<initials>\n",
              "       N\n",
              "      </initials>\n",
              "</author>\n",
              "</authorlist>\n",
              "<language>\n",
              "     eng\n",
              "    </language>\n",
              "<grantlist completeyn=\"Y\">\n",
              "<grant>\n",
              "<grantid>\n",
              "       HS09370\n",
              "      </grantid>\n",
              "<acronym>\n",
              "       HS\n",
              "      </acronym>\n",
              "<agency>\n",
              "       AHRQ HHS\n",
              "      </agency>\n",
              "<country>\n",
              "       United States\n",
              "      </country>\n",
              "</grant>\n",
              "<grant>\n",
              "<grantid>\n",
              "       HSO6664\n",
              "      </grantid>\n",
              "<acronym>\n",
              "       HS\n",
              "      </acronym>\n",
              "<agency>\n",
              "       AHRQ HHS\n",
              "      </agency>\n",
              "<country>\n",
              "       United States\n",
              "      </country>\n",
              "</grant>\n",
              "</grantlist>\n",
              "<publicationtypelist>\n",
              "<publicationtype>\n",
              "      Journal Article\n",
              "     </publicationtype>\n",
              "<publicationtype>\n",
              "      Research Support, U.S. Gov't, P.H.S.\n",
              "     </publicationtype>\n",
              "</publicationtypelist>\n",
              "</article>\n",
              "<medlinejournalinfo>\n",
              "<country>\n",
              "     UNITED STATES\n",
              "    </country>\n",
              "<medlineta>\n",
              "     Med Care\n",
              "    </medlineta>\n",
              "<nlmuniqueid>\n",
              "     0230027\n",
              "    </nlmuniqueid>\n",
              "<issnlinking>\n",
              "     0025-7079\n",
              "    </issnlinking>\n",
              "</medlinejournalinfo>\n",
              "<citationsubset>\n",
              "    IM\n",
              "   </citationsubset>\n",
              "<meshheadinglist>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Acute Disease\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Adult\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Cohort Studies\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Disability Evaluation\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Female\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Follow-Up Studies\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Health Maintenance Organizations\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Humans\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Low Back Pain\n",
              "     </descriptorname>\n",
              "<qualifiername majortopicyn=\"Y\">\n",
              "      psychology\n",
              "     </qualifiername>\n",
              "<qualifiername majortopicyn=\"N\">\n",
              "      rehabilitation\n",
              "     </qualifiername>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Male\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Middle Aged\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\" type=\"Geographic\">\n",
              "      North Carolina\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"Y\">\n",
              "      Patient Acceptance of Health Care\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Patient Care Team\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"N\">\n",
              "      Patient Education as Topic\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "<meshheading>\n",
              "<descriptorname majortopicyn=\"Y\">\n",
              "      Recurrence\n",
              "     </descriptorname>\n",
              "</meshheading>\n",
              "</meshheadinglist>\n",
              "</medlinecitation>\n",
              "<pubmeddata>\n",
              "<history>\n",
              "<pubmedpubdate pubstatus=\"pubmed\">\n",
              "<year>\n",
              "      1999\n",
              "     </year>\n",
              "<month>\n",
              "      2\n",
              "     </month>\n",
              "<day>\n",
              "      19\n",
              "     </day>\n",
              "</pubmedpubdate>\n",
              "<pubmedpubdate pubstatus=\"medline\">\n",
              "<year>\n",
              "      1999\n",
              "     </year>\n",
              "<month>\n",
              "      2\n",
              "     </month>\n",
              "<day>\n",
              "      19\n",
              "     </day>\n",
              "<hour>\n",
              "      0\n",
              "     </hour>\n",
              "<minute>\n",
              "      1\n",
              "     </minute>\n",
              "</pubmedpubdate>\n",
              "<pubmedpubdate pubstatus=\"entrez\">\n",
              "<year>\n",
              "      1999\n",
              "     </year>\n",
              "<month>\n",
              "      2\n",
              "     </month>\n",
              "<day>\n",
              "      19\n",
              "     </day>\n",
              "<hour>\n",
              "      0\n",
              "     </hour>\n",
              "<minute>\n",
              "      0\n",
              "     </minute>\n",
              "</pubmedpubdate>\n",
              "</history>\n",
              "<publicationstatus>\n",
              "    ppublish\n",
              "   </publicationstatus>\n",
              "<articleidlist>\n",
              "<articleid idtype=\"pubmed\">\n",
              "     10024120\n",
              "    </articleid>\n",
              "</articleidlist>\n",
              "</pubmeddata>\n",
              "</pubmedarticle>\n",
              "</pubmedarticleset>"
            ]
          },
          "metadata": {},
          "execution_count": 23
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "kLcq2t3atsS2"
      },
      "source": [
        "bs = bs_data.find_all('articletitle')[0]"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "y9KoAKob_9XL",
        "outputId": "bbb5f989-6078-49c4-a4c6-d6b2cf38854b"
      },
      "source": [
        "bs"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<articletitle>\n",
              "     Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease.\n",
              "    </articletitle>"
            ]
          },
          "metadata": {},
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ZXnbCdj7fF4d",
        "outputId": "b597e451-bc0f-4831-e086-196d2c1c77e6"
      },
      "source": [
        "len(bs)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "11"
            ]
          },
          "metadata": {},
          "execution_count": 26
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "XpdvDB3zuUWL",
        "outputId": "d5358458-09a2-4b56-843e-8bf81064874f"
      },
      "source": [
        "type(bs)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "bs4.element.Tag"
            ]
          },
          "metadata": {},
          "execution_count": 31
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 140
        },
        "id": "W3O5x2BFuYHm",
        "outputId": "4a5ac867-3435-4b43-a489-8b6ead7d76f2"
      },
      "source": [
        "bs.get_text()"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            },
            "text/plain": [
              "'\\n\\n      To explore the relationship between type of initial care as well as the likelihood of recurrence and consequent care seeking behavior.\\n     \\n\\n      Prospective observational cohort recruited from 208 randomly selected North Carolina practices. Cohort study examined the recurrence of low back pain among patients free of back pain 3 months after their index visit to a practitioner for that problem. The following four practitioner strata were examined: primary care providers, chiropractors, orthopedic surgeons, and practitioners in a group model HMO. Patients were interviewed by telephone at 6 and 22 months after the initial visit.\\n     \\n\\n      Rates of disabling and non-disabling low back pain; functional status using the Roland back disability scale; and care seeking.\\n     \\n\\n      Rates of recurrence were substantial; functionally disabling recurrence rates varied between 8% and 14% between 3 to 6 months, and 20% to 35% between 6 to 22 months. Differences in rates among practitioner strata were statistically significant only between 6 to 22 months with higher recurrence rates for HMO patients. Functional status, number of bed days, and time off work were very similar among the practitioner strata. Care seeking, however, was greater among those patients who had initially seen a chiropractor for their back pain. Patients with recurrence saw the same practitioner type they had seen for the index episode 88% of the time. Satisfaction was slightly greater for patients who saw chiropractors when compared with patients seeing allopathic physicians.\\n     \\n\\n      The recurrence of low back pain is common. Severe disability is rare. Patients who had sought care from chiropractors are more likely to return for recurrences than patients who had initially sought care from MDs.\\n     \\n'"
            ]
          },
          "metadata": {},
          "execution_count": 32
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "E_b4j42EuYDX"
      },
      "source": [
        ""
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Mvm6pd9UtZgJ",
        "outputId": "64ffada5-c365-4ec5-97ba-597912915297"
      },
      "source": [
        "bs"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<abstract>\n",
              "<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
              "      To explore the relationship between type of initial care as well as the likelihood of recurrence and consequent care seeking behavior.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"RESEARCH DESIGN\" nlmcategory=\"METHODS\">\n",
              "      Prospective observational cohort recruited from 208 randomly selected North Carolina practices. Cohort study examined the recurrence of low back pain among patients free of back pain 3 months after their index visit to a practitioner for that problem. The following four practitioner strata were examined: primary care providers, chiropractors, orthopedic surgeons, and practitioners in a group model HMO. Patients were interviewed by telephone at 6 and 22 months after the initial visit.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
              "      Rates of disabling and non-disabling low back pain; functional status using the Roland back disability scale; and care seeking.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
              "      Rates of recurrence were substantial; functionally disabling recurrence rates varied between 8% and 14% between 3 to 6 months, and 20% to 35% between 6 to 22 months. Differences in rates among practitioner strata were statistically significant only between 6 to 22 months with higher recurrence rates for HMO patients. Functional status, number of bed days, and time off work were very similar among the practitioner strata. Care seeking, however, was greater among those patients who had initially seen a chiropractor for their back pain. Patients with recurrence saw the same practitioner type they had seen for the index episode 88% of the time. Satisfaction was slightly greater for patients who saw chiropractors when compared with patients seeing allopathic physicians.\n",
              "     </abstracttext>\n",
              "<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
              "      The recurrence of low back pain is common. Severe disability is rare. Patients who had sought care from chiropractors are more likely to return for recurrences than patients who had initially sought care from MDs.\n",
              "     </abstracttext>\n",
              "</abstract>"
            ]
          },
          "metadata": {},
          "execution_count": 30
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "aEuX4peotUjB"
      },
      "source": [
        "bs.keys"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "F3VsAJFo__AH",
        "outputId": "5f36682d-8803-429b-a85d-1b1baeab6c5e"
      },
      "source": [
        "bs.find_all(\"abstracttext\", attrs={\"nlmcategory\":\"OBJECTIVE\"})"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
              "       To explore the relationship between type of initial care as well as the likelihood of recurrence and consequent care seeking behavior.\n",
              "      </abstracttext>]"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "TaPWeqZDrxkg"
      },
      "source": [
        "with open('/content/drive/MyDrive/ALTA/public_dat/trainset.txt', 'r') as f:\n",
        "    data = f.readlines()"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "datCSbBxkf3N"
      },
      "source": [
        "with open('/content/testset_nolabels.txt', 'r') as f:\n",
        "    data = f.readlines()"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "xBqLSSpI5_pV"
      },
      "source": [
        "with open('/content/drive/MyDrive/ALTA/public_dat/devtestset.txt', 'r') as f:\n",
        "    data = f.readlines()"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "F5DKnQxtu9ed",
        "outputId": "ee75458d-584a-46b0-e189-970ba8fcc058"
      },
      "source": [
        "data"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['10001 B 19454119\\n',\n",
              " '10002 A 12531578 11110735\\n',\n",
              " '10003 A 10637680 11762571 2254504 11225739 12025432 8951257\\n',\n",
              " '10004 A 9679792\\n',\n",
              " '10005 C 6726967 9651416\\n',\n",
              " '10006 B 9402381 17133159\\n',\n",
              " '10007 C 11406072\\n',\n",
              " '10008 B 11832527 11333990\\n',\n",
              " '10009 C 3536151 15164315 16424116\\n',\n",
              " '10010 C 11406076\\n',\n",
              " '10011 C 9058407 15095535\\n',\n",
              " '10012 B 15755947 12204020 10995804\\n',\n",
              " '10013 B 11251560\\n',\n",
              " '10014 C 16808770 14567259\\n',\n",
              " '10015 C 14573734 15644481 11330653 15234289\\n',\n",
              " '10016 B 12041718 11930092\\n',\n",
              " '10017 C 9625682\\n',\n",
              " '10018 B 11370690\\n',\n",
              " '10019 B 8257885 14738790 16027691 16188764 9169398 14670769 10582925 12728140 9346984\\n',\n",
              " '10020 A 18685076 19362799\\n',\n",
              " '10021 B 10865273 9862624 14678916 10475183 11072258\\n',\n",
              " '10022 B 18728264\\n',\n",
              " '10023 B 10591433\\n',\n",
              " '10024 B 12086760 12196473 11832527\\n',\n",
              " '10025 A 15617591 15029914\\n',\n",
              " '10026 A 16076830 17182816\\n',\n",
              " '10027 B 9576405\\n',\n",
              " '10028 A 12804462\\n',\n",
              " '10029 C 8411526 14583920 11486289\\n',\n",
              " '10030 C 14707320 1827154\\n',\n",
              " '10031 C 2946314\\n',\n",
              " '10032 A 10736891\\n',\n",
              " '10033 A 10880410 10438259 11289345\\n',\n",
              " '10034 C 17085773 18204101 10380441\\n',\n",
              " '10035 C 3129947 9645824 7503102 15260010 11158037 16185098 11005775 16193071\\n',\n",
              " '10036 C 7441727\\n',\n",
              " '10037 B 14738790 16027691 16188764 10582925 14670769 12728140\\n',\n",
              " '10038 C 16291385 12597752 14567259\\n',\n",
              " '10039 C 9002122 2589384\\n',\n",
              " '10040 A 13678869 11759645 14610160\\n',\n",
              " '10041 A 15623698 15829527 12975222\\n',\n",
              " '10042 A 16034957\\n',\n",
              " '10043 B 11713157\\n',\n",
              " '10044 B 2569550\\n',\n",
              " '10045 C 11417373 9099150\\n',\n",
              " '10046 B 6446157 12911018\\n',\n",
              " '10047 B 3201166 10961470 11174474\\n',\n",
              " '10048 A 10639540 8622332 10465168 9193380\\n',\n",
              " '10049 A 12899587\\n',\n",
              " '10050 B 10920067\\n',\n",
              " '10051 C 14702017\\n',\n",
              " '10052 A 16034897\\n',\n",
              " '10053 A 7606610 8805732 9161648\\n',\n",
              " '10054 C 9651416\\n',\n",
              " '10055 A 10505584 8792761 17592920\\n',\n",
              " '10056 B 10819705\\n',\n",
              " '10057 C 16988643 15138245 12662389 16505744 15788927 16888612 12537734\\n',\n",
              " '10058 B 15869575\\n',\n",
              " '10059 B 16595758 12525800 16895873 14702017 14702015 8989331 15450632 17524711 17015497 17616342\\n',\n",
              " '10060 B 9734940 14584015 15240584\\n',\n",
              " '10061 A 11328254 10383500\\n',\n",
              " '10062 A 11565518 11565519 10675071 11937179 11565517\\n',\n",
              " '10063 A 11985936 12689976 18029834\\n',\n",
              " '10064 B 15800988\\n',\n",
              " '10065 B 10836730 10954007\\n',\n",
              " '10066 C 16498075 12949310 11331711 16186441\\n',\n",
              " '10067 B 7751991 11242425 9164801 1972071 9565411\\n',\n",
              " '10068 C 10888978\\n',\n",
              " '10069 B 9742977\\n',\n",
              " '10070 B 12506950 7636666\\n',\n",
              " '10071 B 12780419 11904599\\n',\n",
              " '10072 A 16274376 15571825 14974003\\n',\n",
              " '10073 A 18697868\\n',\n",
              " '10074 A 1634662 10987614\\n',\n",
              " '10075 C 16948968\\n',\n",
              " '10076 B 14978607 16875507\\n',\n",
              " '10077 B 15142155 12472618 16461091\\n',\n",
              " '10078 C 9737262 1958976 14625699 14634843 2765809 11754850\\n',\n",
              " '10079 B 9918479\\n',\n",
              " '10080 C 7947191\\n',\n",
              " '10081 B 12821233 12944058\\n',\n",
              " '10082 A 14583954 14973991 15470832 16352884\\n',\n",
              " '10083 B 15869575 13679527\\n',\n",
              " '10084 A 16717171 10923571 9829011\\n',\n",
              " '10085 B 8424029 9856427\\n',\n",
              " '10086 C 8600478 2401622\\n',\n",
              " '10087 B 2729383 17253530 2569550\\n',\n",
              " '10088 B 14523141\\n',\n",
              " '10089 A 10792124\\n',\n",
              " '10090 B 11210884 3585263 11136304 9866667\\n',\n",
              " '10091 A 10218746\\n',\n",
              " '10092 B 15029914\\n',\n",
              " '10093 A 3530834 17636672 2397973 3279083 9039201 11270304 9672436 11676116 15130571 1093481 9154395\\n',\n",
              " '10094 B 7464862 9867550 3783255\\n',\n",
              " '10095 B 12780419 14718017 12039088\\n',\n",
              " '10096 A 8067497 14961051\\n',\n",
              " '10097 B 8531589 16027691 10582925 14738790\\n',\n",
              " '10098 B 10380450\\n',\n",
              " '10099 C 11907366 1557997\\n',\n",
              " '10100 A 11181776 11988059\\n',\n",
              " '10101 B 15150204 11822926\\n',\n",
              " '10102 A 16941030 16968832\\n',\n",
              " '10103 B 12535435\\n',\n",
              " '10104 B 18697868\\n',\n",
              " '10105 B 8504041 11995901\\n',\n",
              " '10106 C 15572515 10875955 16877132 8404570 10083953 11419777\\n',\n",
              " '10107 B 10923571 16249822 16594812\\n',\n",
              " '10108 B 11339934\\n',\n",
              " '10109 A 11696804 12137645\\n',\n",
              " '10110 A 9358138 10193252\\n',\n",
              " '10111 B 8740106 11583049 9076817\\n',\n",
              " '10112 C 14973999\\n',\n",
              " '10113 B 15638939 7668955\\n',\n",
              " '10114 B 9315764 8869670 11416690 10862644 10602535 10930181\\n',\n",
              " '10115 B 11914253 15505131\\n',\n",
              " '10116 A 11035889 11706112 12076493 10449550 10908538 10894991 2927639\\n',\n",
              " '10117 B 12135217 12780419\\n',\n",
              " '10118 C 16472560 17267834 17689623\\n',\n",
              " '10119 C 9229283 7755226 10065311 3339302 8343705\\n',\n",
              " '10120 B 9402381\\n',\n",
              " '10121 C 12900480 9279298 8308945 12396679\\n',\n",
              " '10122 C 7650803 3773200 9519336\\n',\n",
              " '10123 B 15716561\\n',\n",
              " '10124 B 15623698 15829527 12975222\\n',\n",
              " '10125 B 15967905 15555974 15685694\\n',\n",
              " '10126 A 16026361 11790216\\n',\n",
              " '10127 B 2797972\\n',\n",
              " '10128 C 7718463 2144249\\n',\n",
              " '10129 B 11380322 11802748\\n',\n",
              " '10130 B 16413844 16102549 15722066\\n',\n",
              " '10131 C 16043733\\n',\n",
              " '10132 B 7790794 6992760 9798179\\n',\n",
              " '10133 A 12571256 8511292\\n',\n",
              " '10134 C 16186441 11331711\\n',\n",
              " '10135 A 9230162 8614419 10376614 11113718 11386263 10023943 11144703\\n',\n",
              " '10136 A 15687461 14702015 15384567\\n',\n",
              " '10137 A 9723629\\n',\n",
              " '10138 B 15846673\\n',\n",
              " '10139 B 11930093\\n',\n",
              " '10140 B 10796458\\n',\n",
              " '10141 C 9651416\\n',\n",
              " '10142 A 12821354 11518884 10227593\\n',\n",
              " '10143 B 11833633\\n',\n",
              " '10144 B 12931367 16879663 16422868\\n',\n",
              " '10145 C 10052444 10589881\\n',\n",
              " '10146 A 12097535\\n',\n",
              " '10147 B 6462823 8414854 6268713 11236719\\n',\n",
              " '10148 A 12213943 12091045 8723400 8388353 7637478\\n',\n",
              " '10149 C 16476868\\n',\n",
              " '10150 B 10513500 9758073 9782811 8035399 12022321 12137713\\n',\n",
              " '10151 C 12415081 1834190 9099150 7484689 11417373\\n',\n",
              " '10152 B 16858177 14625699 16418463\\n',\n",
              " '10153 B 10969225\\n',\n",
              " '10154 C 9707055 7556315 7924745 1626996\\n',\n",
              " '10155 B 8257885 9346984 14738790 16188764\\n',\n",
              " '10156 A 12114037 11757504\\n',\n",
              " '10157 A 15029914\\n',\n",
              " '10158 C 16452102\\n',\n",
              " '10159 B 15477411\\n',\n",
              " '10160 A 9748034 1736162 8417384 8555803 9583926 8572664\\n',\n",
              " '10161 C 12137645\\n',\n",
              " '10162 B 12679432\\n',\n",
              " '10163 B 15784043\\n',\n",
              " '10164 B 17133159 12777590 9402381\\n',\n",
              " '10165 C 8953819\\n',\n",
              " '10166 A 14724869 2995463\\n',\n",
              " '10167 C 9649104\\n',\n",
              " '10168 B 17592905\\n',\n",
              " '10169 B 11930093\\n',\n",
              " '10170 C 9099150\\n',\n",
              " '10171 C 11904599\\n',\n",
              " '10172 B 12137880 11907922 11415950 12588275 11355039 7998591 14716181\\n',\n",
              " '10173 C 16988643\\n',\n",
              " '10174 C 9142003 10965007\\n',\n",
              " '10175 A 17237298 16080084 12514443 15716561 16531939\\n',\n",
              " '10176 A 9723629 9679792 12968085\\n',\n",
              " '10177 B 16543212 11702616\\n',\n",
              " '10178 C 3564971 7441727\\n']"
            ]
          },
          "metadata": {},
          "execution_count": 46
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "KkT9bHwbu-UM"
      },
      "source": [
        "evidence = []\n",
        "label = []\n",
        "xml_files = []\n",
        "for dp in data:\n",
        "  # pd.split(\" \")[0]\n",
        "  evidence.append(dp.split(\" \")[0])\n",
        "  label.append(dp.split(\" \")[1])\n",
        "  xml_files.append(dp.split(\" \")[2])\n",
        "  # xml_files.append(list(map(str.strip,dp.split(\" \")[2])))\n",
        "  # print(dp.split(\" \")[0])"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "wtHkswNelQyR"
      },
      "source": [
        "evidence = []\n",
        "# label = []\n",
        "xml_files = []\n",
        "for dp in data:\n",
        "  # pd.split(\" \")[0]\n",
        "  evidence.append(dp.split(\" \")[0])\n",
        "  # label.append(dp.split(\" \")[1])\n",
        "  xml_files.append(dp.split(\" \")[1])\n",
        "  # xml_files.append(list(map(str.strip,dp.split(\" \")[2])))\n",
        "  # print(dp.split(\" \")[0])"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "MV6KqqJGxCZ0"
      },
      "source": [
        "import pandas as pd\n"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "f3lNDw6QlXOW"
      },
      "source": [
        "test_df = pd.DataFrame(zip(evidence,xml_files),columns = ['evidence','xml_files'])"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "EMbGX78PlkzB",
        "outputId": "7cdf1c23-eb51-435f-9400-2f6f03fe70e4"
      },
      "source": [
        "test_df.head()"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>evidence</th>\n",
              "      <th>xml_files</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>20001</td>\n",
              "      <td>11204585</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>20002</td>\n",
              "      <td>12117397\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>20003</td>\n",
              "      <td>11502313</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>20004</td>\n",
              "      <td>12686036\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>20005</td>\n",
              "      <td>15888839</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "  evidence   xml_files\n",
              "0    20001    11204585\n",
              "1    20002  12117397\\n\n",
              "2    20003    11502313\n",
              "3    20004  12686036\\n\n",
              "4    20005    15888839"
            ]
          },
          "metadata": {},
          "execution_count": 30
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "sJb4d-EymQRc"
      },
      "source": [
        "test_df['xml_files'] = test_df['xml_files'].apply(lambda x:str.strip(x))"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "bNwZIBY2vOlV"
      },
      "source": [
        "train_df = pd.DataFrame(zip(evidence,label,xml_files),columns = ['evidence','label','xml_files'])"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "cdMc6Gb_6VhF"
      },
      "source": [
        "val_df = pd.DataFrame(zip(evidence,label,xml_files),columns = ['evidence','label','xml_files'])"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 36
        },
        "id": "NjsZ2DkwxEvT",
        "outputId": "3f10cd81-8802-4a32-dcf4-f663baa9686f"
      },
      "source": [
        "train_df.xml_files.values[0][-1].strip()"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            },
            "text/plain": [
              "'0'"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "kHTz_Zbs1uvt",
        "outputId": "4b8c363e-5e13-4d75-95a1-c738a0ffc874"
      },
      "source": [
        "train_df.head()"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>evidence</th>\n",
              "      <th>label</th>\n",
              "      <th>xml_files</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00001</td>\n",
              "      <td>C</td>\n",
              "      <td>9149180</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00002</td>\n",
              "      <td>B</td>\n",
              "      <td>4396080</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00003</td>\n",
              "      <td>B</td>\n",
              "      <td>1519858</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00004</td>\n",
              "      <td>A</td>\n",
              "      <td>15547167\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00005</td>\n",
              "      <td>C</td>\n",
              "      <td>11392916\\n</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "  evidence label   xml_files\n",
              "0    00001     C     9149180\n",
              "1    00002     B     4396080\n",
              "2    00003     B     1519858\n",
              "3    00004     A  15547167\\n\n",
              "4    00005     C  11392916\\n"
            ]
          },
          "metadata": {},
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "QdrY5lrA1us0"
      },
      "source": [
        "train_df['xml_files'] = train_df['xml_files'].apply(lambda x:str.strip(x))"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "eZ8dD2DZ6Z2_"
      },
      "source": [
        "val_df['xml_files'] = val_df['xml_files'].apply(lambda x:str.strip(x))"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "wls0H8kg4gem",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "outputId": "69fde0df-7b78-4524-a64c-c36c02caaf20"
      },
      "source": [
        "train_df.head()"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>evidence</th>\n",
              "      <th>label</th>\n",
              "      <th>xml_files</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00001</td>\n",
              "      <td>C</td>\n",
              "      <td>9149180</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00002</td>\n",
              "      <td>B</td>\n",
              "      <td>4396080</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00003</td>\n",
              "      <td>B</td>\n",
              "      <td>1519858</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00004</td>\n",
              "      <td>A</td>\n",
              "      <td>15547167</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00005</td>\n",
              "      <td>C</td>\n",
              "      <td>11392916</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "  evidence label xml_files\n",
              "0    00001     C   9149180\n",
              "1    00002     B   4396080\n",
              "2    00003     B   1519858\n",
              "3    00004     A  15547167\n",
              "4    00005     C  11392916"
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "hbMpwHEh6cx9",
        "outputId": "3d0a1296-42a7-44b6-c94c-6e41c19dba22"
      },
      "source": [
        "val_df.head()"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>evidence</th>\n",
              "      <th>label</th>\n",
              "      <th>xml_files</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10001</td>\n",
              "      <td>B</td>\n",
              "      <td>19454119</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10002</td>\n",
              "      <td>A</td>\n",
              "      <td>12531578</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10003</td>\n",
              "      <td>A</td>\n",
              "      <td>10637680</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10004</td>\n",
              "      <td>A</td>\n",
              "      <td>9679792</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10005</td>\n",
              "      <td>C</td>\n",
              "      <td>6726967</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "  evidence label xml_files\n",
              "0    10001     B  19454119\n",
              "1    10002     A  12531578\n",
              "2    10003     A  10637680\n",
              "3    10004     A   9679792\n",
              "4    10005     C   6726967"
            ]
          },
          "metadata": {},
          "execution_count": 51
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "BDdRB6sP4gcS"
      },
      "source": [
        "attrs={\"nlmcategory\":\"METHODS\"}\n",
        "attrs={\"nlmcategory\":\"RESULTS\"}\n",
        "attrs={\"nlmcategory\":\"CONCLUSIONS\"}"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "iU4Z0tpT4gZK"
      },
      "source": [
        "import os"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "119064XG2E0e",
        "outputId": "6163f509-6636-47e5-8999-afff05787b92"
      },
      "source": [
        "for fils in os.listdir(\"/content/trainset\"):\n",
        "  with open(os.path.join(\"/content/trainset\",fils), 'r') as f:\n",
        "    data = f.read()\n",
        "  bs_data = BeautifulSoup(data, 'xml')\n",
        "  print(fils+\"\\n\")\n",
        "  try:\n",
        "    print(bs_data.find_all('publicationtype')[0].get_text())\n",
        "  except:\n",
        "    print(\"N/A\")"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "9915442.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12917299.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11790072.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2153735.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12219053.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "9128272.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9137847.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11790217.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "10944552.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12693642.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17478135.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14973979.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7091901.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11400894.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1547164.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11073017.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15456116.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11687043.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15337640.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15992389.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15836465.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9508226.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11163477.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14731377.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15106175.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8681614.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1777556.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "7625417.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1830233.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15276392.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8916634.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9563847.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "9841303.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8994481.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10653361.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10200061.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796824.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9002103.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9382560.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10173095.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1834868.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9809732.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11086269.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8276736.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "6851084.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11092281.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9786377.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10494485.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8443307.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11886900.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7968073.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15283004.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8916990.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "1973768.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11903236.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "20556779.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11151865.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1442682.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11576414.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12137645.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14969506.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11333990.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12860582.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11180735.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8682668.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11099588.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15039411.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15096077.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11030795.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "6101629.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8155220.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1447433.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14613379.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11117910.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3512941.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9077426.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7936917.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "11902986.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2298897.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "649776.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17072963.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12821960.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796112.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7667050.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11793113.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9682041.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14732621.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11869639.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11701099.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9146531.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17012266.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "1377359.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11319580.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10877038.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12177639.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3515920.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15699227.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10853852.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8880507.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8607590.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10445069.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8458042.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7972972.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12234230.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15039276.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11266478.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12383547.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12548270.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "8257472.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15479678.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16252313.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11401736.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7998664.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7848421.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15266527.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15345498.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10437125.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15056029.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2631530.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8913977.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15383478.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8364819.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16898898.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10875559.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15314625.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11772681.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12672170.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16895257.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8847720.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1535108.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9491092.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1547173.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11136260.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16206501.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14653589.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14718013.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12137717.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16235323.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9738178.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10195491.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11064964.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11847951.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "12411359.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10505584.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16585303.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10887228.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11212161.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15030339.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2860740.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8284003.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12804443.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10553790.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16280426.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "16006474.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7799040.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7103152.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10794582.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11570113.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "6243391.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9288011.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7797786.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15900004.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11147613.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3681544.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "2221649.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11279782.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8119027.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12875251.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "15483524.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "15122593.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7914611.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10591283.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8201735.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1959720.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11126304.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11054899.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "14530229.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12235640.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14676536.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14993084.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8942775.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "13130084.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10908513.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9680042.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15605687.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12164990.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8900088.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16085790.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12269676.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15575803.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11329407.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10485679.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2890951.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11229451.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11927715.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12618157.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "16235299.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7641412.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15383479.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "15110490.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15846645.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12861153.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12228781.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9169398.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15495008.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11869595.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15602109.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7908358.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9323067.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10366137.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "2099731.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11133566.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "18271889.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8629648.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15508538.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15106262.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10084572.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16034962.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14578227.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8667563.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10543657.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "15374846.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16263986.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8967711.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11192132.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7574120.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10024120.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8981292.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9364387.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1331788.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14973944.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2381171.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "18196670.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9583895.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11734712.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12236627.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1408225.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "11172164.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7622804.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3043548.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16013891.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9523961.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11084175.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10571972.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12954519.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10818662.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11029681.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14973971.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12527566.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11113230.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9732337.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11793114.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12897303.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "11687056.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14678921.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "1519858.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15059788.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12519601.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12069675.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7847285.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17443523.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15550129.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12427050.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8600478.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9563431.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15467530.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11027739.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9569395.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8199076.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14567906.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11335807.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10383366.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16009794.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15266549.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10699138.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9112711.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1615986.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9563990.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2328431.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "11952542.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14578243.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10903648.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16554526.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12917936.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1922532.xml\n",
            "\n",
            "\n",
            "      English Abstract\n",
            "     \n",
            "10644272.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "14665658.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14583769.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8439114.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15531002.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "2801193.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1771153.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11431132.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15294856.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14993586.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10796792.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3520319.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11508256.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "3133668.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "16160424.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17495203.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12137713.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2761587.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10759060.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3889257.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11790216.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16235372.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14506119.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15550401.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10634823.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12370455.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16235297.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16050454.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11219227.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12242171.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14609883.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11279767.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11886019.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9182472.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14754562.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14744823.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8634613.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15692973.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16021069.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "1683420.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12648310.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "16848844.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15495039.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12562057.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12187404.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12941675.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8442808.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "14604738.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12137655.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11463010.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10907384.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12586995.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15187057.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11281473.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9934946.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1830566.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8896509.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3318377.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1444726.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11919097.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16336072.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3969339.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11753181.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2201741.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14871318.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15825125.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3669164.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12119991.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11083348.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9158469.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11465699.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "10807619.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11331055.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15721970.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11034750.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9361646.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "2329430.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11565517.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11900496.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17493754.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11391331.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16391215.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12230356.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17341709.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "18376000.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "16102557.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10524579.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11198016.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3306866.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8096560.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9645831.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "766894.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12614413.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15096072.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9800666.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8611058.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9262298.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11527233.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "6389520.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15257186.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11147989.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17304447.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10639540.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "17110817.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15625418.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "8317528.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12975254.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10443654.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10647110.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16819379.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12076378.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17076973.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14583982.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12230591.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10888690.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10809994.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11352694.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12464709.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "9314443.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "12495278.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9314468.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9624306.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8647965.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12885485.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "18166543.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12027983.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12767648.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8394375.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "8901851.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2172402.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3123132.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10799460.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "17889067.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "6138597.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9269212.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1738794.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10326075.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10790990.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "14663128.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16129478.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9322325.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796721.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796591.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10075518.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "2881129.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11165548.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12269681.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11152056.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12630614.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9504319.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8329916.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11004420.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10796398.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "18279051.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10591338.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16099784.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15451329.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8214994.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12390439.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15571540.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16988082.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12660054.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7053703.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7053190.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10644273.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "15292291.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9735623.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10962168.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14974076.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "20238310.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11642617.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "9848901.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9738550.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15028823.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "163931.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12202466.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11485708.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10366118.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3598228.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796127.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16570091.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9396645.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8571999.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9149180.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "10867092.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15103233.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15026401.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "7710148.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16235324.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8926740.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12167549.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15231980.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7566020.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8173141.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15070788.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8893110.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11466577.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2107241.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2216619.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16914702.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8790035.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10458342.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14584018.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12804510.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16437520.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11251703.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14984232.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12490274.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12869452.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12560416.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15115921.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12079710.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7707596.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9254869.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11978293.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796757.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8301112.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "2201888.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3905544.xml\n",
            "\n",
            "\n",
            "      Biography\n",
            "     \n",
            "11493721.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16235327.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10333620.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8225657.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7575046.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16416346.xml\n",
            "\n",
            "\n",
            "      Controlled Clinical Trial\n",
            "     \n",
            "12786634.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11856693.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10208148.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16957763.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9363015.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11459386.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796511.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12917939.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15186367.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11258778.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15452284.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17943891.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10979796.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9459643.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11419683.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12893397.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9747868.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9500475.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7661497.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "6972693.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14996525.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7915824.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9208356.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10398626.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10596256.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16651493.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11731648.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "15635110.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11126352.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11235924.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15715686.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9121182.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10335685.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12436822.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11093966.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11063447.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9625401.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15846609.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11717594.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10509605.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7617369.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "18298429.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11521913.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "11372038.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11014393.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15625141.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3140269.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2712981.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15333452.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11869609.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7678046.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8322582.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7504424.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12809453.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11844004.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12190367.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10354876.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8918275.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15888715.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3888742.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15056503.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16818461.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11505031.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16676287.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12558362.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10665629.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12371916.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11448655.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8970899.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9722799.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12601075.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12140298.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12451364.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11181776.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "17015870.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9284865.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10587552.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16020410.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9781781.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10671393.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12076503.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17572422.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10028110.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11790165.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11843383.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1955232.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14989387.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9096977.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1868642.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11585485.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8942774.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8708804.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15258862.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1728731.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "344087.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15755765.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10629474.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12174056.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16625602.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14973954.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15021067.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15474764.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12535385.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2857061.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12467690.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2067759.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9109139.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7869070.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14678922.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "20556751.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15831424.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "3398197.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15819726.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9778327.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12472787.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7532241.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "18164508.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16052573.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3063051.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10435606.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10684911.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "6693447.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12478024.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14649781.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15187055.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9555761.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "1824642.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12615832.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12791436.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "14682412.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10518812.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "6310075.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11865128.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14984370.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11729014.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "7539890.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12353945.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "8416468.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11083602.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15198752.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10811540.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3941176.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15613404.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7955452.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10469816.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11485144.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2341917.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15367052.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12751658.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3559288.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7503197.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15166898.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17162986.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8907095.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10796686.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11759078.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3935901.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9672274.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10920726.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "12457519.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15635109.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3350949.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12442064.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11704183.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7576395.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1790394.xml\n",
            "\n",
            "\n",
            "      Editorial\n",
            "     \n",
            "3186087.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8976640.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14985592.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7849885.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3982720.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10352632.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1777557.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15976596.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "872608.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15479938.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9167925.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10436111.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10792566.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15106182.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1518691.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9369817.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16446748.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12917922.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11232013.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15654703.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8497355.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9428952.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "1097985.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8604285.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "10865306.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12783912.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14560344.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14872449.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9236642.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15174889.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9914571.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12685516.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8698944.xml\n",
            "\n",
            "\n",
            "      Comment\n",
            "     \n",
            "8256107.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14584010.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "74457.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15242222.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12187337.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12861176.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "16207391.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14747501.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15266429.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10491376.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11423507.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12107216.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9757979.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15138247.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10925761.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14747031.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12612275.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10382464.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "18299547.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15579363.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10969112.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14711538.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "6863528.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "12557864.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10875288.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14583951.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17678659.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11704584.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11407054.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9517638.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11129515.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7790481.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10350034.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11113085.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2801756.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "9099655.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3156007.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796184.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "629899.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14734335.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "6754120.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "18205800.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11552913.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16358132.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "9667087.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12851867.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12517199.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15383488.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "8169238.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12621794.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11089820.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "18184294.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2193173.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "6529911.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12051216.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "4025675.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9371164.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10739286.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3821822.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9262493.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "8246082.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11849631.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12683477.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8875918.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12637923.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "16336480.xml\n",
            "\n",
            "\n",
            "      Controlled Clinical Trial\n",
            "     \n",
            "10749962.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2709545.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10678340.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15908441.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11834677.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15285276.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11451298.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11050261.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11211617.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10428520.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16856114.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8280820.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9430243.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12394811.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "6700642.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8985189.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12421836.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7264790.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8038475.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9058342.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "3346773.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "20091541.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15111671.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2221647.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10637680.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796833.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15001941.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11006203.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12519615.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16198776.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15633203.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11289288.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7673531.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10085797.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9170464.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9220205.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9879160.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8668411.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8900550.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "2910090.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "17443559.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15486746.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11343045.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12882847.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11560453.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "17626140.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12917703.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7755059.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10381965.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10613168.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "17943857.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9516745.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8449054.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11405989.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12121581.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9918527.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17179478.xml\n",
            "\n",
            "\n",
            "      Clinical Trial, Phase III\n",
            "     \n",
            "11326182.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1734290.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "9988787.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8309029.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7224353.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2473403.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8381089.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14557142.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15951574.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12565715.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8613604.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15459412.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "17420682.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15111779.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "9091013.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10399422.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17682990.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8345037.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11207873.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10182646.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15265350.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15788823.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "11698781.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15329425.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1565551.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7391096.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8426621.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15494989.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11735756.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9596593.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11711507.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16340941.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9643743.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15564985.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "8747507.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10190360.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12423708.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8345434.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "321002.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11061763.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15358010.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9036306.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7861574.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16098855.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11466188.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "15994719.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1337553.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16286171.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8535469.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12490470.xml\n",
            "\n",
            "\n",
            "      Comment\n",
            "     \n",
            "12457784.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2656959.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7633770.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16437473.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15046273.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12873166.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10714731.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2194334.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11702618.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "3545282.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12180738.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "8445608.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12748199.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "11443569.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10931404.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17636776.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12707429.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12449547.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15795718.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16048355.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14973951.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7657281.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12571845.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8235922.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16856045.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11306234.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10496256.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10732937.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15016485.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "15769914.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "16368032.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11841361.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "10723977.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17054255.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11006762.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12821232.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8517575.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "16428925.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8509358.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14644896.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "11869676.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11034729.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11687009.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10606058.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12913777.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12460095.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11641669.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7935681.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9290622.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "18056558.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "14984373.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "10334745.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12409542.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "2929804.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8896541.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "7942584.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11687054.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1998638.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11567699.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9669977.xml\n",
            "\n",
            "\n",
            "      Guideline\n",
            "     \n",
            "8236597.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10796394.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "6244871.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12114036.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16437528.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7756486.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12114037.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12427500.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12527571.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15935019.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12220783.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "4053146.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "15126259.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10356424.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15315995.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11529209.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "14659983.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "10609710.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10696941.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "1952493.xml\n",
            "\n",
            "\n",
            "      Consensus Development Conference\n",
            "     \n",
            "10659912.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11933571.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12729427.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12076448.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "7771913.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16319919.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9416884.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12529459.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12696781.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10780124.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "8065869.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "16816220.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "12865262.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "12972967.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11083738.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15135147.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "17943896.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17846141.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10649820.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "15765388.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "1474406.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9574657.xml\n",
            "\n",
            "\n",
            "      Case Reports\n",
            "     \n",
            "12519540.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17065637.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "2642673.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "11036118.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12879992.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "16423126.xml\n",
            "\n",
            "\n",
            "      Evaluation Studies\n",
            "     \n",
            "10727588.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "10074011.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "11588078.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "10218753.xml\n",
            "\n",
            "\n",
            "      Clinical Trial\n",
            "     \n",
            "12120909.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n",
            "11847935.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9356004.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "17051752.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "8944521.xml\n",
            "\n",
            "\n",
            "      Journal Article\n",
            "     \n",
            "9834257.xml\n",
            "\n",
            "\n",
            "      Comparative Study\n",
            "     \n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MsvGXbLCxj9w",
        "outputId": "139e3123-93eb-474d-93e6-7bdbc78888ad"
      },
      "source": [
        "for fils in os.listdir(\"/content/trainset\"):\n",
        "  with open(os.path.join(\"/content/trainset\",fils), 'r') as f:\n",
        "    data = f.read()\n",
        "  bs_data = BeautifulSoup(data, 'xml')\n",
        "  print(fils+\"\\n\")\n",
        "  print(bs_data.find_all('articletitle')[0].get_text())"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "9915442.xml\n",
            "\n",
            "\n",
            "     A comparison of noncontrast computerized tomography with excretory urography in the assessment of acute flank pain.\n",
            "    \n",
            "12917299.xml\n",
            "\n",
            "\n",
            "     Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.\n",
            "    \n",
            "11790072.xml\n",
            "\n",
            "\n",
            "     Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.\n",
            "    \n",
            "2153735.xml\n",
            "\n",
            "\n",
            "     Treatment of recurrent herpes simplex labialis with oral acyclovir.\n",
            "    \n",
            "12219053.xml\n",
            "\n",
            "\n",
            "     Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction.\n",
            "    \n",
            "9128272.xml\n",
            "\n",
            "\n",
            "     The diagnostic value of the neutrophil left shift in predicting inflammatory and infectious disease.\n",
            "    \n",
            "9137847.xml\n",
            "\n",
            "\n",
            "     Divalproex sodium in migraine prophylaxis: a dose-controlled study.\n",
            "    \n",
            "11790217.xml\n",
            "\n",
            "\n",
            "     Oral antihyperglycemic therapy for type 2 diabetes: clinical applications.\n",
            "    \n",
            "10944552.xml\n",
            "\n",
            "\n",
            "     Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up.\n",
            "    \n",
            "12693642.xml\n",
            "\n",
            "\n",
            "     Predictors of six-month survival among patients with dementia: an evaluation of hospice Medicare guidelines.\n",
            "    \n",
            "17478135.xml\n",
            "\n",
            "\n",
            "     Pyogenic granuloma - the quest for optimum treatment: audit of treatment of 408 cases.\n",
            "    \n",
            "14973979.xml\n",
            "\n",
            "\n",
            "     Screening for lung cancer.\n",
            "    \n",
            "7091901.xml\n",
            "\n",
            "\n",
            "     Chronic cough: bronchoscopy or pulmonary function testing?\n",
            "    \n",
            "11400894.xml\n",
            "\n",
            "\n",
            "     Shock wave therapy for chronic proximal plantar fasciitis.\n",
            "    \n",
            "1547164.xml\n",
            "\n",
            "\n",
            "     Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension?\n",
            "    \n",
            "11073017.xml\n",
            "\n",
            "\n",
            "     Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group.\n",
            "    \n",
            "15456116.xml\n",
            "\n",
            "\n",
            "     Management of normal pressure hydrocephalus.\n",
            "    \n",
            "11687043.xml\n",
            "\n",
            "\n",
            "     Statins for the reduction of risk of Alzheimer's disease.\n",
            "    \n",
            "15337640.xml\n",
            "\n",
            "\n",
            "     Antidepressants for bipolar depression: a systematic review of randomized, controlled trials.\n",
            "    \n",
            "15992389.xml\n",
            "\n",
            "\n",
            "     Bipolar disorder in women: reproductive events and treatment considerations.\n",
            "    \n",
            "15836465.xml\n",
            "\n",
            "\n",
            "     Rapid growth in infancy and childhood and obesity in later life--a systematic review.\n",
            "    \n",
            "9508226.xml\n",
            "\n",
            "\n",
            "     Reference values for self-recorded blood pressure: a meta-analysis of summary data.\n",
            "    \n",
            "11163477.xml\n",
            "\n",
            "\n",
            "     Surgical prevention of otitis media.\n",
            "    \n",
            "14731377.xml\n",
            "\n",
            "\n",
            "     What is the best imaging strategy for acute stroke?\n",
            "    \n",
            "15106175.xml\n",
            "\n",
            "\n",
            "     Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.\n",
            "    \n",
            "8681614.xml\n",
            "\n",
            "\n",
            "     Nasal-CPAP, surgery, and conservative management for treatment of obstructive sleep apnea syndrome. A randomized study.\n",
            "    \n",
            "1777556.xml\n",
            "\n",
            "\n",
            "     Prevalence of autoantibodies to thyroperoxidase in patients with various thyroid and autoimmune diseases.\n",
            "    \n",
            "7625417.xml\n",
            "\n",
            "\n",
            "     A community-wide outbreak of hepatitis A: risk factors for infection among homosexual and bisexual men.\n",
            "    \n",
            "1830233.xml\n",
            "\n",
            "\n",
            "     Physiotherapy exercises and back pain: a blinded review.\n",
            "    \n",
            "15276392.xml\n",
            "\n",
            "\n",
            "     Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.\n",
            "    \n",
            "8916634.xml\n",
            "\n",
            "\n",
            "     Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.\n",
            "    \n",
            "9563847.xml\n",
            "\n",
            "\n",
            "     Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention.\n",
            "    \n",
            "9841303.xml\n",
            "\n",
            "\n",
            "     Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.\n",
            "    \n",
            "8994481.xml\n",
            "\n",
            "\n",
            "     Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study.\n",
            "    \n",
            "10653361.xml\n",
            "\n",
            "\n",
            "     Internal derangements of the shoulder: decision tree and cost-effectiveness analysis of conventional arthrography, conventional MRI, and MR arthrography.\n",
            "    \n",
            "10200061.xml\n",
            "\n",
            "\n",
            "     Energy and nutrient status of amenorrheic athletes participating in a diet and exercise training intervention program.\n",
            "    \n",
            "10796824.xml\n",
            "\n",
            "\n",
            "     Tonsillectomy versus non-surgical treatment for chronic / recurrent acute tonsillitis.\n",
            "    \n",
            "9002103.xml\n",
            "\n",
            "\n",
            "     Identification of febrile neonates unlikely to have bacterial infections.\n",
            "    \n",
            "9382560.xml\n",
            "\n",
            "\n",
            "     Comparative safety of tetracycline, minocycline, and doxycycline.\n",
            "    \n",
            "10173095.xml\n",
            "\n",
            "\n",
            "     A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine.\n",
            "    \n",
            "1834868.xml\n",
            "\n",
            "\n",
            "     Diagnosing pelvic inflammatory disease. A comprehensive analysis and considerations for developing a new model.\n",
            "    \n",
            "9809732.xml\n",
            "\n",
            "\n",
            "     Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities.\n",
            "    \n",
            "11086269.xml\n",
            "\n",
            "\n",
            "     Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care.\n",
            "    \n",
            "8276736.xml\n",
            "\n",
            "\n",
            "     Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.\n",
            "    \n",
            "6851084.xml\n",
            "\n",
            "\n",
            "     Changes in serum myoglobin, total creatine kinase, lactate dehydrogenase and creatine kinase MB levels in runners.\n",
            "    \n",
            "11092281.xml\n",
            "\n",
            "\n",
            "     Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.\n",
            "    \n",
            "9786377.xml\n",
            "\n",
            "\n",
            "     The rational clinical examination. Is this patient having a myocardial infarction?\n",
            "    \n",
            "10494485.xml\n",
            "\n",
            "\n",
            "     Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.\n",
            "    \n",
            "8443307.xml\n",
            "\n",
            "\n",
            "     Pertussis in Missouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis.\n",
            "    \n",
            "11886900.xml\n",
            "\n",
            "\n",
            "     Evaluation of low-energy extracorporeal shock-wave application for treatment of chronic plantar fasciitis.\n",
            "    \n",
            "7968073.xml\n",
            "\n",
            "\n",
            "     Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)\n",
            "    \n",
            "15283004.xml\n",
            "\n",
            "\n",
            "     A clinical decision rule to prioritize polysomnography in patients with suspected sleep apnea.\n",
            "    \n",
            "8916990.xml\n",
            "\n",
            "\n",
            "     A prospective cohort study of oxytocin plus ergometrine compared with oxytocin alone for prevention of postpartum haemorrhage.\n",
            "    \n",
            "1973768.xml\n",
            "\n",
            "\n",
            "     Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre.\n",
            "    \n",
            "11903236.xml\n",
            "\n",
            "\n",
            "     Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial.\n",
            "    \n",
            "20556779.xml\n",
            "\n",
            "\n",
            "     Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions.\n",
            "    \n",
            "11151865.xml\n",
            "\n",
            "\n",
            "     The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.\n",
            "    \n",
            "1442682.xml\n",
            "\n",
            "\n",
            "     Optimal nonsurgical treatment of hemorrhoids: a comparative analysis of infrared coagulation, rubber band ligation, and injection sclerotherapy.\n",
            "    \n",
            "11576414.xml\n",
            "\n",
            "\n",
            "     Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children.\n",
            "    \n",
            "12137645.xml\n",
            "\n",
            "\n",
            "     Desmopressin for nocturnal enuresis in children.\n",
            "    \n",
            "14969506.xml\n",
            "\n",
            "\n",
            "     Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review.\n",
            "    \n",
            "11333990.xml\n",
            "\n",
            "\n",
            "     Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.\n",
            "    \n",
            "12860582.xml\n",
            "\n",
            "\n",
            "     The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial.\n",
            "    \n",
            "11180735.xml\n",
            "\n",
            "\n",
            "     Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.\n",
            "    \n",
            "8682668.xml\n",
            "\n",
            "\n",
            "     Maintenance of effects in the nonmedical treatment of headaches during pregnancy.\n",
            "    \n",
            "11099588.xml\n",
            "\n",
            "\n",
            "     Infantile colic: crying time reduction with a whey hydrolysate: A double-blind, randomized, placebo-controlled trial.\n",
            "    \n",
            "15039411.xml\n",
            "\n",
            "\n",
            "     Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial.\n",
            "    \n",
            "15096077.xml\n",
            "\n",
            "\n",
            "     Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.\n",
            "    \n",
            "11030795.xml\n",
            "\n",
            "\n",
            "     Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.\n",
            "    \n",
            "6101629.xml\n",
            "\n",
            "\n",
            "     Does dietary elimination in infancy prevent or only postpone a food allergy? A study of fish and citrus allergy in 375 children.\n",
            "    \n",
            "8155220.xml\n",
            "\n",
            "\n",
            "     Prevention of perineal trauma by perineal massage during pregnancy: a pilot study.\n",
            "    \n",
            "1447433.xml\n",
            "\n",
            "\n",
            "     High prevalence of cobalamin deficiency in elderly outpatients.\n",
            "    \n",
            "14613379.xml\n",
            "\n",
            "\n",
            "     Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: analysis of clinical effects, patient satisfaction, compliance, and cost avoidance.\n",
            "    \n",
            "11117910.xml\n",
            "\n",
            "\n",
            "     Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.\n",
            "    \n",
            "3512941.xml\n",
            "\n",
            "\n",
            "     Chronic cough in infants and children.\n",
            "    \n",
            "9077426.xml\n",
            "\n",
            "\n",
            "     Evaluation of six commercially available kits using purified heterophile antigen for the rapid diagnosis of infectious mononucleosis compared with Epstein-Barr virus-specific serology.\n",
            "    \n",
            "7936917.xml\n",
            "\n",
            "\n",
            "     Managing otitis media with effusion in young children. American Academy of Pediatrics The Otitis Media Guideline Panel.\n",
            "    \n",
            "11902986.xml\n",
            "\n",
            "\n",
            "     Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study.\n",
            "    \n",
            "2298897.xml\n",
            "\n",
            "\n",
            "     Natural history of Osgood-Schlatter disease.\n",
            "    \n",
            "649776.xml\n",
            "\n",
            "\n",
            "     High mean red cell volume: its incidence and significance in routine haematology.\n",
            "    \n",
            "17072963.xml\n",
            "\n",
            "\n",
            "     Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.\n",
            "    \n",
            "12821960.xml\n",
            "\n",
            "\n",
            "     The influence of birthweight and intrauterine environment on adiposity and fat distribution in later life.\n",
            "    \n",
            "10796112.xml\n",
            "\n",
            "\n",
            "     Dietary regulation for 'gestational diabetes'.\n",
            "    \n",
            "7667050.xml\n",
            "\n",
            "\n",
            "     Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.\n",
            "    \n",
            "11793113.xml\n",
            "\n",
            "\n",
            "     School urinalysis screening in Korea: prevalence of chronic renal disease.\n",
            "    \n",
            "9682041.xml\n",
            "\n",
            "\n",
            "     Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.\n",
            "    \n",
            "14732621.xml\n",
            "\n",
            "\n",
            "     Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.\n",
            "    \n",
            "11869639.xml\n",
            "\n",
            "\n",
            "     Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children.\n",
            "    \n",
            "11701099.xml\n",
            "\n",
            "\n",
            "     Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.\n",
            "    \n",
            "9146531.xml\n",
            "\n",
            "\n",
            "     Oral contraceptive failure rates and oral antibiotics.\n",
            "    \n",
            "17012266.xml\n",
            "\n",
            "\n",
            "     Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial.\n",
            "    \n",
            "1377359.xml\n",
            "\n",
            "\n",
            "     Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators.\n",
            "    \n",
            "11319580.xml\n",
            "\n",
            "\n",
            "     Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review.\n",
            "    \n",
            "10877038.xml\n",
            "\n",
            "\n",
            "     HMG-CoA reductase inhibitors and myotoxicity.\n",
            "    \n",
            "12177639.xml\n",
            "\n",
            "\n",
            "     C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study.\n",
            "    \n",
            "3515920.xml\n",
            "\n",
            "\n",
            "     Treatment of acute shoulder syndrome with flurbiprofen.\n",
            "    \n",
            "15699227.xml\n",
            "\n",
            "\n",
            "     Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile.\n",
            "    \n",
            "10853852.xml\n",
            "\n",
            "\n",
            "     Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.\n",
            "    \n",
            "8880507.xml\n",
            "\n",
            "\n",
            "     Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis.\n",
            "    \n",
            "8607590.xml\n",
            "\n",
            "\n",
            "     The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis.\n",
            "    \n",
            "10445069.xml\n",
            "\n",
            "\n",
            "     A prospective randomized study of a dental appliance compared with uvulopalatopharyngoplasty in the treatment of obstructive sleep apnoea.\n",
            "    \n",
            "8458042.xml\n",
            "\n",
            "\n",
            "     Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia.\n",
            "    \n",
            "7972972.xml\n",
            "\n",
            "\n",
            "     High-dose nedocromil sodium as an addition to inhaled corticosteroids in the treatment of asthma.\n",
            "    \n",
            "12234230.xml\n",
            "\n",
            "\n",
            "     Ultrasound-guided extracorporeal shock wave therapy for plantar fasciitis: a randomized controlled trial.\n",
            "    \n",
            "15039276.xml\n",
            "\n",
            "\n",
            "     Corticosteroid injections for osteoarthritis of the knee: meta-analysis.\n",
            "    \n",
            "11266478.xml\n",
            "\n",
            "\n",
            "     Mechanical treatment of plantar fasciitis. A prospective study.\n",
            "    \n",
            "12383547.xml\n",
            "\n",
            "\n",
            "     Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina.\n",
            "    \n",
            "12548270.xml\n",
            "\n",
            "\n",
            "     Utility of the peripheral blood white blood cell count for identifying sick young infants who need lumbar puncture.\n",
            "    \n",
            "8257472.xml\n",
            "\n",
            "\n",
            "     Effect of early amniotomy on the risk of dystocia in nulliparous women. The Canadian Early Amniotomy Study Group.\n",
            "    \n",
            "15479678.xml\n",
            "\n",
            "\n",
            "     PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial.\n",
            "    \n",
            "16252313.xml\n",
            "\n",
            "\n",
            "     Systematic review of randomized trials comparing rubber band ligation with excisional haemorrhoidectomy.\n",
            "    \n",
            "11401736.xml\n",
            "\n",
            "\n",
            "     Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.\n",
            "    \n",
            "7998664.xml\n",
            "\n",
            "\n",
            "     Budesonide and terfenadine, separately and in combination, in the treatment of hay fever.\n",
            "    \n",
            "7848421.xml\n",
            "\n",
            "\n",
            "     Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample.\n",
            "    \n",
            "15266527.xml\n",
            "\n",
            "\n",
            "     Interventions for smokeless tobacco use cessation.\n",
            "    \n",
            "15345498.xml\n",
            "\n",
            "\n",
            "     Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.\n",
            "    \n",
            "10437125.xml\n",
            "\n",
            "\n",
            "     Drug dependence and abuse potential of tramadol.\n",
            "    \n",
            "15056029.xml\n",
            "\n",
            "\n",
            "     Stent-supported angioplasty of severe atherosclerotic renal artery stenosis preserves renal function and improves blood pressure control: long-term results from a prospective registry of 456 lesions.\n",
            "    \n",
            "2631530.xml\n",
            "\n",
            "\n",
            "     Serum CA 125 levels in patients with a provisional diagnosis of pelvic inflammatory disease. Clinical and theoretical implications.\n",
            "    \n",
            "8913977.xml\n",
            "\n",
            "\n",
            "     Safety, efficacy and cost of three cervical cytology sampling devices in a prenatal clinic.\n",
            "    \n",
            "15383478.xml\n",
            "\n",
            "\n",
            "     Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.\n",
            "    \n",
            "8364819.xml\n",
            "\n",
            "\n",
            "     Prevalence of and risk factors for sudden infant death syndrome in Canada.\n",
            "    \n",
            "16898898.xml\n",
            "\n",
            "\n",
            "     Cryotherapy in the treatment of pyogenic granuloma.\n",
            "    \n",
            "10875559.xml\n",
            "\n",
            "\n",
            "     Systematic review and meta-analysis of the literature regarding the diagnosis of sleep apnea.\n",
            "    \n",
            "15314625.xml\n",
            "\n",
            "\n",
            "     Breast-feeding and childhood obesity--a systematic review.\n",
            "    \n",
            "11772681.xml\n",
            "\n",
            "\n",
            "     Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia.\n",
            "    \n",
            "12672170.xml\n",
            "\n",
            "\n",
            "     Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder.\n",
            "    \n",
            "16895257.xml\n",
            "\n",
            "\n",
            "     Physical examination: Mallampati score as an independent predictor of obstructive sleep apnea.\n",
            "    \n",
            "8847720.xml\n",
            "\n",
            "\n",
            "     Screening for cutaneous melanoma by skin self-examination.\n",
            "    \n",
            "1535108.xml\n",
            "\n",
            "\n",
            "     Comparison of different metronidazole therapeutic regimens for bacterial vaginosis. A meta-analysis.\n",
            "    \n",
            "9491092.xml\n",
            "\n",
            "\n",
            "     A stepwise approach to evaluation of undernutrition and failure to thrive.\n",
            "    \n",
            "1547173.xml\n",
            "\n",
            "\n",
            "     Randomized trial of amniotomy in labour versus the intention to leave membranes intact until the second stage.\n",
            "    \n",
            "11136260.xml\n",
            "\n",
            "\n",
            "     Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.\n",
            "    \n",
            "16206501.xml\n",
            "\n",
            "\n",
            "     Low-dose gluten challenge in celiac sprue: malabsorptive and antibody responses.\n",
            "    \n",
            "14653589.xml\n",
            "\n",
            "\n",
            "     The influence of immediate surgical treatment of proximal femoral fractures on mortality and quality of life. Operation within six hours of the fracture versus later than six hours.\n",
            "    \n",
            "14718013.xml\n",
            "\n",
            "\n",
            "     Combined diagnostic approach of laparoscopy and hysteroscopy in the evaluation of female infertility: results of 612 patients.\n",
            "    \n",
            "12137717.xml\n",
            "\n",
            "\n",
            "     Cow's milk protein avoidance and development of childhood wheeze in children with a family history of atopy.\n",
            "    \n",
            "16235323.xml\n",
            "\n",
            "\n",
            "     Bed rest with or without hospitalisation for hypertension during pregnancy.\n",
            "    \n",
            "9738178.xml\n",
            "\n",
            "\n",
            "     Trial on timing of introduction to solids and food type on infant growth.\n",
            "    \n",
            "10195491.xml\n",
            "\n",
            "\n",
            "     Can noncontrast helical computed tomography replace intravenous urography for evaluation of patients with acute urinary tract colic?\n",
            "    \n",
            "11064964.xml\n",
            "\n",
            "\n",
            "     Behavior problems and group-based parent education programs.\n",
            "    \n",
            "11847951.xml\n",
            "\n",
            "\n",
            "     FDA adverse event reports on statin-associated rhabdomyolysis.\n",
            "    \n",
            "12411359.xml\n",
            "\n",
            "\n",
            "     Used infant mattresses and sudden infant death syndrome in Scotland: case-control study.\n",
            "    \n",
            "10505584.xml\n",
            "\n",
            "\n",
            "     Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.\n",
            "    \n",
            "16585303.xml\n",
            "\n",
            "\n",
            "     Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters?\n",
            "    \n",
            "10887228.xml\n",
            "\n",
            "\n",
            "     Inferior vena caval filters: review of a 26-year single-center clinical experience.\n",
            "    \n",
            "11212161.xml\n",
            "\n",
            "\n",
            "     Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.\n",
            "    \n",
            "15030339.xml\n",
            "\n",
            "\n",
            "     Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.\n",
            "    \n",
            "2860740.xml\n",
            "\n",
            "\n",
            "     Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group.\n",
            "    \n",
            "8284003.xml\n",
            "\n",
            "\n",
            "     The bone density of female twins discordant for tobacco use.\n",
            "    \n",
            "12804443.xml\n",
            "\n",
            "\n",
            "     Alarm interventions for nocturnal enuresis in children.\n",
            "    \n",
            "10553790.xml\n",
            "\n",
            "\n",
            "     Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments.\n",
            "    \n",
            "16280426.xml\n",
            "\n",
            "\n",
            "     The Medi-RIVAGE study: reduction of cardiovascular disease risk factors after a 3-mo intervention with a Mediterranean-type diet or a low-fat diet.\n",
            "    \n",
            "16006474.xml\n",
            "\n",
            "\n",
            "     Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries.\n",
            "    \n",
            "7799040.xml\n",
            "\n",
            "\n",
            "     Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation.\n",
            "    \n",
            "7103152.xml\n",
            "\n",
            "\n",
            "     Treatment of persistent eustachian tube dysfunction in children with aerosolized nasal dexamethasone phosphate versus placebo.\n",
            "    \n",
            "10794582.xml\n",
            "\n",
            "\n",
            "     Acute otitis media: part II. Treatment in an era of increasing antibiotic resistance.\n",
            "    \n",
            "11570113.xml\n",
            "\n",
            "\n",
            "     Exercise electrocardiogram testing and prognosis. Novel markers and predictive instruments.\n",
            "    \n",
            "6243391.xml\n",
            "\n",
            "\n",
            "     Sexual transmission of hepatitis A in homosexual men: incidence and mechanism.\n",
            "    \n",
            "9288011.xml\n",
            "\n",
            "\n",
            "     Criteria for enrolling dementia patients in hospice.\n",
            "    \n",
            "7797786.xml\n",
            "\n",
            "\n",
            "     The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance.\n",
            "    \n",
            "15900004.xml\n",
            "\n",
            "\n",
            "     Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease.\n",
            "    \n",
            "11147613.xml\n",
            "\n",
            "\n",
            "     Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment.\n",
            "    \n",
            "3681544.xml\n",
            "\n",
            "\n",
            "     Consequences of starting whole cow milk at 6 months of age.\n",
            "    \n",
            "2221649.xml\n",
            "\n",
            "\n",
            "     Exercise thallium-201 scintigraphy in the diagnosis and prognosis of coronary artery disease.\n",
            "    \n",
            "11279782.xml\n",
            "\n",
            "\n",
            "     Glucosamine therapy for treating osteoarthritis.\n",
            "    \n",
            "8119027.xml\n",
            "\n",
            "\n",
            "     Jones fracture. Surgical versus nonsurgical treatment.\n",
            "    \n",
            "12875251.xml\n",
            "\n",
            "\n",
            "     Incorporating HIV prevention into the medical care of persons living with HIV.      Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.\n",
            "    \n",
            "15483524.xml\n",
            "\n",
            "\n",
            "     Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.\n",
            "    \n",
            "15122593.xml\n",
            "\n",
            "\n",
            "     High fat and alcohol intakes are risk factors of postmenopausal breast cancer: a prospective study from the Malm diet and cancer cohort.\n",
            "    \n",
            "7914611.xml\n",
            "\n",
            "\n",
            "     Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)\n",
            "    \n",
            "10591283.xml\n",
            "\n",
            "\n",
            "     A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.\n",
            "    \n",
            "8201735.xml\n",
            "\n",
            "\n",
            "     A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.\n",
            "    \n",
            "1959720.xml\n",
            "\n",
            "\n",
            "     Symptomatic effect of inhaled fenoterol in acute bronchitis: a placebo-controlled double-blind study.\n",
            "    \n",
            "11126304.xml\n",
            "\n",
            "\n",
            "     Is screening mammography effective in elderly women?\n",
            "    \n",
            "11054899.xml\n",
            "\n",
            "\n",
            "     US public health service clinical practice guideline: treating tobacco use and dependence.\n",
            "    \n",
            "14530229.xml\n",
            "\n",
            "\n",
            "     Evaluation of acute knee pain in primary care.\n",
            "    \n",
            "12235640.xml\n",
            "\n",
            "\n",
            "     Fat and protein intake and subsequent breast cancer risk in postmenopausal women.\n",
            "    \n",
            "14676536.xml\n",
            "\n",
            "\n",
            "     Treatment for idiopathic toe-walking: results at skeletal maturity.\n",
            "    \n",
            "14993084.xml\n",
            "\n",
            "\n",
            "     Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial.\n",
            "    \n",
            "8942775.xml\n",
            "\n",
            "\n",
            "     Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.\n",
            "    \n",
            "13130084.xml\n",
            "\n",
            "\n",
            "     Satisfaction with onychomycosis treatment. Pulse versus continuous dosing.\n",
            "    \n",
            "10908513.xml\n",
            "\n",
            "\n",
            "     Opioid antagonists for alcohol dependence.\n",
            "    \n",
            "9680042.xml\n",
            "\n",
            "\n",
            "     Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review.\n",
            "    \n",
            "15605687.xml\n",
            "\n",
            "\n",
            "     Urinary tract infection in men.\n",
            "    \n",
            "12164990.xml\n",
            "\n",
            "\n",
            "     The effect of medicated chewing gums on oral health in frail older people: a 1-year clinical trial.\n",
            "    \n",
            "8900088.xml\n",
            "\n",
            "\n",
            "     Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease.\n",
            "    \n",
            "16085790.xml\n",
            "\n",
            "\n",
            "     Subjective memory complaints with and without objective memory impairment: relationship with risk factors for dementia.\n",
            "    \n",
            "12269676.xml\n",
            "\n",
            "\n",
            "     Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series.\n",
            "    \n",
            "15575803.xml\n",
            "\n",
            "\n",
            "     Cognitive-behavioral approaches to the treatment of insomnia.\n",
            "    \n",
            "11329407.xml\n",
            "\n",
            "\n",
            "     Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study.\n",
            "    \n",
            "10485679.xml\n",
            "\n",
            "\n",
            "     Adenoidectomy and adenotonsillectomy for recurrent acute otitis media: parallel randomized clinical trials in children not previously treated with tympanostomy tubes.\n",
            "    \n",
            "2890951.xml\n",
            "\n",
            "\n",
            "     The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group.\n",
            "    \n",
            "11229451.xml\n",
            "\n",
            "\n",
            "     Strategies for the treatment of antidepressant-related sexual dysfunction.\n",
            "    \n",
            "11927715.xml\n",
            "\n",
            "\n",
            "     Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis.\n",
            "    \n",
            "12618157.xml\n",
            "\n",
            "\n",
            "     Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.\n",
            "    \n",
            "16235299.xml\n",
            "\n",
            "\n",
            "     Dietary advice for reducing cardiovascular risk.\n",
            "    \n",
            "7641412.xml\n",
            "\n",
            "\n",
            "     The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.\n",
            "    \n",
            "15383479.xml\n",
            "\n",
            "\n",
            "     Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.\n",
            "    \n",
            "15110490.xml\n",
            "\n",
            "\n",
            "     Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.\n",
            "    \n",
            "15846645.xml\n",
            "\n",
            "\n",
            "     Glucosamine therapy for treating osteoarthritis.\n",
            "    \n",
            "12861153.xml\n",
            "\n",
            "\n",
            "     Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis.\n",
            "    \n",
            "12228781.xml\n",
            "\n",
            "\n",
            "     High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease.\n",
            "    \n",
            "9169398.xml\n",
            "\n",
            "\n",
            "     Case-control study of sudden infant death syndrome in Scotland, 1992-5.\n",
            "    \n",
            "15495008.xml\n",
            "\n",
            "\n",
            "     Psychosocial and psychological interventions for preventing postpartum depression.\n",
            "    \n",
            "11869595.xml\n",
            "\n",
            "\n",
            "     Nedocromil sodium for preventing exercise-induced bronchoconstriction.\n",
            "    \n",
            "15602109.xml\n",
            "\n",
            "\n",
            "     Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.\n",
            "    \n",
            "7908358.xml\n",
            "\n",
            "\n",
            "     Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.\n",
            "    \n",
            "9323067.xml\n",
            "\n",
            "\n",
            "     Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study.\n",
            "    \n",
            "10366137.xml\n",
            "\n",
            "\n",
            "     Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP).\n",
            "    \n",
            "2099731.xml\n",
            "\n",
            "\n",
            "     Is mucaine an appropriate medication for the relief of heartburn during pregnancy?\n",
            "    \n",
            "11133566.xml\n",
            "\n",
            "\n",
            "     The solitary pulmonary nodule on chest radiography: can we really tell if the nodule is calcified?\n",
            "    \n",
            "18271889.xml\n",
            "\n",
            "\n",
            "     Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial.\n",
            "    \n",
            "8629648.xml\n",
            "\n",
            "\n",
            "     Intensity of murmurs correlates with severity of valvular regurgitation.\n",
            "    \n",
            "15508538.xml\n",
            "\n",
            "\n",
            "     Epstein-Barr virus infectious mononucleosis.\n",
            "    \n",
            "15106262.xml\n",
            "\n",
            "\n",
            "     Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings.\n",
            "    \n",
            "10084572.xml\n",
            "\n",
            "\n",
            "     Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism.\n",
            "    \n",
            "16034962.xml\n",
            "\n",
            "\n",
            "     Screening for amblyopia in childhood.\n",
            "    \n",
            "14578227.xml\n",
            "\n",
            "\n",
            "     Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.\n",
            "    \n",
            "8667563.xml\n",
            "\n",
            "\n",
            "     Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles.\n",
            "    \n",
            "10543657.xml\n",
            "\n",
            "\n",
            "     Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP).\n",
            "    \n",
            "15374846.xml\n",
            "\n",
            "\n",
            "     Loss of bone density with inhaled triamcinolone in Lung Health Study II.\n",
            "    \n",
            "16263986.xml\n",
            "\n",
            "\n",
            "     Effect of a low-allergen maternal diet on colic among breastfed infants: a randomized, controlled trial.\n",
            "    \n",
            "8967711.xml\n",
            "\n",
            "\n",
            "     Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment.\n",
            "    \n",
            "11192132.xml\n",
            "\n",
            "\n",
            "     Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.\n",
            "    \n",
            "7574120.xml\n",
            "\n",
            "\n",
            "     Derivation of a decision rule for the use of radiography in acute knee injuries.\n",
            "    \n",
            "10024120.xml\n",
            "\n",
            "\n",
            "     Recurrence and care seeking after acute back pain: results of a long-term follow-up study. North Carolina Back Pain Project.\n",
            "    \n",
            "8981292.xml\n",
            "\n",
            "\n",
            "     European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.\n",
            "    \n",
            "9364387.xml\n",
            "\n",
            "\n",
            "     The kinematic patterns of toe-walkers.\n",
            "    \n",
            "1331788.xml\n",
            "\n",
            "\n",
            "     Vitamin D3 and calcium to prevent hip fractures in the elderly women.\n",
            "    \n",
            "14973944.xml\n",
            "\n",
            "\n",
            "     Acupuncture for chronic asthma.\n",
            "    \n",
            "2381171.xml\n",
            "\n",
            "\n",
            "     Microscopic haematuria as a predictor of urological diseases among steel workers.\n",
            "    \n",
            "18196670.xml\n",
            "\n",
            "\n",
            "     Dental considerations for the treatment of patients with diabetes mellitus.\n",
            "    \n",
            "9583895.xml\n",
            "\n",
            "\n",
            "     The absolute neutrophil count: is it the best indicator for occult bacteremia in infants?\n",
            "    \n",
            "11734712.xml\n",
            "\n",
            "\n",
            "     Use of purified protein derivative to assess the risk of infection in children in close contact with adults with tuberculosis in a population with high Calmette-Gurin bacillus coverage.\n",
            "    \n",
            "12236627.xml\n",
            "\n",
            "\n",
            "     Fluoxetine treatment of depressed patients with comorbid anxiety disorders.\n",
            "    \n",
            "1408225.xml\n",
            "\n",
            "\n",
            "     The canalith repositioning procedure: for treatment of benign paroxysmal positional vertigo.\n",
            "    \n",
            "11172164.xml\n",
            "\n",
            "\n",
            "     Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.\n",
            "    \n",
            "7622804.xml\n",
            "\n",
            "\n",
            "     Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis.\n",
            "    \n",
            "3043548.xml\n",
            "\n",
            "\n",
            "     The bird's nest inferior vena cava filter: progress report.\n",
            "    \n",
            "16013891.xml\n",
            "\n",
            "\n",
            "     Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.\n",
            "    \n",
            "9523961.xml\n",
            "\n",
            "\n",
            "     Injection accuracy and clinical relief of de Quervain's tendinitis.\n",
            "    \n",
            "11084175.xml\n",
            "\n",
            "\n",
            "     Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding.\n",
            "    \n",
            "10571972.xml\n",
            "\n",
            "\n",
            "     Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardial perfusion defects on radionuclide imaging.\n",
            "    \n",
            "12954519.xml\n",
            "\n",
            "\n",
            "     A multicenter, randomized study of an extended cycle oral contraceptive.\n",
            "    \n",
            "10818662.xml\n",
            "\n",
            "\n",
            "     Should sexual partners of women with bacterial vaginosis receive treatment?\n",
            "    \n",
            "11029681.xml\n",
            "\n",
            "\n",
            "     Treatment of fibromyalgia with antidepressants: a meta-analysis.\n",
            "    \n",
            "14973971.xml\n",
            "\n",
            "\n",
            "     Beta2-agonists for acute bronchitis.\n",
            "    \n",
            "12527566.xml\n",
            "\n",
            "\n",
            "     Screening for lung cancer: a review of the current literature.\n",
            "    \n",
            "11113230.xml\n",
            "\n",
            "\n",
            "     The value of informant versus individual's complaints of memory impairment in early dementia.\n",
            "    \n",
            "9732337.xml\n",
            "\n",
            "\n",
            "     Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.\n",
            "    \n",
            "11793114.xml\n",
            "\n",
            "\n",
            "     Circumcision for the prevention of significant bacteriuria in boys.\n",
            "    \n",
            "12897303.xml\n",
            "\n",
            "\n",
            "     Prevention of pediatric overweight and obesity.\n",
            "    \n",
            "11687056.xml\n",
            "\n",
            "\n",
            "     Eletriptan for acute migraine.\n",
            "    \n",
            "14678921.xml\n",
            "\n",
            "\n",
            "     Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians.\n",
            "    \n",
            "1519858.xml\n",
            "\n",
            "\n",
            "     Factors associated with tuberculin reactivity among the foreign-born in Montreal.\n",
            "    \n",
            "15059788.xml\n",
            "\n",
            "\n",
            "     Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens.\n",
            "    \n",
            "12519601.xml\n",
            "\n",
            "\n",
            "     Deep transverse friction massage for treating tendinitis.\n",
            "    \n",
            "12069675.xml\n",
            "\n",
            "\n",
            "     Vitamins for chronic disease prevention in adults: scientific review.\n",
            "    \n",
            "7847285.xml\n",
            "\n",
            "\n",
            "     Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?\n",
            "    \n",
            "17443523.xml\n",
            "\n",
            "\n",
            "     Ginkgo biloba for cognitive impairment and dementia.\n",
            "    \n",
            "15550129.xml\n",
            "\n",
            "\n",
            "     Self-detected cutaneous melanomas in Italian patients.\n",
            "    \n",
            "12427050.xml\n",
            "\n",
            "\n",
            "     Dietary recommendations and athletic menstrual dysfunction.\n",
            "    \n",
            "8600478.xml\n",
            "\n",
            "\n",
            "     Nonpharmacological management of headaches during pregnancy.\n",
            "    \n",
            "9563431.xml\n",
            "\n",
            "\n",
            "     Anemia and red cell distribution width at the 12-month well-baby examination.\n",
            "    \n",
            "15467530.xml\n",
            "\n",
            "\n",
            "     A practical approach to the diagnosis of polycystic ovary syndrome.\n",
            "    \n",
            "11027739.xml\n",
            "\n",
            "\n",
            "     Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group.\n",
            "    \n",
            "9569395.xml\n",
            "\n",
            "\n",
            "     Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration.\n",
            "    \n",
            "8199076.xml\n",
            "\n",
            "\n",
            "     A multicentre randomised trial of amniotomy in spontaneous first labour at term. The UK Amniotomy Group.\n",
            "    \n",
            "14567906.xml\n",
            "\n",
            "\n",
            "     The effectiveness of diagnostic tests for the assessment of shoulder pain due to soft tissue disorders: a systematic review.\n",
            "    \n",
            "11335807.xml\n",
            "\n",
            "\n",
            "     Breast implants and cancer: causation, delayed detection, and survival.\n",
            "    \n",
            "10383366.xml\n",
            "\n",
            "\n",
            "     Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States.\n",
            "    \n",
            "16009794.xml\n",
            "\n",
            "\n",
            "     Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study.\n",
            "    \n",
            "15266549.xml\n",
            "\n",
            "\n",
            "     Effect of longer-term modest salt reduction on blood pressure.\n",
            "    \n",
            "10699138.xml\n",
            "\n",
            "\n",
            "     The highly protective effect of newborn circumcision against invasive penile cancer.\n",
            "    \n",
            "9112711.xml\n",
            "\n",
            "\n",
            "     Exercises: which ones are worth trying, for which patients, and when?\n",
            "    \n",
            "1615986.xml\n",
            "\n",
            "\n",
            "     Cervical cytology: a randomized comparison of four sampling methods.\n",
            "    \n",
            "9563990.xml\n",
            "\n",
            "\n",
            "     Outcome of low back pain in general practice: a prospective study.\n",
            "    \n",
            "2328431.xml\n",
            "\n",
            "\n",
            "     Clinical management of orbital cellulitis in children.\n",
            "    \n",
            "11952542.xml\n",
            "\n",
            "\n",
            "     Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial.\n",
            "    \n",
            "14578243.xml\n",
            "\n",
            "\n",
            "     The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.\n",
            "    \n",
            "10903648.xml\n",
            "\n",
            "\n",
            "     Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.\n",
            "    \n",
            "16554526.xml\n",
            "\n",
            "\n",
            "     Medication augmentation after the failure of SSRIs for depression.\n",
            "    \n",
            "12917936.xml\n",
            "\n",
            "\n",
            "     Oral sumatriptan for acute migraine.\n",
            "    \n",
            "1922532.xml\n",
            "\n",
            "\n",
            "     [The spontaneous course of otitis media with effusion in young children].\n",
            "    \n",
            "10644272.xml\n",
            "\n",
            "\n",
            "     Hepatic failure in a patient taking rosiglitazone.\n",
            "    \n",
            "14665658.xml\n",
            "\n",
            "\n",
            "     Trends in pertussis among infants in the United States, 1980-1999.\n",
            "    \n",
            "14583769.xml\n",
            "\n",
            "\n",
            "     Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature.\n",
            "    \n",
            "8439114.xml\n",
            "\n",
            "\n",
            "     Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes.\n",
            "    \n",
            "15531002.xml\n",
            "\n",
            "\n",
            "     Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.\n",
            "    \n",
            "2801193.xml\n",
            "\n",
            "\n",
            "     Macrocytosis as an indicator of human disease.\n",
            "    \n",
            "1771153.xml\n",
            "\n",
            "\n",
            "     Electroconvulsive therapy in the treatment-resistant patient.\n",
            "    \n",
            "11431132.xml\n",
            "\n",
            "\n",
            "     The effects of intense exercise on the female reproductive system.\n",
            "    \n",
            "15294856.xml\n",
            "\n",
            "\n",
            "     Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery.\n",
            "    \n",
            "14993586.xml\n",
            "\n",
            "\n",
            "     Fiber (glucomannan) is beneficial in the treatment of childhood constipation.\n",
            "    \n",
            "10796792.xml\n",
            "\n",
            "\n",
            "     Topical treatments for fungal infections of the skin and nails of the foot.\n",
            "    \n",
            "3520319.xml\n",
            "\n",
            "\n",
            "     Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis.\n",
            "    \n",
            "11508256.xml\n",
            "\n",
            "\n",
            "     ACOG Practice Bulletin. Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins.\n",
            "    \n",
            "3133668.xml\n",
            "\n",
            "\n",
            "     Comparison of three treatment procedures for minimizing ankle sprain swelling.\n",
            "    \n",
            "16160424.xml\n",
            "\n",
            "\n",
            "     Development of guidelines for idiopathic normal-pressure hydrocephalus: introduction.\n",
            "    \n",
            "17495203.xml\n",
            "\n",
            "\n",
            "     Weight gain prevention among women.\n",
            "    \n",
            "12137713.xml\n",
            "\n",
            "\n",
            "     Exercise for treating fibromyalgia syndrome.\n",
            "    \n",
            "2761587.xml\n",
            "\n",
            "\n",
            "     A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.\n",
            "    \n",
            "10759060.xml\n",
            "\n",
            "\n",
            "     Hormonal replacement regimens and bleeding.\n",
            "    \n",
            "3889257.xml\n",
            "\n",
            "\n",
            "     Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci.\n",
            "    \n",
            "11790216.xml\n",
            "\n",
            "\n",
            "     Oral antihyperglycemic therapy for type 2 diabetes: scientific review.\n",
            "    \n",
            "16235372.xml\n",
            "\n",
            "\n",
            "     Laxatives for the treatment of hemorrhoids.\n",
            "    \n",
            "14506119.xml\n",
            "\n",
            "\n",
            "     Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study.\n",
            "    \n",
            "15550401.xml\n",
            "\n",
            "\n",
            "     Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials.\n",
            "    \n",
            "10634823.xml\n",
            "\n",
            "\n",
            "     Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers.\n",
            "    \n",
            "12370455.xml\n",
            "\n",
            "\n",
            "     Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial.\n",
            "    \n",
            "16235297.xml\n",
            "\n",
            "\n",
            "     Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.\n",
            "    \n",
            "16050454.xml\n",
            "\n",
            "\n",
            "     Diagnosis of lyme disease.\n",
            "    \n",
            "11219227.xml\n",
            "\n",
            "\n",
            "     Hypomagnesemic disorders.\n",
            "    \n",
            "12242171.xml\n",
            "\n",
            "\n",
            "     Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.\n",
            "    \n",
            "14609883.xml\n",
            "\n",
            "\n",
            "     Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.\n",
            "    \n",
            "11279767.xml\n",
            "\n",
            "\n",
            "     Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).\n",
            "    \n",
            "11886019.xml\n",
            "\n",
            "\n",
            "     Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.\n",
            "    \n",
            "9182472.xml\n",
            "\n",
            "\n",
            "     Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.\n",
            "    \n",
            "14754562.xml\n",
            "\n",
            "\n",
            "     Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care.\n",
            "    \n",
            "14744823.xml\n",
            "\n",
            "\n",
            "     Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services.\n",
            "    \n",
            "8634613.xml\n",
            "\n",
            "\n",
            "     Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.\n",
            "    \n",
            "15692973.xml\n",
            "\n",
            "\n",
            "     Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).\n",
            "    \n",
            "16021069.xml\n",
            "\n",
            "\n",
            "     Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization.\n",
            "    \n",
            "1683420.xml\n",
            "\n",
            "\n",
            "     Prevention of ultraviolet-light-induced herpes labialis by sunscreen.\n",
            "    \n",
            "12648310.xml\n",
            "\n",
            "\n",
            "     Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease.\n",
            "    \n",
            "16848844.xml\n",
            "\n",
            "\n",
            "     Diagnosis, treatment, and management of breast cancer in previously augmented women.\n",
            "    \n",
            "15495039.xml\n",
            "\n",
            "\n",
            "     Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.\n",
            "    \n",
            "12562057.xml\n",
            "\n",
            "\n",
            "     Novel treatments for attention-deficit/hyperactivity disorder in children.\n",
            "    \n",
            "12187404.xml\n",
            "\n",
            "\n",
            "     Does using the Internet facilitate the maintenance of weight loss?\n",
            "    \n",
            "12941675.xml\n",
            "\n",
            "\n",
            "     Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.\n",
            "    \n",
            "8442808.xml\n",
            "\n",
            "\n",
            "     Cytobrush versus swab endocervical sampling for the detection of obstetric chlamydial infection.\n",
            "    \n",
            "14604738.xml\n",
            "\n",
            "\n",
            "     Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor.\n",
            "    \n",
            "12137655.xml\n",
            "\n",
            "\n",
            "     Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.\n",
            "    \n",
            "11463010.xml\n",
            "\n",
            "\n",
            "     Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.\n",
            "    \n",
            "10907384.xml\n",
            "\n",
            "\n",
            "     The canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo: a randomized controlled trial.\n",
            "    \n",
            "12586995.xml\n",
            "\n",
            "\n",
            "     Early determinants of childhood overweight and adiposity in a birth cohort study: role of breast-feeding.\n",
            "    \n",
            "15187057.xml\n",
            "\n",
            "\n",
            "     Is this child dehydrated?\n",
            "    \n",
            "11281473.xml\n",
            "\n",
            "\n",
            "     Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception.\n",
            "    \n",
            "9934946.xml\n",
            "\n",
            "\n",
            "     Effects of SSRIs on sexual function: a critical review.\n",
            "    \n",
            "1830566.xml\n",
            "\n",
            "\n",
            "     Propranolol in the management of recurrent migraine: a meta-analytic review.\n",
            "    \n",
            "8896509.xml\n",
            "\n",
            "\n",
            "     Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections.\n",
            "    \n",
            "3318377.xml\n",
            "\n",
            "\n",
            "     High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial.\n",
            "    \n",
            "1444726.xml\n",
            "\n",
            "\n",
            "     Naltrexone and coping skills therapy for alcohol dependence. A controlled study.\n",
            "    \n",
            "11919097.xml\n",
            "\n",
            "\n",
            "     Family and parenting interventions for conduct disorder and delinquency: a meta-analysis of randomised controlled trials.\n",
            "    \n",
            "16336072.xml\n",
            "\n",
            "\n",
            "     Self-weighing in weight gain prevention and weight loss trials.\n",
            "    \n",
            "3969339.xml\n",
            "\n",
            "\n",
            "     Lack of adverse side effects of oral ferrous sulfate therapy in 1-year-old infants.\n",
            "    \n",
            "11753181.xml\n",
            "\n",
            "\n",
            "     Applicability of Ottawa knee rule for knee injury in children.\n",
            "    \n",
            "2201741.xml\n",
            "\n",
            "\n",
            "     Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta.\n",
            "    \n",
            "14871318.xml\n",
            "\n",
            "\n",
            "     Pyogenic granuloma in children.\n",
            "    \n",
            "15825125.xml\n",
            "\n",
            "\n",
            "     The diagnostic accuracy of serologic tests for celiac disease: a systematic review.\n",
            "    \n",
            "3669164.xml\n",
            "\n",
            "\n",
            "     The evaluation of microscopic hematuria: a population-based study.\n",
            "    \n",
            "12119991.xml\n",
            "\n",
            "\n",
            "     Does physical activity prevent weight gain--a systematic review.\n",
            "    \n",
            "11083348.xml\n",
            "\n",
            "\n",
            "     The effect of exercise on percentile rank aerobic capacity, pain, and self-rated disability in patients with chronic low-back pain: a retrospective chart review.\n",
            "    \n",
            "9158469.xml\n",
            "\n",
            "\n",
            "     Comparison of physiotherapy, manipulation, and corticosteroid injection for treating shoulder complaints in general practice: randomised, single blind study.\n",
            "    \n",
            "11465699.xml\n",
            "\n",
            "\n",
            "     Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.\n",
            "    \n",
            "10807619.xml\n",
            "\n",
            "\n",
            "     Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.\n",
            "    \n",
            "11331055.xml\n",
            "\n",
            "\n",
            "     Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS).\n",
            "    \n",
            "15721970.xml\n",
            "\n",
            "\n",
            "     Promoting physical activity in Australian general practices: a randomised trial of health promotion advice versus hypertension management.\n",
            "    \n",
            "11034750.xml\n",
            "\n",
            "\n",
            "     Nedocromil sodium vs. sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics.\n",
            "    \n",
            "9361646.xml\n",
            "\n",
            "\n",
            "     Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.\n",
            "    \n",
            "2329430.xml\n",
            "\n",
            "\n",
            "     Influence of early feeding style on adiposity at 6 years of age.\n",
            "    \n",
            "11565517.xml\n",
            "\n",
            "\n",
            "     Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.\n",
            "    \n",
            "11900496.xml\n",
            "\n",
            "\n",
            "     J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data.\n",
            "    \n",
            "17493754.xml\n",
            "\n",
            "\n",
            "     Development and validation of the Current Opioid Misuse Measure.\n",
            "    \n",
            "11391331.xml\n",
            "\n",
            "\n",
            "     Antibiotics for the prevention of urinary tract infection in children: A systematic review of randomized controlled trials.\n",
            "    \n",
            "16391215.xml\n",
            "\n",
            "\n",
            "     Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial.\n",
            "    \n",
            "12230356.xml\n",
            "\n",
            "\n",
            "     Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force.\n",
            "    \n",
            "17341709.xml\n",
            "\n",
            "\n",
            "     Computed tomography screening and lung cancer outcomes.\n",
            "    \n",
            "18376000.xml\n",
            "\n",
            "\n",
            "     Simvastatin with or without ezetimibe in familial hypercholesterolemia.\n",
            "    \n",
            "16102557.xml\n",
            "\n",
            "\n",
            "     Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study.\n",
            "    \n",
            "10524579.xml\n",
            "\n",
            "\n",
            "     How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?\n",
            "    \n",
            "11198016.xml\n",
            "\n",
            "\n",
            "     An outbreak of scabies in a teaching hospital: lessons learned.\n",
            "    \n",
            "3306866.xml\n",
            "\n",
            "\n",
            "     Effect of exercise on serum enzyme activities in humans.\n",
            "    \n",
            "8096560.xml\n",
            "\n",
            "\n",
            "     Long-term malaria prophylaxis with weekly mefloquine.\n",
            "    \n",
            "9645831.xml\n",
            "\n",
            "\n",
            "     Physical examination and chronic lower-extremity ischemia: a critical review.\n",
            "    \n",
            "766894.xml\n",
            "\n",
            "\n",
            "     Diverticular disease: threee studies. Part II - Treatment with bran.\n",
            "    \n",
            "12614413.xml\n",
            "\n",
            "\n",
            "     Shave excision of benign facial melanocytic naevi: a patient's satisfaction survey.\n",
            "    \n",
            "15096072.xml\n",
            "\n",
            "\n",
            "     Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression.\n",
            "    \n",
            "9800666.xml\n",
            "\n",
            "\n",
            "     Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses.\n",
            "    \n",
            "8611058.xml\n",
            "\n",
            "\n",
            "     Six-month follow-up of naltrexone and psychotherapy for alcohol dependence.\n",
            "    \n",
            "9262298.xml\n",
            "\n",
            "\n",
            "     Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production.\n",
            "    \n",
            "11527233.xml\n",
            "\n",
            "\n",
            "     The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation.\n",
            "    \n",
            "6389520.xml\n",
            "\n",
            "\n",
            "     Evaluation of lithium therapy for alcoholism.\n",
            "    \n",
            "15257186.xml\n",
            "\n",
            "\n",
            "     Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.\n",
            "    \n",
            "11147989.xml\n",
            "\n",
            "\n",
            "     The rational clinical examination. Does this patient have strep throat?\n",
            "    \n",
            "17304447.xml\n",
            "\n",
            "\n",
            "     Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.\n",
            "    \n",
            "10639540.xml\n",
            "\n",
            "\n",
            "     Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.\n",
            "    \n",
            "17110817.xml\n",
            "\n",
            "\n",
            "     Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).\n",
            "    \n",
            "15625418.xml\n",
            "\n",
            "\n",
            "     Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.\n",
            "    \n",
            "8317528.xml\n",
            "\n",
            "\n",
            "     The influence of elective amniotomy on fetal heart rate patterns and the course of labor in term patients: a randomized study.\n",
            "    \n",
            "12975254.xml\n",
            "\n",
            "\n",
            "     Exercise capacity and the risk of death in women: the St James Women Take Heart Project.\n",
            "    \n",
            "10443654.xml\n",
            "\n",
            "\n",
            "     Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.\n",
            "    \n",
            "10647110.xml\n",
            "\n",
            "\n",
            "     Idiopathic toe-walking: does treatment alter the natural history?\n",
            "    \n",
            "16819379.xml\n",
            "\n",
            "\n",
            "     Treatment of faecal impaction with polyethelene glycol plus electrolytes (PGE + E) followed by a double-blind comparison of PEG + E versus lactulose as maintenance therapy.\n",
            "    \n",
            "12076378.xml\n",
            "\n",
            "\n",
            "     Holding chambers versus nebulisers for beta-agonist treatment of acute asthma.\n",
            "    \n",
            "17076973.xml\n",
            "\n",
            "\n",
            "     A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children.\n",
            "    \n",
            "14583982.xml\n",
            "\n",
            "\n",
            "     Progestogen for preventing miscarriage.\n",
            "    \n",
            "12230591.xml\n",
            "\n",
            "\n",
            "     Migraine: preventive treatment.\n",
            "    \n",
            "10888690.xml\n",
            "\n",
            "\n",
            "     A systematic review of treatments for infant colic.\n",
            "    \n",
            "10809994.xml\n",
            "\n",
            "\n",
            "     Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials.\n",
            "    \n",
            "11352694.xml\n",
            "\n",
            "\n",
            "     Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.\n",
            "    \n",
            "12464709.xml\n",
            "\n",
            "\n",
            "     What is the role of serial bone mineral density measurements in patient management?\n",
            "    \n",
            "9314443.xml\n",
            "\n",
            "\n",
            "     Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Infectious Diseases Society of America.\n",
            "    \n",
            "12495278.xml\n",
            "\n",
            "\n",
            "     Factors affecting outcome after percutaneous renal artery stent insertion.\n",
            "    \n",
            "9314468.xml\n",
            "\n",
            "\n",
            "     Hepatitis A among homosexual men and injection drug users: more evidence for vaccination.\n",
            "    \n",
            "9624306.xml\n",
            "\n",
            "\n",
            "     Predictors of occult pneumococcal bacteremia in young febrile children.\n",
            "    \n",
            "8647965.xml\n",
            "\n",
            "\n",
            "     Cimetidine therapy for warts: a placebo-controlled, double-blind study.\n",
            "    \n",
            "12885485.xml\n",
            "\n",
            "\n",
            "     Are imprecise methods obscuring a relation between fat and breast cancer?\n",
            "    \n",
            "18166543.xml\n",
            "\n",
            "\n",
            "     Timing of solid food introduction in relation to eczema, asthma, allergic rhinitis, and food and inhalant sensitization at the age of 6 years: results from the prospective birth cohort study LISA.\n",
            "    \n",
            "12027983.xml\n",
            "\n",
            "\n",
            "     Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease.\n",
            "    \n",
            "12767648.xml\n",
            "\n",
            "\n",
            "     Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.\n",
            "    \n",
            "8394375.xml\n",
            "\n",
            "\n",
            "     Herpes simplex virus detection from genital lesions: a comparative study using antigen detection (HerpChek) and culture.\n",
            "    \n",
            "8901851.xml\n",
            "\n",
            "\n",
            "     Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.\n",
            "    \n",
            "2172402.xml\n",
            "\n",
            "\n",
            "     Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers.\n",
            "    \n",
            "3123132.xml\n",
            "\n",
            "\n",
            "     Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.\n",
            "    \n",
            "10799460.xml\n",
            "\n",
            "\n",
            "     Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies.\n",
            "    \n",
            "17889067.xml\n",
            "\n",
            "\n",
            "     Solid food introduction in relation to eczema: results from a four-year prospective birth cohort study.\n",
            "    \n",
            "6138597.xml\n",
            "\n",
            "\n",
            "     Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.\n",
            "    \n",
            "9269212.xml\n",
            "\n",
            "\n",
            "     Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.\n",
            "    \n",
            "1738794.xml\n",
            "\n",
            "\n",
            "     Smokeless tobacco abstinence effects and nicotine gum dose.\n",
            "    \n",
            "10326075.xml\n",
            "\n",
            "\n",
            "     Management of renovascular disease: a review of renal artery stenting in ten studies.\n",
            "    \n",
            "10790990.xml\n",
            "\n",
            "\n",
            "     Treatment of attention-deficit/hyperactivity disorder.\n",
            "    \n",
            "14663128.xml\n",
            "\n",
            "\n",
            "     Diagnosis of pelvic inflammatory disease: time for a rethink.\n",
            "    \n",
            "16129478.xml\n",
            "\n",
            "\n",
            "     Screening families for intracranial aneurysms: anxiety, perceived risk, and informed choice.\n",
            "    \n",
            "9322325.xml\n",
            "\n",
            "\n",
            "     Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized controlled trials of the most common interventions.\n",
            "    \n",
            "10796721.xml\n",
            "\n",
            "\n",
            "     Dieting to reduce body weight for controlling hypertension in adults.\n",
            "    \n",
            "10796591.xml\n",
            "\n",
            "\n",
            "     Short course antibiotics for acute otitis media.\n",
            "    \n",
            "10075518.xml\n",
            "\n",
            "\n",
            "     Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry.\n",
            "    \n",
            "2881129.xml\n",
            "\n",
            "\n",
            "     Benefits and potential harm of lowering high blood pressure.\n",
            "    \n",
            "11165548.xml\n",
            "\n",
            "\n",
            "     Lack of clinical utility of folate levels in the evaluation of macrocytosis or anemia.\n",
            "    \n",
            "12269681.xml\n",
            "\n",
            "\n",
            "     Randomised controlled trial of reflexology for menopausal symptoms.\n",
            "    \n",
            "11152056.xml\n",
            "\n",
            "\n",
            "     Immunomodulatory effects of acupuncture in the treatment of allergic asthma: a randomized controlled study.\n",
            "    \n",
            "12630614.xml\n",
            "\n",
            "\n",
            "     Gastric bypass is an effective treatment for obstructive sleep apnea in patients with clinically significant obesity.\n",
            "    \n",
            "9504319.xml\n",
            "\n",
            "\n",
            "     Swedish obese subjects (SOS)--an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity.\n",
            "    \n",
            "8329916.xml\n",
            "\n",
            "\n",
            "     Relation between early introduction of solid food to infants and their weight and illnesses during the first two years of life.\n",
            "    \n",
            "11004420.xml\n",
            "\n",
            "\n",
            "     Comparison of ultrasound, radiography, and clinical examination in the diagnosis of acute maxillary sinusitis: a systematic review.\n",
            "    \n",
            "10796398.xml\n",
            "\n",
            "\n",
            "     Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.\n",
            "    \n",
            "18279051.xml\n",
            "\n",
            "\n",
            "     Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate.\n",
            "    \n",
            "10591338.xml\n",
            "\n",
            "\n",
            "     Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness.\n",
            "    \n",
            "16099784.xml\n",
            "\n",
            "\n",
            "     A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome.\n",
            "    \n",
            "15451329.xml\n",
            "\n",
            "\n",
            "     Contraceptive efficacy and safety of DMPA-SC.\n",
            "    \n",
            "8214994.xml\n",
            "\n",
            "\n",
            "     An algorithmic approach to chronic cough.\n",
            "    \n",
            "12390439.xml\n",
            "\n",
            "\n",
            "     Effect of exclusive breast-feeding and early solid food avoidance on the incidence of atopic dermatitis in high-risk infants at 1 year of age.\n",
            "    \n",
            "15571540.xml\n",
            "\n",
            "\n",
            "     Subjective memory deterioration and future dementia in people aged 65 and older.\n",
            "    \n",
            "16988082.xml\n",
            "\n",
            "\n",
            "     A family-based approach to preventing excessive weight gain.\n",
            "    \n",
            "12660054.xml\n",
            "\n",
            "\n",
            "     Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial.\n",
            "    \n",
            "7053703.xml\n",
            "\n",
            "\n",
            "     Levothyroxine replacement dose for primary hypothyroidism decreases with age.\n",
            "    \n",
            "7053190.xml\n",
            "\n",
            "\n",
            "     Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.\n",
            "    \n",
            "10644273.xml\n",
            "\n",
            "\n",
            "     Hepatocellular injury in a patient receiving rosiglitazone. A case report.\n",
            "    \n",
            "15292291.xml\n",
            "\n",
            "\n",
            "     The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.\n",
            "    \n",
            "9735623.xml\n",
            "\n",
            "\n",
            "     Conservative treatment of plantar fasciitis. A prospective study.\n",
            "    \n",
            "10962168.xml\n",
            "\n",
            "\n",
            "     Factors predicting peri- and neonatal outcome in diabetic pregnancy.\n",
            "    \n",
            "14974076.xml\n",
            "\n",
            "\n",
            "     Complex behavioural and educational interventions for nocturnal enuresis in children.\n",
            "    \n",
            "20238310.xml\n",
            "\n",
            "\n",
            "     Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures.\n",
            "    \n",
            "11642617.xml\n",
            "\n",
            "\n",
            "     Medical management of orbital cellulitis.\n",
            "    \n",
            "9848901.xml\n",
            "\n",
            "\n",
            "     Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials.\n",
            "    \n",
            "9738550.xml\n",
            "\n",
            "\n",
            "     Clinic-based vs. home-based interventions for preventing weight gain in men.\n",
            "    \n",
            "15028823.xml\n",
            "\n",
            "\n",
            "     Ten years' experience with alendronate for osteoporosis in postmenopausal women.\n",
            "    \n",
            "163931.xml\n",
            "\n",
            "\n",
            "     Increased virus shedding with aspirin treatment of rhinovirus infection.\n",
            "    \n",
            "12202466.xml\n",
            "\n",
            "\n",
            "     Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.\n",
            "    \n",
            "11485708.xml\n",
            "\n",
            "\n",
            "     Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.\n",
            "    \n",
            "10366118.xml\n",
            "\n",
            "\n",
            "     Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.\n",
            "    \n",
            "3598228.xml\n",
            "\n",
            "\n",
            "     Health problems after travel to developing countries.\n",
            "    \n",
            "10796127.xml\n",
            "\n",
            "\n",
            "     Human chorionic gonadotrophin for recurrent miscarriage.\n",
            "    \n",
            "16570091.xml\n",
            "\n",
            "\n",
            "     Early determinants of overweight at 4.5 years in a population-based longitudinal study.\n",
            "    \n",
            "9396645.xml\n",
            "\n",
            "\n",
            "     Rhinitis and inhalant allergens.\n",
            "    \n",
            "8571999.xml\n",
            "\n",
            "\n",
            "     Bone-sparing properties of oral contraceptives.\n",
            "    \n",
            "9149180.xml\n",
            "\n",
            "\n",
            "     Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.\n",
            "    \n",
            "10867092.xml\n",
            "\n",
            "\n",
            "     Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men.\n",
            "    \n",
            "15103233.xml\n",
            "\n",
            "\n",
            "     A double-blinded, randomized controlled trial of oxytocin at the beginning versus the end of the third stage of labor for prevention of postpartum hemorrhage.\n",
            "    \n",
            "15026401.xml\n",
            "\n",
            "\n",
            "     Cardiovascular prognosis of \"masked hypertension\" detected by blood pressure self-measurement in elderly treated hypertensive patients.\n",
            "    \n",
            "7710148.xml\n",
            "\n",
            "\n",
            "     Is admission medically justified for all patients with acute stroke or transient ischemic attack?\n",
            "    \n",
            "16235324.xml\n",
            "\n",
            "\n",
            "     Shock wave therapy for lateral elbow pain.\n",
            "    \n",
            "8926740.xml\n",
            "\n",
            "\n",
            "     Drug testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug?\n",
            "    \n",
            "12167549.xml\n",
            "\n",
            "\n",
            "     Tramadol post-marketing surveillance in health care professionals.\n",
            "    \n",
            "15231980.xml\n",
            "\n",
            "\n",
            "     Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.\n",
            "    \n",
            "7566020.xml\n",
            "\n",
            "\n",
            "     Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.\n",
            "    \n",
            "8173141.xml\n",
            "\n",
            "\n",
            "     Magnesium homeostasis and clinical disorders of magnesium deficiency.\n",
            "    \n",
            "15070788.xml\n",
            "\n",
            "\n",
            "     C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.\n",
            "    \n",
            "8893110.xml\n",
            "\n",
            "\n",
            "     Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria.\n",
            "    \n",
            "11466577.xml\n",
            "\n",
            "\n",
            "     The Swedish Obese Subjects (SOS) study--rationale and results.\n",
            "    \n",
            "2107241.xml\n",
            "\n",
            "\n",
            "     Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis.\n",
            "    \n",
            "2216619.xml\n",
            "\n",
            "\n",
            "     Early solid feeding and recurrent childhood eczema: a 10-year longitudinal study.\n",
            "    \n",
            "16914702.xml\n",
            "\n",
            "\n",
            "     Methicillin-resistant S. aureus infections among patients in the emergency department.\n",
            "    \n",
            "8790035.xml\n",
            "\n",
            "\n",
            "     Interaction between exercise training and ejection fraction in predicting prognosis after a first myocardial infarction.\n",
            "    \n",
            "10458342.xml\n",
            "\n",
            "\n",
            "     Reexamining the value of hematuria testing in patients with acute flank pain.\n",
            "    \n",
            "14584018.xml\n",
            "\n",
            "\n",
            "     Folic acid with or without vitamin B12 for cognition and dementia.\n",
            "    \n",
            "12804510.xml\n",
            "\n",
            "\n",
            "     Intensity of exercise for the treatment of osteoarthritis.\n",
            "    \n",
            "16437520.xml\n",
            "\n",
            "\n",
            "     Antenatal perineal massage for reducing perineal trauma.\n",
            "    \n",
            "11251703.xml\n",
            "\n",
            "\n",
            "     Amitriptyline treatment in chronic drug-induced headache: a double-blind comparative pilot study.\n",
            "    \n",
            "14984232.xml\n",
            "\n",
            "\n",
            "     Out-patient detoxification in chronic migraine: comparison of strategies.\n",
            "    \n",
            "12490274.xml\n",
            "\n",
            "\n",
            "     Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.\n",
            "    \n",
            "12869452.xml\n",
            "\n",
            "\n",
            "     Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.\n",
            "    \n",
            "12560416.xml\n",
            "\n",
            "\n",
            "     Relationship between pain and opioid analgesics on the development of delirium following hip fracture.\n",
            "    \n",
            "15115921.xml\n",
            "\n",
            "\n",
            "     The natural history of diverticulitis: fact and theory.\n",
            "    \n",
            "12079710.xml\n",
            "\n",
            "\n",
            "     The effects of time-to-surgery on mortality and morbidity in patients following hip fracture.\n",
            "    \n",
            "7707596.xml\n",
            "\n",
            "\n",
            "     Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men.\n",
            "    \n",
            "9254869.xml\n",
            "\n",
            "\n",
            "     Evaluation of febrile infants under 3 months of age: is routine lumbar puncture warranted?\n",
            "    \n",
            "11978293.xml\n",
            "\n",
            "\n",
            "     Body weight and risk of oral contraceptive failure.\n",
            "    \n",
            "10796757.xml\n",
            "\n",
            "\n",
            "     Antibiotics for acute bacterial conjunctivitis.\n",
            "    \n",
            "8301112.xml\n",
            "\n",
            "\n",
            "     Short report: ambulatory blood pressure in normotensive compared with hypertensive subjects. The Ad-Hoc Working Group.\n",
            "    \n",
            "2201888.xml\n",
            "\n",
            "\n",
            "     Evening primrose oil and treatment of premenstrual syndrome.\n",
            "    \n",
            "3905544.xml\n",
            "\n",
            "\n",
            "     The Jones' fracture in the nonathlete.\n",
            "    \n",
            "11493721.xml\n",
            "\n",
            "\n",
            "     Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis.\n",
            "    \n",
            "16235327.xml\n",
            "\n",
            "\n",
            "     Cardioselective beta-blockers for chronic obstructive pulmonary disease.\n",
            "    \n",
            "10333620.xml\n",
            "\n",
            "\n",
            "     Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts.\n",
            "    \n",
            "8225657.xml\n",
            "\n",
            "\n",
            "     The effects of oral ibopamine in patients with mild heart failure--a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group.\n",
            "    \n",
            "7575046.xml\n",
            "\n",
            "\n",
            "     An analysis of the effectiveness of interventions intended to help people stop smoking.\n",
            "    \n",
            "16416346.xml\n",
            "\n",
            "\n",
            "     TSH may not be a good marker for adequate thyroid hormone replacement therapy.\n",
            "    \n",
            "12786634.xml\n",
            "\n",
            "\n",
            "     Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole.\n",
            "    \n",
            "11856693.xml\n",
            "\n",
            "\n",
            "     Usefulness of an artificial neural network for differentiating benign from malignant pulmonary nodules on high-resolution CT: evaluation with receiver operating characteristic analysis.\n",
            "    \n",
            "10208148.xml\n",
            "\n",
            "\n",
            "     Pharmacological treatment of alcohol dependence: a review of the evidence.\n",
            "    \n",
            "16957763.xml\n",
            "\n",
            "\n",
            "     The diagnosis and management of asymptomatic primary hyperparathyroidism.\n",
            "    \n",
            "9363015.xml\n",
            "\n",
            "\n",
            "     Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status.\n",
            "    \n",
            "11459386.xml\n",
            "\n",
            "\n",
            "     Long-term outcome of panic disorder with agoraphobia treated by exposure.\n",
            "    \n",
            "10796511.xml\n",
            "\n",
            "\n",
            "     Drugs for treating giardiasis.\n",
            "    \n",
            "12917939.xml\n",
            "\n",
            "\n",
            "     Ionisers for chronic asthma.\n",
            "    \n",
            "15186367.xml\n",
            "\n",
            "\n",
            "     Allergic contact dermatitis: pathophysiology applied to future therapy.\n",
            "    \n",
            "11258778.xml\n",
            "\n",
            "\n",
            "     Breast cancer after augmentation mammoplasty.\n",
            "    \n",
            "15452284.xml\n",
            "\n",
            "\n",
            "     Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.\n",
            "    \n",
            "17943891.xml\n",
            "\n",
            "\n",
            "     Amniotomy for shortening spontaneous labour.\n",
            "    \n",
            "10979796.xml\n",
            "\n",
            "\n",
            "     Alendronate for the treatment of osteoporosis in men.\n",
            "    \n",
            "9459643.xml\n",
            "\n",
            "\n",
            "     A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prvention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.\n",
            "    \n",
            "11419683.xml\n",
            "\n",
            "\n",
            "     Comparative clinical trial of mebendazole and metronidazole in giardiasis of children.\n",
            "    \n",
            "12893397.xml\n",
            "\n",
            "\n",
            "     Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia.\n",
            "    \n",
            "9747868.xml\n",
            "\n",
            "\n",
            "     Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.\n",
            "    \n",
            "9500475.xml\n",
            "\n",
            "\n",
            "     Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations.\n",
            "    \n",
            "7661497.xml\n",
            "\n",
            "\n",
            "     The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.\n",
            "    \n",
            "6972693.xml\n",
            "\n",
            "\n",
            "     Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in patients after myocardial infarction. The National Exercise and Heart Disease Project.\n",
            "    \n",
            "14996525.xml\n",
            "\n",
            "\n",
            "     Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.\n",
            "    \n",
            "7915824.xml\n",
            "\n",
            "\n",
            "     A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.\n",
            "    \n",
            "9208356.xml\n",
            "\n",
            "\n",
            "     Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia.\n",
            "    \n",
            "10398626.xml\n",
            "\n",
            "\n",
            "     Systematic review of topical treatments for fungal infections of the skin and nails of the feet.\n",
            "    \n",
            "10596256.xml\n",
            "\n",
            "\n",
            "     A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.\n",
            "    \n",
            "16651493.xml\n",
            "\n",
            "\n",
            "     Systematic review of the relationship between early introduction of solid foods to infants and the development of allergic disease.\n",
            "    \n",
            "11731648.xml\n",
            "\n",
            "\n",
            "     C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection.\n",
            "    \n",
            "15635110.xml\n",
            "\n",
            "\n",
            "     Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.\n",
            "    \n",
            "11126352.xml\n",
            "\n",
            "\n",
            "     Risk factors of obesity in preschool children in China: a population-based case--control study.\n",
            "    \n",
            "11235924.xml\n",
            "\n",
            "\n",
            "     Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.\n",
            "    \n",
            "15715686.xml\n",
            "\n",
            "\n",
            "     Holotranscobalamin--a first choice assay for diagnosing early vitamin B deficiency?\n",
            "    \n",
            "9121182.xml\n",
            "\n",
            "\n",
            "     Diagnostic options for assessment of postmenopausal bleeding.\n",
            "    \n",
            "10335685.xml\n",
            "\n",
            "\n",
            "     Diagnosing pneumonia by physical examination: relevant or relic?\n",
            "    \n",
            "12436822.xml\n",
            "\n",
            "\n",
            "     Antibiotics and oral contraceptives.\n",
            "    \n",
            "11093966.xml\n",
            "\n",
            "\n",
            "     A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.\n",
            "    \n",
            "11063447.xml\n",
            "\n",
            "\n",
            "     Prenatal compared with parental origins of adolescent fatness.\n",
            "    \n",
            "9625401.xml\n",
            "\n",
            "\n",
            "     From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults.\n",
            "    \n",
            "15846609.xml\n",
            "\n",
            "\n",
            "     Manual therapy for asthma.\n",
            "    \n",
            "11717594.xml\n",
            "\n",
            "\n",
            "     Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis.\n",
            "    \n",
            "10509605.xml\n",
            "\n",
            "\n",
            "     Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study.\n",
            "    \n",
            "7617369.xml\n",
            "\n",
            "\n",
            "     Combined continuous hormone replacement therapy: a critical review.\n",
            "    \n",
            "18298429.xml\n",
            "\n",
            "\n",
            "     A systematic review of the evidence regarding efficacy of obesity prevention interventions among adults.\n",
            "    \n",
            "11521913.xml\n",
            "\n",
            "\n",
            "     Recommendations for using fluoride to prevent and control dental caries in the United States. Centers for Disease Control and Prevention.\n",
            "    \n",
            "11372038.xml\n",
            "\n",
            "\n",
            "     Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenectomized and nonsplenectomized patients with Cooley anemia.\n",
            "    \n",
            "11014393.xml\n",
            "\n",
            "\n",
            "     Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study.\n",
            "    \n",
            "15625141.xml\n",
            "\n",
            "\n",
            "     Body mass index, weight, and oral contraceptive failure risk.\n",
            "    \n",
            "3140269.xml\n",
            "\n",
            "\n",
            "     Continuing outbreak of hepatitis A linked with intravenous drug abuse in Multnomah County.\n",
            "    \n",
            "2712981.xml\n",
            "\n",
            "\n",
            "     Clinical benefits of early cold therapy in accident and emergency following ankle sprain.\n",
            "    \n",
            "15333452.xml\n",
            "\n",
            "\n",
            "     Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial.\n",
            "    \n",
            "11869609.xml\n",
            "\n",
            "\n",
            "     Orthotic devices for the treatment of tennis elbow.\n",
            "    \n",
            "7678046.xml\n",
            "\n",
            "\n",
            "     Reversal of developmental delays in iron-deficient anaemic infants treated with iron.\n",
            "    \n",
            "8322582.xml\n",
            "\n",
            "\n",
            "     Naproxen and paracetamol compared with naproxen only in coxarthrosis. Increased effect of the combination in 18 patients.\n",
            "    \n",
            "7504424.xml\n",
            "\n",
            "\n",
            "     Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.\n",
            "    \n",
            "12809453.xml\n",
            "\n",
            "\n",
            "     Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis.\n",
            "    \n",
            "11844004.xml\n",
            "\n",
            "\n",
            "     Zolpidem use and hip fractures in older people.\n",
            "    \n",
            "12190367.xml\n",
            "\n",
            "\n",
            "     Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.\n",
            "    \n",
            "10354876.xml\n",
            "\n",
            "\n",
            "     Diagnostic and therapeutic impact of MRI and arthrography in the investigation of full-thickness rotator cuff tears.\n",
            "    \n",
            "8918275.xml\n",
            "\n",
            "\n",
            "     A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.\n",
            "    \n",
            "15888715.xml\n",
            "\n",
            "\n",
            "     Early screw fixation versus casting in the treatment of acute Jones fractures.\n",
            "    \n",
            "3888742.xml\n",
            "\n",
            "\n",
            "     Antepartum fetal surveillance in gestational diabetes mellitus.\n",
            "    \n",
            "15056503.xml\n",
            "\n",
            "\n",
            "     Management of bipolar disorder during pregnancy and the postpartum period.\n",
            "    \n",
            "16818461.xml\n",
            "\n",
            "\n",
            "     Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis.\n",
            "    \n",
            "11505031.xml\n",
            "\n",
            "\n",
            "     Influence of alcohol intake on risk for increased low-density lipoprotein cholesterol in middle-aged Japanese men.\n",
            "    \n",
            "16676287.xml\n",
            "\n",
            "\n",
            "     Do subjective memory complaints predict cognitive dysfunction over time? A six-year follow-up of the Maastricht Aging Study.\n",
            "    \n",
            "12558362.xml\n",
            "\n",
            "\n",
            "     Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force.\n",
            "    \n",
            "10665629.xml\n",
            "\n",
            "\n",
            "     Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.\n",
            "    \n",
            "12371916.xml\n",
            "\n",
            "\n",
            "     Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study.\n",
            "    \n",
            "11448655.xml\n",
            "\n",
            "\n",
            "     Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.\n",
            "    \n",
            "8970899.xml\n",
            "\n",
            "\n",
            "     Correcting calcium nutritional deficiency prevents spine fractures in elderly women.\n",
            "    \n",
            "9722799.xml\n",
            "\n",
            "\n",
            "     A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis.\n",
            "    \n",
            "12601075.xml\n",
            "\n",
            "\n",
            "     Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.\n",
            "    \n",
            "12140298.xml\n",
            "\n",
            "\n",
            "     A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates.\n",
            "    \n",
            "12451364.xml\n",
            "\n",
            "\n",
            "     Approach to the adult female patient with diffuse nonscarring alopecia.\n",
            "    \n",
            "11181776.xml\n",
            "\n",
            "\n",
            "     Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.\n",
            "    \n",
            "17015870.xml\n",
            "\n",
            "\n",
            "     Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.\n",
            "    \n",
            "9284865.xml\n",
            "\n",
            "\n",
            "     A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments.\n",
            "    \n",
            "10587552.xml\n",
            "\n",
            "\n",
            "     Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy.\n",
            "    \n",
            "16020410.xml\n",
            "\n",
            "\n",
            "     Prevention of and therapies for nipple pain: a systematic review.\n",
            "    \n",
            "9781781.xml\n",
            "\n",
            "\n",
            "     Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure.\n",
            "    \n",
            "10671393.xml\n",
            "\n",
            "\n",
            "     Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention.\n",
            "    \n",
            "12076503.xml\n",
            "\n",
            "\n",
            "     Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults.\n",
            "    \n",
            "17572422.xml\n",
            "\n",
            "\n",
            "     Low-dose hormone therapy in the perimenopause.\n",
            "    \n",
            "10028110.xml\n",
            "\n",
            "\n",
            "     Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.\n",
            "    \n",
            "11790165.xml\n",
            "\n",
            "\n",
            "     The combined continuous-wave/pulsed carbon dioxide laser for treatment of pyogenic granuloma.\n",
            "    \n",
            "11843383.xml\n",
            "\n",
            "\n",
            "     Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes.\n",
            "    \n",
            "1955232.xml\n",
            "\n",
            "\n",
            "     Verrucae treated by levamisole.\n",
            "    \n",
            "14989387.xml\n",
            "\n",
            "\n",
            "     Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis.\n",
            "    \n",
            "9096977.xml\n",
            "\n",
            "\n",
            "     Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.\n",
            "    \n",
            "1868642.xml\n",
            "\n",
            "\n",
            "     Intrapartum antibiotic therapy for suspected intraamniotic infection: impact on the fetus and neonate.\n",
            "    \n",
            "11585485.xml\n",
            "\n",
            "\n",
            "     The rational clinical examination. Does this patient have a torn meniscus or ligament of the knee? Value of the physical examination.\n",
            "    \n",
            "8942774.xml\n",
            "\n",
            "\n",
            "     Randomised study of screening for colorectal cancer with faecal-occult-blood test.\n",
            "    \n",
            "8708804.xml\n",
            "\n",
            "\n",
            "     Use of the Cytobrush for Papanicolaou smear screens in pregnant women.\n",
            "    \n",
            "15258862.xml\n",
            "\n",
            "\n",
            "     Cosmetic outcomes of facial lacerations repaired with tissue-adhesive, absorbable, and nonabsorbable sutures.\n",
            "    \n",
            "1728731.xml\n",
            "\n",
            "\n",
            "     The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection.\n",
            "    \n",
            "344087.xml\n",
            "\n",
            "\n",
            "     Randomized controlled trial of Syn-Ergel and an active placebo in the treatment of heartburn of pregnancy.\n",
            "    \n",
            "15755765.xml\n",
            "\n",
            "\n",
            "     Intensive lipid lowering with atorvastatin in patients with stable coronary disease.\n",
            "    \n",
            "10629474.xml\n",
            "\n",
            "\n",
            "     Diagnosis and treatment of uncomplicated acute bacterial rhinosinusitis: summary of the Agency for Health Care Policy and Research evidence-based report.\n",
            "    \n",
            "12174056.xml\n",
            "\n",
            "\n",
            "     Removal of keratinous and pilar cysts with the punch incision technique: analysis of surgical outcomes.\n",
            "    \n",
            "16625602.xml\n",
            "\n",
            "\n",
            "     Antibiotics for exacerbations of chronic obstructive pulmonary disease.\n",
            "    \n",
            "14973954.xml\n",
            "\n",
            "\n",
            "     Homeopathy for chronic asthma.\n",
            "    \n",
            "15021067.xml\n",
            "\n",
            "\n",
            "     Allergen immunotherapy in the prevention of asthma.\n",
            "    \n",
            "15474764.xml\n",
            "\n",
            "\n",
            "     Headaches in pregnancy.\n",
            "    \n",
            "12535385.xml\n",
            "\n",
            "\n",
            "     Immunotherapy for recurrent miscarriage.\n",
            "    \n",
            "2857061.xml\n",
            "\n",
            "\n",
            "     Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group.\n",
            "    \n",
            "12467690.xml\n",
            "\n",
            "\n",
            "     Pertussis of adults and infants.\n",
            "    \n",
            "2067759.xml\n",
            "\n",
            "\n",
            "     Oral magnesium successfully relieves premenstrual mood changes.\n",
            "    \n",
            "9109139.xml\n",
            "\n",
            "\n",
            "     Continuous twice daily or once daily amoxicillin prophylaxis compared with placebo for children with recurrent acute otitis media.\n",
            "    \n",
            "7869070.xml\n",
            "\n",
            "\n",
            "     Recall bias in case-control studies: an empirical analysis and theoretical framework.\n",
            "    \n",
            "14678922.xml\n",
            "\n",
            "\n",
            "     Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography.\n",
            "    \n",
            "20556751.xml\n",
            "\n",
            "\n",
            "     Surgery for cervical intraepithelial neoplasia.\n",
            "    \n",
            "15831424.xml\n",
            "\n",
            "\n",
            "     Solitary pulmonary nodule diagnosis on CT: results of an observer study.\n",
            "    \n",
            "3398197.xml\n",
            "\n",
            "\n",
            "     Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome.\n",
            "    \n",
            "15819726.xml\n",
            "\n",
            "\n",
            "     The effectiveness of psychological treatments for treatment-resistant depression: a systematic review.\n",
            "    \n",
            "9778327.xml\n",
            "\n",
            "\n",
            "     Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups.\n",
            "    \n",
            "12472787.xml\n",
            "\n",
            "\n",
            "     Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).\n",
            "    \n",
            "7532241.xml\n",
            "\n",
            "\n",
            "     Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association.\n",
            "    \n",
            "18164508.xml\n",
            "\n",
            "\n",
            "     Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids.\n",
            "    \n",
            "16052573.xml\n",
            "\n",
            "\n",
            "     Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.\n",
            "    \n",
            "3063051.xml\n",
            "\n",
            "\n",
            "     Treatment of angular cheilitis. The significance of microbial analysis, antimicrobial treatment, and interfering factors.\n",
            "    \n",
            "10435606.xml\n",
            "\n",
            "\n",
            "     A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.\n",
            "    \n",
            "10684911.xml\n",
            "\n",
            "\n",
            "     Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.\n",
            "    \n",
            "6693447.xml\n",
            "\n",
            "\n",
            "     Fractures of the base of the fifth metatarsal distal to the tuberosity. Classification and guidelines for non-surgical and surgical management.\n",
            "    \n",
            "12478024.xml\n",
            "\n",
            "\n",
            "     Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively.\n",
            "    \n",
            "14649781.xml\n",
            "\n",
            "\n",
            "     Cognitive behavioural therapy for obesity: one-year follow-up in a clinical setting.\n",
            "    \n",
            "15187055.xml\n",
            "\n",
            "\n",
            "     Estimating prognosis for nursing home residents with advanced dementia.\n",
            "    \n",
            "9555761.xml\n",
            "\n",
            "\n",
            "     Prevention of invasive group A streptococcal disease among household contacts of case-patients: is prophylaxis warranted? The Working Group on Prevention of Invasive Group A Streptococcal Infections.\n",
            "    \n",
            "1824642.xml\n",
            "\n",
            "\n",
            "     The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?\n",
            "    \n",
            "12615832.xml\n",
            "\n",
            "\n",
            "     Ultrasound examination of polycystic ovaries: is it worth counting the follicles?\n",
            "    \n",
            "12791436.xml\n",
            "\n",
            "\n",
            "     The impact of post-operative pain on outcomes following hip fracture.\n",
            "    \n",
            "14682412.xml\n",
            "\n",
            "\n",
            "     Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study.\n",
            "    \n",
            "10518812.xml\n",
            "\n",
            "\n",
            "     A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis.\n",
            "    \n",
            "6310075.xml\n",
            "\n",
            "\n",
            "     Lubricant versus laxative in the treatment of chronic functional constipation of children: a comparative study.\n",
            "    \n",
            "11865128.xml\n",
            "\n",
            "\n",
            "     Treatment of ADHD in children with tics: a randomized controlled trial.\n",
            "    \n",
            "14984370.xml\n",
            "\n",
            "\n",
            "     Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.\n",
            "    \n",
            "11729014.xml\n",
            "\n",
            "\n",
            "     An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.\n",
            "    \n",
            "7539890.xml\n",
            "\n",
            "\n",
            "     Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.\n",
            "    \n",
            "12353945.xml\n",
            "\n",
            "\n",
            "     Statin-associated myopathy with normal creatine kinase levels.\n",
            "    \n",
            "8416468.xml\n",
            "\n",
            "\n",
            "     Essential fatty acids in the treatment of premenstrual syndrome.\n",
            "    \n",
            "11083602.xml\n",
            "\n",
            "\n",
            "     The use of clinical prediction formulas in the evaluation of obstructive sleep apnea.\n",
            "    \n",
            "15198752.xml\n",
            "\n",
            "\n",
            "     Preventing postnatal depression in mothers of very preterm infants: a randomised controlled trial.\n",
            "    \n",
            "10811540.xml\n",
            "\n",
            "\n",
            "     Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study.\n",
            "    \n",
            "3941176.xml\n",
            "\n",
            "\n",
            "     Electromyography of idiopathic toe walking.\n",
            "    \n",
            "15613404.xml\n",
            "\n",
            "\n",
            "     Serum thyroid hormones in preterm infants and relationships to indices of severity of intercurrent illness.\n",
            "    \n",
            "7955452.xml\n",
            "\n",
            "\n",
            "     Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.\n",
            "    \n",
            "10469816.xml\n",
            "\n",
            "\n",
            "     Growth and fatness at three to six years of age of children born small- or large-for-gestational age.\n",
            "    \n",
            "11485144.xml\n",
            "\n",
            "\n",
            "     Statin-fibrate combination therapy.\n",
            "    \n",
            "2341917.xml\n",
            "\n",
            "\n",
            "     Recognition and evaluation of red blood cell macrocytosis in the primary care setting.\n",
            "    \n",
            "15367052.xml\n",
            "\n",
            "\n",
            "     The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial.\n",
            "    \n",
            "12751658.xml\n",
            "\n",
            "\n",
            "     A practical approach to hypercalcemia.\n",
            "    \n",
            "3559288.xml\n",
            "\n",
            "\n",
            "     Diagnosis of bacteriuria in men: specimen collection and culture interpretation.\n",
            "    \n",
            "7503197.xml\n",
            "\n",
            "\n",
            "     Antepartum surveillance in diabetic pregnancies: predictors of fetal distress in labor.\n",
            "    \n",
            "15166898.xml\n",
            "\n",
            "\n",
            "     Preparticipation evaluation: an evidence-based review.\n",
            "    \n",
            "17162986.xml\n",
            "\n",
            "\n",
            "     Psychological and behavioral treatment of insomnia:update of the recent evidence (1998-2004).\n",
            "    \n",
            "8907095.xml\n",
            "\n",
            "\n",
            "     Effects of behavioral and pharmacological treatment on smokeless tobacco users.\n",
            "    \n",
            "10796686.xml\n",
            "\n",
            "\n",
            "     Interventions for helping patients to follow prescriptions for medications.\n",
            "    \n",
            "11759078.xml\n",
            "\n",
            "\n",
            "     Treatment of hypothyroidism.\n",
            "    \n",
            "3935901.xml\n",
            "\n",
            "\n",
            "     Correlates of sexual desire in post-menopausal women.\n",
            "    \n",
            "9672274.xml\n",
            "\n",
            "\n",
            "     Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.\n",
            "    \n",
            "10920726.xml\n",
            "\n",
            "\n",
            "     Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.\n",
            "    \n",
            "12457519.xml\n",
            "\n",
            "\n",
            "     Oral contraceptive failures and body weight: findings in a large cohort study.\n",
            "    \n",
            "15635109.xml\n",
            "\n",
            "\n",
            "     C-reactive protein levels and outcomes after statin therapy.\n",
            "    \n",
            "3350949.xml\n",
            "\n",
            "\n",
            "     Differentiation of idiopathic toe-walking and cerebral palsy.\n",
            "    \n",
            "12442064.xml\n",
            "\n",
            "\n",
            "     Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.\n",
            "    \n",
            "11704183.xml\n",
            "\n",
            "\n",
            "     Drug interactions between oral contraceptives and antibiotics.\n",
            "    \n",
            "7576395.xml\n",
            "\n",
            "\n",
            "     White coat hypertension and white coat effect. Similarities and differences.\n",
            "    \n",
            "1790394.xml\n",
            "\n",
            "\n",
            "     Calcium supplements: practical considerations.\n",
            "    \n",
            "3186087.xml\n",
            "\n",
            "\n",
            "     A randomized trial of intrapartum versus immediate postpartum treatment of women with intra-amniotic infection.\n",
            "    \n",
            "8976640.xml\n",
            "\n",
            "\n",
            "     Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response.\n",
            "    \n",
            "14985592.xml\n",
            "\n",
            "\n",
            "     Households contaminated by environmental tobacco smoke: sources of infant exposures.\n",
            "    \n",
            "7849885.xml\n",
            "\n",
            "\n",
            "     Metered-dose inhalers with spacers vs nebulizers for pediatric asthma.\n",
            "    \n",
            "3982720.xml\n",
            "\n",
            "\n",
            "     First-trimester drug use and congenital disorders.\n",
            "    \n",
            "10352632.xml\n",
            "\n",
            "\n",
            "     Risk factors for resistance to \"first-line\" antimicrobials among urinary tract isolates of Escherichia coli in children.\n",
            "    \n",
            "1777557.xml\n",
            "\n",
            "\n",
            "     Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases.\n",
            "    \n",
            "15976596.xml\n",
            "\n",
            "\n",
            "     Comparison of acute and subclinical pelvic inflammatory disease.\n",
            "    \n",
            "872608.xml\n",
            "\n",
            "\n",
            "     Constipation in childhood: a controlled comparison between lactulose and standardized senna.\n",
            "    \n",
            "15479938.xml\n",
            "\n",
            "\n",
            "     Bariatric surgery: a systematic review and meta-analysis.\n",
            "    \n",
            "9167925.xml\n",
            "\n",
            "\n",
            "     Treatment of fractures of the fifth metatarsal: a prospective study.\n",
            "    \n",
            "10436111.xml\n",
            "\n",
            "\n",
            "     Cost-effectiveness analysis of screening for asymptomatic, unruptured intracranial aneurysms. A mathematical model.\n",
            "    \n",
            "10792566.xml\n",
            "\n",
            "\n",
            "     The marker of cobalamin deficiency, plasma methylmalonic acid, correlates to plasma creatinine.\n",
            "    \n",
            "15106182.xml\n",
            "\n",
            "\n",
            "     Digitalis for treatment of congestive heart failure in patients in sinus rhythm.\n",
            "    \n",
            "1518691.xml\n",
            "\n",
            "\n",
            "     Iron status in exclusively breast-fed infants.\n",
            "    \n",
            "9369817.xml\n",
            "\n",
            "\n",
            "     Controlled cord traction versus minimal intervention techniques in delivery of the placenta: a randomized controlled trial.\n",
            "    \n",
            "16446748.xml\n",
            "\n",
            "\n",
            "     Monitoring weight daily blocks the freshman weight gain: a model for combating the epidemic of obesity.\n",
            "    \n",
            "12917922.xml\n",
            "\n",
            "\n",
            "     Tricyclic and related drugs for nocturnal enuresis in children.\n",
            "    \n",
            "11232013.xml\n",
            "\n",
            "\n",
            "     Rosiglitazone monotherapy is effective in patients with type 2 diabetes.\n",
            "    \n",
            "15654703.xml\n",
            "\n",
            "\n",
            "     Screening for correctable visual acuity deficits in school-age children and adolescents.\n",
            "    \n",
            "8497355.xml\n",
            "\n",
            "\n",
            "     Abnormal cervical cytology in pregnancy: a 17-year experience.\n",
            "    \n",
            "9428952.xml\n",
            "\n",
            "\n",
            "     ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists.\n",
            "    \n",
            "1097985.xml\n",
            "\n",
            "\n",
            "     Nystatin and amphotericin B in the treatment of denture-related candidiasis.\n",
            "    \n",
            "8604285.xml\n",
            "\n",
            "\n",
            "     Practice parameter: the management of acute gastroenteritis in young children. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis.\n",
            "    \n",
            "10865306.xml\n",
            "\n",
            "\n",
            "     The rational clinical examination. Does this patient have carpal tunnel syndrome?\n",
            "    \n",
            "12783912.xml\n",
            "\n",
            "\n",
            "     Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.\n",
            "    \n",
            "14560344.xml\n",
            "\n",
            "\n",
            "     Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study.\n",
            "    \n",
            "14872449.xml\n",
            "\n",
            "\n",
            "     Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis.\n",
            "    \n",
            "9236642.xml\n",
            "\n",
            "\n",
            "     Antenatal perineal massage and subsequent perineal outcomes: a randomised controlled trial.\n",
            "    \n",
            "15174889.xml\n",
            "\n",
            "\n",
            "     Management of exercise-induced bronchospasm in children: the role of leukotriene antagonists.\n",
            "    \n",
            "9914571.xml\n",
            "\n",
            "\n",
            "     Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol.\n",
            "    \n",
            "12685516.xml\n",
            "\n",
            "\n",
            "     Forty years of methylphenidate treatment in Attention-Deficit/ Hyperactivity Disorder.\n",
            "    \n",
            "8698944.xml\n",
            "\n",
            "\n",
            "     Hypnosis as an adjunct to cognitive-behavioral psychotherapy for obesity: a meta-analytic reappraisal.\n",
            "    \n",
            "8256107.xml\n",
            "\n",
            "\n",
            "     Tolerability of prophylactic Lariam regimens.\n",
            "    \n",
            "14584010.xml\n",
            "\n",
            "\n",
            "     The effect of vitamin B6 on cognition.\n",
            "    \n",
            "74457.xml\n",
            "\n",
            "\n",
            "     Prophylactic treatment of alcoholism by lithium carbonate. A controlled study.\n",
            "    \n",
            "15242222.xml\n",
            "\n",
            "\n",
            "     Intrauterine contraceptive devices and risk of pelvic inflammatory disease: standard of care in high STI prevalence settings.\n",
            "    \n",
            "12187337.xml\n",
            "\n",
            "\n",
            "     Comparison between sonography and mammography for breast cancer diagnosis in oriental women after augmentation mammaplasty.\n",
            "    \n",
            "12861176.xml\n",
            "\n",
            "\n",
            "     2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia.\n",
            "    \n",
            "16207391.xml\n",
            "\n",
            "\n",
            "     Brain reserve and dementia: a systematic review.\n",
            "    \n",
            "14747501.xml\n",
            "\n",
            "\n",
            "     Effect of breast augmentation on the accuracy of mammography and cancer characteristics.\n",
            "    \n",
            "15266429.xml\n",
            "\n",
            "\n",
            "     Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.\n",
            "    \n",
            "10491376.xml\n",
            "\n",
            "\n",
            "     Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.\n",
            "    \n",
            "11423507.xml\n",
            "\n",
            "\n",
            "     A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.\n",
            "    \n",
            "12107216.xml\n",
            "\n",
            "\n",
            "     Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in premenopausal women.\n",
            "    \n",
            "9757979.xml\n",
            "\n",
            "\n",
            "     The safety of omeprazole during pregnancy: a multicenter prospective controlled study.\n",
            "    \n",
            "15138247.xml\n",
            "\n",
            "\n",
            "     Drug treatment of hyperlipidemia in women.\n",
            "    \n",
            "10925761.xml\n",
            "\n",
            "\n",
            "     Practical management of hair loss.\n",
            "    \n",
            "14747031.xml\n",
            "\n",
            "\n",
            "     Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation.\n",
            "    \n",
            "12612275.xml\n",
            "\n",
            "\n",
            "     Maternal gestational diabetes, birth weight, and adolescent obesity.\n",
            "    \n",
            "10382464.xml\n",
            "\n",
            "\n",
            "     Do apnea monitors decrease emotional distress in parents of infants at high risk for cardiopulmonary arrest?\n",
            "    \n",
            "18299547.xml\n",
            "\n",
            "\n",
            "     The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.\n",
            "    \n",
            "15579363.xml\n",
            "\n",
            "\n",
            "     Asthma associated with exercise.\n",
            "    \n",
            "10969112.xml\n",
            "\n",
            "\n",
            "     American Academy of Pediatrics. Committee on Sports Medicine and Fitness. Medical concerns in the female athlete.\n",
            "    \n",
            "14711538.xml\n",
            "\n",
            "\n",
            "     Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.\n",
            "    \n",
            "6863528.xml\n",
            "\n",
            "\n",
            "     Surgical treatment of Osgood-Schlatter's disease.\n",
            "    \n",
            "12557864.xml\n",
            "\n",
            "\n",
            "     Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials.\n",
            "    \n",
            "10875288.xml\n",
            "\n",
            "\n",
            "     Etiology and diagnostic evaluation of macrocytosis.\n",
            "    \n",
            "14583951.xml\n",
            "\n",
            "\n",
            "     Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction.\n",
            "    \n",
            "17678659.xml\n",
            "\n",
            "\n",
            "     Role of sonographic examination in traumatic knee internal derangement.\n",
            "    \n",
            "11704584.xml\n",
            "\n",
            "\n",
            "     Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial.\n",
            "    \n",
            "11407054.xml\n",
            "\n",
            "\n",
            "     Topical antibiotics for acute bacterial conjunctivitis: a systematic review.\n",
            "    \n",
            "9517638.xml\n",
            "\n",
            "\n",
            "     Laparoscopic antireflux surgery in the elderly.\n",
            "    \n",
            "11129515.xml\n",
            "\n",
            "\n",
            "     Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS).\n",
            "    \n",
            "7790481.xml\n",
            "\n",
            "\n",
            "     Tibial tuberosity excision for symptomatic Osgood-Schlatter disease.\n",
            "    \n",
            "10350034.xml\n",
            "\n",
            "\n",
            "     Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.\n",
            "    \n",
            "11113085.xml\n",
            "\n",
            "\n",
            "     Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.\n",
            "    \n",
            "2801756.xml\n",
            "\n",
            "\n",
            "     Hepatitis and hematemesis complicating nicotinic acid use.\n",
            "    \n",
            "9099655.xml\n",
            "\n",
            "\n",
            "     A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.\n",
            "    \n",
            "3156007.xml\n",
            "\n",
            "\n",
            "     The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population.\n",
            "    \n",
            "10796184.xml\n",
            "\n",
            "\n",
            "     Very tight versus tight control for diabetes in pregnancy.\n",
            "    \n",
            "629899.xml\n",
            "\n",
            "\n",
            "     Copper intrauterine contraceptive devices in adolescent nulliparae.\n",
            "    \n",
            "14734335.xml\n",
            "\n",
            "\n",
            "     The accuracy of the Ottawa knee rule to rule out knee fractures: a systematic review.\n",
            "    \n",
            "6754120.xml\n",
            "\n",
            "\n",
            "     Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.\n",
            "    \n",
            "18205800.xml\n",
            "\n",
            "\n",
            "     Neuromodulators for migraine prevention.\n",
            "    \n",
            "11552913.xml\n",
            "\n",
            "\n",
            "     Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru.\n",
            "    \n",
            "16358132.xml\n",
            "\n",
            "\n",
            "     Accuracy of magnetic resonance in identifying traumatic intraarticular knee lesions.\n",
            "    \n",
            "9667087.xml\n",
            "\n",
            "\n",
            "     A randomized controlled trial of exercise therapy for dizziness and vertigo in primary care.\n",
            "    \n",
            "12851867.xml\n",
            "\n",
            "\n",
            "     Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.\n",
            "    \n",
            "12517199.xml\n",
            "\n",
            "\n",
            "     Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department.\n",
            "    \n",
            "15383488.xml\n",
            "\n",
            "\n",
            "     Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.\n",
            "    \n",
            "8169238.xml\n",
            "\n",
            "\n",
            "     Ultrasonography versus clinical examination in evaluation of testicular tumors.\n",
            "    \n",
            "12621794.xml\n",
            "\n",
            "\n",
            "     Limitations of the obstetric group B Streptococcus protocol.\n",
            "    \n",
            "11089820.xml\n",
            "\n",
            "\n",
            "     Statins and the risk of dementia.\n",
            "    \n",
            "18184294.xml\n",
            "\n",
            "\n",
            "     Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?\n",
            "    \n",
            "2193173.xml\n",
            "\n",
            "\n",
            "     Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients.\n",
            "    \n",
            "6529911.xml\n",
            "\n",
            "\n",
            "     Influence of removal of intrauterine contraceptive devices on colonisation of the cervix by actinomyces-like organisms.\n",
            "    \n",
            "12051216.xml\n",
            "\n",
            "\n",
            "     The clinical diagnosis of acute purulent sinusitis in general practice--a review.\n",
            "    \n",
            "4025675.xml\n",
            "\n",
            "\n",
            "     Osgood-Schlatter's disease in adolescent athletes. Retrospective study of incidence and duration.\n",
            "    \n",
            "9371164.xml\n",
            "\n",
            "\n",
            "     Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.\n",
            "    \n",
            "10739286.xml\n",
            "\n",
            "\n",
            "     Serial casting in idiopathic toe-walkers and children with spastic cerebral palsy.\n",
            "    \n",
            "3821822.xml\n",
            "\n",
            "\n",
            "     Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans.\n",
            "    \n",
            "9262493.xml\n",
            "\n",
            "\n",
            "     The acquisition of herpes simplex virus during pregnancy.\n",
            "    \n",
            "8246082.xml\n",
            "\n",
            "\n",
            "     Use of a cervical brush for Papanicolaou smear collection. A meta-analysis.\n",
            "    \n",
            "11849631.xml\n",
            "\n",
            "\n",
            "     Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.\n",
            "    \n",
            "12683477.xml\n",
            "\n",
            "\n",
            "     A primary care \"friendly\" cognitive behavioral insomnia therapy.\n",
            "    \n",
            "8875918.xml\n",
            "\n",
            "\n",
            "     Clinical outcome of mitral regurgitation due to flail leaflet.\n",
            "    \n",
            "12637923.xml\n",
            "\n",
            "\n",
            "     Evaluating invasive cutaneous melanoma: is the initial biopsy representative of the final depth?\n",
            "    \n",
            "16336480.xml\n",
            "\n",
            "\n",
            "     Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.\n",
            "    \n",
            "10749962.xml\n",
            "\n",
            "\n",
            "     The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group.\n",
            "    \n",
            "2709545.xml\n",
            "\n",
            "\n",
            "     The aging thyroid. The use of thyroid hormone in older persons.\n",
            "    \n",
            "10678340.xml\n",
            "\n",
            "\n",
            "     The evidence regarding the drugs used for ventricular rate control.\n",
            "    \n",
            "15908441.xml\n",
            "\n",
            "\n",
            "     Early life risk factors for obesity in childhood: cohort study.\n",
            "    \n",
            "11834677.xml\n",
            "\n",
            "\n",
            "     A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD.\n",
            "    \n",
            "15285276.xml\n",
            "\n",
            "\n",
            "     A pilot study of mind-body changes in adults with asthma who practice mental imagery.\n",
            "    \n",
            "11451298.xml\n",
            "\n",
            "\n",
            "     Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men.\n",
            "    \n",
            "11050261.xml\n",
            "\n",
            "\n",
            "     Herbal medicines for asthma: a systematic review.\n",
            "    \n",
            "11211617.xml\n",
            "\n",
            "\n",
            "     Comparison of four enzyme immunoassays with a western blot assay for the determination of type-specific antibodies to herpes simplex virus.\n",
            "    \n",
            "10428520.xml\n",
            "\n",
            "\n",
            "     Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial.\n",
            "    \n",
            "16856114.xml\n",
            "\n",
            "\n",
            "     Donepezil for mild cognitive impairment.\n",
            "    \n",
            "8280820.xml\n",
            "\n",
            "\n",
            "     A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children.\n",
            "    \n",
            "9430243.xml\n",
            "\n",
            "\n",
            "     First- and second-year effects in trials of calcium supplementation on the loss of bone density in postmenopausal women.\n",
            "    \n",
            "12394811.xml\n",
            "\n",
            "\n",
            "     Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children.\n",
            "    \n",
            "6700642.xml\n",
            "\n",
            "\n",
            "     Efficacy of tonsillectomy for recurrent throat infection in severely affected children. Results of parallel randomized and nonrandomized clinical trials.\n",
            "    \n",
            "8985189.xml\n",
            "\n",
            "\n",
            "     Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients.\n",
            "    \n",
            "12421836.xml\n",
            "\n",
            "\n",
            "     Iron supplementation affects growth and morbidity of breast-fed infants: results of a randomized trial in Sweden and Honduras.\n",
            "    \n",
            "7264790.xml\n",
            "\n",
            "\n",
            "     Diagnosis of iron deficiency: the limitations of laboratory tests in predicting response to iron treatment in 1-year-old infants.\n",
            "    \n",
            "8038475.xml\n",
            "\n",
            "\n",
            "     Treatment of bacterial vaginosis.\n",
            "    \n",
            "9058342.xml\n",
            "\n",
            "\n",
            "     Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole.\n",
            "    \n",
            "3346773.xml\n",
            "\n",
            "\n",
            "     Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections.\n",
            "    \n",
            "20091541.xml\n",
            "\n",
            "\n",
            "     Symptomatic treatment of the cough in whooping cough.\n",
            "    \n",
            "15111671.xml\n",
            "\n",
            "\n",
            "     Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life.\n",
            "    \n",
            "2221647.xml\n",
            "\n",
            "\n",
            "     Clinical prediction rule for pulmonary infiltrates.\n",
            "    \n",
            "10637680.xml\n",
            "\n",
            "\n",
            "     Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies.\n",
            "    \n",
            "10796833.xml\n",
            "\n",
            "\n",
            "     Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation.\n",
            "    \n",
            "15001941.xml\n",
            "\n",
            "\n",
            "     Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis.\n",
            "    \n",
            "11006203.xml\n",
            "\n",
            "\n",
            "     Recurrent miscarriage--an aspirin a day?\n",
            "    \n",
            "12519615.xml\n",
            "\n",
            "\n",
            "     Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease.\n",
            "    \n",
            "16198776.xml\n",
            "\n",
            "\n",
            "     Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.\n",
            "    \n",
            "15633203.xml\n",
            "\n",
            "\n",
            "     Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction.\n",
            "    \n",
            "11289288.xml\n",
            "\n",
            "\n",
            "     Conservative treatment of acute thrombosed external hemorrhoids with topical nifedipine.\n",
            "    \n",
            "7673531.xml\n",
            "\n",
            "\n",
            "     Preventing escalation in problem behaviors with high-risk young adolescents: immediate and 1-year outcomes.\n",
            "    \n",
            "10085797.xml\n",
            "\n",
            "\n",
            "     Criteria for enrolling dementia patients in hospice: a replication.\n",
            "    \n",
            "9170464.xml\n",
            "\n",
            "\n",
            "     Induction of labor versus expectant management in macrosomia: a randomized study.\n",
            "    \n",
            "9220205.xml\n",
            "\n",
            "\n",
            "     Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996.\n",
            "    \n",
            "9879160.xml\n",
            "\n",
            "\n",
            "     Screening for addiction in patients with chronic pain and \"problematic\" substance use: evaluation of a pilot assessment tool.\n",
            "    \n",
            "8668411.xml\n",
            "\n",
            "\n",
            "     Efficacy of glucose-based oral rehydration therapy.\n",
            "    \n",
            "8900550.xml\n",
            "\n",
            "\n",
            "     Use of symptoms, signs, and blood tests to diagnose acute sinus infections in primary care: comparison with computed tomography.\n",
            "    \n",
            "2910090.xml\n",
            "\n",
            "\n",
            "     Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.\n",
            "    \n",
            "17443559.xml\n",
            "\n",
            "\n",
            "     Topical lidocaine for the treatment of postherpetic neuralgia.\n",
            "    \n",
            "15486746.xml\n",
            "\n",
            "\n",
            "     Thrombosed external hemorrhoids: outcome after conservative or surgical management.\n",
            "    \n",
            "11343045.xml\n",
            "\n",
            "\n",
            "     Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.\n",
            "    \n",
            "12882847.xml\n",
            "\n",
            "\n",
            "     Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\n",
            "    \n",
            "11560453.xml\n",
            "\n",
            "\n",
            "     Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis.\n",
            "    \n",
            "17626140.xml\n",
            "\n",
            "\n",
            "     Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study.\n",
            "    \n",
            "12917703.xml\n",
            "\n",
            "\n",
            "     Family involvement in weight control, weight maintenance and weight-loss interventions: a systematic review of randomised trials.\n",
            "    \n",
            "7755059.xml\n",
            "\n",
            "\n",
            "     Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study.\n",
            "    \n",
            "10381965.xml\n",
            "\n",
            "\n",
            "     Mefloquine for malaria chemoprophylaxis 1992-1998: a review.\n",
            "    \n",
            "10613168.xml\n",
            "\n",
            "\n",
            "     Night splint treatment for plantar fasciitis. A prospective randomized study.\n",
            "    \n",
            "17943857.xml\n",
            "\n",
            "\n",
            "     Antidepressants for neuropathic pain.\n",
            "    \n",
            "9516745.xml\n",
            "\n",
            "\n",
            "     Maternal illness, including fever and medication use as risk factors for neural tube defects.\n",
            "    \n",
            "8449054.xml\n",
            "\n",
            "\n",
            "     Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group.\n",
            "    \n",
            "11405989.xml\n",
            "\n",
            "\n",
            "     Iron therapy for improving psychomotor development and cognitive function in children under the age of three with iron deficiency anaemia.\n",
            "    \n",
            "12121581.xml\n",
            "\n",
            "\n",
            "     A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women.\n",
            "    \n",
            "9918527.xml\n",
            "\n",
            "\n",
            "     Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications.\n",
            "    \n",
            "17179478.xml\n",
            "\n",
            "\n",
            "     Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.\n",
            "    \n",
            "11326182.xml\n",
            "\n",
            "\n",
            "     Accuracy and clinical effect of out-of-hospital electrocardiography in the diagnosis of acute cardiac ischemia: a meta-analysis.\n",
            "    \n",
            "1734290.xml\n",
            "\n",
            "\n",
            "     Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup.\n",
            "    \n",
            "9988787.xml\n",
            "\n",
            "\n",
            "     Cold-knife conization versus conization by the loop electrosurgical excision procedure: a randomized, prospective study.\n",
            "    \n",
            "8309029.xml\n",
            "\n",
            "\n",
            "     A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.\n",
            "    \n",
            "7224353.xml\n",
            "\n",
            "\n",
            "     Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy.\n",
            "    \n",
            "2473403.xml\n",
            "\n",
            "\n",
            "     Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.\n",
            "    \n",
            "8381089.xml\n",
            "\n",
            "\n",
            "     The clinical efficacy of inhaled nedocromil sodium (Tilade) in the treatment of asthma.\n",
            "    \n",
            "14557142.xml\n",
            "\n",
            "\n",
            "     Relationship between antidepressant medication treatment and suicide in adolescents.\n",
            "    \n",
            "15951574.xml\n",
            "\n",
            "\n",
            "     Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.\n",
            "    \n",
            "12565715.xml\n",
            "\n",
            "\n",
            "     Low-dose warfarin in rehabilitating stroke survivors.\n",
            "    \n",
            "8613604.xml\n",
            "\n",
            "\n",
            "     Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery.\n",
            "    \n",
            "15459412.xml\n",
            "\n",
            "\n",
            "     Diagnosis of genital herpes by real time PCR in routine clinical practice.\n",
            "    \n",
            "17420682.xml\n",
            "\n",
            "\n",
            "     Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials.\n",
            "    \n",
            "15111779.xml\n",
            "\n",
            "\n",
            "     Efficacy of daily and weekly iron supplementation on iron status in exclusively breast-fed infants.\n",
            "    \n",
            "9091013.xml\n",
            "\n",
            "\n",
            "     Randomised trial comparing a policy of early with selective amniotomy in uncomplicated labour at term.\n",
            "    \n",
            "10399422.xml\n",
            "\n",
            "\n",
            "     Muscle enzyme release does not predict muscle function impairment after triathlon.\n",
            "    \n",
            "17682990.xml\n",
            "\n",
            "\n",
            "     Treatment of naturally acquired common colds with zinc: a structured review.\n",
            "    \n",
            "8345037.xml\n",
            "\n",
            "\n",
            "     Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.\n",
            "    \n",
            "11207873.xml\n",
            "\n",
            "\n",
            "     Hormone replacement therapy and fractures in older adults.\n",
            "    \n",
            "10182646.xml\n",
            "\n",
            "\n",
            "     National Ambulatory Medical Care Survey: 1996 summary.\n",
            "    \n",
            "15265350.xml\n",
            "\n",
            "\n",
            "     Barriers to hospice care and referrals: survey of physicians' knowledge, attitudes, and perceptions in a health maintenance organization.\n",
            "    \n",
            "15788823.xml\n",
            "\n",
            "\n",
            "     Does leucocytosis identify bacterial infections in febrile neonates presenting to the emergency department?\n",
            "    \n",
            "11698781.xml\n",
            "\n",
            "\n",
            "     Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials.\n",
            "    \n",
            "15329425.xml\n",
            "\n",
            "\n",
            "     Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.\n",
            "    \n",
            "1565551.xml\n",
            "\n",
            "\n",
            "     Efficacy of antimicrobial prophylaxis and of tympanostomy tube insertion for prevention of recurrent acute otitis media: results of a randomized clinical trial.\n",
            "    \n",
            "7391096.xml\n",
            "\n",
            "\n",
            "     The so-called unresolved Osgood-Schlatter lesion: a concept based on fifteen surgically treated lesions.\n",
            "    \n",
            "8426621.xml\n",
            "\n",
            "\n",
            "     The association of changes in physical-activity level and other lifestyle characteristics with mortality among men.\n",
            "    \n",
            "15494989.xml\n",
            "\n",
            "\n",
            "     Physician advice for smoking cessation.\n",
            "    \n",
            "11735756.xml\n",
            "\n",
            "\n",
            "     Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.\n",
            "    \n",
            "9596593.xml\n",
            "\n",
            "\n",
            "     Effectiveness of treatments for infantile colic: systematic review.\n",
            "    \n",
            "11711507.xml\n",
            "\n",
            "\n",
            "     Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials.\n",
            "    \n",
            "16340941.xml\n",
            "\n",
            "\n",
            "     Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.\n",
            "    \n",
            "9643743.xml\n",
            "\n",
            "\n",
            "     Complications of use of intrauterine devices among HIV-1-infected women.\n",
            "    \n",
            "15564985.xml\n",
            "\n",
            "\n",
            "     Determinants of white-coat hypertension.\n",
            "    \n",
            "8747507.xml\n",
            "\n",
            "\n",
            "     Evaluation of macrocytosis by general practitioners.\n",
            "    \n",
            "10190360.xml\n",
            "\n",
            "\n",
            "     Pulmonary embolus after vena cava filter placement.\n",
            "    \n",
            "12423708.xml\n",
            "\n",
            "\n",
            "     Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.\n",
            "    \n",
            "8345434.xml\n",
            "\n",
            "\n",
            "     Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.\n",
            "    \n",
            "321002.xml\n",
            "\n",
            "\n",
            "     A randomized controlled trial of bed rest and sedation or normal activity and non-sedation in the management of non-albuminuric hypertension in late pregnancy.\n",
            "    \n",
            "11061763.xml\n",
            "\n",
            "\n",
            "     Predictors of bacteremia in febrile children 3 to 36 months of age.\n",
            "    \n",
            "15358010.xml\n",
            "\n",
            "\n",
            "     Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.\n",
            "    \n",
            "9036306.xml\n",
            "\n",
            "\n",
            "     The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group.\n",
            "    \n",
            "7861574.xml\n",
            "\n",
            "\n",
            "     The effect of passive smoking and tobacco exposure through breast milk on sudden infant death syndrome.\n",
            "    \n",
            "16098855.xml\n",
            "\n",
            "\n",
            "     Common use of inaccurate antibody assays to identify infection status with herpes simplex virus type 2.\n",
            "    \n",
            "11466188.xml\n",
            "\n",
            "\n",
            "     An evidence and consensus based guideline for acute diarrhoea management.\n",
            "    \n",
            "15994719.xml\n",
            "\n",
            "\n",
            "     A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.\n",
            "    \n",
            "1337553.xml\n",
            "\n",
            "\n",
            "     Clinical comparative study of azithromycin versus erythromycin in the treatment of acute respiratory tract infections in children.\n",
            "    \n",
            "16286171.xml\n",
            "\n",
            "\n",
            "     Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.\n",
            "    \n",
            "8535469.xml\n",
            "\n",
            "\n",
            "     A review of the McMurray test: definition, interpretation, and clinical usefulness.\n",
            "    \n",
            "12490470.xml\n",
            "\n",
            "\n",
            "     Accuracy of MR imaging of the knee in adolescents.\n",
            "    \n",
            "12457784.xml\n",
            "\n",
            "\n",
            "     Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.\n",
            "    \n",
            "2656959.xml\n",
            "\n",
            "\n",
            "     Acetaminophen: more harm than good for chickenpox?\n",
            "    \n",
            "7633770.xml\n",
            "\n",
            "\n",
            "     Shave excision of benign papular naevocytic naevi.\n",
            "    \n",
            "16437473.xml\n",
            "\n",
            "\n",
            "     Herbal medicines for treatment of irritable bowel syndrome.\n",
            "    \n",
            "15046273.xml\n",
            "\n",
            "\n",
            "     The natural history of idiopathic toe-walking: a long-term follow-up of fourteen conservatively treated children.\n",
            "    \n",
            "12873166.xml\n",
            "\n",
            "\n",
            "     Findings to date from the ASCUS-LSIL Triage Study (ALTS).\n",
            "    \n",
            "10714731.xml\n",
            "\n",
            "\n",
            "     Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.\n",
            "    \n",
            "2194334.xml\n",
            "\n",
            "\n",
            "     [Infantile constipation and Allomin-lactulose. Treatment of infantile obstipation in infants fed with breast milk substitutes. A controlled clinical trial of 2 per cent and 4 per cent Allomin-lactulose].\n",
            "    \n",
            "11702618.xml\n",
            "\n",
            "\n",
            "     Treatment of urticaria. An evidence-based evaluation of antihistamines.\n",
            "    \n",
            "3545282.xml\n",
            "\n",
            "\n",
            "     A clinical trial using danazol for the treatment of premenstrual tension.\n",
            "    \n",
            "12180738.xml\n",
            "\n",
            "\n",
            "     Therapeutic exercise for people with osteoarthritis of the hip or knee. A systematic review.\n",
            "    \n",
            "8445608.xml\n",
            "\n",
            "\n",
            "     Comparison of cytobrush and cotton swab for Papanicolaou smears in pregnancy.\n",
            "    \n",
            "12748199.xml\n",
            "\n",
            "\n",
            "     The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.\n",
            "    \n",
            "11443569.xml\n",
            "\n",
            "\n",
            "     Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide.\n",
            "    \n",
            "10931404.xml\n",
            "\n",
            "\n",
            "     Nutritional rickets in African American breast-fed infants.\n",
            "    \n",
            "17636776.xml\n",
            "\n",
            "\n",
            "     Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.\n",
            "    \n",
            "12707429.xml\n",
            "\n",
            "\n",
            "     Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.\n",
            "    \n",
            "12449547.xml\n",
            "\n",
            "\n",
            "     Preventing diverticular disease. Review of recent evidence on high-fibre diets.\n",
            "    \n",
            "15795718.xml\n",
            "\n",
            "\n",
            "     Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature.\n",
            "    \n",
            "16048355.xml\n",
            "\n",
            "\n",
            "     Treating mood disorders during pregnancy: safety considerations.\n",
            "    \n",
            "14973951.xml\n",
            "\n",
            "\n",
            "     Antibiotics for acute otitis media in children.\n",
            "    \n",
            "7657281.xml\n",
            "\n",
            "\n",
            "     Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure.\n",
            "    \n",
            "12571845.xml\n",
            "\n",
            "\n",
            "     Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial.\n",
            "    \n",
            "8235922.xml\n",
            "\n",
            "\n",
            "     Comparative evaluation of ofloxacin and metronidazole in the treatment of bacterial vaginosis.\n",
            "    \n",
            "16856045.xml\n",
            "\n",
            "\n",
            "     Steroids for symptom control in infectious mononucleosis.\n",
            "    \n",
            "11306234.xml\n",
            "\n",
            "\n",
            "     Screening for bacterial vaginosis in pregnancy.\n",
            "    \n",
            "10496256.xml\n",
            "\n",
            "\n",
            "     Aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors. MARS Study Group. Magnetic Resonance Angiography in Relatives of patients with Subarachnoid hemorrhage.\n",
            "    \n",
            "10732937.xml\n",
            "\n",
            "\n",
            "     Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis.\n",
            "    \n",
            "15016485.xml\n",
            "\n",
            "\n",
            "     Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.\n",
            "    \n",
            "15769914.xml\n",
            "\n",
            "\n",
            "     Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review.\n",
            "    \n",
            "16368032.xml\n",
            "\n",
            "\n",
            "     A randomized controlled trial of psychological interventions for postnatal depression.\n",
            "    \n",
            "11841361.xml\n",
            "\n",
            "\n",
            "     U.K. guidelines for the management of cutaneous melanoma.\n",
            "    \n",
            "10723977.xml\n",
            "\n",
            "\n",
            "     New therapies for alcohol problems: application to primary care.\n",
            "    \n",
            "17054255.xml\n",
            "\n",
            "\n",
            "     Stapled versus conventional surgery for hemorrhoids.\n",
            "    \n",
            "11006762.xml\n",
            "\n",
            "\n",
            "     Evaluating the benefits of antimicrobial prophylaxis to prevent urinary tract infections in children: a systematic review.\n",
            "    \n",
            "12821232.xml\n",
            "\n",
            "\n",
            "     Secondary prevention with folic acid: effects on clinical outcomes.\n",
            "    \n",
            "8517575.xml\n",
            "\n",
            "\n",
            "     Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research.\n",
            "    \n",
            "16428925.xml\n",
            "\n",
            "\n",
            "     The treatment of psoriatic arthritis.\n",
            "    \n",
            "8509358.xml\n",
            "\n",
            "\n",
            "     Therapeutic strategies for the patient with treatment-resistant anxiety.\n",
            "    \n",
            "14644896.xml\n",
            "\n",
            "\n",
            "     Screening for obesity in adults: recommendations and rationale.\n",
            "    \n",
            "11869676.xml\n",
            "\n",
            "\n",
            "     Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease.\n",
            "    \n",
            "11034729.xml\n",
            "\n",
            "\n",
            "     Exercise-based rehabilitation for coronary heart disease.\n",
            "    \n",
            "11687009.xml\n",
            "\n",
            "\n",
            "     What is the role of stimulant laxatives in the management of childhood constipation and soiling?.\n",
            "    \n",
            "10606058.xml\n",
            "\n",
            "\n",
            "     An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis.\n",
            "    \n",
            "12913777.xml\n",
            "\n",
            "\n",
            "     Clinical evaluation of a quantitative real time polymerase chain reaction assay for diagnosis of primary Epstein-Barr virus infection in children.\n",
            "    \n",
            "12460095.xml\n",
            "\n",
            "\n",
            "     Risk factors for sudden infant death syndrome among northern plains Indians.\n",
            "    \n",
            "11641669.xml\n",
            "\n",
            "\n",
            "     A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage.\n",
            "    \n",
            "7935681.xml\n",
            "\n",
            "\n",
            "     Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.\n",
            "    \n",
            "9290622.xml\n",
            "\n",
            "\n",
            "     Celiac disease and selective immunoglobulin A deficiency.\n",
            "    \n",
            "18056558.xml\n",
            "\n",
            "\n",
            "     Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents.\n",
            "    \n",
            "14984373.xml\n",
            "\n",
            "\n",
            "     Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.\n",
            "    \n",
            "10334745.xml\n",
            "\n",
            "\n",
            "     Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review.\n",
            "    \n",
            "12409542.xml\n",
            "\n",
            "\n",
            "     Sex-based differences in the effect of digoxin for the treatment of heart failure.\n",
            "    \n",
            "2929804.xml\n",
            "\n",
            "\n",
            "     Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87.\n",
            "    \n",
            "8896541.xml\n",
            "\n",
            "\n",
            "     Efficacy of high-titer live attenuated varicella vaccine in healthy young children.\n",
            "    \n",
            "7942584.xml\n",
            "\n",
            "\n",
            "     A prospective study of diet and the risk of symptomatic diverticular disease in men.\n",
            "    \n",
            "11687054.xml\n",
            "\n",
            "\n",
            "     Rizatriptan for acute migraine.\n",
            "    \n",
            "1998638.xml\n",
            "\n",
            "\n",
            "     A randomized controlled trial of early amniotomy.\n",
            "    \n",
            "11567699.xml\n",
            "\n",
            "\n",
            "     Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study.\n",
            "    \n",
            "9669977.xml\n",
            "\n",
            "\n",
            "     Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians.\n",
            "    \n",
            "8236597.xml\n",
            "\n",
            "\n",
            "     Varicocele: a progressive or static lesion?\n",
            "    \n",
            "10796394.xml\n",
            "\n",
            "\n",
            "     Calcium and vitamin D for corticosteroid-induced osteoporosis.\n",
            "    \n",
            "6244871.xml\n",
            "\n",
            "\n",
            "     Does a high fibre diet prevent the complications of diverticular disease?\n",
            "    \n",
            "12114036.xml\n",
            "\n",
            "\n",
            "     MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.\n",
            "    \n",
            "16437528.xml\n",
            "\n",
            "\n",
            "     Omega 3 fatty acid for the prevention of dementia.\n",
            "    \n",
            "7756486.xml\n",
            "\n",
            "\n",
            "     Concurrent outbreaks of pertussis and Mycoplasma pneumoniae infection: clinical and epidemiological characteristics of illnesses manifested by cough.\n",
            "    \n",
            "12114037.xml\n",
            "\n",
            "\n",
            "     MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.\n",
            "    \n",
            "12427500.xml\n",
            "\n",
            "\n",
            "     Screening for esophageal adenocarcinoma: an evidence-based approach.\n",
            "    \n",
            "12527571.xml\n",
            "\n",
            "\n",
            "     Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence.\n",
            "    \n",
            "15935019.xml\n",
            "\n",
            "\n",
            "     The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial.\n",
            "    \n",
            "12220783.xml\n",
            "\n",
            "\n",
            "     Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.\n",
            "    \n",
            "4053146.xml\n",
            "\n",
            "\n",
            "     Adverse effects of iron supplementation: a comparative trial of a wax-matrix iron preparation and conventional ferrous sulfate tablets.\n",
            "    \n",
            "15126259.xml\n",
            "\n",
            "\n",
            "     Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force.\n",
            "    \n",
            "10356424.xml\n",
            "\n",
            "\n",
            "     Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate.\n",
            "    \n",
            "15315995.xml\n",
            "\n",
            "\n",
            "     Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.\n",
            "    \n",
            "11529209.xml\n",
            "\n",
            "\n",
            "     Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women.\n",
            "    \n",
            "14659983.xml\n",
            "\n",
            "\n",
            "     International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions.\n",
            "    \n",
            "10609710.xml\n",
            "\n",
            "\n",
            "     Plantar fasciitis: how successful is surgical intervention?\n",
            "    \n",
            "10696941.xml\n",
            "\n",
            "\n",
            "     A protocol of early spiral computed tomography for the detection of stones in patients with renal colic has reduced the time to diagnosis and overall management costs.\n",
            "    \n",
            "1952493.xml\n",
            "\n",
            "\n",
            "     NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel.\n",
            "    \n",
            "10659912.xml\n",
            "\n",
            "\n",
            "     Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials.\n",
            "    \n",
            "11933571.xml\n",
            "\n",
            "\n",
            "     Clinical utility of the band count.\n",
            "    \n",
            "12729427.xml\n",
            "\n",
            "\n",
            "     Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.\n",
            "    \n",
            "12076448.xml\n",
            "\n",
            "\n",
            "     Tricyclic drugs for depression in children and adolescents.\n",
            "    \n",
            "7771913.xml\n",
            "\n",
            "\n",
            "     A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.\n",
            "    \n",
            "16319919.xml\n",
            "\n",
            "\n",
            "     ACNP Task Force report on SSRIs and suicidal behavior in youth.\n",
            "    \n",
            "9416884.xml\n",
            "\n",
            "\n",
            "     Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)\n",
            "    \n",
            "12529459.xml\n",
            "\n",
            "\n",
            "     Imaging studies after a first febrile urinary tract infection in young children.\n",
            "    \n",
            "12696781.xml\n",
            "\n",
            "\n",
            "     Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program.\n",
            "    \n",
            "10780124.xml\n",
            "\n",
            "\n",
            "     Treatment of spit tobacco users with transdermal nicotine system and mint snuff.\n",
            "    \n",
            "8065869.xml\n",
            "\n",
            "\n",
            "     Febrile infants at low risk for serious bacterial infection--an appraisal of the Rochester criteria and implications for management. Febrile Infant Collaborative Study Group.\n",
            "    \n",
            "16816220.xml\n",
            "\n",
            "\n",
            "     A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.\n",
            "    \n",
            "12865262.xml\n",
            "\n",
            "\n",
            "     Mortality in Barrett's oesophagus: results from a population based study.\n",
            "    \n",
            "12972967.xml\n",
            "\n",
            "\n",
            "     Excision of thrombosed external hemorrhoid under local anesthesia: a retrospective evaluation of 340 patients.\n",
            "    \n",
            "11083738.xml\n",
            "\n",
            "\n",
            "     Baseline predictors of tolerability to carvedilol in patients with chronic heart failure.\n",
            "    \n",
            "15135147.xml\n",
            "\n",
            "\n",
            "     Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals.\n",
            "    \n",
            "17943896.xml\n",
            "\n",
            "\n",
            "     Vena caval filters for the prevention of pulmonary embolism.\n",
            "    \n",
            "17846141.xml\n",
            "\n",
            "\n",
            "     Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.\n",
            "    \n",
            "10649820.xml\n",
            "\n",
            "\n",
            "     Implications of not treating hyperprolactinemia.\n",
            "    \n",
            "15765388.xml\n",
            "\n",
            "\n",
            "     Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.\n",
            "    \n",
            "1474406.xml\n",
            "\n",
            "\n",
            "     The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys.\n",
            "    \n",
            "9574657.xml\n",
            "\n",
            "\n",
            "     Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the \"high-dose hook effect\": case report.\n",
            "    \n",
            "12519540.xml\n",
            "\n",
            "\n",
            "     Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures.\n",
            "    \n",
            "17065637.xml\n",
            "\n",
            "\n",
            "     Survival of patients with stage I lung cancer detected on CT screening.\n",
            "    \n",
            "2642673.xml\n",
            "\n",
            "\n",
            "     Decision rules and clinical prediction of pneumonia: evaluation of low-yield criteria.\n",
            "    \n",
            "11036118.xml\n",
            "\n",
            "\n",
            "     A comparison of glyburide and insulin in women with gestational diabetes mellitus.\n",
            "    \n",
            "12879992.xml\n",
            "\n",
            "\n",
            "     Hepatotoxicity of hypolipidemic drugs.\n",
            "    \n",
            "16423126.xml\n",
            "\n",
            "\n",
            "     Brief report: Utility of a short screening scale for DSM-IV PTSD in primary care.\n",
            "    \n",
            "10727588.xml\n",
            "\n",
            "\n",
            "     Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.\n",
            "    \n",
            "10074011.xml\n",
            "\n",
            "\n",
            "     Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study.\n",
            "    \n",
            "11588078.xml\n",
            "\n",
            "\n",
            "     Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review.\n",
            "    \n",
            "10218753.xml\n",
            "\n",
            "\n",
            "     Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH).\n",
            "    \n",
            "12120909.xml\n",
            "\n",
            "\n",
            "     Comparison of open carpal tunnel release and local steroid treatment outcomes in idiopathic carpal tunnel syndrome.\n",
            "    \n",
            "11847935.xml\n",
            "\n",
            "\n",
            "     Effect of tablet splitting on serum cholesterol concentrations.\n",
            "    \n",
            "9356004.xml\n",
            "\n",
            "\n",
            "     Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination.\n",
            "    \n",
            "17051752.xml\n",
            "\n",
            "\n",
            "     Preseptal and orbital cellulitis: a 10-year review of hospitalized patients.\n",
            "    \n",
            "8944521.xml\n",
            "\n",
            "\n",
            "     Is the conservative management of the acute scrotum justified on clinical grounds?\n",
            "    \n",
            "9834257.xml\n",
            "\n",
            "\n",
            "     Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease.\n",
            "    \n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "FGo-ByXpwZhi"
      },
      "source": [
        "fyles = []\n",
        "abs = []\n",
        "tit = []\n",
        "pt = []\n",
        "for fils in os.listdir(\"/content/devtestset\"):\n",
        "  with open(os.path.join(\"/content/devtestset\",fils), 'r') as f:\n",
        "    data = f.read()\n",
        "  bs_data = BeautifulSoup(data, 'xml')\n",
        "  fyles.append(fils)\n",
        "  try:\n",
        "    abs.append(bs_data.find_all('abstract')[0].get_text())\n",
        "  except:\n",
        "    abs.append(bs_data.find_all('abstracttext')[0].get_text())\n",
        "  tit.append(bs_data.find_all('articletitle')[0].get_text())\n",
        "  try:\n",
        "    pt.append(bs_data.find_all('publicationtype')[0].get_text())\n",
        "  except:\n",
        "    pt.append(\"N/A\")\n",
        "\n",
        "  # print(bs_data.find_all('abstract')[0].find_all('abstracttext',attrs={\"nlmcategory\":\"METHODS\"}))\n",
        "  # print(bs_data.find_all('abstract')[0].find_all('abstracttext',attrs={\"nlmcategory\":\"RESULTS\"}))\n",
        "  # print(bs_data.find_all('abstract')[0].find_all('abstracttext',attrs={\"nlmcategory\":\"CONCLUSIONS\"}))"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "Nd3vBniCJGNu"
      },
      "source": [
        "data = pd.DataFrame(zip(fyles,abs,tit,pt),columns = ['xml_files','abstract','title','pt'])"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "Sqa5tIjxKS8c",
        "outputId": "2cba06ff-0a13-4dc0-b38f-7c1b69bf077f"
      },
      "source": [
        "train_df.head()"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>evidence</th>\n",
              "      <th>label</th>\n",
              "      <th>xml_files</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00001</td>\n",
              "      <td>C</td>\n",
              "      <td>9149180</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00002</td>\n",
              "      <td>B</td>\n",
              "      <td>4396080</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00003</td>\n",
              "      <td>B</td>\n",
              "      <td>1519858</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00004</td>\n",
              "      <td>A</td>\n",
              "      <td>15547167</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00005</td>\n",
              "      <td>C</td>\n",
              "      <td>11392916</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "  evidence label xml_files\n",
              "0    00001     C   9149180\n",
              "1    00002     B   4396080\n",
              "2    00003     B   1519858\n",
              "3    00004     A  15547167\n",
              "4    00005     C  11392916"
            ]
          },
          "metadata": {},
          "execution_count": 17
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "rzjQ6A5nMWrj",
        "outputId": "bafe4b0c-6955-4cf0-bd46-4d88df40c00a"
      },
      "source": [
        "train_df.shape"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(677, 3)"
            ]
          },
          "metadata": {},
          "execution_count": 18
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "id": "XRG-CAHArs3G",
        "outputId": "a0e831e4-5722-4088-d9c9-61ee6ff22268"
      },
      "source": [
        "test_df"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>evidence</th>\n",
              "      <th>xml_files</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>20001</td>\n",
              "      <td>11204585</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>20002</td>\n",
              "      <td>12117397</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>20003</td>\n",
              "      <td>11502313</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>20004</td>\n",
              "      <td>12686036</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>20005</td>\n",
              "      <td>15888839</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>178</th>\n",
              "      <td>20179</td>\n",
              "      <td>9405900</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>179</th>\n",
              "      <td>20180</td>\n",
              "      <td>18078406</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>180</th>\n",
              "      <td>20181</td>\n",
              "      <td>12671151</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>181</th>\n",
              "      <td>20182</td>\n",
              "      <td>15542510</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>182</th>\n",
              "      <td>20183</td>\n",
              "      <td>3517206</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>183 rows  2 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "    evidence xml_files\n",
              "0      20001  11204585\n",
              "1      20002  12117397\n",
              "2      20003  11502313\n",
              "3      20004  12686036\n",
              "4      20005  15888839\n",
              "..       ...       ...\n",
              "178    20179   9405900\n",
              "179    20180  18078406\n",
              "180    20181  12671151\n",
              "181    20182  15542510\n",
              "182    20183   3517206\n",
              "\n",
              "[183 rows x 2 columns]"
            ]
          },
          "metadata": {},
          "execution_count": 38
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "lNVwuU-Ushgn"
      },
      "source": [
        "test_df['xml_files'] = test_df['xml_files'].apply(lambda x: str(x)+\".xml\")"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "HUtvtQ5xL4y0"
      },
      "source": [
        "train_df['xml_files'] = train_df['xml_files'].apply(lambda x: str(x)+\".xml\")"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "N6BpdWdj69K2"
      },
      "source": [
        "val_df['xml_files'] = val_df['xml_files'].apply(lambda x: str(x)+\".xml\")"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "9lC_itF2KNkc"
      },
      "source": [
        "import pandas as pd\n",
        "fin = pd.merge(val_df, data, on=\"xml_files\")"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "id": "KC4cLkr8dYU4",
        "outputId": "fba4e5f3-1120-4131-b9fc-76bf29f72d62"
      },
      "source": [
        "fin"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>evidence</th>\n",
              "      <th>label</th>\n",
              "      <th>xml_files</th>\n",
              "      <th>abstract</th>\n",
              "      <th>title</th>\n",
              "      <th>pt</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10001</td>\n",
              "      <td>B</td>\n",
              "      <td>19454119.xml</td>\n",
              "      <td>\\n\\n      Diverticula (mucosal outpouching thr...</td>\n",
              "      <td>\\n     Colonic diverticular disease.\\n</td>\n",
              "      <td>\\n      Journal Article\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10002</td>\n",
              "      <td>A</td>\n",
              "      <td>12531578.xml</td>\n",
              "      <td>\\n\\n      Present angiotensin-converting-enzym...</td>\n",
              "      <td>\\n     Combination treatment of angiotensin-II...</td>\n",
              "      <td>\\n      Clinical Trial\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10003</td>\n",
              "      <td>A</td>\n",
              "      <td>10637680.xml</td>\n",
              "      <td>\\n\\n      To obtain estimates of the relative ...</td>\n",
              "      <td>\\n     Attention-deficit hyperactivity disorde...</td>\n",
              "      <td>\\n      Journal Article\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10004</td>\n",
              "      <td>A</td>\n",
              "      <td>9679792.xml</td>\n",
              "      <td>\\n\\n      Despite the efficacy of warfarin sod...</td>\n",
              "      <td>\\n     Fixed minidose warfarin and aspirin alo...</td>\n",
              "      <td>\\n      Clinical Trial\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10005</td>\n",
              "      <td>C</td>\n",
              "      <td>6726967.xml</td>\n",
              "      <td>\\n\\n      The correlation between the presence...</td>\n",
              "      <td>\\n     The importance of the cremasteric refle...</td>\n",
              "      <td>\\n      Journal Article\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>173</th>\n",
              "      <td>10172</td>\n",
              "      <td>B</td>\n",
              "      <td>12137880.xml</td>\n",
              "      <td>\\n\\n      To determine, for a woman aged &gt;45 y...</td>\n",
              "      <td>\\n     Time to the final menstrual period.\\n</td>\n",
              "      <td>\\n      Journal Article\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>174</th>\n",
              "      <td>10174</td>\n",
              "      <td>C</td>\n",
              "      <td>9142003.xml</td>\n",
              "      <td>\\n\\n      Only limited data on the rate of hem...</td>\n",
              "      <td>\\n     Prospective study of asymptomatic valvu...</td>\n",
              "      <td>\\n      Journal Article\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>175</th>\n",
              "      <td>10175</td>\n",
              "      <td>A</td>\n",
              "      <td>17237298.xml</td>\n",
              "      <td>\\n\\n      To examine the effectiveness of meth...</td>\n",
              "      <td>\\n     Improved effectiveness of partner notif...</td>\n",
              "      <td>\\n      Journal Article\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>176</th>\n",
              "      <td>10177</td>\n",
              "      <td>B</td>\n",
              "      <td>16543212.xml</td>\n",
              "      <td>\\n\\n      Some clinicians are under the impres...</td>\n",
              "      <td>\\n     The evidence supporting the use of hone...</td>\n",
              "      <td>\\n      Journal Article\\n</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>177</th>\n",
              "      <td>10178</td>\n",
              "      <td>C</td>\n",
              "      <td>3564971.xml</td>\n",
              "      <td>\\n\\n      In an experimental study to determin...</td>\n",
              "      <td>\\n     Infant self-regulation of breast milk i...</td>\n",
              "      <td>\\n      Comparative Study\\n</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>178 rows  6 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "    evidence  ...                                pt\n",
              "0      10001  ...    \\n      Journal Article\\n     \n",
              "1      10002  ...     \\n      Clinical Trial\\n     \n",
              "2      10003  ...    \\n      Journal Article\\n     \n",
              "3      10004  ...     \\n      Clinical Trial\\n     \n",
              "4      10005  ...    \\n      Journal Article\\n     \n",
              "..       ...  ...                               ...\n",
              "173    10172  ...    \\n      Journal Article\\n     \n",
              "174    10174  ...    \\n      Journal Article\\n     \n",
              "175    10175  ...    \\n      Journal Article\\n     \n",
              "176    10177  ...    \\n      Journal Article\\n     \n",
              "177    10178  ...  \\n      Comparative Study\\n     \n",
              "\n",
              "[178 rows x 6 columns]"
            ]
          },
          "metadata": {},
          "execution_count": 56
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "A6AX1dU3cQj9"
      },
      "source": [
        "fin.to_csv(\"Dekho_ab_val.csv\",index=False)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "l26u1BJQ4gWC",
        "outputId": "aec32843-d5cd-4a2b-d03e-e68f2129cf57"
      },
      "source": [
        "# for fils in os.listdir(\"/content/trainset\"):\n",
        "#   with open(os.path.join(\"/content/trainset\",fils), 'r') as f:\n",
        "#     data = f.read()\n",
        "#   bs_data = BeautifulSoup(data, 'xml')\n",
        "#   print(fils+\"\\n\")\n",
        "#   print(bs_data.find_all('abstract')[0].find_all('abstracttext',attrs={\"nlmcategory\":\"OBJECTIVE\"}))\n",
        "#   print(bs_data.find_all('abstract')[0].find_all('abstracttext',attrs={\"nlmcategory\":\"METHODS\"}))\n",
        "#   print(bs_data.find_all('abstract')[0].find_all('abstracttext',attrs={\"nlmcategory\":\"RESULTS\"}))\n",
        "#   print(bs_data.find_all('abstract')[0].find_all('abstracttext',attrs={\"nlmcategory\":\"CONCLUSIONS\"}))"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Sodium valproate is a well-tolerated drug and provides significant subjective improvement in painful diabetic neuropathy. These data provide a basis for future trials of longer duration in a larger group of patients.\n",
            "     </abstracttext>]\n",
            "11448655.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SUBJECTS AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for &gt; or = 30 days and with a glycosylated hemoglobin (HbA1C) level &gt; or = 8.0%. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Patients receiving pioglitazone + sulfonylurea had significant (P &lt; 0.05) decreases from baseline in HbA1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9% (95% confidence interval [CI]: 0.06% to 1.2%) with pioglitazone 15 mg and 1.3% (CI: 1% to 1.6%) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95% CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95% CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P &lt; 0.05) mean percent decreases in triglyceride levels (17%, 95% CI: 6% to 27% for 15 mg; 26%, 95% CI: 16% to 36% for 30 mg) and increases in high-density lipoprotein cholesterol levels (6%, 95% CI: 1% to 11% for 15 mg; 13%, CI: 8% to 18% for 30 mg) compared with placebo + sulfonylurea. There were small but statistically significant mean percent increases in low-density lipoprotein cholesterol levels in all groups. Pioglitazone was well tolerated, and the rates of adverse events were similar in all groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In patients with type 2 diabetes, pioglitazone plus sulfonylurea significantly improves HbA1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.\n",
            "     </abstracttext>]\n",
            "8970899.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9722799.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Six hundred patients with seasonal allergic rhinitis were treated for 2 weeks with either FP ANS 200 microgram once daily, loratadine 10 mg once daily, the FP ANS and loratadine regimens combined, or placebo in a multicenter, randomized, double-blind, double-dummy, parallel-group study.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Clinician- and patient-rated total and individual nasal symptom scores after 7 and 14 days of therapy and overall evaluations were significantly lower (P &lt; .001) in the FP ANS and FP ANS plus loratadine groups compared with the loratadine only and placebo groups. Loratadine was not statistically different from placebo in clinician and patient symptom score ratings nor in overall clinician and patient evaluations. FP ANS plus loratadine and FP ANS monotherapy were comparable in efficacy in almost all evaluations; for some patient-rated symptoms the combination was found superior. Mean score changes in the Rhinoconjunctivitis Quality of Life Questionnaire from baseline to day 14 showed significantly greater improvement (P &lt; .001) in quality of life in the FP ANS group than in the group of patients receiving loratadine only or placebo and no significant benefit was demonstrated in the FP ANS plus loratadine group over the FP ANS monotherapy group. No serious or unusual drug-related adverse events were reported. Combining loratadine with FP ANS did not alter the adverse events profile or frequency.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "12601075.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months were randomly assigned to placebo or low-intensity warfarin (target INR, 1.5 to 2.0). Participants were followed for recurrent venous thromboembolism, major hemorrhage, and death.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The trial was terminated early after 508 patients had undergone randomization and had been followed for up to 4.3 years (mean, 2.1). Of 253 patients assigned to placebo, 37 had recurrent venous thromboembolism (7.2 per 100 person-years), as compared with 14 of 255 patients assigned to low-intensity warfarin (2.6 per 100 person-years), a risk reduction of 64 percent (hazard ratio, 0.36 [95 percent confidence interval, 0.19 to 0.67]; P&lt;0.001). Risk reductions were similar for all subgroups, including those with and those without inherited thrombophilia. Major hemorrhage occurred in two patients assigned to placebo and five assigned to low-intensity warfarin (P=0.25). Eight patients in the placebo group and four in the group assigned to low-intensity warfarin died (P=0.26). Low-intensity warfarin was thus associated with a 48 percent reduction in the composite end point of recurrent venous thromboembolism, major hemorrhage, or death. According to per-protocol and as-treated analyses, the reduction in the risk of recurrent venous thromboembolism was between 76 and 81 percent.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.\n",
            "     </abstracttext>]\n",
            "12140298.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In a multistate retrospective cohort study, we compared the effectiveness of the screening and risk-based approaches in preventing early-onset group B streptococcal disease (in infants less than seven days old). We studied a stratified random sample of the 629,912 live births in 1998 and 1999 in eight geographical areas where there was active surveillance for group B streptococcal infection, including all births in which the neonate had early-onset disease. Women with no documented culture for group B streptococcus were considered to have been cared for according to the risk-based approach.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      We studied 5144 births, including 312 in which the newborn had early-onset group B streptococcal disease. Antenatal screening was documented for 52 percent of the mothers. The risk of early-onset disease was significantly lower among the infants of screened women than among those in the risk-based group (adjusted relative risk, 0.46; 95 percent confidence interval, 0.36 to 0.60). Because women whose providers had no strategy for prophylaxis may have been misclassified in the risk-based group, we excluded all women with risk factors and adequate time for prophylaxis who did not receive antibiotics. The adjusted relative risk of early-onset disease associated with the screening approach in this secondary analysis was similar--0.48 (95 percent confidence interval, 0.37 to 0.63).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Routine screening for group B streptococcus during pregnancy prevents more cases of early-onset disease than the risk-based approach. Recommendations that endorse both strategies as equivalent warrant reconsideration.\n",
            "     </abstracttext>]\n",
            "12451364.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11181776.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      The ASCUS/LSIL (i.e., low-grade squamous intraepithelial lesion) Triage Study (ALTS) is a multicenter, randomized trial comparing the sensitivity and specificity of the following three management strategies to detect cervical intraepithelial neoplasia grade 3 (CIN3): 1) immediate colposcopy (considered to be the reference standard), 2) triage to colposcopy based on human papillomavirus (HPV) results from Hybrid Capture 2(TM) (HC 2) and thin-layer cytology results, or 3) triage based on cytology results alone. This article summarizes the cross-sectional enrollment results for 3488 women with a referral diagnosis of ASCUS. All statistical tests are two-sided.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Among participants with ASCUS, the underlying prevalence of histologically confirmed CIN3 was 5.1%. Sensitivity to detect CIN3 or above by testing for cancer-associated HPV DNA was 96.3% (95% confidence interval [CI] = 91.6% to 98.8%), with 56.1% of women referred to colposcopy. Sensitivity of a single repeat cytology specimen with a triage threshold of HSIL or above was 44.1% (95% CI = 35.6% to 52.9%), with 6.9% referred. Sensitivity of a lower cytology triage threshold of ASCUS or above was 85.3% (95% CI = 78.2% to 90.8%), with 58.6% referred.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      HC 2 testing for cancer-associated HPV DNA is a viable option in the management of women with ASCUS. It has greater sensitivity to detect CIN3 or above and specificity comparable to a single additional cytologic test indicating ASCUS or above.\n",
            "     </abstracttext>]\n",
            "17015870.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9284865.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10587552.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the efficacy of calcitriol and hormonal replacement therapy (HRT) in the treatment of steroid-induced osteoporosis in hypogonadal women.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We studied 28 young patients (aged 37 +/- 6 yr) with systemic lupus erythematosus (SLE) on chronic steroid therapy for 130 +/- 22 months and requiring more than 10 mg/day prednisone. They were amenorrhoeic for more than 2 yr with proven ovarian failure. All had osteopenia with a T score at L2-4 of less than -1. They were randomized to receive HRT (conjugated oestrogen 0.625 mg daily from day 1 to day 21 plus medroxyprogesterone acetate 5 mg daily days 10-21) or calcitriol 0.5 microg daily. All received calcium carbonate 1 g/day.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There were no differences in the baseline demographic, bone mineral density (BMD) and biochemical data between the two groups. Lumbar spine BMD increased by 2.0 +/- 0.4% after 2 yr with HRT (P&lt;0.05), but reduced by 1.74 +/- 0.4% (P&lt;0.05) with calcitriol treatment. No change was seen at the distal one-third radius with HRT treatment but significant bone loss (2.3 +/- 1.4%, P&lt;0.02) was observed with calcitriol therapy. BMD at the hip did not change in both groups. Comparing both treatment groups, significant differences in the BMD at the spine (P&lt;0.03) and radius (P&lt;0.05) were seen at the end of 2 yr. The changes in urinary n-telopeptide excretion but not serum osteocalcin at 6 months and 12 months were inversely correlated with the changes in lumbar spine BMD at 24 months. HRT did not cause an adverse effect on SLE disease activity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      HRT but not calcitriol could prevent bone loss in young hypogonadal women on chronic steroid therapy.\n",
            "     </abstracttext>]\n",
            "16020410.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To review the literature on nipple pain and to delineate effective strategies for the prevention and treatment of nipple pain in breastfeeding mothers.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      Computerized searches on MEDLINE, Pre-MEDLINE, CINAHL, and the Cochrane Library.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Articles from indexed journals relevant to the objective were reviewed from January 1983 to April 2004. Preference was given to research-based studies in English.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Data were extracted and organized under two headings: prevention of nipple pain or trauma and treatment of nipple pain or trauma. The Critical Appraisal Form by J. Briggs was used to extract the data from research-based articles.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      The health benefits of breastfeeding for mother and infant are well documented; however, nipple pain is a common reason reported by women for the early termination of breastfeeding. Several studies have compared various treatments for either the prevention of or treatment for nipple pain. These treatments include warm water compresses, tea bag compresses, heat, application of expressed mother's milk, lanolin, vitamin A, collagenase, dexpanthenol, hydrogel therapy, glycerin gel therapy, moist occlusive dressing, education regarding proper latch-on and positioning, and no treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      No one topical agent showed superior results in the relief of nipple discomfort. The most important factor in decreasing the incidence of nipple pain is the provision of education in relation to proper breastfeeding technique and latch-on as well as anticipatory guidance regarding the high incidence of early postpartum nipple pain.\n",
            "     </abstracttext>]\n",
            "9781781.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10671393.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Few controlled trials of pharmacologic intervention in women with antidepressant-associated sexual dysfunction have been reported, and there is uncertainty about the usefulness of putative treatments and the assessment methodologies. The authors evaluated the efficacy of buspirone and amantadine in the treatment of sexual dysfunction associated with fluoxetine administration.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Women who had been successfully treated with fluoxetine for at least 8 weeks and who had reported a deterioration in sexual function not present before the initiation of fluoxetine entered a 4-week assessment period. After assessment they were randomly assigned to an 8-week treatment trial with buspirone (N=19), amantadine (N=18), or placebo (N=20). Outcomes were assessed by using a patient-rated daily diary and a clinician-rated structured interview.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      While the amantadine-treated women did report significantly greater improvements in energy levels than women in the placebo group, all treatment groups experienced improvement in overall sexual function as well as in most individual measures. There were no statistically significant differences among the three groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Neither buspirone nor amantadine was more effective than placebo in ameliorating antidepressant-associated sexual dysfunction. All groups experienced marked nonspecific improvement during treatment, which suggests the importance of placebo-controlled trials for this condition.\n",
            "     </abstracttext>]\n",
            "12076503.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess effectiveness of NSAIDs (oral or topical) in the treatment of adults with lateral elbow pain with respect to symptom (pain) reduction, improvement in function, grip strength and adverse effects.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Musculoskeletal Review Group's trials register database, the Cochrane Clinical Trials Register (Cochrane Library issue 2, 2001), MEDLINE, CINAHL, EMBASE and SCISEARCH up to June 2001.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised and pseudo randomised trials in all languages of NSAIDs (oral or topical) compared to placebo or another intervention, or comparing two NSAIDs (oral or topical) to each other, in adults with lateral elbow pain (tennis elbow). Outcomes of interest were pain, function, disability and quality of life, strength, participant satisfaction with treatment and adverse effect.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two reviewers independently applied selection criteria and assessed study quality.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Fourteen trials were included in the review. Few trials used intention to treat analysis, and the sample size of most was small. The median follow up was 2 weeks (range 1-12 weeks). There is evidence that topical NSAIDs are significantly more effective than placebo with respect to pain [weighted main difference= -1.88, (95% confidence intervals -2.54 to -1.21)] and participant satisfaction [relative risk 0.39, (95% confidence intervals 0.23 to 0.66)] in the short term, and this finding is robust against the possible bias introduced by the inclusion of unblinded trials and publication bias. The adverse effects reported were minor. Only two included trials assessed the effect of oral NSAID and these were not able to be pooled. There is some evidence for short term benefit with respect to pain and function from oral NSAIDs, but this benefit was not sustained. Significantly more gastrointestinal adverse effects were reported by those taking oral NSAIDs [relative risk = 3.17, (95% confidence intervals 1.35 to 7.41)]. In the short term there may be some advantage in steroid injection over oral NSAID [patient's perception of benefit relative risk = 3.06, (95% confidence intervals 1.55 to 6.06)], but this was not sustained in the longer term.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is some support for the use of topical NSAIDs to relieve lateral elbow pain at least in the short term. There remains insufficient evidence to recommend or discourage the use of oral NSAID, although it appears injection may be more effective than oral NSAID in the short term. A direct comparison between topical and oral NSAID has not been made and so no conclusions can be drawn regarding the best method of administration.\n",
            "     </abstracttext>]\n",
            "17572422.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the effects of low-dose hormone therapy (LD-HT) on bleeding pattern and vasomotor symptoms in perimenopausal women.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In a prospective, open-label study at an University clinic, 120 perimenopausal women suffering from irregular menstrual cycles and hot flushes were randomized to micronized 17beta-estradiol 1 mg plus dydrogesterone 10 mg sequential added (LD-HT; group A: 60 subjects) or dydrogesterone 10 mg from day 15 to 28 (group B: 60 subjects). Number and severity of hot flushes and bleeding pattern were assessed throughout the study.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Women in group A experienced a significant reduction in number of hot flushes while no significant variation was observed in group B. The incidence of cyclic bleeding was 86% in group A and 76% in group B, the mean duration was significantly lower in group A than in group B.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      LD-HT may control both irregular bleeding and hot flushes in perimenopausal women.\n",
            "     </abstracttext>]\n",
            "10028110.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11790165.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To present the use of the combined continuous-wave/pulsed carbon dioxide (CO2) laser as an innovative therapeutic method, to compare it with established methods, and to assess its results.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Prospective observational study between March 1998 and July 2000, comprising 1 treatment session with 6-week and 6-month follow-up examinations and evaluations.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Private or institutional practices as well as ambulatory or hospitalized care.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      One hundred patients with pyogenic granuloma selected from a population-based sample.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Treatment with CO2 laser. The laser was first used in continuous mode (power, 15 W) and then in pulsed mode (pulse length, 0.6-0.9 milliseconds; energy fluence, 500 mJ/pulse).\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURE\" nlmcategory=\"METHODS\">\n",
            "      Complete resolution of treated granuloma pyogenicum.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Pyogenic granuloma was removed completely in 1 treatment session in 98 patients without recurrence. In 88 cases there were no visible scars; in 10 cases slight textural changes of the skin were observed. Hypertrophic scars or keloids did not occur. Sixty-three patients were very satisfied with the result of the treatment, 37 were satisfied (ie, 100% patient satisfaction), and none indicated that they were not satisfied. No permanent hypopigmentation, hyperpigmentation, or erythema was observed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The combined continuous-wave/pulsed CO2 laser is our treatment of choice for pyogenic granuloma because this kind of laser is widely available, produces excellent results with few adverse effects, is easy to use, yields low recurrence rates, and is well tolerated by most patients.\n",
            "     </abstracttext>]\n",
            "11843383.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess clinical status, changes in health related quality of life, and subsequent management five years after medical management or transcervical resection of the endometrium for treatment of heavy menstrual loss.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Five year follow up using postal questionnaires and operative databank review.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Gynaecology department of a large UK teaching hospital.\n",
            "     </abstracttext>, <abstracttext label=\"POPULATION\" nlmcategory=\"METHODS\">\n",
            "      Women referred to the gynaecologist for treatment of heavy menstrual loss.\n",
            "     </abstracttext>, <abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Eligible women, without a treatment preference, were randomised equally to either medical treatment or transcervical resection of the endometrium.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Women's satisfaction with treatment, menstrual status, changes in health related quality of life, and additional treatments received at five years.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      One hundred and forty-four patients completed questionnaires, achieving 77% follow up (medical n = 71/94; transcervical resection of the endometrium n = 73/93). At five-year follow up, 7/71 (10%) of those randomised to the medical arm still used medical treatment, while 72/94 (77%) had undergone surgical treatment and 17/94 (18%) a hysterectomy. Twenty-five (27%) women allocated to transcervical resection of the endometrium had undergone further surgery, 18/93 (19%) a hysterectomy. At five years women initially randomised to medical treatment were significantly less likely to be totally satisfied (P &lt; 0.01, difference 21%, 95% CI -37% to -4%), or to recommend their allocated treatment to a friend (P &lt; 0.001, difference 59%, 95% CI -73% to -45%). Bleeding and pain scores were similar in both groups and highly significantly reduced. Significantly more women in the transcervical resection of the endometrium arm had no bleeding or very light bleeding (P &lt; 0.02, difference -22%, CI -31% to -4%), and they had significantly less days heavy bleeding (P &lt; 0.02). Short Form 36 health survey scores were significantly improved from baseline for all eight health scales in the transcervical resection of the endometrium arm, and four in the medical arm.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A policy of immediate transcervical resection of the endometrium for women referred to a gynaecologist for treatment of heavy menstrual loss achieves higher levels of satisfaction, better menstrual status, and greater improvements in health related quality of life than medical treatment. In addition, transcervical resection of the endometrium is safe and does not lead to an increase in the number of hysterectomies. An effective endometrial ablative technique should be offered to all eligible women seeking treatment of their heavy menses from a gynaecologist.\n",
            "     </abstracttext>]\n",
            "1955232.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14989387.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the impact of long-term ICS use on BMD.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Random-effects meta-analysis. Published and unpublished literature were identified by searches of MEDLINE and EMBASE databases and consultation with experts. Studies reporting BMD among adult asthma and chronic obstructive pulmonary disease (COPD) patients using ICS and non-ICS controls were identified. Studies selected for review included at least 1 year of follow-up. Two independent reviewers evaluated studies; data from those meeting specified inclusion criteria were abstracted for inclusion in the meta-analysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Fourteen (5.3%) of 266 reviewed studies met specified inclusion criteria. Sufficient data were available to perform meta-analysis on 3 measures for ICS-using patients (lumbar, femoral neck, and major trochanter BMD) and 1 measure (lumbar BMD) for non-ICS-using controls. Using current National Asthma Education and Prevention Program definitions, the majority of studies (12 of 14) included patients receiving moderate to high doses of ICSs. Among ICS users, annual changes from baseline in lumbar, femoral neck, and major trochanter BMD (-0.23%, -0.17%, and +1.46%, respectively) were not statistically significant. Mean changes in lumbar BMD were also not significantly different from controls (-0.02%). Further, annual changes in lumbar BMD were not statistically significant for subgroups of patients with asthma or COPD.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Long-term use of ICSs in patients with asthma or COPD was not associated with significant changes in BMD.\n",
            "     </abstracttext>]\n",
            "9096977.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Individuals with impaired glucose tolerance (IGT) have a high risk of developing NIDDM. The purpose of this study was to determine whether diet and exercise interventions in those with IGT may delay the development of NIDDM, i.e., reduce the incidence of NIDDM, and thereby reduce the overall incidence of diabetic complications, such as cardiovascular, renal, and retinal disease, and the excess mortality attributable to these complications.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESEARCH DESIGN AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      In 1986, 110,660 men and women from 33 health care clinics in the city of Da Qing, China, were screened for IGT and NIDDM. Of these individuals, 577 were classified (using World Health Organization criteria) as having IGT. Subjects were randomized by clinic into a clinical trial, either to a control group or to one of three active treatment groups: diet only, exercise only, or diet plus exercise. Follow-up evaluation examinations were conducted at 2-year intervals over a 6-year period to identify subjects who developed NIDDM. Cox's proportional hazard analysis was used to determine if the incidence of NIDDM varied by treatment assignment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The cumulative incidence of diabetes at 6 years was 67.7% (95% CI, 59.8-75.2) in the control group compared with 43.8% (95% CI, 35.5-52.3) in the diet group, 41.1% (95% CI, 33.4-49.4) in the exercise group, and 46.0% (95% CI, 37.3-54.7) in the diet-plus-exercise group (P &lt; 0.05). When analyzed by clinic, each of the active intervention groups differed significantly from the control clinics (P &lt; 0.05). The relative decrease in rate of development of diabetes in the active treatment groups was similar when subjects were stratified as lean or overweight (BMI &lt; or &gt; or = 25 kg/m2). In a proportional hazards analysis adjusted for differences in baseline BMI and fasting glucose, the diet, exercise, and diet-plus-exercise interventions were associated with 31% (P &lt; 0.03), 46% (P &lt; 0.0005), and 42% (P &lt; 0.005) reductions in risk of developing diabetes, respectively.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Diet and/or exercise interventions led to a significant decrease in the incidence of diabetes over a 6-year period among those with IGT.\n",
            "     </abstracttext>]\n",
            "1868642.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11585485.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To analyze the accuracy of the clinical examination for meniscal or ligamentous knee injuries.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      MEDLINE (1966-December 31, 2000) and HealthSTAR (1975-December 31, 2000) databases were searched for English-language articles describing the diagnostic accuracy of individual examination items for the knee and a combination of physical examination items (composite examination). Other data sources included reference lists from relevant articles.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Studies selected for data extraction were those that compared the performance of the physical examination of the knee with a reference standard, such as arthroscopy, arthrotomy, or magnetic resonance imaging. Eighty-eight articles were identified, of which 23 (26%) met inclusion criteria.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      A rheumatologist and an orthopedic surgeon independently reviewed each article using a standardized rating scale that scored the assembly of the study, the relevance of the patients enrolled, the appropriateness of the reference standard, and the blinding of the examiner.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Summary likelihood ratios (LRs) were estimated from random effects models. The summary LRs for physical examination for tears of the anterior cruciate ligament, using the anterior drawer test, were 3.8 (95% confidence interval [CI], 0.7-22.0) for a positive examination and 0.30 (95% CI, 0.05-1.50) for a negative examination; the Lachman test, 25.0 (95% CI, 2.7-651.0) and 0.1 (95% CI, 0.0-0.4); and the composite assessment, 25.0 (95% CI, 2.1-306.0) and 0.04 (95% CI, 0.01-0.48), respectively. The LRs could not be generated for any specific examination maneuver for a posterior cruciate ligament tear, but the composite assessment had an LR of 21.0 (95% CI, 2.1-205.0) for a positive examination and 0.05 (95% CI, 0.01-0.50) for a negative examination. Determination of meniscal lesions, using McMurray test, had an LR of 1.3 (95% CI, 0.9-1.7) for a positive examination and 0.8 (95% CI, 0.6-1.1) for a negative examination; joint line tenderness, 0.9 (95% CI, 0.8-1.0) and 1.1 (95% CI, 1.0-1.3); and the composite assessment, 2.7 (95% CI, 1.4-5.1) and 0.4 (95% CI, 0.2-0.7), respectively.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The composite examination for specific meniscal or ligamentous injuries of the knee performed much better than specific maneuvers, suggesting that synthesis of a group of examination maneuvers and historical items may be required for adequate diagnosis.\n",
            "     </abstracttext>]\n",
            "8942774.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      140,000 people aged 45-75 years lived in Funen, Denmark, in August, 1985, and were considered for inclusion in our study. Before randomisation we excluded individuals who had CRC or precursor adenomas and those who had taken part in a previous pilot study. Randomisation of 137,485 people in blocks of 14 allocated three per 14 to the screening group (30,967), three per 14 to the control group (30,966), and eight not to be enrolled in the study (75,552). Controls were not told about the study and continued to use health-care facilities as normal. Hemoccult-II blood tests (with dietary restrictions but without rehydration) were sent to screening-group participants. Only those participants who completed the first screening round were invited for further screening--five rounds of screening during a 10-year period. Participants with positive tests were asked to attend to full examination and were offered colonoscopy whenever possible. The primary endpoint was death from CRC.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      Of the 30,967 screening-group participants, 20,672 (67%) completed the first screening round and were invited for further screening; more than 90% accepted repeated screenings. During the 10-year study, 481 people in the screening group had a diagnosis of CRC, compared with 483 unscreened controls. There were 205 deaths attributable to CRC in the screening group, compared with 249 deaths in controls. CRC mortality, including deaths attributable to complications from CRC treatment, was significantly lower in the screening group than in controls (mortality ratio 0.82 [95% CI 0.68-0.99]) p = 0.03).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our findings indicate that biennial screening by FOB tests can reduce CRC mortality. This study is being continued to improve its statistical power and to assess the effect of the removal of more precursor adenomas in the screening-group participants than in controls on CRC incidence.\n",
            "     </abstracttext>]\n",
            "8708804.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15258862.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "1728731.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We prospectively monitored the timing of antibiotic prophylaxis and studied the occurrence of surgical-wound infections in 2847 patients undergoing elective clean or \"clean-contaminated\" surgical procedures at a large community hospital. The administration of antibiotics 2 to 24 hours before the surgical incision was defined as early; that during the 2 hours before the incision, as preoperative; that during the 3 hours after the incision, as perioperative; and that more than 3 but less than 24 hours after the incision, as postoperative.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of the 1708 patients who received the prophylactic antibiotics preoperatively, 10 (0.6 percent) subsequently had surgical-wound infections. Of the 282 patients who received the antibiotics perioperatively, 4 (1.4 percent) had such infections (P = 0.12; relative risk as compared with the preoperatively treated group, 2.4; 95 percent confidence interval, 0.9 to 7.9). Of 488 patients who received the antibiotics postoperatively, 16 (3.3 percent) had wound infections (P less than 0.0001; relative risk, 5.8; 95 percent confidence interval, 2.6 to 12.3). Finally, of 369 patients who had antibiotics administered early, 14 (3.8 percent) had wound infections (P less than 0.0001; relative risk, 6.7; 95 percent confidence interval, 2.9 to 14.7). Stepwise logistic-regression analysis confirmed that the administration of antibiotics in the preoperative period was associated with the lowest risk of surgical-wound infection.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      We conclude that in surgical practice there is considerable variation in the timing of prophylactic administration of antibiotics and that administration in the two hours before surgery reduces the risk of wound infection.\n",
            "     </abstracttext>]\n",
            "344087.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15755765.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The mean LDL cholesterol levels were 77 mg per deciliter (2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter (2.6 mmol per liter) during treatment with 10 mg of atorvastatin. The incidence of persistent elevations in liver aminotransferase levels was 0.2 percent in the group given 10 mg of atorvastatin and 1.2 percent in the group given 80 mg of atorvastatin (P&lt;0.001). A primary event occurred in 434 patients (8.7 percent) receiving 80 mg of atorvastatin, as compared with 548 patients (10.9 percent) receiving 10 mg of atorvastatin, representing an absolute reduction in the rate of major cardiovascular events of 2.2 percent and a 22 percent relative reduction in risk (hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P&lt;0.001). There was no difference between the two treatment groups in overall mortality.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.\n",
            "     </abstracttext>]\n",
            "10629474.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      The goal was to critically examine evidence regarding the performance of diagnostic tests and the efficacy of antibiotic and other treatments for uncomplicated acute bacterial rhinosinusitis (ABR).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Scientific literature was reviewed, and meta-analysis methods were used to assess diagnostic test and antibiotic efficacy. A decision analysis and cost-effective analysis were performed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Although more sensitive than clinical examination for diagnosis of ABR, sinus radiograms are not cost-effective as an initial management strategy. Antibiotics reduce the incidence of clinical failures by one half compared to no treatment and, when coupled with clinical criteria-based diagnosis, present the most cost-effective treatment strategy. However, without antibiotics, symptoms in two thirds of patients improve by 14 days with no serious complications. The risk of treatment failure does not differ significantly between amoxicillin or folate inhibitors and newer, more expensive antibiotics.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The current literature shows that treatment of uncomplicated ABR with amoxicillin or folate inhibitors and based on clinical criteria is the most cost-effective strategy.\n",
            "     </abstracttext>]\n",
            "12174056.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the overall recurrence rates of keratinous and pilar cysts removed by the punch incision technique and rates of recurrence by location and using other cyst characteristics.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A preliminary retrospective chart review of cysts removed exclusively by the punch incision technique from 1989 to 1998 was performed. The rate of cyst recurrence and average time to patient-initiated follow-up visit for evaluation and removal were determined. In a second study, a survey requested information on the presence of cyst recurrence. This was mailed to all 646 patients who had cysts removed by the punch incision technique from 1989 to 1998 to evaluate possible cyst recurrence in patients who did not choose to follow-up at the office. Statistical analysis was performed to determine the overall recurrence rates and recurrence rates based on location and other cyst characteristics.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Preliminary chart review revealed a recurrence rate of 3.6%, with a mean time to patient-initiated follow-up of 79.3 weeks. In the second study, an analysis of cyst recurrence rates in patients returning the survey revealed an 8.3% recurrence rate. Subanalysis revealed a trend showing that inflamed cysts had a lower recurrence rate. Another trend noted was that cysts removed from the back and ear had the highest recurrence rates (13.8 and 13.0%, respectively) compared to those removed from other locations. Most cysts (54.5%) recurred within the first year after punch incision removal.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This is the first study to document recurrence rates using the punch incision technique for removal of epithelial cysts. Though most recurrences occur within the first year, there is a delay in patients reporting to their doctors for reexcision, perhaps because recurrent cysts are often asymptomatic. Studies to determine the recurrence rates for cyst excision using other techniques should be performed. The punch incision technique, when properly performed, is a satisfactory removal method with a recurrence rate of less then 10%.\n",
            "     </abstracttext>]\n",
            "16625602.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To conduct a systematic review of the literature estimating the value of antibiotics in the management of acute COPD exacerbations.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2005); MEDLINE (1966 to December 2005); EMBASE (1974 to December 2005); Web of Science (December 2005), and other electronically available databases.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised controlled trials (RCTs) in patients with acute COPD exacerbations comparing antibiotic (for a minimum of five days) and placebo.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Data were analysed using Review Manager software. Continuous data were analysed using weighted mean differences (WMD) and 95% confidence intervals (CI). Relative risks (RR) (and 95% CI) were calculated for all dichotomous data. Where appropriate, number needed to treat to benefit (NNT) and 95% CI were calculated.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Eleven trials with 917 patients were included. Ten trials used increased cough, sputum volume and purulence diagnostic criteria for COPD exacerbation. Eight-hundred and fifty-seven patients provided data for outcomes including mortality, treatment failure, increased sputum volume, sputum purulence, PaCO(2), PaO(2), peak flow and adverse events. Antibiotic therapy regardless of antibiotic choice significantly reduced mortality (RR 0.23; 95% CI 0.10 to 0.52 with NNT of 8; 95% CI 6 to 17), treatment failure (RR 0.47; 95% CI 0.36 to 0.62 with NNT of 3; 95% CI 3 to 5) and sputum purulence (RR 0.56; 95% CI 0.41 to 0.77 with NNT of 8; 95% CI 6 to 17). There was a small increase in risk of diarrhoea with antibiotics (RR 2.86; 95% CI 1.06 to 7.76). Antibiotics did not improve arterial blood gases and peak flow.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This review shows that in COPD exacerbations with increased cough and sputum purulence antibiotics, regardless of choice, reduce the risk of short-term mortality by 77%, decrease the risk of treatment failure by 53% and the risk of sputum purulence by 44%; with a small increase in the risk of diarrhoea. These results should be interpreted with caution due to the differences in patient selection, antibiotic choice, small number of included trials and lack of control for interventions that influence outcome, such as use of systemic corticosteroids and ventilatory support. Nevertheless, this review supports antibiotics for patients with COPD exacerbations with increased cough and sputum purulence who are moderately or severely ill.\n",
            "     </abstracttext>]\n",
            "14973954.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of this review was to assess the effects of homeopathy in people with chronic stable asthma.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Airways Group trials register, the Cochrane Complementary Medicine Field trials register, the Glasgow Homeopathic Hospital database, the Mnchener Modell database and reference lists of articles. Searches were current as of August 2003.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised trials of homeopathy for the treatment of stable chronic asthma, with observation periods of at least one week were included.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Data extraction was undertaken by two reviewers. Trial quality was assessed by the reviewers.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Six trials with a total of 556 people were included. These trials were all placebo-controlled and double-blind, but of variable quality. They used different homeopathic treatments which precluded quantitative pooling of results for the primary outcome. Standardised treatments in these trials are unlikely to represent common homeopathic practice, where treatment tends to be individualised. No trial reported a significant difference on validated symptom scales. There were conflicting results in terms of lung function between the studies. There has been only a limited attempt to measure a 'package of care' effect (i.e., the effect of the medication as well as the consultation, which is considered a vital part of individualised homeopathic practice).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is not enough evidence to reliably assess the possible role of homeopathy in asthma. As well as randomised trials, there is a need for observational data to document the different methods of homeopathic prescribing and how patients respond. This will help to establish to what extent people respond to a 'package of care' rather than the homeopathic intervention alone.\n",
            "     </abstracttext>]\n",
            "15021067.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE OF REVIEW\" nlmcategory=\"OBJECTIVE\">\n",
            "      Asthma is a disease causing significant morbidity and mortality. In the recent past, there has been an explosion of pharmacotherapeutic options attempting to control the disease. Unfortunately, none of the current options offers the promise of prevention or a permanent cure. However, there appear to be exciting, new data emerging to support the hypothesis that the prevention or early treatment of allergic rhinitis, such as with the use of allergen immunotherapy, may help mitigate the severity of bronchial symptoms and even prevent the development of asthma. In this paper, we review recent research published proposing immunotherapy as a means of preventing the development of, or at least ameliorating, allergic asthma.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "[<abstracttext label=\"RECENT FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      There is evidence that the upper and lower airways may be considered a single unit, with the nasal and bronchial mucosa having features in common. Epidemiological, pathophysiological and clinical studies have shown that they can be affected by similar inflammatory triggers, with interconnected mechanisms amplifying the inflammatory cascade. Allergic rhinitis is interrelated to, and is a risk factor for, the development of asthma. An evidence-based review validates the successful use of allergen immunotherapy in treating allergic rhinitis and asthma. There is promising evidence advocating its use in the prevention of clinical asthma.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SUMMARY\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This article explores current research pertaining to the use of immunomodulation, such as by using allergen immunotherapy, to ameliorate and prevent the development of allergic asthma.\n",
            "     </abstracttext>]\n",
            "15474764.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12535385.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of this review was to assess the effects of leukocyte immunisation or other immunologic treatments such as intravenous immune globulin (IVIG) on the live birth rate in women with previous unexplained recurrent miscarriages.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The Cochrane Pregnancy and Childbirth Group trials register was searched (September 2002). Individual patient data were obtained from the American Society for Reproductive Immunology.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised trials of immunotherapy in women with three or more prior miscarriages and no more than one live birth; all recognised non-immunologic causes ruled out and no simultaneous treatment intervention.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Eligibility and trial quality were assessed by one reviewer.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Nineteen trials of high quality were included. The various forms of immunotherapy did not show significant differences between treatment and control groups in terms of subsequent live births: paternal cell immunisation (11 trials, 596 women), odds ratio (OR) 1.05, 95% confidence intervals (CI) 0.75 to 1.47; third party donor cell immunization (3 trials, 156 women), OR 1.39, 95% CI 0.68 to 2.82; trophoblast membrane infusion (1 trial, 37 women), OR 0.40, 95% CI 0.11 to 1.45; intravenous immune globulin (IVIG), OR 0.98, 95% CI 0.61 to 1.58.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Paternal cell immunization, third party donor leukocytes, trophoblast membranes, and intravenous immune globulin provide no significant beneficial effect over placebo in preventing further miscarriages.\n",
            "     </abstracttext>]\n",
            "2857061.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12467690.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "2067759.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9109139.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the effectiveness of amoxicillin administered continuously twice daily vs. once daily vs. placebo to prevent new episodes of acute otitis media (AOM).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Randomized, double blind, placebo-controlled clinical trial at a hospital-based general pediatric clinic and a private pediatric practice, both in Denver, CO.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      One hundred ninety-four children (age 3 months through 6 years) were enrolled with 3 documented AOM episodes within the prior 6 months, without ventilating tubes or associated anatomic defects, immunodeficiency disorders or allergy to penicillin. Thirty-six were noncompliant and were excluded from the study, leaving 158 evaluable subjects.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      The amoxicillin dosage was 20 mg/kg/day either bid or qd. After randomization to placebo twice daily (bid), amoxicillin once daily (qd)/placebo qd or amoxicillin bid, patients were followed monthly and were also seen for upper respiratory infection symptoms during enrollment in the trial. Development of two new AOM episodes terminated the patients from the study.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MEASUREMENTS/MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Incidence density (ID) measurements were calculated for all study subjects and were stratified by age and season. Overall study subjects in all 3 arms of the trial had 7243 days at risk during which time they developed 56 new AOM episodes for a annual ID of 2.82. There were no significant differences in the IDs between amoxicillin qd vs. bid or amoxicillin (bid or qd) vs. placebo. After stratifying by age and season of enrollment, there were no significant differences in ID rates among the 3 groups. The proportion of subjects remaining otitis-free was 63% for the placebo group, 64% for once daily amoxicillin and 61% for twice daily amoxicillin.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      While once-a-day dosing was equivalent to twice-a-day dosing for amoxicillin prophylaxis, there was no benefit of amoxicillin prophylaxis compared with a placebo control in preventing new AOM episodes. Because of the potential of excessive antibiotic use to promote the acquisition of resistant pneumococci and the lack of effectiveness in this trial, routine use of amoxicillin prophylaxis should be discouraged.\n",
            "     </abstracttext>]\n",
            "7869070.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14678922.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      This review summarizes the available evidence regarding the efficacy of medications used for ventricular rate control, stroke prevention, acute conversion, and maintenance of sinus rhythm, as well as the efficacy of electrical cardioversion and the use of echocardiography in patients with atrial fibrillation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      The Cochrane Collaboration's database of controlled clinical trials and MEDLINE.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Primarily randomized, controlled trials of medications.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Paired reviewers obtained data on efficacy and safety. Strength of evidence was assessed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Recent clinical trial results showed that most patients with atrial fibrillation have similar outcomes with strategies for controlling ventricular rate compared with strategies for restoring sinus rhythm. For efficacy of primary stroke prevention, compared with placebo, evidence was strong for warfarin and suggestive for aspirin. The evidence for an increased risk for major bleeding was suggestive for warfarin and inconclusive for aspirin. For ventricular rate control, verapamil, diltiazem, atenolol, and metoprolol were qualitatively superior to digoxin and placebo, particularly during exercise. For efficacy of acute conversion, compared with placebo, evidence was strong for ibutilide, flecainide, dofetilide, propafenone, amiodarone, and quinidine. For efficacy of maintenance of sinus rhythm after conversion from atrial fibrillation, evidence was strong for amiodarone, propafenone, disopyramide, and sotalol. Echocardiography was found to be useful in estimating risk for thromboembolism and potentially useful in estimating likelihood of successful cardioversion and maintenance.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      For several key questions in the pharmacologic management of atrial fibrillation, strong evidence exists to support 1 or more treatment options.\n",
            "     </abstracttext>]\n",
            "20556751.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effectiveness and safety of alternative surgical treatments for CIN.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE and EMBASE (up to April 2009). We also searched registers of clinical trials, abstracts of scientific meetings and reference lists of included studies.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised controlled trials (RCTs) of alternative surgical treatments in women with cervical intraepithelial neoplasia.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two review authors independently abstracted data and assessed risks of bias. Risk ratios that compared residual disease after the follow-up examination and adverse events in women who received one of either laser ablation, laser conisation, large loop excision of the transformation zone (LLETZ), knife conisation or cryotherapy were pooled in random-effects model meta-analyses.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Twenty-nine trials were included. Seven surgical techniques were tested in various comparisons. No significant differences in treatment failures were demonstrated in terms of persistent disease after treatment. Large loop excision of the transformation zone appeared to provide the most reliable specimens for histology with the least morbidity. Morbidity was lower than with laser conisation, although the trials did not provide data for every outcome measure. There were not enough data to assess the effect on morbidity when compared with laser ablation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The evidence suggests that there is no obvious superior surgical technique for treating cervical intraepithelial neoplasia in terms of treatment failures or operative morbidity.\n",
            "     </abstracttext>]\n",
            "15831424.xml\n",
            "\n",
            "[<abstracttext label=\"RATIONALE AND OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To investigate the performance of observers with different levels of experience in distinguishing between benign and malignant solitary pulmonary nodules (SPN) on CT, and to determine the effects on interpretation of three different conditions: image data alone, the addition of clinical data, and the addition of output from a computer-aided diagnosis (CAD) system.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MATERIALS AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      28 thin-section CT datasets of SPNs with proven diagnoses (15 malignant and 13 benign) were used to measure observer performance. Readers were categorized according to their experience and read the cases in random order. For each case readers were asked to assign a level of confidence on a scale from 0.0-1.0 (0.0 benign, 1.0 malignant) for the diagnosis of the nodule. Each reader scored the cases based on review of image data alone (phase 1), then with limited clinical data (phase 2), and finally with CAD output (phase 3). To assess performance, multiple reader multiple case (MRMC) receiver operating characteristic (ROC) analysis was used.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      2 thoracic radiologists, 1 thoracic radiology fellow, 2 nonthoracic radiologists, and 3 radiology residents read the cases. The average area under the ROC curve for all readers (A(z)) at each stage was 0.68, 0.75, and 0.81, for image data alone, with clinical data, and with CAD output respectively. The difference in performance between phases (2 and 3) and (1 and 3) was significantly different (P = 0.018 and P = 0.020). However, the difference between phases (1 and 2) was not significantly different (P = 0.155).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Diagnostic performance increased significantly with the addition of CAD output. With further validation CAD output may play a significant role in SPN management.\n",
            "     </abstracttext>]\n",
            "3398197.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15819726.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      A systematic review of all studies (controlled and uncontrolled) to evaluate psychological interventions with treatment-resistant depression.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      A systematic search to identify studies evaluating a psychological intervention with adults with a diagnosis of major depressive disorder who had not responded to at least one course of antidepressant medication.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Twelve studies met inclusion criteria, of which four were controlled and eight uncontrolled. Treatment effect sizes were computable for four studies and ranged from 1.23 to 3.10 with a number of better quality studies demonstrating some improvements in patients following a psychological intervention.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Psychological treatments for depression are commonly delivered and often recommended following the failure of medication. The paucity of evidence for their effectiveness in these situations is a significant problem. There is a need for studies with a strong controlled design investigating the effectiveness of psychological treatments for patients with treatment-resistant depression.\n",
            "     </abstracttext>]\n",
            "9778327.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[<abstracttext label=\"METHODS AND RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A logistic regression model was used to predict significant (&gt;/=75% stenosis) and severe (3-vessel or left main) coronary artery disease, and a Cox regression analysis was used to predict cardiac survival. After adjustment for baseline clinical risk, the DTS was effectively diagnostic for significant (P&lt;0.0001) and severe (P&lt;0.0001) coronary artery disease. For low-risk patients (score &gt;/=+5), 60% had no coronary stenosis &gt;/=75% and 16% had single-vessel &gt;/=75% stenosis. By comparison, 74% of high-risk patients (score &lt;-11) had 3-vessel or left main coronary disease. Five-year mortality was 3%, 10%, and 35% for low-, moderate-, and high-risk DTS groups (P&lt;0.0001).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The composite DTS provides accurate diagnostic and prognostic information for the evaluation of symptomatic patients evaluated for clinically suspected ischemic heart disease.\n",
            "     </abstracttext>]\n",
            "12472787.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Using observed and modeled data from 5097 subjects in the UK Prospective Diabetes Study, we measured the annual probability of transition from stage to stage (incidence), prevalence, cumulative incidence, ten-year survival, median duration per stage, and risk of death from all-causes or cardiovascular disease.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      From diagnosis of diabetes, progression to microalbuminuria occurred at 2.0% per year, from microalbuminuria to macroalbuminuria at 2.8% per year, and from macroalbuminuria to elevated plasma creatinine (&gt;or=175 micromol/L) or renal replacement therapy at 2.3% per year. Ten years following diagnosis of diabetes, the prevalence of microalbuminuria was 24.9%, of macroalbuminuria was 5.3%, and of elevated plasma creatinine or RRT was 0.8%. Patients with elevated plasma creatinine or RRT had an annual death rate of 19.2% (95% confidence interval, CI, 14.0 to 24.4%). There was a trend for increasing risk of cardiovascular death with increasing nephropathy (P &lt; 0.0001), with an annual rate of 0.7% for subjects in the stage of no nephropathy, 2.0% for those with microalbuminuria, 3.5% for those with macroalbuminuria, and 12.1% with elevated plasma creatinine or RRT. Individuals with macroalbuminuria were more likely to die in any year than to develop renal failure.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The proportion of patients with type 2 diabetes who develop microalbuminuria is substantial with one quarter affected by 10 years from diagnosis. Relatively fewer patients develop macroalbuminuria, but in those who do, the death rate exceeds the rate of progression to worse nephropathy.\n",
            "     </abstracttext>]\n",
            "7532241.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To develop a set of minimum clinical guidelines for use by primary care physicians in the evaluation and management of patients with hyperthyroidism and hypothyroidism.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Guidelines were developed by a nine-member ad hoc Standards of Care Committee of the American Thyroid Association (the authors of this article). The participants were selected by the committee chair and the president of the American Thyroid Association on the basis of their clinical experience. The committee members represented different geographic areas within the United States, in order to take into account different practice styles.\n",
            "     </abstracttext>, <abstracttext label=\"EVIDENCE\" nlmcategory=\"METHODS\">\n",
            "      Guidelines were developed on the basis of expert opinion of the participants, as well as on available published information.\n",
            "     </abstracttext>, <abstracttext label=\"CONSENSUS PROCESS\" nlmcategory=\"METHODS\">\n",
            "      Input was obtained from all of the participants, each of whom wrote an initial section of the document. A complete draft document was then written by three participants (P.A.S., D.S.C., and E.G.L.) and resubmitted to the entire committee for revision. The revised document was then submitted to the entire membership of the American Thyroid Association for written comments, which were then reviewed (mainly by P.A.S., D.S.C., and E.G.L.). Many of the suggestions of the American Thyroid Association members were incorporated into the final draft, which was then approved by the Executive Council of the American Thyroid Association. The entire process, from initial drafts to final approval, took approximately 18 months.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A set of minimum clinical guidelines for the diagnosis and treatment of hyperthyroidism and hypothyroidism were developed by consensus of a group of experienced thyroidologists. The guidelines are intended to be used by physicians in their care of patients with thyroid disorders, with the expectation that more effective care can be provided, and at a cost savings.\n",
            "     </abstracttext>]\n",
            "18164508.xml\n",
            "\n",
            "[<abstracttext label=\"BACKGROUND/AIMS\" nlmcategory=\"OBJECTIVE\">\n",
            "      In severe alcoholic hepatitis (AH), 40% of patients will obtain no benefit from corticosteroids. Improvement in management of non-responders is warranted and only pentoxifylline can be considered an alternative. A two-step strategy was evaluated consisting of early withdrawal of corticosteroids and a switch to pentoxifylline for 28 additional days in non-responders identified using early change in bilirubin level.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      One hundred and twenty-one patients with AH were treated prospectively with corticosteroids, and the two-step strategy was proposed to 29 non-responders treated according to a two-step strategy who were compared to 58 matched non-responders treated with corticosteroids only.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Clinical and biological features of the two groups were similar. There was no survival improvement at 2 months in patients treated with the two-step strategy compared to controls: 35.5+/-6.3% vs 31+/-8.6%. After 21 days, biological evolution was similar for prothrombin time (-0.25s vs +0.2s), bilirubin (0.8 mg/dl vs 2.03 mg/dl) and creatinine (+0.16 mg/dl vs -0.7 mg/dl). In multivariate analysis, only age, evolution of bilirubin during the first week, creatinine and DF were associated with 2-month survival.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Non-responders to corticosteroids do not obtain any benefit from an early switch to pentoxifylline. Thus, the issue of management of non-responders remains unresolved.\n",
            "     </abstracttext>]\n",
            "16052573.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Standard therapy for antineutrophil cytoplasmic antibody-associated systemic vasculitis (AASV) with cyclophosphamide (CYC) and prednisolone is limited by toxicity. This unblinded, prospective, randomized, controlled trial was undertaken to determine whether methotrexate (MTX) could replace CYC in the early treatment of AASV.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Patients with newly diagnosed AASV, with serum creatinine levels &lt;150 mumoles/liter, and without critical organ manifestations of disease were randomized to receive either standard oral CYC, 2 mg/kg/day or oral MTX, 20-25 mg/week; both groups received the same prednisolone regimen. All drug treatments were gradually tapered and withdrawn by 12 months. Followup continued to 18 months. The primary end point was the remission rate at 6 months (noninferiority testing).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      One hundred patients were recruited from 26 European centers; 51 patients were randomized to the MTX group and 49 to the CYC group. At 6 months, the remission rate in patients treated with MTX (89.8%) was not inferior to that in patients treated with CYC (93.5%) (P = 0.041). In the MTX group, remission was delayed among patients with more extensive disease (P = 0.04) or pulmonary involvement (P = 0.03). Relapse rates at 18 months were 69.5% in the MTX group and 46.5% in the CYC group; the median time from remission to relapse was 13 months and 15 months, respectively (P = 0.023, log rank test). Two patients from each group died. Adverse events (mean 0.87 episodes/patient) included leukopenia, which was less frequent in the MTX versus the CYC group (P = 0.012), and liver dysfunction, which was more frequent in the MTX group (P = 0.036).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      MTX can replace CYC for initial treatment of early AASV. The MTX regimen used in the present study was less effective for induction of remission in patients with extensive disease and pulmonary involvement and was associated with more relapses than the CYC regimen after termination of treatment. The high relapse rates in both treatment arms support the practice of continuation of immunosuppressive treatment beyond 12 months.\n",
            "     </abstracttext>]\n",
            "3063051.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10435606.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A double-blind, placebo-controlled trial was conducted to evaluate the safety and efficacy of 2 doses of oral nalmefene for alcohol dependence. The 105 outpatient volunteers were abstinent for a mean of 2 weeks prior to random assignment to the placebo or 20- or 80-mg/d dose nalmefene groups for 12 weeks. Cognitive behavioral therapy was provided weekly during treatment. Self-reported drinking or abstinence was confirmed by determinations of breath alcohol concentration and by collateral informant reports.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Outcomes did not differ between the 20- and 80-mg dose nalmefene groups. Significantly fewer patients treated with nalmefene than patients given placebo relapsed to heavy drinking through 12 weeks of treatment (P&lt;.02), with a significant treatment effect at the first weekly study visit (P&lt;.02). The odds ratio of relapsing to heavy drinking was 2.4 times greater with placebo compared with nalmefene (95% confidence interval, 1.05-5.59). Patients treated with nalmefene also had fewer subsequent relapses (P&lt;.03) than patients given placebo.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Treatment with nalmefene was effective in preventing relapse to heavy drinking relative to placebo in alcohol-dependent outpatients and was accompanied by acceptable side effects.\n",
            "     </abstracttext>]\n",
            "10684911.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      To determine whether treating women in a general obstetrical population who have asymptomatic bacterial vaginosis (as diagnosed on the basis of vaginal Gram's staining and pH) prevents preterm delivery, we randomly assigned 1953 women who were 16 to less than 24 weeks pregnant to receive two 2-g doses of metronidazole or placebo. The diagnostic studies were repeated and a second treatment was administered to all the women at 24 to less than 30 weeks' gestation. The primary outcome was the rate of delivery before 37 weeks' gestation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Bacterial vaginosis resolved in 657 of 845 women who had follow-up Gram's staining in the metronidazole group (77.8 percent) and 321 of 859 women in the placebo group (37.4 percent). Data on the time and characteristics of delivery were available for 953 women in the metronidazole group and 966 in the placebo group. Preterm delivery occurred in 116 women in the metronidazole group (12.2 percent) and 121 women in the placebo group (12.5 percent) (relative risk, 1.0; 95 percent confidence interval, 0.8 to 1.2). Treatment did not prevent preterm deliveries that resulted from spontaneous labor (5.1 percent in the metronidazole group vs. 5.7 percent in the placebo group) or spontaneous rupture of the membranes (4.2 percent vs. 3.7 percent), nor did it prevent delivery before 32 weeks (2.3 percent vs. 2.7 percent). Treatment with metronidazole did not reduce the occurrence of preterm labor, intraamniotic or postpartum infections, neonatal sepsis, or admission of the infant to the neonatal intensive care unit.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The treatment of asymptomatic bacterial vaginosis in pregnant women does not reduce the occurrence of preterm delivery or other adverse perinatal outcomes.\n",
            "     </abstracttext>]\n",
            "6693447.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12478024.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Forty surviving patients undergoing emergent splenectomy were randomized to receive Pneumovax at 14 or 28 days after splenectomy. Blood samples were drawn at the time of vaccination (prevaccination) and 4 weeks later (postvaccination). A control group of 24 healthy adults was used for comparison. Antibody titers to four of the most common serotypes were determined by enzyme-linked immunosorbent assay and opsonophagocytic assay (OPA).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Samples from 38 patient were analyzed. Each serotype and each group tested demonstrated a statistically significant increase in geometric mean enzyme-linked immunosorbent assay immunoglobulin G antibody concentration (microg/mL) and OPA titer (1/dilution) after vaccination. There were no statistically significant differences (p &gt;or= 0.07) in the immunoglobulin G antibody concentrations and OPA titers between the 14-day or the 28-day study groups when compared with normal healthy adults regardless of the serotype tested. In addition, there were no differences in the antibody responses between the 14-day and the 28-day study groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Despite our previous study suggesting that delay in vaccination after emergent splenectomy resulted in improved antibody response, antibody response was not improved any further by delaying vaccination to 28 days.\n",
            "     </abstracttext>]\n",
            "14649781.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15187055.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To identify factors associated with 6-month mortality in newly admitted nursing home residents with advanced dementia and to create a practical risk score to predict 6-month mortality in this population.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN, SETTING, AND PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      This was a retrospective cohort study of data from the Minimum Data Set (MDS). All Medicare or Medicaid licensed nursing homes in New York and Michigan were included. Participants had advanced dementia and were admitted to New York nursing homes between June 1, 1994, and December 30, 1998 (derivation cohort, n = 6799), and to Michigan nursing homes from October 1, 1998, through July 30, 2000 (validation cohort, n = 4631).\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      MDS factors associated with 6-month mortality were determined in the derivation group, and the resulting mortality risk score was evaluated in the validation cohort. Risk score performance was compared with the cut point of 7c on the Functional Assessment Staging (FAST) scale.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Among residents with advanced dementia, 28.3% (n = 1922) died within 6 months of nursing home admission in the derivation cohort; 35.1% (n = 1626) died in the validation cohort. The 6-month mortality rate increased across risk scores (possible range, 0-19): 0 points, 8.9% mortality; 1 to 2, 10.8%; 3 to 5, 23.2%; 6 to 8, 40.4%; 9 to 11, 57.0%; and at least 12, 70.0% in the validation cohort. The area under the receiver operating characteristic (AUROC) curve for predicting 6-month mortality was 0.74 and 0.70 in the derivation and validation cohorts, respectively. Our risk score demonstrated better discrimination to predict 6-month mortality (AUROC, 0.64 for a cutoff of &gt; or =6 points vs 0.51 for FAST stage 7c).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A risk score based on 12 variables from the MDS estimates 6-month mortality for nursing home residents with advanced dementia with greater accuracy than existing prognostic guidelines.\n",
            "     </abstracttext>]\n",
            "9555761.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The Centers for Disease Control and Prevention (CDC) convened a Working Group in October 1995 to summarize the data regarding the risk of invasive group A streptococcal (GAS) disease among household contacts of an index patient and the potential efficacy of chemoprophylaxis. This statement on chemoprophylaxis for prevention of subsequent cases among household contacts is intended for use by public health professionals and clinicians.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      The CDC invited representatives of the American Academy of Pediatrics, the Council of State and Territorial Epidemiologists, the Hospital Infection Control Practice Advisory Committee, the Infectious Diseases Society of America, and experts from academia to participate.\n",
            "     </abstracttext>, <abstracttext label=\"EVIDENCE\" nlmcategory=\"METHODS\">\n",
            "      Data on the transmission of GAS and risk factors for severe infection were considered. Population-based surveillance data were used to estimate the risk of invasive GAS disease among household contacts of a case patient. The potential efficacy of chemoprophylaxis was considered using estimates of the efficacy of various regimens in eradicating pharyngeal carriage.\n",
            "     </abstracttext>, <abstracttext label=\"CONSENSUS PROCESS\" nlmcategory=\"METHODS\">\n",
            "      This document summarizes the data considered by the Working Group to develop its position. The consensus achieved by group discussion at the meeting was incorporated in a draft document, which was reviewed by all members and revised to include suggested changes.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The Working Group concluded that no definite recommendations can be made at this time regarding chemoprophylaxis for household contacts of persons with invasive GAS infection. More data are needed to assess the risk of subsequent cases and to determine an optimal regimen for chemoprophylaxis. Until such data are available, physicians and health departments should base decisions regarding chemoprophylaxis on their assessment of the risk associated with each individual case.\n",
            "     </abstracttext>]\n",
            "1824642.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12615832.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      This prospective study included 214 women with PCOS compared with 112 women with normal ovaries. Main clinical, biological and ultrasonographic markers of PCOS were assessed during the early follicular phase.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The mean FNPO of follicles 2-5 mm in size was significantly higher in polycystic ovaries than in controls, while it was similar within the 6-9 mm range. Setting the threshold at 12 for the 2-9 mm FNPO offered the best compromise between specificity (99%) and sensitivity (75%). Within the 2-5 mm follicular range, we found significant positive relationships between the FNPO and androgens. The FNPO within the 6-9 mm range was significantly and negatively related to body mass index and fasting insulin serum level.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      We propose to modify the definition of polycystic ovaries by adding the presence of &gt; or =12 follicles measuring 2-9 mm in diameter (mean of both ovaries). Also, our findings strengthen the hypothesis that the intra-ovarian hyperandrogenism promotes excessive early follicular growth and that further progression cannot proceed normally because of hyperinsulinism and/or other metabolic influence linked to obesity.\n",
            "     </abstracttext>]\n",
            "12791436.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14682412.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Study subjects were detected in a general population screening and monitoring program. Those with a moderately accelerated annual FEV1 decline and persistent respiratory symptoms were invited to participate in a 2-year randomized controlled trial comparing fluticasone propionate DPI 250 microg b.i.d. with placebo. Pre- and post-bronchodilator (BD) FEV1, PC20 histamine, functional status (COOP/WONCA charts) and occurrence of exacerbations were periodically assessed. Subjects recorded respiratory symptoms. Post-BD FEV1 decline served as the main outcome. Multivariable repeated measurements analysis techniques were applied.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      48 subjects were randomized (24 fluticasone, 24 placebo). After 3 months, the post-BD FEV1 had increased with 125 ml (SE = 68, P = 0.075) and the pre-BD FEV1 with 174 ml (SE 90, P = 0.059) in the fluticasone relative to the placebo group. The subsequent post-BD and pre-BD FEV1 decline were not beneficially modified by fluticasone treatment. There were no statistically significant differences in respiratory symptoms, functional status, or exacerbations favoring fluticasone. Subgroup analysis indicated that the presence of bronchial hyperresponsiveness modified the initial FEV1 response on fluticasone, but not the subsequent annual FEV1 decline.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Early initiation of inhaled steroid treatment does not seem to affect the progressive deterioration of lung function or other respiratory health outcomes in subjects with early signs and symptoms of COPD. In subjects at risk for, or in an early stage of COPD, long-term inhaled steroid treatment should not be based on a single spirometric evaluation after 3 months.\n",
            "     </abstracttext>]\n",
            "10518812.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "6310075.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11865128.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      The authors conducted a multicenter, randomized, double-blind clinical trial in which 136 children with ADHD and a chronic tic disorder were randomly administered CLON alone, MPH alone, combined CLON + MPH, or placebo (2 x 2 factorial design). Each subject participated for 16 weeks (weeks 1-4 CLON/placebo dose titration, weeks 5-8 added MPH/placebo dose titration, weeks 9-16 maintenance therapy).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Thirty-seven children were administered MPH alone, 34 were administered CLON alone, 33 were administered CLON + MPH, and 32 were administered placebo. For our primary outcome measure of ADHD (Conners Abbreviated Symptom Questionnaire--Teacher), significant improvement occurred for subjects assigned to CLON (p &lt; 0.002) and those assigned to MPH (p &lt; 0.003). Compared with placebo, the greatest benefit occurred with combined CLON + MPH (p &lt; 0.0001). CLON appeared to be most helpful for impulsivity and hyperactivity; MPH appeared to be most helpful for inattention. The proportion of individual subjects reporting a worsening of tics as an adverse effect was no higher in those treated with MPH (20%) than those being administered CLON alone (26%) or placebo (22%). Compared with placebo, measured tic severity lessened in all active treatment groups in the following order: CLON + MPH, CLON alone, MPH alone. Sedation was common with CLON treatment (28% reported moderate or severe sedation), but otherwise the drugs were tolerated well, including absence of any evident cardiac toxicity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Methylphenidate and clonidine (particularly in combination) are effective for ADHD in children with comorbid tics. Prior recommendations to avoid methylphenidate in these children because of concerns of worsening tics are unsupported by this trial.\n",
            "     </abstracttext>]\n",
            "14984370.xml\n",
            "\n",
            "[<abstracttext label=\"AIM\" nlmcategory=\"OBJECTIVE\">\n",
            "      To quantify the effect of different types of fibre on global and symptom relief from irritable bowel syndrome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Using a structured literature search in MEDLINE (1966-2002), we selected randomized controlled trials involving irritable bowel syndrome patients treated with fibre. Analyses were performed for the total group and for trials using soluble and insoluble fibre separately.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Seventeen studies were included in the analysis. None investigated primary care irritable bowel syndrome patients. Fibre, in general, was effective in the relief of global irritable bowel syndrome symptoms [relative risk, 1.33; 95% confidence interval (CI), 1.19-1.50]. Irritable bowel syndrome patients with constipation may receive benefit from fibre treatment (relative risk, 1.56; 95% CI, 1.21-2.02), but there was no evidence that fibre was effective in the relief of abdominal pain in irritable bowel syndrome. Soluble and insoluble fibre, separately, had different effects on global irritable bowel syndrome symptoms. Soluble fibre (psyllium, ispaghula, calcium polycarbophil) showed significant improvement (relative risk, 1.55; 95% CI, 1.35-1.78), whereas insoluble fibre (corn, wheat bran), in some cases, worsened the clinical outcome, but there was no significant difference compared with placebo (relative risk, 0.89; 95% CI, 0.72-1.11).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The benefits of fibre in the treatment of irritable bowel syndrome are marginal for global irritable bowel syndrome symptom improvement and irritable bowel syndrome-related constipation. Soluble and insoluble fibres have different effects on global irritable bowel syndrome symptoms. Indeed, in some cases, insoluble fibres may worsen the clinical outcome. Future clinical studies evaluating the effect and tolerability of fibre therapy are needed in primary care.\n",
            "     </abstracttext>]\n",
            "11729014.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Serotonin selective reuptake inhibitors (SSRIs) are now considered the first-line pharmacotherapy for panic disorder. The preferential use and the presumption of greater tolerability of SSRIs relative to older agents, such as tricyclic antidepressants, occurred without direct comparisons between the two classes of medication. In this study the authors used an effect-size analysis to provide an initial comparison.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      The authors conducted an effect-size analysis of 12 placebo-controlled, efficacy trials of SSRIs for panic disorder and compared these results to findings obtained in a recent meta-analysis of non-SSRI treatments for panic disorder.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The mean effect size for acute treatment outcome for SSRIs relative to placebo was 0.55, not significantly different from that for antidepressants in general (0.55) and for imipramine in particular (0.48). More recent studies of SSRIs, and studies using larger samples, were associated with lower effect sizes. No significant differences were found in dropout rates between those taking SSRIs and those taking older agents during acute treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      An effect-size analysis of controlled studies of treatments for panic disorder revealed no significant differences between SSRIs and older antidepressants in terms of efficacy or tolerability in short-term trials. An inverse relationship was evident between sample size and effect size for SSRIs. Early studies of small samples may have led to initial overestimations of the efficacy of SSRIs for panic disorder.\n",
            "     </abstracttext>]\n",
            "7539890.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We used a double-blind, placebo-controlled protocol in which 674 patients with symptoms of congestive heart failure, cardiac enlargement, 10 or more premature ventricular contractions per hour, and a left ventricular ejection fraction of 40 percent or less were randomly assigned to receive amiodarone (336 patients) or placebo (338 patients). The primary end point was overall mortality, and the median follow-up was 45 months (range, 0 to 54).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There was no significant difference in overall mortality between the two treatment groups (P = 0.6). The two-year actuarial survival rate was 69.4 percent (95 percent confidence interval, 64.2 to 74.6) for the patients in the amiodarone group and 70.8 percent (95 percent confidence interval, 65.7 to 75.9) for those in the placebo group. At two years, the rate of sudden death was 15 percent in the amiodarone group and 19 percent in the placebo group (P = 0.43). There was a trend toward a reduction in overall mortality among the patients with nonischemic cardiomyopathy who received amiodarone (P = 0.07). Amiodarone was significantly more effective in suppressing ventricular arrhythmias and increased the left ventricular ejection fraction by 42 percent at two years.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy.\n",
            "     </abstracttext>]\n",
            "12353945.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Case reports from preliminary analysis of an ongoing clinical trial.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Clinical research center in a community hospital.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use.\n",
            "     </abstracttext>, <abstracttext label=\"MEASUREMENTS\" nlmcategory=\"METHODS\">\n",
            "      1) Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      All four patients repeatedly distinguished blinded statin therapy from placebo. Strength testing confirmed weakness during statin therapy that reversed during placebo use. Muscle biopsies showed evidence of mitochondrial dysfunction, including abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy when they were not receiving statins. Creatine kinase levels were normal in all four patients despite the presence of significant myopathy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Some patients who develop muscle symptoms while receiving statin therapy have demonstrable weakness and histopathologic findings of myopathy despite normal serum creatine kinase levels.\n",
            "     </abstracttext>]\n",
            "8416468.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether essential fatty acids are effective in the treatment of premenstrual syndrome (PMS).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In a randomized, double-blind, crossover trial, we studied 27 women diagnosed with PMS over ten menstrual cycles and 22 symptom-free controls over one cycle. The first cycle was used for diagnostic assessment. For the women with PMS, placebos were administered during the second cycle. This was followed by randomization to four cycles of active treatment with essential fatty acids and four cycles of placebo, with a crossover after completion of the fourth cycle. Assessment of symptoms and diagnosis of PMS were based on daily self-ratings made by the women throughout the study.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Treatment with essential fatty acids did not reduce premenstrual symptoms or symptom cyclicity. However, time had a significant effect on a number of symptoms, indicating either a placebo effect or an effect from participation in the study. Women with PMS had a significantly higher frequency of dysmenorrhea and familial PMS than did the symptom-free controls.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Treatment with essential fatty acids is ineffective therapy for PMS. The improvement we observed over time can be ascribed to either a placebo effect or participation in the study.\n",
            "     </abstracttext>]\n",
            "11083602.xml\n",
            "\n",
            "[<abstracttext label=\"STUDY OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To prospectively study the utility of four clinical prediction models for either predicting the presence of obstructive sleep apnea (OSA, apnea-hypopnea index [AHI] &gt; or = 10/hour), or prioritizing patients for a split-night protocol (AHI(3)20/hour).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      All patients presenting for OSA evaluation completed a research questionnaire that included questions from previously developed clinical prediction models. The probability of sleep apnea for each patient for each model was calculated based upon the equation used in the model. Based upon two cutoffs of apnea-hypopnea index, 10 and 20, the sensitivity, specificity, and positive predictive value were calculated. For the cutoffs AHI &gt; or =10 and &gt; or =20, receiver operating characteristic curves were generated and the areas under the curves calculated. Comparisons of demographic information and symptom response were compared between patients with and without OSA, and men vs. women.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Urban, accredited sleep disorders center.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS OR PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      All patients referred for evaluation of OSA who underwent polysomnography.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      N/A.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      370 patients (191 men, 179 women) completed the study. 248 of the 370 (67%) patients had an AHI(3)10; 180 of the 370 (49%) had an AHI&gt; or =20. For AHI &gt; or =10, the sensitivities ranged from 76 to 96%, specificities from 13%-54%, positive predictive values from 69%-77% using the probability cutoff of the original investigators; the areas under the curve from 0.669 to 0.736. For AHI(3)20, the areas under the ROC curves ranged from 0.700 to 0.757; using cutoffs to maximized specificity, the sensitivities ranged from 33%-39%, specificities from 87%-93%, and positive predictive values from 72%-85%. All the models performed better for men.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The clinical prediction models tested are not be sufficiently accurate to discriminate between patients with or without OSA but could be useful in prioritizing patients for split-night polysomnography.\n",
            "     </abstracttext>]\n",
            "15198752.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To test whether a cognitive-behaviour therapy intervention program reduces the prevalence of depression during the first postnatal year in mothers of very preterm babies.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Prospective, single blind, randomised, controlled study.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Perinatal centre in Western Australia.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      One hundred and ninety-nine out of 673 English-speaking mothers of infants admitted to the neonatal unit.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      A six-session cognitive-behaviour therapy intervention program provided by a research midwife between weeks two and six after birth. Women in the control group received standard care.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Depression and anxiety disorders occurring in the first year assessed by a clinical psychologist at structured interview using the Schedule for Affective Disorders and Schizophrenia (SADS) at 2 weeks, 2, 6 and 12 months.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      One hundred and one women were randomised to the intervention group and 98 to the control group. Fifty-four mothers (27%) in the trial were diagnosed with minor or major depression in the 12 months following very preterm delivery, 29 (29%) in the intervention group and 25 (26%) in the control group (relative risk 1.1 [95% CI 0.80-1.5]). There were no differences in the time of onset or the duration of the episodes of depression between the groups. Overall, 74 mothers (37%) of the 199 met criteria for a diagnosis of psychological morbidity during the first year.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our intervention program did not alter the prevalence of depression in these mothers. Rates of depression and stress reactions are high in these mothers.\n",
            "     </abstracttext>]\n",
            "10811540.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare the effects of MA oral suspension (O.S.), 800 mg/day, versus placebo on weight in geriatric nursing home patients with weight loss or low body weight.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Twelve-week, randomized, double-blind, placebo-controlled trial with a 13-week follow-up period.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Veterans Administration Medical Center (VMAC) nursing home.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Nursing home patients with weight loss of &gt; or =5% of usual body weight over the past 3 months, or body weight 20% below their ideal body weight.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Patients were randomly assigned to receive placebo or MA 800 mg/day for 12 weeks and were then followed for 13 weeks off treatment.\n",
            "     </abstracttext>, <abstracttext label=\"MEASUREMENTS\" nlmcategory=\"METHODS\">\n",
            "      Primary outcome was measured by weight and appetite change. Secondary outcome measures included sense of well-being, enjoyment of life, change in depression scale, laboratory nutrition parameters, energy intake counts, body composition, and adverse events.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      At 12 weeks there were no significant differences in weight gain between treatment groups, whereas MA-treated patients reported significantly greater improvement in appetite, enjoyment of life, and well-being. Body composition was not statistically different between the two groups. At Week 25 (3 months after treatment), 61.9% of MA-treated patients had gained &gt; or =1.82 kg (4 lbs) compared to 21.7% of placebo patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In geriatric patients with weight loss or low body weight MA improves appetite and well-being after 12 weeks of treatment. During the 3 months of MA treatment, there was no statistically significant weight gain (&gt; or =4 lbs). Three months after treatment, weight gain (&gt; or =4 lbs) was significantly increased in MA-treated patients.\n",
            "     </abstracttext>]\n",
            "3941176.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15613404.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "7955452.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      There is recent evidence that both exogenous and endogenous subclinical thyrotoxicoses are associated with decreased bone mineral density. Scanty information is available on bone metabolism in these conditions when euthyroidism is restored. We evaluated the effect of anti-thyroid drug treatment on bone metabolism in endogenous subclinical hyperthyroidism.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Prospective follow-up study over 2 years during treatment with methimazole, with an untreated control group.\n",
            "     </abstracttext>, <abstracttext label=\"SUBJECTS\" nlmcategory=\"METHODS\">\n",
            "      Sixteen post-menopausal women with endogenous subclinical hyperthyroidism associated with multinodular goitre, eight of whom were treated with methimazole.\n",
            "     </abstracttext>, <abstracttext label=\"MEASUREMENTS\" nlmcategory=\"METHODS\">\n",
            "      Serum concentrations of free T4, total T3, TSH, osteocalcin, urinary excretion of hydroxyproline and forearm bone mineral density were measured at regular intervals.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Significant changes in serum osteocalcin concentration or urinary hydroxyproline excretion were not observed in either group. Distal, but not proximal, forearm bone mineral density, expressed as a percentage of the base-line value, was significantly (P &lt; 0.05) higher in the treated than in the untreated subjects in the second year of treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Treatment with methimazole in post-menopausal women with endogenous subclinical hyperthyroidism associated with multinodular goitre can prevent excessive loss of bone, at least in the distal forearm.\n",
            "     </abstracttext>]\n",
            "10469816.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare young children 3 to 6 years of age who were born small-for-gestational age (SGA; &lt;10th percentile for gestational age) or large-for-gestational age (LGA; &gt;/=90th percentile) with those who were born appropriate-for-gestational age (10th-89th percentile) to determine whether there are differences in growth and fatness in early childhood associated with birth weight status.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      National sample of 3192 US-born non-Hispanic white, non-Hispanic black, and Mexican-American children 3 to 6 years of age (36-83 months) examined in the third National Health and Nutrition Examination Survey and for whom birth certificates were obtained. On the birth certificates, length of gestation from the mother's last menstrual period was examined for completeness, validity, and whether the pattern of missing (n = 141) and invalid data (n = 147) on gestation was random. Gestation was considered invalid when &gt;44 weeks, or when at gestations of &lt;/=35 weeks, birth weight was inconsistent with gestation. To reclaim cases with missing or invalid data on gestation for analysis, a multiple imputation (MI) procedure was used. MI procedures are recommended when, as in this case, a critical covariate (length of gestation) is not missing at random, and complete-subject analysis may be biased. Using the results of the MI procedure, children were categorized, and growth outcome was assessed by birth weight-for-gestational age status. The growth outcomes considered in these analyses were body weight (kg), height (cm), head circumference (cm), mid-upper arm circumference (MUAC; cm), and triceps and subscapular skinfold thicknesses (mm). The anthropometric outcomes first were transformed to approximate normal distributions and converted into z scores (standard deviation units [SDU]) to scale the data for comparison across ages. Outcomes at each age then were estimated using regression procedures. SUDAAN software that adjusts variance estimates to account for the sample design was used in analysis for prevalence estimates and to calculate regression coefficients (in SDU).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Over these ages, children born SGA remained significantly shorter and weighed less (-0.70 to -0.60 SDU). Children born LGA remained taller and weighed more (0.40-0.60 SDU). For weight and height among LGA children, there was a divergence from the mean with age compared with those born appropriate-for-gestational age (10th-89th percentile). Head circumference and MUAC followed these same patterns. The coefficients for MUAC show values for SGA children fairly consistently at about -0.50 SDU and children born LGA show increasing MUAC from +0.40 to +0.50 SDU from 36 to 83 months of age. As with weight, there is a trend toward increased MUAC coefficients with age. Measures of fatness (triceps and subscapular skinfolds), which are more prone to environmental influences, showed less association with birth weight-for-gestational age status. Only a single age group, the oldest (6 years of age) group showed a significant deficit in fatness for children born SGA. For children born LGA, there was an increase in fatness at both the triceps and subscapular sites after 3 years of age.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      These findings on a national sample of US-born non-Hispanic white, non-Hispanic black, and Mexican-American children show that children born SGA remain significantly shorter and lighter throughout early childhood and do not seem to catch up from 36 to 83 months of age. LGA infants remain longer and heavier through 83 months of age, but unlike children born SGA, children born LGA may be prone to an increasing accumulation of fat in early childhood. Thus, early childhood may be a particularly sensitive period in which there is increase in variation in levels of fatness associated with size at birth. These findings have implications for the evaluation of the growth of young children. The results indicate that intrauterine growth is associated with size in early childhood. (ABSTR\n",
            "     </abstracttext>]\n",
            "11485144.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To provide recommendations for clinicians in the treatment of refractory mixed hyperlipidemia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      A comprehensive MEDLINE (1966-July 2000) and bibliographic search was performed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Thirty-six published clinical trials and 29 case reports involving combination therapy with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and fibric acid derivatives regarding the occurrence of rhabdomyolysis or myopathy were reviewed. The literature review demonstrated that combination therapy with a statin and fibrate increases the risk of muscle damage, with an incidence of 0.12%. Risk factors that predispose patients to myopathy caused by combination statin-fibrate therapy include increased age, female gender, renal or liver disease, diabetes, hypothyroidism, debilitated status, surgery, trauma, excessive alcohol intake, and heavy exercise.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or refractory mixed hyperlipidemia. Although such a combination does increase the risk of myopathy, with an incidence of approximately 0.12%, this small risk of myopathy rarely outweighs the established morbidity and mortality benefits of achieving lipid goals. Nevertheless, a higher incidence of myopathy has been reported with statin monotherapy. When monotherapy with a statin fails to control mixed hyperlipidemia, combination therapy may be considered. Niacin may be added before a fibrate is considered, as it appears to have less risk of myopathy. Statin-fibrate combination therapy must be undertaken cautiously and only after careful risk-benefit analysis. Patient counseling on the risks and warning signs of myopathy is extremely important.\n",
            "     </abstracttext>]\n",
            "2341917.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To investigate primary care physicians' recognition and evaluation of red blood cell (RBC) macrocytosis in adults.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Retrospective chart review. Utilizing a computerized laboratory result system, all complete blood counts (CBCs) with RBC indices performed between May 1986 and May 1987 were retrieved. Patients having mean corpuscular volumes (MCVs) more than three standard deviations from the mean (greater than 98.5 fL) were selected for evaluation.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      The primary care clinics of a public university hospital.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      138 (3.7%) of 3,805 adult outpatients had MCVs greater than 98.5 fL, and of these, 128 (93.4%) had medical charts available for review.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      55 patients with elevated MCVs were not evaluated for this finding, and their mean MCV (100.6 fL) was significantly lower than that of the 73 patients who were evaluated (102.5 fL; p = 0.003). The investigation of macrocytosis included vitamin B12 and folate levels consistently, and the reticulocyte count and peripheral smear were examined infrequently. Five patients had vitamin B12 deficiency, and two had hypothyroidism. Macrocytosis was ascribed to alcohol abuse in 47 patients, six of whom had no laboratory evaluation. Nine alcoholic patients with macrocytosis had other causes for this finding. Among the 55 patients whose macrocytosis was not evaluated, 12 were anemic and one had a peripheral neuropathy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Clinically significant and treatable disease was often associated with macrocytosis in our study. Macrocytosis was common, and its recognition and evaluation were variable in this primary care outpatient setting.\n",
            "     </abstracttext>]\n",
            "15367052.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Thirty-five women referred to a tertiary care hospital outpatient program with a DSM-IV diagnosis of postpartum depression with comorbid anxiety disorder were randomly assigned to 1 of 2 treatment groups-paroxetine-only monotherapy group (N = 16) or paroxetine plus 12 sessions of CBT combination therapy group (N = 19)-for a 12-week trial. Progress was monitored by a psychiatrist blinded to treatment group, using the Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impressions scale, and Edinburgh Postnatal Depression Scale. Data were analyzed using 2-tailed statistical tests at an alpha level of.05. The study was conducted from April 1, 2002, to June 30, 2003.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Both treatment groups showed a highly significant improvement (p &lt;.01) in mood and anxiety symptoms. Groups did not differ significantly in week of recovery, dose of paroxetine at remission, or measures of depression, anxiety, and obsessive-compulsive symptoms at outcome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Antidepressant monotherapy and combination therapy with antidepressants and CBT were both efficacious in reducing depression and anxiety symptoms. However, in this sample of acutely depressed/anxious postpartum women, there were no additional benefits from combining the 2 treatment modalities. Further research into the efficacy of combination therapy in the treatment of moderate-to-severe depression with comorbid disorders in postpartum women is recommended.\n",
            "     </abstracttext>]\n",
            "12751658.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "3559288.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "7503197.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our purpose was to evaluate an antepartum testing program based on twice-weekly nonstress testing and amniotic fluid evaluation in pregnancies complicated by diabetes mellitus and to weight the test components in the prediction of fetal distress requiring cesarean delivery.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      During the 4-year period of 1987 through 1990, 2134 women with pregnancies complicated by diabetes underwent antepartum testing. Of these 1501 women (class A1, n = 505; A2-diet, n = 305; A2-insulin, n = 580; B, n = 71; C to D, n = 29; R to F, n = 11) were delivered within 4 days of their last test. Categoric analysis of data was performed according to diabetic class, fetal heart rate results, and the presence of decreased, normal, or increased amniotic fluid assessment. A univariate logistical regression was first conducted with cesarean delivery for fetal distress as outcome variable by use of the following variables: fetal weight and sex, diabetic class, gestational age at delivery, presence of additional indications for antepartum testing, largest vertical pocket, amniotic fluid index (summation of the four quadrants of the largest vertical pocket), nonstress test reactivity (two accelerations of &gt; or = 15 beats/min of 15 seconds' duration), presence of decelerations (&gt; or = 15 beats/min for 15 seconds) during the nonstress test, and the interactions of the nonstress test with deceleration, largest vertical pocket, and amniotic fluid index. Multivariate analysis was then applied to predict the best model.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      No stillbirths occurred within 4 days of the last antepartum test. However, the corrected stillbirth rate of the entire tested population was 1.4 per 1000. Eighty-five women required cesarean delivery for fetal distress. The factors most predictive of cesarean delivery for fetal distress (p &lt; 0.05, odds ratio and 95% confidence interval) were a deceleration (3.60, 2.14 to 6.06), nonreactive nonstress test (2.68, 1.60 to 4.49), and the interaction of both a nonreactive nonstress test and decelerations (5.63, 2.67 to 11.9). Amniotic fluid assessment by largest vertical pocket or amniotic fluid index were not statistically significant. The multivariate analysis selected the interaction of nonstress test and deceleration as the best significant predictor for cesarean delivery for fetal distress.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      An antepartum fetal surveillance program using twice-weekly nonstress test and fluid index assessment in pregnancies complicated by diabetes was successful in preventing stillbirth. The absence of fetal heart rate reactivity and the presence of decelerations were predictive of the diagnosis of fetal distress in labor requiring cesarean delivery. Ultrasonographic assessment of amniotic fluid volume was not a significant predictor of fetal distress in labor in the diabetic pregnancy.\n",
            "     </abstracttext>]\n",
            "15166898.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To review available evidence establishing the validity of the preparticipation evaluation (PPE) as a method for screening health risk prior to participation in exercise and sport. Specific emphasis was placed on reviewing original research evaluating methods to screen participants for risk of sudden cardiovascular death. Literature on the current state of the PPE as a screening tool for athletic participation was examined.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      Electronic databases were searched for articles relating to mass screening for sports participation and sudden cardiac death in athletes published up to January 2004. Databases searched included Medline (OVID Web, 1966-2004), PubMed (1966-2004), Sport Discuss (1975-2004), Current Contents, CISTI Source (1993-2004), Cochrane Database of Systematic Reviews, and EBM Reviews. Additional references from the bibliographies of retrieved articles were also reviewed.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All study designs were retrieved, but only those studying athletes and/or student-athletes under age 36 years were reviewed. Of the original research retrieved, the majority of the articles sought to establish incidence or prevalence of cardiovascular causes of sudden death in athletes or the validity of various screening tools. Original research articles seeking to establish the current use of the PPE in all its various forms were also reviewed. All of the articles selected for review consisted of type II, population-based data.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION AND SYNTHESIS\" nlmcategory=\"METHODS\">\n",
            "      The initial literature search identified 639 papers. Of these, 310 articles that met the selection criteria were reviewed, and 25 articles were identified as original research directly relating to the PPE. All of these contained type II evidence-population-based clinical studies. The majority of the literature on the PPE consists of type III evidence-case-based opinion papers and position papers from respected authors and sports medicine societies and reports of expert committees. This literature was also reviewed, but only original research relevant to the PPE is reported in this article. The majority of these studies examined cardiovascular diseases and screening procedures.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The 5 studies that assessed the format or effectiveness of the PPE concluded that it was inadequate. The format of the PPE is not standardized and does not consistently address the American Heart Association recommendations for cardiovascular screening history and physical exams. A variety of health care professionals, some without proper training, administer the PPE. The 12 original studies that looked at specific cardiovascular screening techniques were divided on the effectiveness of history, physical examination, electrocardiogram, and echocardiography for detecting cardiovascular risks for sudden death in athletes.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A PPE is required by most sport organizations in America, but research as to its effectiveness is very limited. PPEs have been mandatory in Italy for many years, and we can draw on some the data recorded over this time. Otherwise, very few studies in America or elsewhere have been performed on the PPE process. The research available indicates that the PPE is not implemented adequately or uniformly. An opportunity exists to create a standardized, validated PPE that meets medical standards for quality and provides sensitive, specific screening of potential participants in sport and exercise.\n",
            "     </abstracttext>]\n",
            "17162986.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A systematic review was conducted on 37 treatment studies (N = 2246 subjects/patients) published between 1998 and 2004 inclusively and identified through Psyclnfo and Medline searches. Each study was systematically reviewed with a standard coding sheet and the following information was extracted: Study design, sample (number of participants, age, gender), diagnosis, type of treatments and controls, primary and secondary outcome measures, and main findings. Criteria for inclusion of a study were as follows: (a) the main sleep diagnosis was insomnia (primary or comorbid), (b) at least 1 treatment condition was psychological or behavioral in content, (c) the study design was a randomized controlled trial, a nonrandomized group design, a clinical case series or a single subject experimental design with a minimum of 10 subjects, and (d) the study included at least 1 of the following as dependent variables: sleep onset latency, number and/or duration of awakenings, total sleep time, sleep efficiency, or sleep quality.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Psychological and behavioral therapies produced reliable changes in several sleep parameters of individuals with either primary insomnia or insomnia associated with medical and psychiatric disorders. Nine studies documented the benefits of insomnia treatment in older adults or for facilitating discontinuation of medication among chronic hypnotic users. Sleep improvements achieved with treatment were well sustained over time; however, with the exception of reduced psychological symptoms/ distress, there was limited evidence that improved sleep led to clinically meaningful changes in other indices of morbidity (e.g., daytime fatigue). Five treatments met criteria for empirically-supported psychological treatments for insomnia: Stimulus control therapy, relaxation, paradoxical intention, sleep restriction, and cognitive-behavior therapy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DISCUSSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      These updated findings provide additional evidence in support of the original review's conclusions as to the efficacy and generalizability of psychological and behavioral therapies for persistent insomnia. Nonetheless, further research is needed to develop therapies that would optimize outcomes and reduce morbidity, as would studies of treatment mechanisms, mediators, and moderators of outcomes. Effectiveness studies are also needed to validate those therapies when implemented in clinical settings (primary care), by non-sleep specialists. There is also a need to disseminate more effectively the available evidence in support of psychological and behavioral interventions to health-care practitioners working on the front line.\n",
            "     </abstracttext>]\n",
            "8907095.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10796686.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "</abstracttext>, <abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To update an ongoing review summarising the results of randomised controlled trials (RCTs) of interventions to help patients follow prescriptions for medications, focusing on trials that measured both adherence and clinical outcomes.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      Computerised searches to July 1998 in MEDLINE, CINAHL, The Cochrane Library, International Pharmaceutical Abstracts (IPA), PsychInfo, Sociofile, and HSTAR; bibliographies in articles on patient adherence; articles in the reviewers' personal collections; and contact with authors.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Articles were selected if they reported an unconfounded RCT of an intervention to improve adherence with prescribed medications, measuring both medication adherence and treatment outcome, with at least 80% follow-up of each group studied and, for long-term treatments, at least six months follow-up for studies with positive initial findings.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Information on study design features, interventions and controls, and findings were extracted by one reviewer (PM) and a research assistant and confirmed by two of the other reviewers. The studies were too disparate to warrant meta-analysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      For short-term treatments, one study, of counselling and written information, showed an effect on adherence and clinical outcome. Ten of 19 interventions for long-term treatments reported in 17 RCTs were associated with improvements in adherence, but only nine interventions led to improvements in treatment outcomes. Almost all of the interventions that were effective for long-term care were complex, including combinations of more convenient care, information, counselling, reminders, self-monitoring, reinforcement, family therapy, and other forms of additional supervision or attention. Even the most effective interventions did not lead to large improvements in adherence and treatment outcomes. Two studies showed that telling patients about adverse effects of treatment did not affect their adherence.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The full benefits of medications cannot be realised at currently achievable levels of adherence. Current methods of improving adherence for chronic health problems are mostly complex and not very effective. More studies of innovative approaches to assist patients to follow medication prescriptions are needed.\n",
            "     </abstracttext>]\n",
            "11759078.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "3935901.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9672274.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Between October, 1986, and April, 1996, we accrued 2494 healthy women aged between 30 and 70 with a family history of breast cancer. They have been randomised (double blind) to receive tamoxifen 20 mg per day orally or placebo for up to 8 years. Follow-up included clinical assessment, annual mammography, and assessment of toxicity and compliance. The primary endpoint was the occurrence of breast cancer, which was analysed on an intention-to-treat basis with a survival curve.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      With a median follow-up of 70 months, 2471 women (tamoxifen 1238, placebo 1233) were suitable for analysis. The groups were evenly matched at baseline, and compliance was good. The overall frequency of breast cancer is the same for women on tamoxifen or placebo (tamoxifen 34, placebo 36, relative risk 1.06 [95% CI 0.7-1.7], p=0.8). Participants who were already on hormone-replacement therapy when they entered the study had an increased risk of breast cancer compared with non-users. Those participants who started such therapy while on trial had a significantly reduced risk. The safety profile of tamoxifen was as expected.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      We have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction in healthy women given tamoxifen versus placebo. Differences in the study populations for the two trials may underlie these conflicting findings: eligibility in our trial was based predominantly on a strong family history of breast cancer whereas in the NSABP trial was mostly based on non-genetic risk factors. The importance of oestrogen promotion may vary between such populations.\n",
            "     </abstracttext>]\n",
            "10920726.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To establish guidelines for the screening and treatment of hyperhomocysteinemia in the investigation and management of coronary artery disease (CAD).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"OPTIONS\" nlmcategory=\"METHODS\">\n",
            "      Measurement of plasma total homocysteine (tHcy) levels in the fasting state or 4-6 hours after oral methionine load; vitamin supplementation with folic acid and vitamins B6 and B12; adherence to the recommended daily allowance of dietary sources of folate and vitamins B6 and B12.\n",
            "     </abstracttext>, <abstracttext label=\"EVIDENCE\" nlmcategory=\"METHODS\">\n",
            "      MEDLINE was searched for relevant English-language articles published from January 1966 to June 1999; also reviewed were additional articles identified from the bibliographies.\n",
            "     </abstracttext>, <abstracttext label=\"VALUES\" nlmcategory=\"METHODS\">\n",
            "      The strength of evidence was evaluated using the methods of the Canadian Task Force on Preventive Health Care.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"OUTCOMES\" nlmcategory=\"RESULTS\">\n",
            "      This article reviews the available evidence on the association between plasma tHcy levels and CAD and the effect of lowering tHcy levels through vitamin supplementation or dietary intake.\n",
            "     </abstracttext>, <abstracttext label=\"BENEFITS, HARMS AND COSTS\" nlmcategory=\"RESULTS\">\n",
            "      Cardiovascular disease is the leading cause of death in Canada. Homocysteine, generated in the metabolism of methionine, may have a role in the development of cardiovascular disease. The prevalence of hyperhomocysteinemia in the general population is between 5% and 10% and may be as high as 30%-40% in the elderly population. If population-based studies are correct, tHcy may be responsible for up to 10% of CAD events and thus may represent an important and potentially modifiable risk factor for cardiovascular disease. Laboratory testing for tHcy is currently restricted to research centres, and costs range from $30 to $50 per person. Newer, less costly techniques have been developed and should become readily available with time.\n",
            "     </abstracttext>, <abstracttext label=\"VALIDATION\" nlmcategory=\"RESULTS\">\n",
            "      The findings of this analysis were reviewed through an iterative process by the members of the Canadian Task Force on Preventive Health Care.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RECOMMENDATIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Although there is insufficient evidence to recommend the screening or management of hyperhomocysteinemia at present (grade C recommendation), adherence to recommended daily allowance of dietary sources of folate and vitamins B12 and B6 should be encouraged. If elevated tHcy levels are discovered, vitamin deficiency should be ruled out to allow specific treatment and prevention of complications, such as neurological sequelae due to vitamin B12 deficiency. Experts in the field advocate treatment of elevated tHcy levels in high-risk people, such as those with a personal or family history of premature atherosclerosis or a predisposition to develop hyperhomocysteinemia. Definitive guidelines for the management of hyperhomocysteinemia await the completion of randomized trials to establish the effect of vitamin supplementation on CAD events.\n",
            "     </abstracttext>]\n",
            "12457519.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15635109.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P&lt;0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.\n",
            "     </abstracttext>]\n",
            "3350949.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12442064.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Sixteen patients treated with oral hypoglycaemic agents (6 men and 10 women) were included in this open-label, randomized, parallel group study. Their age was 62 +/- 2 (mean +/- SEM) years (range 44-79 years), body weight 71.3 +/- 2.9 kg, body mass index (BMI) 24.6 +/- 0.8 kg/m(2). The patients were switched to insulin treatment with bedtime NPH insulin combined with daytime sulphonylurea (combination group) or twice daily injections of a premixed combination of regular human and NPH insulin (insulin twice daily group) with measurements as given below before and after 12 and 24 weeks of treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      HbA(1c) was lowered from 8.3 +/- 0.3% to 7.0 +/- 0.2% in the insulin twice daily group (p&lt;0.05) and from 8.3 +/- 0.3% to 6.8 +/- 0.5% in the combination group (p&lt;0.03; ns between treatment groups). Body weight increased from 71.7 +/- 4.0 kg to 77.6 +/- 4.4 kg in the insulin twice daily group (p&lt;0.001) and from 70.8 +/- 4.6 kg to 72.7 +/- 5.1 kg in the combination group (ns; p&lt;0.02 between groups). The dose of insulin at 24 weeks in the insulin twice daily group was 45.8 +/- 4.2 U and 29.4 +/- 5.4 U in the combination group (p=0.03). Combination treatment reduced fasting and stimulated C-peptide levels.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Both treatments improved glycaemic control to the same extent but the combination of bedtime NPH insulin and daytime sulphonylurea gave a very small increase of body weight over a 6 months period. We conclude that combination therapy is an attractive alternative when starting insulin treatment in patients with Type 2 diabetes as this is a critical period for weight gain in such patients.\n",
            "     </abstracttext>]\n",
            "11704183.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the evidence on possible drug interactions between antibiotics and oral contraceptives (OCs) that may lead to OC failure.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      MEDLINE and Lexis/Nexis Medical Library searches for 1966-1999 using the key word \"oral contraceptives,\" cross-indexed with the terms \"antibiotics,\" \"adverse effects,\" and \"pregnancy,\" and MEDLINE search using the additional MeSH term \"drug interactions.\" No language restrictions were used.\n",
            "     </abstracttext>, <abstracttext label=\"METHODS OF STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      A total of 167 articles were retrieved for analysis. Another 32 articles were identified by review of the references cited in these publications. Articles were selected based on their ability to provide information on the relationship between antibiotic therapy and OC efficacy in otherwise compliant users (defined as women with unplanned pregnancies who reported compliance with their OC regimen). Additionally, studies that either directly measured the effects of antibiotics on the pharmacokinetics of OC components, or that analyzed the effects of antibiotics on measures of ovulation in OC users were accepted.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"TABULATION, INTEGRATION, AND RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      At least 30 cases have been reported of pregnancies occurring in women taking OCs and antibiotics, particularly rifampin. Approximately 20% of pregnant women reporting to family planning or abortion clinics reported concomitant OC and antibiotic use. Information from adverse event reporting databases generally mirrors the types of information gleaned from these case reports and clinical surveys and accounts for approximately one-third of reported cases. Retrospective surveys, primarily from dermatology-based practices, also have reported 24 pregnancies in OC users who concomitantly received therapy with antibiotics, most commonly tetracyclines and penicillins. Apparent OC failure rates in clinical surveys were within the usual range expected for patterns of typical use. In pooled results obtained from relatively small populations, oral antibiotics, with the exception of rifampin, have not significantly affected the pharmacokinetics of ethinyl estradiol, levonorgestrel, and norethindrone or reduced the serum concentrations of gonadotropins. However, individual patients have been identified who experienced significant decreases in the plasma concentration of these components of OCs and who appeared to ovulate.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Rifampin impairs the effectiveness of OCs. Pharmacokinetic studies of other antibiotics have not shown any systematic interaction between antibiotics and OC steroids. However, individual patients do show large decreases in the plasma concentrations of ethinyl estradiol when they take certain other antibiotics, notably tetracycline and penicillin derivatives. Because it is not possible to identify these women in advance, a cautious approach is advised.\n",
            "     </abstracttext>]\n",
            "7576395.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "1790394.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "3186087.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8976640.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To show whether intra-articular steroid injections are effective in osteoarthritis; to determine factors that predict response; and to determine whether injection has a beneficial effect on muscle strength.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Double blind, placebo controlled, crossover study in 59 patients with symptomatic osteoarthritis of the knee. Outcome measure-Primary outcome measure: change in visual analogue score for pain at three weeks. Predictors of response analysed using logistic regression with a 15% decrease in pain score at three weeks defining response.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Intra-articular methyl prednisolone acetate produced a significant reduction in visual analogue pain score at three weeks compared to both baseline (median change -2.0 mm, interquartile range -16.25 to 4.0) and placebo (median 0.0 mm, interquartile range -9.0 to 6.25). No clinical predictors of response could be identified. Muscle strength was not significantly improved in the short term by intra-articular injection.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Intra-articular corticosteroids are effective for short term relief of pain in osteoarthritis but predicting responders is not possible. There may be a place for their more widespread use.\n",
            "     </abstracttext>]\n",
            "14985592.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine (1) whether dust and surfaces in households of smokers are contaminated with environmental tobacco smoke (ETS); (2) whether smoking parents can protect their infants by smoking outside and away from the infant; and (3) whether contaminated dust, surfaces, and air contribute to ETS exposure in infants.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Quasi-experiment comparing three types of households with infants: (1) non-smokers who believe they have protected their children from ETS; (2) smokers who believe they have protected their children from ETS; (3) smokers who expose their children to ETS.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Homes of smokers and non-smokers.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Smoking and non-smoking mothers and their infants &lt; or = 1 year.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      ETS contamination as measured by nicotine in household dust, indoor air, and household surfaces. ETS exposure as measured by cotinine levels in infant urine.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      ETS contamination and ETS exposure were 5-7 times higher in households of smokers trying to protect their infants by smoking outdoors than in households of non-smokers. ETS contamination and exposure were 3-8 times higher in households of smokers who exposed their infants to ETS by smoking indoors than in households of smokers trying to protect their children by smoking outdoors.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Dust and surfaces in homes of smokers are contaminated with ETS. Infants of smokers are at risk of ETS exposure in their homes through dust, surfaces, and air. Smoking outside the home and away from the infant reduces but does not completely protect a smoker's home from ETS contamination and a smoker's infant from ETS exposure.\n",
            "     </abstracttext>]\n",
            "7849885.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether the administration of beta-agonists by metered-dose inhaler (MDI) with a spacer device is as effective as the administration of beta-agonists by nebulizer for the treatment of acute asthma exacerbations in children.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Randomized trial with two arms.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Urban pediatric emergency department (ED) in Bronx, NY.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Convenience sample of 152 children 2 years and older with a history of at least two episodes of wheezing presenting to the ED with an acute asthma exacerbation.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Patients were randomly assigned to receive standard doses of a beta-agonist (albuterol) by an MDI with spacer or by a nebulizer. Dosing intervals and the use of other medications were determined by the treating physician.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MEASUREMENTS/MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Baseline characteristics and asthma history were recorded. Asthma severity score, peak expiratory flow rate in children 5 years or older, and oxygen saturation were determined at presentation and before admission or discharge. The groups did not differ in age, sex, ethnicity, age of onset of asthma, or asthma severity score at presentation. There were no significant differences between the groups in outcomes, including mean changes in respiratory rate, asthma severity score, and peak expiratory flow rate, oxygen saturation, number of treatments given, administration of steroids in the ED, and admission rate. Patients given MDIs with spacers required shorter treatment times in the ED (66 minutes vs 103 minutes, P &lt; .001). Fewer patients in the spacer group had episodes of vomiting in the ED (9% vs 20%, P &lt; .04), and patients in the nebulizer group had a significantly greater mean percent increase in heart rate from baseline to final disposition (15% vs 5%, P &lt; .001).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      These data suggest that MDIs with spacers may be an effective alternative to nebulizers for the treatment of children with acute asthma exacerbations in the ED.\n",
            "     </abstracttext>]\n",
            "3982720.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10352632.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A surveillance study was conducted from December 1992 to December 1994. Susceptibility testing of urinary tract isolates of E. coli was performed using a panel of antimicrobial agents. A case-control study was also conducted for subjects with isolates resistant to trimethoprim-sulfamethoxazole (T-S), this drug being used a representative \"first-line\" agent.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 1636 consecutive isolates were obtained from 967 subjects. Of the 1636 isolates, 736 (45.0%) were resistant to ampicillin, 514 (31.4%) were resistant to T-S, 363 (22.2%) were resistant to both ampicillin and T-S, and 27 (1.7%) were resistant to both ampicillin and gentamicin. In the case-control study 274 children with isolates resistant to T-S were matched with 274 children who had T-S-sensitive isolates obtained during the study period or the preceding or subsequent 6 months. Multivariate analyses indicated that subjects who had received antimicrobials for more than 4 weeks in the previous 6 months were about 23 times more likely to have isolates resistant to T-S than were subjects without this risk factor (odds ratio [OR] 23.4, 95% confidence interval [CI] 12.0-47.6). Children with genitourinary tract abnormalities were 2.4 times more likely to have resistant isolates than those without such abnormalities (95% CI 1.2-4.5). Compared with children who had no hospital admissions in the previous year, those with 1 admission in that period were more likely to have resistant isolates (OR 2.3, 95% CI 1.4-7.5), as were those with 2 or more admissions in that period (OR 3.2, 95% CI 1.1-4.8). Compared with children aged 2-6 years, children under 2 years of age were less likely to have resistant isolates (OR 0.3, 95% CI 0.2-0.8).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Selective antimicrobial pressure and multiple admissions to hospital were among the risk factors associated with antimicrobial resistance. The finding of a low but definite level of resistance to both ampicillin and gentamicin is important for the selection of empiric therapy for sepsis in neonates. The role of inexpensive first-line agents in the outpatient treatment and prevention of urinary tract infections requires re-examination, particularly in children who have recently received antimicrobial therapy.\n",
            "     </abstracttext>]\n",
            "1777557.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15976596.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of this study was to compare the demographic, clinical, and microbiologic findings in women with subclinical pelvic inflammatory disease (PID) and women with acute PID.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY\" nlmcategory=\"METHODS\">\n",
            "      A cross-sectional study was performed using cohorts from 2 separate studies of 1293 women at risk for PID. Most participants were recruited from emergency departments, sexually transmitted disease clinics, and family planning clinics in metropolitan centers. We compared demographic, clinical, and microbiologic findings among women with acute PID, women with subclinical PID, and women without endometritis (controls). Statistical analyses included chi-square for categorical variables, calculation of odds ratio and 95% confidence intervals, and polychotomous logistic regression when appropriate.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Similar proportions of women with acute and subclinical PID tested positive for cervical Chlamydia trachomatis (odds ratio [OR], 1.1; 95% confidence interval, 0.6-2.0) and had bacterial vaginosis (OR, 0.7; 95% CI, 0.2-1.8). The rate of cervical Neisseria gonorrhoeae infection in women with subclinical PID was intermediate between the rates in women with acute PID and controls (21% vs. 49% vs. 7%, respectively, P &lt;0.001, test for trend). Endometrial recovery of N. gonorrhoeae and C. trachomatis in women with subclinical PID was also seen at intermediate levels. Similar distributions of teenagers, women who smoked or used illicit drugs, and women engaging in sexual intercourse during menses were found in each group. Proportions of women with subclinical PID who were black and with lower education levels were intermediate between the proportions of these characteristics in women with acute PID and controls.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Demographic and microbiologic characteristics of women with subclinical and acute PID are comparable. These findings suggest that the pathophysiological mechanisms of acute and subclinical PID are similar.\n",
            "     </abstracttext>]\n",
            "872608.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15479938.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the impact of bariatric surgery on weight loss, operative mortality outcome, and 4 obesity comorbidities (diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES AND STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Electronic literature search of MEDLINE, Current Contents, and the Cochrane Library databases plus manual reference checks of all articles on bariatric surgery published in the English language between 1990 and 2003. Two levels of screening were used on 2738 citations.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      A total of 136 fully extracted studies, which included 91 overlapping patient populations (kin studies), were included for a total of 22,094 patients. Nineteen percent of the patients were men and 72.6% were women, with a mean age of 39 years (range, 16-64 years). Sex was not reported for 1537 patients (8%). The baseline mean body mass index for 16 944 patients was 46.9 (range, 32.3-68.8).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      A random effects model was used in the meta-analysis. The mean (95% confidence interval) percentage of excess weight loss was 61.2% (58.1%-64.4%) for all patients; 47.5% (40.7%-54.2%) for patients who underwent gastric banding; 61.6% (56.7%-66.5%), gastric bypass; 68.2% (61.5%-74.8%), gastroplasty; and 70.1% (66.3%-73.9%), biliopancreatic diversion or duodenal switch. Operative mortality (&lt; or =30 days) in the extracted studies was 0.1% for the purely restrictive procedures, 0.5% for gastric bypass, and 1.1% for biliopancreatic diversion or duodenal switch. Diabetes was completely resolved in 76.8% of patients and resolved or improved in 86.0%. Hyperlipidemia improved in 70% or more of patients. Hypertension was resolved in 61.7% of patients and resolved or improved in 78.5%. Obstructive sleep apnea was resolved in 85.7% of patients and was resolved or improved in 83.6% of patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Effective weight loss was achieved in morbidly obese patients after undergoing bariatric surgery. A substantial majority of patients with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea experienced complete resolution or improvement.\n",
            "     </abstracttext>]\n",
            "9167925.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10436111.xml\n",
            "\n",
            "[<abstracttext label=\"BACKGROUND AND PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Subarachnoid hemorrhage (SAH) due to aneurysmal rupture is a major cause of cerebrovascular disease-related death. This problem could be eliminated by diagnosis and successful treatment of aneurysms before rupture. Recent developments in high-resolution imaging technology have made screening for unruptured aneurysms possible in the general population. Such screening has become widespread in Japan (\"No Dokku, \" or brain checkup). As a result, unruptured aneurysms are being identified with increasing frequency. However, the economic implications of treatment decisions for unruptured aneurysms have not been analyzed. Therefore, we performed such an analysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We used a Markov model to evaluate the cost-effectiveness of screening for asymptomatic, unruptured intracranial aneurysms. The model involved a set of variables describing discrete health states. Each state was assigned a quality of life score and an associated medical cost. A comparison of the expected outcomes was then made between 2 hypothetical cohorts, one receiving screening and the other no screening. A sensitivity analysis was performed by altering the input values within clinically reasonable ranges to reflect uncertainty in the baseline analysis and then assessing the effects on outcomes.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Combining the incremental cost and effectiveness data revealed a cost per quality-adjusted life-year of $7760 for an annual rate of subarachnoid hemorrhage due to unruptured aneurysms (rupture rate) of 0.02; this cost was $39 450 for a rupture rate of 0.01. There was no benefit (negative quality-adjusted life-year benefit) for a rupture rate of 0.005, the rupture rate found in a recently published international cooperative study. The risks of surgery for unruptured aneurysms and the discounting ratio used to assess the impact of timing of costs and benefits on future outcomes also had significant effects on the results. Other variables had little impact on cost-effectiveness.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The cost-effectiveness of screening for an unruptured aneurysm is highly sensitive to the annual rate of subarachnoid hemorrhage due to unruptured aneurysms. The low annual rupture rate seen in the recent large international cooperative study implies that screening asymptomatic populations to identify and treat unruptured aneurysms would not be cost cost-effective.\n",
            "     </abstracttext>]\n",
            "10792566.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine the relationship between the two diagnostic tests, plasma methylmalonic acid and plasma cobalamins, and their association with plasma creatinine, age and sex.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Cross-sectional study of simultaneous laboratory measurements.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      County of Aarhus, Denmark.\n",
            "     </abstracttext>, <abstracttext label=\"SUBJECTS\" nlmcategory=\"METHODS\">\n",
            "      Records on 1689 patients who had their first plasma methylmalonic acid measurement during 1995 and 1996, and who had a simultaneous measurement of plasma cobalamins. Plasma creatinine values measured within a week of measurements of plasma methylmalonic acid and plasma cobalamins were available for 1255 of the patients.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Predictors of variation in plasma methylmalonic acid; plasma cobalamins, plasma creatinine, age and sex.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Plasma methylmalonic acid was positively correlated with plasma creatinine, even for plasma creatinine within the normal range. These associations remained in a multiple regression analysis. For plasma cobalamins below 200 pmol L-1, there was a strong negative correlation between plasma methylmalonic acid and plasma cobalamins, whilst the association was weak for higher plasma cobalamin levels. Plasma methylmalonic acid increased and plasma cobalamins decreased with age.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The strong correlation between plasma methylmalonic acid and plasma creatinine suggests that plasma creatinine - also within the normal range - must be taken into consideration when interpreting plasma methylmalonic acid.\n",
            "     </abstracttext>]\n",
            "15106182.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine the effectiveness of digitalis glycosides in treating CHF in patients with normal sinus rhythm. To examine the effect of digitalis in patients taking diuretics, angiotensin converting enzyme inhibitors, and beta-blockers; patients with varying severity and duration of disease; patients with prior exposure to digitalis vs. no prior exposure; and patients with \"CHF due to systolic dysfunction\" vs. \"CHF with preserved systolic function.\"\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The Cochrane Central Register of Controlled Trials (CENTRAL) 2003 Issue 4, MEDLINE (1966 to December 2003) and EMBASE (1990 to December 2003) were searched. Dissertation Abstracts and annual meeting abstracts of the American Heart Association, American College of Cardiology, and European Society of Cardiology were also searched from 1996-2003. In addition, reference lists provided by the pharmaceutical industry (Glaxo Wellcome Inc.) were searched.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Included were randomized placebo-controlled trials of 20 or more adult patients of either sex with symptomatic CHF who were studied for seven weeks or more. Excluded were trials in which the prevalence of atrial fibrillation was 2% or greater, or in which any arrhythmia that might compromise cardiac function or any potentially reversible cause of CHF such as acute ischemic heart disease or myocarditis was present.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Articles selected from the searches described above were evaluated as a joint effort of the coauthors. The staff of the Cochrane Heart Group ran searches on the Cochrane Central Register of Controlled Trials.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Thirteen articles meeting the defined criteria were identified, and major endpoints of mortality, hospitalization, and clinical status, based respectively upon 8, 4, and 12 of these selected studies, were recorded and analyzed. The data show that there is no evidence of a difference in mortality between treatment and control groups, whereas digitalis therapy is associated with a lower rate of hospitalization and of clinical deterioration.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWERS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The literature indicates that digitalis has a useful role in the treatment of patients with CHF who are in normal sinus rhythm.\n",
            "     </abstracttext>]\n",
            "1518691.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9369817.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our purpose was to compare the controlled cord traction technique with the minimal intervention technique for delivery of the placenta. The primary outcome was the incidence of postpartum hemorrhage. Secondary outcomes included duration of third stage of labor, frequency of retained placenta, hemorrhagic shock, the need for blood transfusion, and the need for uterotonic agents to control postpartum hemorrhage.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      A total of 1648 women who were delivered vaginally were randomly allocated during labor to the controlled cord traction group (n = 827) or the minimal intervention group (n = 821). In the controlled cord traction group women received oxytocin, 10 units intramuscularly, with delivery of the baby's anterior shoulder, after which the placenta was delivered actively by controlled cord traction (Brandt-Andrews method). In the minimal intervention group the placenta was delivered by maternal pushing. Continuous intravenous oxytocin was given after delivery of the placenta. Odds ratios with 95% confidence intervals were calculated for each variable.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The overall incidence of postpartum hemorrhage was significantly lower in the controlled cord traction group (5.8% vs 11%; odds ratio 0.50, 95% confidence interval 0.34 to 0.73). The incidence of retained placenta (&gt; or = 30 minutes) was 1.6% in the controlled cord traction group and 4.5% in the minimal intervention group (odds ratio 0.31, 95% confidence interval 0.15 to 0.63). Significantly more patients in the minimal intervention group required additional uterotonic agents to control hemorrhage (5.1% vs 2.3%; odds ratio 0.44, 95% confidence interval 0.24 to 0.78).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The controlled cord traction technique for delivery of the placenta results in a significantly lower incidence of postpartum hemorrhage and retained placenta, as well as less need for uterotonic agents, compared with the minimal intervention technique.\n",
            "     </abstracttext>]\n",
            "16446748.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In two similar but independent studies (Fall 2002, 2003), female freshmen college students were given analog bathroom scales and instructed to weigh themselves each morning immediately after rising from bed, then e-mail their weight to our staff. After 7 days, a linear function was performed on the most recent 7 days of the weight-day function for each participant. In the first study, the slope of this function was e-mailed back to the participants. In the second study, the difference between last point and the original weight was determined, using linear regression techniques, converted to calories, and the information was e-mailed back to the participants. Control participants in both studies were weighed at the beginning and the end of the semester.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The untreated controls gained 3.1+/-0.51 kg and 2.0+/-0.65 kg, respectively (P&lt;0.01 for both studies), whereas weight gain of the experimental groups was 0.1+/-0.99 kg and -0.82+/-0.56 kg, values that were not significantly different than zero.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The TMS appears to be an effective technique to help female college freshmen resist gaining weight in an environment that is conducive to weight gain. These results suggest that the TMS may be a useful method to help curb the slow increase in the prevalence of overweight and obesity that is characteristic of all industrialized societies.\n",
            "     </abstracttext>]\n",
            "12917922.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effects of tricyclic and related drugs on nocturnal enuresis in children, and to compare them with other interventions.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Incontinence Group trials register (December 2002) and the reference lists of relevant articles including two previously published versions of this review. Date of the most recent searches: December 2002.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All randomised and quasi-randomised trials of tricyclics or related drugs for nocturnal enuresis in children were included in the review. Comparison interventions included placebo, other drugs, alarms, behavioural methods or complementary/miscellaneous interventions. Trials focused solely on daytime wetting were excluded.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two reviewers independently assessed the quality of the eligible trials, and extracted data.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Fifty four randomised trials met the inclusion criteria, involving 3379 children. The quality of many of the trials was poor. Most comparisons or outcomes were addressed only by single trials. Treatment with most tricyclic drugs (such as imipramine, amitriptyline, viloxazine, nortriptyline, clomipramine and desipramine) was associated with a reduction of about one wet night per week while on treatment (eg imipramine compared with placebo, weighted mean difference (WMD) -1.19, 95% CI -1.56 to -0.82). The exception was mianserin, where results from one small trial did not reach statistical significance. About a fifth of the children became dry while on treatment (relative risk for failure (RR) 0.77, 95% CI 0.72 to 0.83), but this effect was not sustained after treatment stopped (eg imipramine versus placebo, RR 0.98, 95% CI 0.95 to 1.03). There was not enough information to assess the relative performance of one tricyclic against another, except that imipramine was better than mianserin. The evidence comparing desmopressin with tricyclics was unreliable or conflicting, but in one small trial all the children failed or relapsed after stopping active treatment with either drug.The evidence comparing tricyclics with alarms was also unreliable or conflicting during treatment. In one small trial all the children failed or relapsed after tricyclics stopped, compared with about half after alarms. This result was compatible with the results in the Cochrane review of alarm treatment, which found that about half the children remained dry after alarm treatment was finished. There was a little evidence from single trials to suggest that imipramine might be better than a simple reward system with star charts during treatment; worse than a complex intervention involving education, counseling, waking and retention control training; better than a restricted diet; and worse than hypnosis. However, these results need to be confirmed by further research.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Although tricyclics and desmopressin are effective in reducing the number of wet nights while taking the drugs, most children relapse after stopping active treatment. In contrast, only half the children relapse after alarm treatment. Parents should be warned of the potentially serious adverse effects of tricyclic overdose when choosing treatment. Further research is needed into comparisons between drug and behavioural or complementary treatments, and should include relapse rates after treatment is finished.\n",
            "     </abstracttext>]\n",
            "11232013.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15654703.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of this review is to evaluate the effectiveness of vision screening programmes carried out in schools in reducing the prevalence of undetected, correctable visual acuity deficits due to refractive error in school-age children.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Central Register of Controlled Trials - CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) on The Cochrane Library (Issue 3 2004), MEDLINE (1966 to August 2004) and EMBASE (1980 to August 2004). No language or date restrictions were placed on these searches. To date it has not been possible to carry out any manual searches but it is hoped to include these in a future update.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      We planned to include randomised controlled trials including randomised cluster controlled trials.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two reviewers independently assessed study abstracts identified by the electronic searches. No trials were identified that met the inclusion criteria.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      As no trials were identified, no formal analysis was performed. A narrative synthesis of other retrieved studies was undertaken in order to explain current practice.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      At present there are no robust trials available that allow the benefits of school vision screening to be measured. The disadvantage of attending school with a visual acuity deficit also needs to be quantified. The impact of a screening programme will depend on the geographical, and socio-economic setting in which it is conducted. There is therefore clearly a need for well planned randomised controlled trials, in various settings, to be undertaken so that the potential benefits and harms of vision screening can be measured.\n",
            "     </abstracttext>]\n",
            "8497355.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the safety and accuracy of colposcopy and colposcopically directed biopsy in pregnant women with abnormal cervical cytology.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A retrospective analysis of 612 gravidas with abnormal cervical cytology was conducted. Colposcopy and directed biopsy were performed using standard techniques. Two patients underwent diagnostic conization during the second trimester. One hundred twelve patients had procedures that provided a final specimen. Endocervical curettage was omitted. The transformation zone was fully visualized in all patients by the 20th week of gestation. Directed cervical biopsy was performed on the following patients: 1) with colposcopic evidence of invasion or cervical intraepithelial neoplasia (CIN) III, 2) with discordancy between colposcopy and cytology, 3) electing termination of pregnancy, and 4) whose anticipated reliability was even remotely questioned.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A colposcopically directed biopsy was performed in 449 patients (73%). Ninety-one patients (15%) did not have biopsies because of normal colposcopic findings, and the remaining 72 patients (12%) had either CIN I or II. Thirty-nine of these patients (6%) were lost to follow-up. Colposcopically directed biopsy and colposcopic impression had a 95% concordancy within one degree of severity; however, 14% of CIN I colposcopic impressions and 54% of normal colposcopic findings turned out to be CIN III and CIN I or II, respectively. Ninety-five percent of the biopsy diagnoses correlated with the final pathology to within one degree of severity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The data confirm previous findings that colposcopically directed biopsy is a safe and reliable method of evaluating pregnant patients with abnormal cervical cytology.\n",
            "     </abstracttext>]\n",
            "9428952.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "1097985.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8604285.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10865306.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To systematically review the precision and accuracy of history taking and physical examination in diagnosing CTS in adults.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      English-language literature was searched using MEDLINE (January 1966-February 2000) as well as bibliographies of relevant articles.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Studies of patients presenting to clinicians with symptoms suggestive of CTS in which findings from clearly described physical examination maneuvers were independently compared with electrodiagnostic testing. Twelve of 42 initially identified articles met these criteria and were included in the review.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Two authors independently reviewed and abstracted data from all of the articles and reached consensus about any discrepancies.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      In patients presenting with hand dysesthesias, the findings that best distinguish between patients with electrodiagnostic evidence of CTS and patients without it are hypalgesia in the median nerve territory (likelihood ratio [LR], 3. 1; 95% confidence interval [CI], 2.0-5.1), classic or probable Katz hand diagram results (LR, 2.4; 95% CI, 1.6-3.5), and weak thumb abduction strength (LR, 1.8; 95% CI, 1.4-2.3). Findings that argue against the diagnosis of carpal tunnel syndrome are unlikely Katz hand diagram results (LR, 0.2; 95% CI, 0.0-0.7) and normal thumb abduction strength (LR, 0.5; 95% CI, 0.4-0.7). Several traditional findings of CTS have little or no diagnostic value, including nocturnal paresthesias; Phalen and Tinel signs; thenar atrophy; and 2-point, vibratory, and monofilament sensory testing. Other less commonly used maneuvers, including the square wrist sign, flick sign, and closed fist sign, require validation by other studies before they can be recommended.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Hand symptom diagrams, hypalgesia, and thumb abduction strength testing are helpful in establishing the [corrected] electrodiagnosis of CTS. The utility of these results is limited, however, by problems inherent in using nerve conduction studies as a criterion standard. JAMA. 2000.\n",
            "     </abstracttext>]\n",
            "12783912.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows cognitive decline in patients with mild-to-moderate AD.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with 1-year exposure to study medications.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Forty ambulatory treatment centers affiliated with the Alzheimer's Disease Cooperative Study consortium.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Participants with mild-to-moderate AD (Mini-Mental State Examination score of 13-26) were recruited from December 1999 to November 2000 using clinic populations, referrals from community physicians, and local advertising. Stable use of cholinesterase inhibitors, estrogen, low-dose aspirin, and vitamin E was allowed. Participants with inflammatory diseases that might respond to the study medications were excluded. Of 474 participants screened, 351 were enrolled.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Once-daily rofecoxib, 25 mg, or twice-daily naproxen sodium, 220 mg, or placebo.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      The primary outcome measure was the 1-year change in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score. Secondary outcome measures included the Clinical Dementia Rating scale sum-of-boxes, the Neuropsychiatric Inventory, the Quality of Life-AD, and the time to attainment of significant end points (4-point decline from baseline ADAS-Cog score, 1-step worsening on the global Clinical Dementia Rating scale, 15-point decline on the ADCS activities of daily living inventory, institutionalization, or death).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The 1-year mean (SD) change in ADAS-Cog scores in participants treated with naproxen (5.8 [8.0]) or rofecoxib (7.6 [7.7]) was not significantly different from the change in participants treated with placebo (5.7 [8.2]). Results of secondary analyses showed no consistent benefit of either treatment. Fatigue, dizziness, and hypertension were more commonly reported in the active drug groups, and more serious adverse events were found in the active treatment group than in the placebo group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD.\n",
            "     </abstracttext>]\n",
            "14560344.xml\n",
            "\n",
            "[<abstracttext label=\"AIM\" nlmcategory=\"OBJECTIVE\">\n",
            "      HOT CAFE Polish Study (How To Treat Chronic Atrial Fibrillation) was designed to evaluate in a randomised, multicentre and prospective manner the risks and advantages of two therapeutical strategies - rate control or rhythm control, in patients with persistent AF.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      The study group consisted of 205 patients (71 females and 134 males; mean age 60.8+/-11.2 years) with a mean time of AF duration of 273.7+/-112.4 days; 101 patients were randomly assigned to rate control (Group I) whereas 104 patients were randomised to sinus rhythm (SR) restoration by DC cardioversion (CV) and subsequent antiarrhythmic drug treatment (Group II). At the end of follow-up (12 months) SR was present in 75% of patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The incidence of hospital admissions was higher in group II in comparison to group I (12% vs 74%; p&lt;0.001). Mortality was similar in both groups (1.0% versus 2.9%, NS). In both groups a significant improvement of heart failure symptoms was observed during the first 2 months (p&lt;0.02 and p&lt;0.001). In group II exercise tolerability measured by maximal workload during treadmill test significantly improved compared with baseline (5.2+/-5.1 vs 7.6+/-3.3 MET; p&lt;0.0001). In patients in whom SR was restored, the left ventricular function improved and an increase in the shortening fraction was observed (29+/-7% vs 31+/-7%; p&lt;0.01). No thromboembolic complications were observed in patients left with AF. Three patients from group II suffered ischaemic stroke; in two cases stroke was associated with CV whereas in the third patient - with late AF recurrence.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The HOT CAFE Polish Study did not reveal significant differences in mortality between the two treatment strategies in patients with persistent AF. Although patients with SR had better improvement in some haemodynamical parameters, the hospitalisation rate was higher and the incidence of stroke was not reduced compared with the rate control group.\n",
            "     </abstracttext>]\n",
            "14872449.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To systematically review the effectiveness of cyclobenzaprine in the treatment of fibromyalgia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Articles describing randomized, placebo-controlled trials of cyclobenzaprine in people with fibromyalgia were obtained from Medline, EMBase, Psyclit, the Cochrane Library, and Federal Research in Progress Database. Unpublished literature and bibliographies were also reviewed. Outcomes, including global improvement, treatment effects on pain, fatigue, sleep, and tender points over time, were abstracted.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Five randomized, placebo-controlled trials were identified. The odds ratio for global improvement with therapy was 3.0 (95% confidence interval [95% CI] 1.6-5.6) with a pooled risk difference of 0.21 (95% CI 0.09-0.34), which calculates to 4.8 (95% CI 3.0-11) individuals needing treatment for 1 patient to experience symptom improvement. Pain improved early on, but there was no improvement in fatigue or tender points at any time.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Cyclobenzaprine-treated patients were 3 times as likely to report overall improvement and to report moderate reductions in individual symptoms, particularly sleep.\n",
            "     </abstracttext>]\n",
            "9236642.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To study the effects of antenatal perineal massage on subsequent perineal outcomes at delivery.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      A randomised, single-blind prospective study.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Department of Obstetrics and Gynaecology, Watford General Hospital.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Eight hundred and sixty-one nulliparous women with singleton pregnancy and fulfilling criteria for entry to the trial between June 1994 and October 1995.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Comparison of the group assigned to massage with the group assigned to no massage showed a reduction of 6.1% in second or third degree tears or episiotomies. This corresponded to tear rates of 75.1% in the no-massage group and 69.0% in the massage group (P = 0.073). There was a corresponding reduction in instrumental deliveries from 40.9% to 34.6% (P = 0.094). After adjustment for mother's age and infant's birthweight these reductions achieved statistical significance (P = 0.024 and P = 0.034, respectively). Analysis by mother's age showed a much larger benefit due to massage in those aged 30 and over and a smaller benefit in those under 30.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Antenatal perineal massage appears to have some benefit in reducing second or third degree tears or episiotomies and instrumental deliveries. This effect was stronger in the age group 30 years and above.\n",
            "     </abstracttext>]\n",
            "15174889.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9914571.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our goal was to evaluate the efficacy and side effects of danazol 200 mg daily given only in the luteal phase of the menstrual cycle to treat premenstrual syndrome and premenstrual mastalgia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      We conducted a randomized, double-blind, placebo-controlled study of 3 menstrual cycles in a postgraduate medical school and National Health Service hospital. The subjects of the study were 100 women who had been referred to the premenstrual syndrome clinic at the North Staffordshire Hospital for the management of premenstrual syndrome and premenstrual breast pain. Outcome measures for the study included assessment of improvement in symptoms measured by specific daily visual analogue scales for 4 principal symptoms of premenstrual syndrome and for premenstrual mastalgia and assessment of side effects and adverse events.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Significant improvement in symptoms was seen in visual analog scores for mastalgia in months 1 (P =.03), 2 (P =.004), and 3 (P =.01) of the study during active therapy compared with placebo. No improvement was seen for any other symptom or for the global premenstrual syndrome score. Side effects on danazol and on placebo were equal and minimal.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Luteal phase-only danazol is not effective for the treatment of the general symptoms of premenstrual syndrome but appears highly effective for the relief of premenstrual mastalgia. This approach to therapy is associated with few side effects. Studies of cyclic mastalgia using strict diagnostic criteria are required to see whether the freedom from symptomatic side effects is found in longer-term studies and to determine whether such a regimen avoids potentially detrimental effects on the lipid status.\n",
            "     </abstracttext>]\n",
            "12685516.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8698944.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8256107.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14584010.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the efficacy of vitamin B6 supplementation in reducing the risk of developing cognitive impairment by older healthy people, or improving cognitive functioning of people with cognitive decline and dementia, whether or not vitamin B6 deficiency has been diagnosed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group was searched on 20 May 2003 using the terms: vitamin B6, pyridoxine, pyridoxamine, pyridoxal. For relevant trials on healthy elderly people MEDLINE, EMBASE and CENTRAL were searched using the previously mentioned terms as well as the term cognit *\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All unconfounded, double-blind randomized controlled trials in which the intervention with vitamin B6 was compared with placebo for healthy older people or people with cognitive decline or dementia. The primary outcome of interest was the efficacy of vitamin B6 supplementation on cognitive function.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      The two reviewers independently evaluated all studies identified as possibly meeting the criteria for inclusion. One reviewer independently extracted the data. Studies were rated for their overall quality. The weighted mean differences between treatment and placebo groups, with 95% confidence intervals, were calculated for each outcome. Review Manager version 4.2 was used to analyse the variance.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      No trials of vitamin B6 involving people with cognitive impairment or dementia were found. The two trials included in the review (Bryan 2002; Deijen 1992) used a double-blind, randomized, placebo-controlled design and involved 109 healthy older people. One trial restricted enrolment to women and the other to men. Vitamin B6 supplementation and healthy older women: Bryan 2002 enrolled 211 healthy women from various age groups into a 5-week study. The trial was of multifactorial design with folic acid, vitamin B12, vitamin B6 and placebo in its four arms. Twelve healthy women aged 65 to 92 years received 75 mg vitamin B6 orally per day and were compared with 21 healthy women who were allocated to placebo. No statistically significant benefits from vitamin B6 on mood or cognition were observed. Vitamin B6 supplementation and healthy older men: Deijen 1992 recruited 76 healthy men aged 70 to 79 years. They were divided into 38 matched pairs, one member of each pair randomly allocated to 20 mg of vitamin B6 (pyridoxine hydrochloride) per day for 12 weeks the other to placebo. No statistically significant differences between treatment and placebo were found in their effects on cognition or mood. Effect of vitamin B6 supplementation on vitamin B6 status: Deijen 1992 reported that 20 mg of pyridoxine hydrochloride per day for 12 weeks increased blood vitamin B6 activity as assessed as by plasma pyridoxal-5'-phosphate (WMD 238, 95%CI 211.58 to 264.42, P&lt;0.00001) and erythrocyte enzyme asparate aminotransferase (WMD 0.43, 95%CI 0.30 to 0.56, P&lt;0.00001). Effect of vitamin B6 supplementation on blood homocysteine concentration: Neither of the included trials measured homocysteine levels. Drop-outs: All participants allocated to vitamin B6 or placebo completed the trial protocol. Adverse Events: No adverse effects were reported. Effect of vitamin B6 on carer burden, care costs and institutionalization rate: We found no trials in which these outcomes were assessed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This review found no evidence for short-term benefit from vitamin B6 in improving mood (depression, fatigue and tension symptoms) or cognitive functions. For the older people included in one of the two trials included in the review, oral vitamin B6 supplements improved biochemical indices of vitamin B6 status, but potential effects on blood homocysteine levels were not assessed in either study. This review found evidence that there is scope for increasing some biochemical indices of vitamin B6 status among older people. More randomized controlled trials are needed to explore possible benefits from vitamin B6 supplementation for healthy older people and those with cognitively impairment or dementia.\n",
            "     </abstracttext>]\n",
            "74457.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15242222.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12187337.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12861176.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      The study was undertaken to provide consensus guidelines for the management of women with histologically confirmed cervical intraepithelial neoplasia (CIN) that can act as a precursor to invasive cervical cancer and represents one of the most common significant gynecologic diseases of women of reproductive age.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      An independent panel of 121 experts in various aspects of the diagnosis and management of cervical cancer precursors, including representatives from 29 participating professional organizations, federal agencies, national and international health organizations, and others were invited by the American Society for Colposcopy and Cervical Pathology (ASCCP).Consensus Process: Guidelines for the management of women with CIN were developed through a multistep process. Draft management guidelines were developed by working groups who performed formal literature reviews and obtained input from the professional community at large by way of an interactive internet-based bulletin board. At the ASCCP Consensus Conference, September 6 through 8, 2001, in Bethesda, Md, all guidelines were discussed, revised, and adopted by formal vote.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Evidence-based guidelines have been developed for the management of women with biopsy-confirmed CIN.\n",
            "     </abstracttext>]\n",
            "16207391.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Cohort studies of the effects of education, occupation, premorbid IQ and mental activities on dementia risk were of interest. Abstracts were identified in MEDLINE (1966-September 2004), CURRENT CONTENTS (to September, 2004), PsychINFO (1984-September 2004), Cochrane Library Databases and reference lists from relevant articles. Twenty-two studies met inclusion criteria. Key information was extracted by both reviewers onto a standard template with a high level of agreement. Studies were combined through a quantitative random-effects meta-analysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Higher brain reserve was associated with a lowered risk for incident dementia (summary odds ratio, 0.54; 95% confidence interval, 0.49-0.59). This effect was found over a median of 7.1 years follow-up and resulted from integrating data across more than 29000 individuals. Notably, increased complex mental activity in late life was associated with lower dementia rates independent of other predictors; a dose-response relationship was also evident between extent of complex mental activities in late life and dementia risk.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This study demonstrates robust evidence that complex patterns of mental activity in the early, mid- and late-life stages is associated with a significant reduction in dementia incidence. Randomized control trials based on brain-reserve principles are now required.\n",
            "     </abstracttext>]\n",
            "14747501.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether mammography accuracy and tumor characteristics are different for women with and without augmentation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN, SETTING, AND PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      A prospective cohort of 137 women with augmentation and 685 women without augmentation diagnosed with breast cancer between January 1, 1995, and October 15, 2002, matched (1:5) by age, race/ethnicity, previous mammography screening, and mammography registry, and 10 533 women with augmentation and 974 915 women without augmentation and without breast cancer among 7 mammography registries in Denver, Colo; Lebanon, NH; Albuquerque, NM; Chapel Hill, NC; San Francisco, Calif; Seattle, Wash; and Burlington, Vt.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Comparison between women with and without augmentation of mammography performance measures and cancer characteristics, including invasive carcinoma or ductal carcinoma in situ, tumor stage, nodal status, size, grade, and estrogen-receptor status.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Among asymptomatic women, the sensitivity of screening mammography based on the final assessment was lower in women with breast augmentation vs women without (45.0% [95% confidence interval [CI], 29.3%-61.5%] vs 66.8% [95% CI, 60.4%-72.8%]; P =.008), and specificity was slightly higher in women with augmentation (97.7% [95% CI, 97.4%-98.0%] vs 96.7% [95% CI, 96.6%-96.7%]; P&lt;.001). Among symptomatic women, both sensitivity and specificity were lower for women with augmentation compared with women without but these differences were not significant. Tumors were of similar stage, size, estrogen-receptor status, and nodal status but tended to be lower grade (P =.052) for women with breast augmentation vs without.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Breast augmentation decreases the sensitivity of screening mammography among asymptomatic women but does not increase the false-positive rate. Despite the lower accuracy of mammography in women with augmentation, the prognostic characteristics of tumors are not influenced by augmentation.\n",
            "     </abstracttext>]\n",
            "15266429.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of this review is to assess which hormone replacement therapy regimens provide effective protection against the development of endometrial hyperplasia and/or carcinoma with a low rate of abnormal vaginal bleeding.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Menstrual Disorders and Subfertility Group trials register (searched January 2003), The Cochrane Library (Issue 2, 2003), MEDLINE (1966 to January 2003), EMBASE (1980 to January 2003), Current Contents (1993 to January 2003), Biological Abstracts (1969 to 2002), Social Sciences Index (1980 to January 2003), PsycINFO (1972 to February 2003) and CINAHL (1982 to January 2003). The search strategy was developed by the Cochrane Menstrual Disorder and Subfertility Group. Attempts were also made to identify trials from citation lists of review articles and drug companies were contacted for unpublished data. In most cases, the corresponding author of each included trial was contacted for additional information.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      The inclusion criteria were randomised comparisons of unopposed oestrogen therapy, combined continuous oestrogen-progestogen therapy and sequential oestrogen-progestogen therapy with each other and placebo administered over a minimum treatment period of six months. Trials had to assess which regimen was the most protective against the development of endometrial hyperplasia/carcinoma and/or caused the lowest rate of irregular bleeding.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Sixty RCTs were identified. Of these 23 were excluded and seven remain awaiting assessment. The reviewers assessed the thirty included studies for quality, extracted the data independently and odds ratios for dichotomous outcomes were estimated. Outcomes analysed included frequency of endometrial hyperplasia or carcinoma, frequency of irregular bleeding and unscheduled biopsies or dilation and curettage, and adherence to therapy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Unopposed moderate or high dose oestrogen therapy when compared to placebo was associated with a significant increase in rates of endometrial hyperplasia with increasing rates at longer duration of treatment and follow up. Odds ratios ranged from (1 RCT; OR 5.4, 95% CI 1.4 to 20.9) for 6 months of treatment to (4 RCTs; OR 9.6, 95% CI 5.9 to 15.5) for 24 months treatment and (1 RCT; OR 15.0, 95% CI 9.3 to 27.5) for 36 months of treatment with moderate dose oestrogen (in the PEPI trial, 62% of those who took moderate dose oestrogen had some form of hyperplasia at 36 months compared to 2% of those who took placebo). Irregular bleeding and non adherence to treatment were also significantly more likely under these unopposed oestrogen regimens that increased bleeding with higher dose therapy. Although not statistically significant, there was a 3% incidence (2 RCTs) of hyperplasia in women who took low dose oestrogen compared to no incidence of hyperplasia in the placebo group. The addition of progestogens, either in continuous combined or sequential regimens, helped to reduce the risk of endometrial hyperplasia and improved adherence to therapy. At longer duration of treatment, continuous therapy was more effective than sequential therapy in reducing the risk of endometrial hyperplasia. There was evidence of a higher incidence of hyperplasia under long cycle sequential therapy (progestogen given every three months) compared to monthly sequential therapy (progestogen given every month). No increase in endometrial cancer was seen in any of t in any of the treatment groups during the duration (maximum of six years) of these trials. During the first year of therapy irregular bleeding and spotting was more likely in continuous combined therapy than sequential therapy. However, during the second year of therapy bleeding and spotting was more likely under sequential regimens.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWERS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is strong and consistent evidence in this review that unopposed oestrogen therapy, at moderate and high doses, is associated with increased rates of endometrial hyperplasia, irregular bleeding and consequent non adherence to therapy. The addition of oral progestogens administered either sequentially or continuously is associated with reduced rates of hyperplasia and improved adherence to therapy. Irregular bleeding is less likely under sequential than continuous therapy during the first year of therapy but there is a suggestion that continuous therapy over long duration is more protective than sequential therapy in the prevention of endometrial hyperplasia. Hyperplasia is more likely when progestogen is given every three months in a sequential regimen compared to a monthly progestogen sequential regimen.\n",
            "     </abstracttext>]\n",
            "10491376.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11423507.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESEARCH DESIGN AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      After 8 weeks of insulin standardization and placebo (PBO) run-in, 319 type 2 diabetic patients with mean baseline HbA(1c) &gt; or = 7.5% (8.9 +/- 1.1 to 9.1 +/- 1.3) on twice-daily insulin therapy (total daily dose &gt; or = 30 U) were randomized to 26 weeks of additional treatment with RSG (4 or 8 mg daily) or PBO. Insulin dose could be down- titrated only for safety reasons. The primary end point was reduction of HbA(1c) from baseline.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      RSG 4 and 8 mg daily significantly improved glycemic control, which was unchanged on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean reduction from baseline in HbA(1c) of 1.2% (P &lt; 0.0001), despite a 12% mean reduction of insulin dosage. Over 50% of subjects treated daily with RSG 8 mg plus insulin had a reduction of HbA(1c) &gt; or = 1.0%. Neither total:HDL cholesterol nor LDL:HDL cholesterol ratios significantly changed with RSG treatment. Serious adverse events did not differ among groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The addition of RSG to insulin treatment results in significant improvement in glycemic control and is generally well tolerated.\n",
            "     </abstracttext>]\n",
            "12107216.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9757979.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our purpose was to determine whether omeprazole use during pregnancy is associated with an increased risk of malformations, spontaneous abortions, decreased birth weight, or perinatal complications.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      In a multicenter, prospective controlled study, pregnant women exposed to omeprazole during gestation were matched with controls exposed to nonteratogens and with disease-paired controls who used histamine blockers for similar indications. The primary end point was the incidence of major malformations.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      One hundred thirteen pregnant women were exposed to omeprazole during pregnancy. Rates of major malformations in the omeprazole group (4%) did not differ from controls exposed to nonteratogens (2%) (P = .68, relative risk = 1.94, 95% confidence interval 0.36 to 10.36) and disease-paired controls (2.8%). Birth weight, gestational age at delivery, preterm deliveries, and neonatal complications were comparable among the three groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      No association was found between exposure to omeprazole during the period of organogenesis and increased risk for major malformations. Exposure throughout pregnancy is not associated with increased risk of spontaneous abortions, decreased birth weight, or perinatal complications.\n",
            "     </abstracttext>]\n",
            "15138247.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess and synthesize the evidence regarding drug treatment of hyperlipidemia for the prevention of CHD events in women and to conduct a meta-analysis of the effect of drug treatment on mortality.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      We searched MEDLINE, the Cochrane Database, and the Database of Abstracts of Reviews of Effectiveness for articles published from 1966 through December 2003. We reviewed reference lists of articles and consulted content experts.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION AND DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Studies of outpatients that had a treatment duration of at least 1 year, assessed the impact of lipid lowering on clinical outcomes, and reported results by sex were included. Outcomes evaluated were total mortality, CHD mortality, nonfatal myocardial infarction, revascularization, and total CHD events. Summary estimates of the relative risks (RRs) with therapy were calculated using a random-effects model for patients with and without a previous history of cardiovascular disease.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Thirteen studies were included. Six trials included a total of 11 435 women without cardiovascular disease and assessed the effects of lipid-lowering medications. Lipid lowering did not reduce total mortality (RR, 0.95; 95% confidence interval [CI], 0.62-1.46), CHD mortality (RR, 1.07; 95% CI, 0.47-2.40), nonfatal myocardial infarction (RR, 0.61; 95% CI, 0.22-1.68), revascularization (RR, 0.87; 95% CI, 0.33-2.31), or CHD events (RR, 0.87; 95% CI, 0.69-1.09). However, some analyses were limited by too few CHD events in the available trials. Eight trials included 8272 women with cardiovascular disease and assessed the effects of lipid-lowering medications. Lipid lowering did not reduce total mortality in women with cardiovascular disease (RR, 1.00; 95% CI, 0.77-1.29). However, lipid lowering reduced CHD mortality (RR, 0.74; 95% CI, 0.55-1.00), nonfatal myocardial infarction (RR, 0.71; 95% CI, 0.58-0.87), revascularization (RR, 0.70; 95% CI, 0.55-0.89), and total CHD events (RR, 0.80; CI, 0.71-0.91).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      For women without cardiovascular disease, lipid lowering does not affect total or CHD mortality. Lipid lowering may reduce CHD events, but current evidence is insufficient to determine this conclusively. For women with known cardiovascular disease, treatment of hyperlipidemia is effective in reducing CHD events, CHD mortality, nonfatal myocardial infarction, and revascularization, but it does not affect total mortality.\n",
            "     </abstracttext>]\n",
            "10925761.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To describe an organized diagnostic approach for both nonscarring and scarring alopecias to help family physicians establish an accurate in-office diagnosis. To explain when ancillary laboratory workup is necessary to confirm the diagnosis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"QUALITY OF EVIDENCE\" nlmcategory=\"METHODS\">\n",
            "      Current diagnostic and therapeutic interventions for hair loss are based on randomized controlled studies, uncontrolled studies, and case series. MEDLINE was searched from January 1966 to December 1998 with the MeSH words alopecia, hair, and alopecia areata. Articles were selected on the basis of experimental design, with priority given to the most current large multicentre controlled studies. Overall global evidence for therapeutic intervention for hair loss is quite strong.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN MESSAGE\" nlmcategory=\"RESULTS\">\n",
            "      The most common forms of nonscarring alopecias are androgenic alopecia, telogen effluvium, and alopecia areata. Other disorders include trichotillomania, traction alopecia, tinea capitis, and hair shaft abnormalities. Scarring alopecia is caused by trauma, infections, discoid lupus erythematosus, or lichen planus. Key to establishing an accurate diagnosis is a detailed history, including medication use, systemic illnesses, endocrine dysfunction, hair-care practices, and family history. All hair-bearing sites should be examined. A 4-mm punch biopsy of the scalp is useful, particularly to diagnose scarring alopecias. Once a diagnosis has been established, specific therapy can be initiated.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Diagnosis and management of hair loss is an interesting challenge for family physicians. An organized approach to recognizing characteristic differential features of hair loss disorders is key to diagnosis and management.\n",
            "     </abstracttext>]\n",
            "14747031.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To set up and evaluate HSV-1, HSV-2 and VZV qualitative real-time PCR on the Lightcycler system and to compare the results with those of the 'in-house' nested PCR and virus isolation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      110 consecutive samples from dermal or genital lesions from patients suspected of having HSV infections and another 110 samples from patients with suspected VZV infections were tested with real-time PCR, nested PCR and virus isolation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      24 samples (22%) were positive for HSV-1 by virus isolation and nested PCR, whereas 26 (24%) were positive by real-time PCR. HSV-2 was detected in 28 samples (25%) by virus isolation, in 41 (37%) by nested PCR and in 40 (36%) by real-time PCR. VZV was isolated in 15 samples (14%) and VZV DNA was detected in 51 samples (46%) by nested PCR as well as by real-time PCR. Nucleic acid amplification increased the detection rate of HSV-2 and VZV DNA in particular compared to virus isolation. No significant difference in sensitivity was found between real-time PCR and nested PCR.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Real-time PCR has the advantage of rapid amplification, a reduced risk for contamination and it is a suitable method for diagnosis of VZV and HSV in specimens from skin lesions.\n",
            "     </abstracttext>]\n",
            "12612275.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Obesity increases risk of many adverse outcomes, but its early origins are obscure. Gestational diabetes mellitus (GDM) reflects a metabolically altered fetal environment associated with high birth weight, itself associated with later obesity. Previous studies of GDM and offspring obesity, however, have been few and conflicting. The objectives of this study were to examine associations of birth weight and GDM with adolescent body mass index (BMI) and to determine the extent to which the effect of GDM is explained by its influence on birth weight or by maternal adiposity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a survey of 7981 girls and 6900 boys, 9 to 14 years of age, who are participants in the Growing Up Today Study, a US nationwide study of diet, activity, and growth. In 1996, participants reported height, weight, diet, activity, and other variables by self-administered mailed questionnaire. We linked these data with information reported by their mothers, participants in the Nurses' Health Study II, including GDM, height, current weight, and child's birth weight. We excluded births &lt;34 weeks' gestation and mothers who had preexisting diabetes. We defined overweight as BMI (kg/m(2)) &gt;95th percentile, and at risk for overweight as 85th to 95th percentile, for age and gender from US national data.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Mean birth weight was 3.4 kg for girls and 3.6 kg for boys. Among the 465 subjects whose mothers had GDM, 17.1% were at risk for overweight and 9.7% were overweight in early adolescence. In the group without maternal diabetes, these estimates were 14.2% and 6.6%, respectively. In multiple logistic regression analysis, controlling for age, gender, and Tanner stage, the odds ratio for adolescent overweight for each 1-kg increment in birth weight was 1.4 (95% confidence interval: 1.2-1.6). Adjustment for physical activity, television watching, energy intake, breastfeeding duration, mother's BMI, and other maternal and family variables reduced the estimate to 1.3 (1.1-1.5). For offspring of mothers with GDM versus no diabetes, the odds ratio for adolescent overweight was 1.4 (1.1-2.0), which was unchanged after controlling for energy balance and socioeconomic factors. Adjustment for birth weight slightly attenuated the estimate (1.3; 0.9-1.9); adjustment for maternal BMI reduced the odds ratio to 1.2 (0.8-1.7).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Higher birth weight predicted increased risk of overweight in adolescence. Having been born to a mother with GDM was also associated with increased adolescent overweight. However, the effect of GDM on offspring obesity seemed only partially explained by its influence on birth weight, and adjustment for mother's own BMI attenuated the GDM associations. Our results only modestly support a causal role of altered maternal-fetal glucose metabolism in the genesis of obesity in the offspring. Alternatively, GDM may program risk for a postnatal insult leading to obesity, or it may merely be a risk marker, not in the causal pathway.\n",
            "     </abstracttext>]\n",
            "10382464.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      We studied 104 parents of infants at high risk for cardiopulmonary arrest. Fifty-two parents had infants who used home apnea monitors, and 52 parents were age-matched and gender-matched control subjects. Data were collected during the infant's hospitalization, and then at 2 weeks, 3 months, and 6 months after discharge. At 1 year, parents were interviewed about their attitudes toward using the apnea monitor.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Both groups experienced elevated levels of emotional distress, but the group with infants who used the monitors had significant increases in depression and hostility immediately following discharge from the hospital compared with baseline, whereas the non-monitored group had a significant increase in hostility at 6 months. At 1-year follow-up, the majority of the parents reported that they used the monitor every night, felt more secure in using it, and judged it helpful.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DISCUSSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The immediate period following hospital discharge of infants who need to use a home apnea monitor is characterized by significant emotional distress for the parents, which resolves over time. Anticipatory education and counseling of parents is recommended.\n",
            "     </abstracttext>]\n",
            "18299547.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We searched electronic databases (MEDLINE, EMBASE, Cochrane Central Registery of Controlled Trials, Web of Science) for randomized controlled trials published up to July 19, 2007, that compared statin regimens of different intensities in adults with coronary artery disease and that reported cardiovascular events or mortality. Data were pooled using random-effects models to calculate odds ratios (OR).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 7 trials (29 395 patients) were included. Compared with less intensive statin regimens, more intensive regimens further reduced LDL levels (0.72 mmol/L reduction, 95% confidence interval [CI] 0.60-0.84 mmol/L), and reduced the risk of myocardial infarction (OR 0.83, 95% CI 0.77-0.91) and stroke (OR 0.82, 95% CI 0.71-0.95). Although there was no effect on mortality among patients with chronic coronary artery disease (OR 0.96, 95% CI 0.80-1.14), all-cause mortality was reduced among patients with acute coronary syndromes treated with more intensive statin regimens (OR 0.75, 95% CI 0.61-0.93). Compared with lower intensity regimens, more intensive regimens were associated with small absolute increases in rates of drug discontinuation (2.5%), elevated levels of aminotransferases (1%) and myopathy (0.5%), and there was no difference in noncardiovascular mortality. All 7 trials reported events by randomization arm rather than by LDL level achieved. About half of the patients treated with more intensive statin therapy did not achieve an LDL level of less than 2.0 mmol/L, and none of the trials tested combination therapies.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our analysis supports the use of more intensive statin regimens in patients with established coronary artery disease. There is insufficient evidence to advocate treating to particular LDL targets, using combination lipid-lowering therapy to achieve these targets or for using more intensive regimens in patients without established coronary artery disease.\n",
            "     </abstracttext>]\n",
            "15579363.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10969112.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14711538.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "6863528.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12557864.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      The optimal treatment for hypertensive patients with atherosclerotic renal artery stenosis is controversial. We performed a meta-analysis comparing the effects of balloon angioplasty and medical therapy in these patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We searched MEDLINE, EMBASE, the Science Citation Index, the Cochrane Controlled Trials Registry, and reference lists. Authors of published trials were contacted.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      We identified three trials involving a total of 210 patients with moderate-to-severe (&gt; or = 50%) unilateral or bilateral atherosclerotic renal artery stenosis and poorly controlled hypertension who were followed for at least 3 months after intervention. Balloon angioplasty was significantly more effective in reducing blood pressure than was medical therapy; the weighted mean difference between the two treatments was -7 mm Hg (95% confidence interval [CI]: -12 to -1 mm Hg) for systolic blood pressure and -3 mm Hg (95% CI: -6 to -1 mm Hg) for diastolic blood pressure. There was no consistent difference in changes in renal function. Patients treated with balloon angioplasty were more likely to have patent renal arteries after 12 months (52% vs. 19%; odds ratio [OR] = 4.2; 95% CI: 1.8 to 9.8), used fewer antihypertensive medications, and appeared to have fewer major cardiovascular and renovascular complications (OR = 0.27; 95% CI: 0.06 to 1.23; P = 0.09).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Balloon angioplasty has a modest but significant effect on blood pressure and should be considered for patients with atherosclerotic renal artery stenosis and poorly controlled hypertension. There is no evidence supporting its use in improving or preserving renal function, although none of the trials were designed to address this issue.\n",
            "     </abstracttext>]\n",
            "10875288.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We studied 300 consecutive hospitalized adult patients with MCV values &gt; or = 100 fL. Assessment included complete blood counts, morphologic review, liver function tests, and levels of serum cobalamin (Cbl), methylmalonic acid, and total homocysteine.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The most common cause of macrocytosis was drug therapy, followed by alcohol, liver disease, and reticulocytosis. Megaloblastic hematopoiesis accounted for less than 10% of cases. MCV values &gt; 120 fL were usually caused by Cbl deficiency. Anisocytosis, macro-ovalocytosis, and teardrop erythrocytes were most prominent in megaloblastic hematopoiesis. Elevated levels of serum methylmalonic acid and total homocysteine were useful in the diagnosis of Cbl deficiency.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Drugs and alcohol are the most common causes of macrocytosis in hospitalized patients in a New York City teaching hospital. We have formulated tentative guidelines for the evaluation of high MCV values in this setting.\n",
            "     </abstracttext>]\n",
            "14583951.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To quantitatively compare the effects of inhaling a single dose of either mast cell stabiliser - nedocromil sodium or sodium cromoglycate - to a single dose of short acting beta-agonists or anti-cholinergic agents - atropine or ipratropium bromide - prior to a strenuous exercise challenge in participants with asthma who are at least 6 years of age and suffer from reproducible exercise-induced bronchoconstriction. The review also compares the effects between a short acting beta-agonist alone to a combination of a short acting beta-agonist + mast cell stabiliser.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Airways Group ASTHMA and WHEEZ* trials register, Cochrane CENTRAL, Current Contents, review articles, textbooks and reference lists of articles. We also contacted the drug manufacturer and primary authors for additional citations.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised trials comparing a single prophylactic dose of a mast cell stabiliser to a short acting beta-agonist, anti-cholinergic agent, or a short acting beta-agonist alone to a combination of short acting beta-agonist plus a mast cell stabiliser to prevent exercise-induced bronchoconstriction in asthmatics over six years old. The exercise challenge had to conform to acceptable standards and pulmonary function (PFT) reported as percent decrease from baseline of FEV1 or peak flow. Complete protection (maximum % fall PFT &lt;15% post-exercise) and clinical protection (50% improvement over placebo effect) measures were included.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Trial inclusion and quality assessments were conducted independently by two reviewers using standardised forms. A second reviewer confirmed data extraction and calculations. Attempts were made to contact study authors. The pooled estimate involving continuous pulmonary function measures are reported as a weighted mean difference (WMD), dichotomous data as an odds ratio (OR), both with 95% confidence intervals (95%CI) using a random effects model. Heterogeneity tests for pooled results were performed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Twenty-four trials (518 participants) conducted in 13 countries between 1976 and 1998 were included. All drugs were effective at attenuating the exercise-induced bronchoconstriction response but to varying degrees even within the same individual. Compared to anti-cholinergic agents, mast cell stabilisers were somewhat more effective at attenuating bronchoconstriction. On average the maximum fall on MCS was reduced to 7.1% compared to 13.8% on AC ( WMD = 6.7%; 95% CI: 3.3 to 10.0), provided more individuals with complete protection (73% vs 56%; OR = 2.2; 95% CI: 1.3 to 3.7) and clinical protection (73% vs 52%; OR = 2.7; 95% CI: 1.1 to 6.4). There were no subgroup differences based on age, severity, or study quality, and no adverse effects were reported for either agent group. When compared to short acting beta-agonists mast cell stabilisers were not as effective at preventing deterioration. On average the maximum fall on MCS was 11.2% compared to 4.3% on beta agonists ( WMD = 6.8%; 95% CI: 4.5 to 9.2). MCS provided fewer individuals with complete protection (66% vs 85%; OR = 0.3; 95% CI: 0.2 to 0.5) or clinical protection (55% vs 77%; OR = 0.4; 95% CI: 0.2 to 0.8). There were no significant subgroup differences based on age, severity, drug, delivery, or study quality. A non-significant difference in side effects was demonstrated with 11% of short acting beta-agonist patients experiencing side effects compared to 3% of those receiving mast cell stabilisers (OR = 0.2; 95% CI: 0.0 to 8.2). Combining masta-agonist patients experiencing side effects compared to 3% of those receiving mast cell stabilisers (OR = 0.2; 95% CI: 0.0 to 8.2). Combining mast cell stabilisers with a short acting beta-agonist did not produce significant advantages to pulmonary function over short acting beta-agonists alone. On average the maximum fall on SABA only was reduced to 5.3% compared to 3.5% on the combination ( WMD = 1.8%; 95% CI: -1.1 to 4.6). Beta-agonists alone provided fewer individuals with complete protection (68% vs 80%; OR = 0.5; 95% CI: 0.2 to 1.4) or clinical protection (70% vs 86%; OR=0.4; 95% CI: 0.1 to 1.2) but the difference did not reach significance (p=0.17). There were no subgroup differences.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In a population of stable asthmatics short acting beta-agonists, mast cell stabilisers, or anticholinergics will provide a significant protective effect against exercise-induced bronchoconstriction with few adverse effects. On average, SABAs resulted in more effective attenuation than mast cell stabilisers, while mast cell stabilisers were more effective than anti-cholinergic agents. Combining SABA and mast cell stabilisers may be appropriate in selected cases. The variability in the individual degree of response to these drugs in multi arm trials suggests clinicians and patients work together to identify the most effective prophylactic therapy.\n",
            "     </abstracttext>]\n",
            "17678659.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To define the accuracy (compared with magnetic resonance imaging [MRI]) of sonographic examination in detecting knee effusion and to determine whether the presence of knee effusions in patients with traumatic knee injury can predict knee internal derangement as assessed by MRI.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Prospective study.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Hospital rehabilitation department.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Thirty patients (19 men, 11 women) with traumatic knee injury were recruited. Subjects received sonographic examination and MRI on the same day.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Not applicable.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      The presence or absence of knee effusion was assessed by sonographic examination. MRI was used as criterion standard to evaluate whether the presence of knee effusion and internal derangement, which included tear of anterior and posterior cruciate ligaments, as well as meniscus tear.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The sensitivity of sonographic examination for detecting knee effusion was 79.1%, and specificity was 50%. The positive-predictive value (PPV) was 86.3% and negative-predictive value (NPV) was 37.5%. The PPV of sonographic effusion to internal derangement was 90.9%, and the NPV was 37.5%.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Sonographic examination can accurately detect effusion of the knee. The detection of knee effusion in patients with traumatic knee injury by sonographic examination is highly indicative of internal knee derangement.\n",
            "     </abstracttext>]\n",
            "11704584.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11407054.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9517638.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Laparoscopic antireflux surgery is indicated in young patients with medication-dependent gastroesophageal reflux disease (GERD), both because of their need for lifelong medical treatment and the need to prevent the complications of GERD. Many elderly patients with GERD have similar concerns. We compared the safety and efficacy of laparoscopic antireflux surgery in the elderly with the results achieved in patients &lt;65 yr.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A total of 359 patients have had laparoscopic antireflux surgery in our hospital, 42 of whom were &gt; or = 65 yr of age. Symptoms were scored from 0 (none) to 4 (severe) before and after surgery. Ambulatory pH monitoring was also performed before and after surgery. Results were compared between age groups with the Mann-Whitney U test.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Elderly patients had significantly higher preoperative American Society of Anesthesiologists (ASA) scores (mean 2.4 vs 2.0) (p = 0.0024), but otherwise there were no significant differences in preoperative symptom scores or pH results. Both groups demonstrated equivalent postoperative improvement in symptoms and 24-h pH study. There was no mortality in either group, and there was no significant difference in morbidity or hospital stay between the two groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Laparoscopic antireflux surgery is a safe and effective treatment of GERD in the elderly and should not be refused solely on the basis of age.\n",
            "     </abstracttext>]\n",
            "11129515.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "7790481.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10350034.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11113085.xml\n",
            "\n",
            "[<abstracttext label=\"BACKGROUND &amp; AIMS\" nlmcategory=\"OBJECTIVE\">\n",
            "      An earlier pilot study from our liver unit suggested benefit from treatment with pentoxifylline (PTX), an inhibitor of tumor necrosis factor (TNF), in severe acute alcoholic hepatitis. The aim of the present study was to evaluate this treatment in a larger cohort of patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      One hundred one patients with severe alcoholic hepatitis (Maddrey discriminant factor &gt; or = 32) entered a 4-week double-blind randomized trial of PTX (400 mg orally 3 times daily) vs. placebo. Primary endpoints of the study were the effect of PTX on (1) short-term survival and (2) progression to hepatorenal syndrome. On randomization, there were no differences in demographic and clinical characteristics or laboratory values (including TNF) between the 2 groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Twelve (24.5%) of the 49 patients who received PTX and 24 (46.1%) of the 52 patients who received placebo died during the index hospitalization (P = 0.037; relative risk, 0.59; 95% confidence interval, 0.35-0.97). Hepatorenal syndrome was the cause of death in 6 (50%) and 22 (91.7%) patients (P = 0.009; relative risk, 0.29; 95% confidence interval, 0.13-0.65). Three variables (age, creatinine level on randomization, and treatment with PTX) were independently associated with survival. TNF values on randomization were not predictive of survival; however, during the study period they increased markedly in nonsurvivors compared with survivors in both groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Treatment with PTX improves short-term survival in patients with severe alcoholic hepatitis. The benefit appears to be related to a significant decrease in the risk of developing hepatorenal syndrome. Increasing TNF levels during the hospital course are associated with an increase in mortality rate.\n",
            "     </abstracttext>]\n",
            "2801756.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9099655.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We enrolled 459 adults with systolic blood pressures of less than 160 mm Hg and diastolic blood pressures of 80 to 95 mm Hg. For three weeks, the subjects were fed a control diet that was low in fruits, vegetables, and dairy products, with a fat content typical of the average diet in the United States. They were then randomly assigned to receive for eight weeks the control diet, a diet rich in fruits and vegetables, or a \"combination\" diet rich in fruits, vegetables, and low-fat dairy products and with reduced saturated and total fat. Sodium intake and body weight were maintained at constant levels.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      At base line, the mean (+/-SD) systolic and diastolic blood pressures were 131.3+/-10.8 mm Hg and 84.7+/-4.7 mm Hg, respectively. The combination diet reduced systolic and diastolic blood pressure by 5.5 and 3.0 mm Hg more, respectively, than the control diet (P&lt;0.001 for each); the fruits-and-vegetables diet reduced systolic blood pressure by 2.8 mm Hg more (P&lt;0.001) and diastolic blood pressure by 1.1 mm Hg more than the control diet (P=0.07). Among the 133 subjects with hypertension (systolic pressure, &gt; or =140 mm Hg; diastolic pressure, &gt; or =90 mm Hg; or both), the combination diet reduced systolic and diastolic blood pressure by 11.4 and 5.5 mm Hg more, respectively, than the control diet (P&lt;0.001 for each); among the 326 subjects without hypertension, the corresponding reductions were 3.5 mm Hg (P&lt;0.001) and 2.1 mm Hg (P=0.003).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A diet rich in fruits, vegetables, and low-fat dairy foods and with reduced saturated and total fat can substantially lower blood pressure. This diet offers an additional nutritional approach to preventing and treating hypertension.\n",
            "     </abstracttext>]\n",
            "3156007.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10796184.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of this review was to assess the effects of very tight glycaemic control in established insulin dependence.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The Cochrane Pregnancy and Childbirth Group trials register was searched.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised trials comparing very tight with tight control of diabetes in pregnancy.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      One reviewer assessed trial quality and extracted data.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Two trials involving 182 women were involved. The two trials were difficult to compare. Maternal hypoglycaemia was more common among women whose diabetic control was very tight compared to tight control (odds ratio 25.96, 95% confidence interval 4.91 to 137.26) based on one trial. There was no difference detected in perinatal outcome between the groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There appears to be no clear evidence of benefit from very tight glycaemic control for pregnant diabetic women. Since very strict control may have a substantial impact on lifestyle, this suggests caution in advising such a degree of control.\n",
            "     </abstracttext>]\n",
            "629899.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14734335.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To summarize evidence about the accuracy of the Ottawa knee rule.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      Relevant English- and non-English-language articles were identified from PreMEDLINE and MEDLINE (1966-2003), EMBASE (1980-2003), CINAHL (1982-2003), BIOSIS (1990-2003), the Cochrane Library (2002, Issue 3), the Science Citation Index database, reference lists of included studies, and experts.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Articles were included if they reported enough information to determine the sensitivity and specificity of the Ottawa knee rule for detecting fractures confirmed either radiologically or in combination with follow-up.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Two reviewers independently extracted data on study samples, the ways that the Ottawa knee rule was used, and methodologic characteristics of studies.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Of 11 identified studies, 6 involving 4249 adult patients were considered appropriate for pooled analysis. The pooled negative likelihood ratio was 0.05 (95% CI, 0.02 to 0.23), the pooled sensitivity was 98.5% (CI, 93.2% to 100%), and the pooled specificity was 48.6% (CI, 43.4% to 51.0%).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A negative result on an Ottawa knee rule test accurately excluded knee fractures after acute knee injury. However, because the rule is calibrated toward 100% sensitivity and actual fracture prevalences are usually low, large-scale, multicentered studies are still needed to establish the cost-effectiveness of routinely implementing the rule.\n",
            "     </abstracttext>]\n",
            "6754120.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "18205800.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11552913.xml\n",
            "\n",
            "[<abstracttext label=\"AIM\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare the efficacy and safety of nitazoxanide and metronidazole in the treatment of diarrhoea caused by G. intestinalis in children.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A total of 110 children presenting with diarrhoea caused by G. intestinalis were randomized to treatment with either a 3-day course of nitazoxanide (100 mg b.d., age range 2-3 years; 200 mg b.d., age range 4-11 years) or a 5-day course of metronidazole (125 mg b.d., age range 2-5 years; 250 mg b.d., age range 6-11 years). The patients were followed-up for a determination of clinical response 7 days after the initiation of treatment, and two subsequent stool samples were collected for parasitological examination.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Diarrhoea had resolved in 47 children out of 55 (85%) in the nitazoxanide treatment group before the day 7 follow-up visit, compared to 44 out of 55 (80%) for metronidazole. Diarrhoea resolved within 4 days in most cases. Only mild, transient adverse events were reported.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A 3-day course of nitazoxanide suspension is as efficacious as a standard 5-day course of metronidazole suspension in treating giardiasis in children.\n",
            "     </abstracttext>]\n",
            "16358132.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the diagnostic accuracy of magnetic resonance imaging of the knee in identifying traumatic intraarticular knee lesions.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      300 patients with a clinical diagnosis of traumatic intraarticular knee lesions underwent prearthoscopic magnetic resonance imaging. The sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio for a positive test, likelihood ratio for a negative test, and accuracy of magnetic resonance imaging were calculated relative to the findings during arthroscopy in the studied structures of the knee (medial meniscus, lateral meniscus, anterior cruciate ligament, posterior cruciate ligament, and articular cartilage).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Magnetic resonance imaging produced the following results regarding detection of lesions: medial meniscus: sensitivity 97.5%, specificity 92.9%, positive predictive value 93.9%, positive negative value 97%, likelihood positive ratio 13.7, likelihood negative ratio 0.02, and accuracy 95.3%; lateral meniscus: sensitivity 91.9%, specificity 93.6%, positive predictive value 92.7%, positive negative value 92.9%, likelihood positive ratio 14.3, likelihood negative ratio 0.08, and accuracy 93.6%; anterior cruciate ligament: sensitivity 99.0%, specificity 95.9%, positive predictive value 91.9%, positive negative value 99.5%, likelihood positive ratio 21.5, likelihood negative ratio 0.01, and accuracy 96.6%; posterior cruciate ligament: sensitivity 100%, specificity 99%, positive predictive value 80.0%, positive negative value 100%, likelihood positive ratio 100, likelihood negative ratio 0.01, and accuracy 99.6%; articular cartilage: sensitivity 76.1%, specificity 94.9%, positive predictive value 94.7%, positive negative value 76.9%, likelihood positive ratio 14.9, likelihood negative ratio 0.25, and accuracy 84.6%.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Magnetic resonance imaging is a satisfactory diagnostic tool for evaluating meniscal and ligamentous lesions of the knee, but it is unable to clearly identify articular cartilage lesions.\n",
            "     </abstracttext>]\n",
            "9667087.xml\n",
            "\n",
            "[<abstracttext label=\"AIM\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the benefits of VR compared with standard medical care, using a brief intervention for dizzy patients in primary care.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Adults consulting their general practitioner (GP) with dizziness or vertigo were randomly assigned to treatment or control groups. Patients in both groups received the same evaluation at baseline, six-week follow-up, and six-month follow-up, comprising examination of nystagmus, postural control, and movement-provoked dizziness, and a questionnaire assessment of subjective status, symptoms, handicap, anxiety, and depression. At baseline and six weeks later, the treatment group also received an individualized 30-minute therapy session, in which they were taught head, eye, and body exercises designed to promote vestibular compensation and enhance skill and confidence in balance.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The treatment group (n = 67) improved on all measures, whereas the control group (n = 76) showed no improvement, resulting in a significant difference between the two groups on physical indices of balance and subjective indices of symptoms and distress. Odds ratios for improvement in treated patients relative to untreated patients were 3.1:1 at six weeks (95% CI = 1.4-6.8) and 3.8:1 at six months (95% CI = 1.6-8.7).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      VR is a simple, inexpensive, and beneficial treatment, and may be an appropriate first stage of management for many dizzy patients in primary care.\n",
            "     </abstracttext>]\n",
            "12851867.xml\n",
            "\n",
            "[<abstracttext label=\"BACKGROUND &amp; AIMS\" nlmcategory=\"OBJECTIVE\">\n",
            "      Studies of antidepressants and psychological treatments in functional bowel disorders (FBD) are methodologically limited. The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD). We also evaluated the amenability of clinically meaningful subgroups to these treatments.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      This randomized, comparator-controlled, multicenter trial enrolled 431 adults from the University of North Carolina and the University of Toronto with moderate to severe symptoms of FBD. Participants received psychological (CBT vs. EDU) or antidepressant (DES vs. PLA) treatment for 12 weeks. Clinical, physiologic, and psychosocial assessments were performed before and at the end of treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The intention-to-treat analysis showed CBT as significantly more effective than EDU (P = 0.0001; responder rate, 70% CBT vs. 37% EDU; number needed to treat [NNT ], 3.1). DES did not show significant benefit over PLA in the intention-to-treat analysis (P = 0.16; responder rate, 60% DES vs. 47% PLA; NNT, 8.1) but did show a statistically significant benefit in the per-protocol analysis (P = 0.01; responder rate, 73% DES vs. 49% PLA; NNT, 5.2), especially when participants with nondetectable blood levels of DES were excluded (P = 0.002). Improvement was best gauged by satisfaction with treatment. Subgroup analyses showed that DES was beneficial over PLA for moderate more than severe symptoms, abuse history, no depression, and diarrhea-predominant symptoms; CBT was beneficial over EDU for all subgroups except for depression.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      For female patients with moderate to severe FBD, CBT is effective and DES may be effective when taken adequately. Certain clinical subgroups are more or less amenable to these treatments.\n",
            "     </abstracttext>]\n",
            "12517199.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine if administration of albuterol by a metered-dose inhaler with a spacer device is as efficacious as administration of albuterol by nebulizer to treat wheezing in children aged 2 years and younger.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Double-blind, randomized, placebo-controlled clinical trial.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Pediatric emergency department.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      From a convenience sample of wheezing children aged 2 to 24 months, 85 patients were enrolled in the nebulizer group and 83 in the spacer group.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      The nebulizer group received a placebo metered-dose inhaler with a spacer followed by nebulized albuterol. The spacer group received albuterol by a metered-dose inhaler with a spacer followed by nebulized isotonic sodium chloride solution. Treatments were given every 20 minutes by a single investigator blinded to group assignment.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      The primary outcome was admission rate. Pulmonary Index score and oxygen saturation were measured initially and 10 minutes after each treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The nebulizer group had a significantly higher mean (SD) initial Pulmonary Index score compared with the spacer group (7.6 [2.5] vs 6.6 [2.0]; P =.002). With the initial Pulmonary Index score controlled, children in the spacer group were admitted less (5% vs 20%; P =.05). Analyses also revealed an interaction between group and initial Pulmonary Index score; lower admission rates in the spacer group were found primarily in children having a more severe asthma exacerbation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our data suggest that metered-dose inhalers with spacers may be as efficacious as nebulizers for the emergency department treatment of wheezing in children aged 2 years or younger.\n",
            "     </abstracttext>]\n",
            "15383488.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8169238.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12621794.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess compliance with the Centers for Disease Control and Prevention (CDC) screening-based protocol for obstetric group B Streptococcus (GBS) and to determine an acceptable threshold for protocol failure.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      A retrospective chart review was carried out for all deliveries performed through the resident-run community clinic from January through June 1999. Compliance with the CDC protocol was assessed by reviewing collected data from patient charts and comparing it to CDC requirements. Data were collected regarding patient demographics, antenatal GBS status, gestational age at screening, time of rupture of the membranes, time the antibiotic was given and time of delivery.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 248 charts were reviewed. Elective cesarean deliveries were excluded (25 charts). Unknown culture status was found for 22 (9.9%) patients. Cultures were collected before 35 weeks' gestation in 39 (17.5%) patients and at &gt; 37 weeks' gestation in 28 (12.6%) patients. Of those with known positive GBS status, 4 (7.0%) were not treated, and antibiotics were given less than four hours before delivery in 13 (24.5%) patients. Of those with unknown status, six (27.2%) were not treated. Overall, there was 70% compliance with the culture collection arm of the protocol and 87% compliance with the treatment arm.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Fulfillment of CDC guidelines in this community setting is imperfect. There are several areas beyond physician control, including precipitous delivery and patient non-compliance. However, perhaps an acceptable threshold for limitations of adherence to the protocol can be reached.\n",
            "     </abstracttext>]\n",
            "11089820.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We used a nested case-control design with information derived from 368 practices which contribute to the UK-based General Practice Research Database. The base study population included three groups of patients age 50 years and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a clinical diagnosis of untreated hyperlipidaemia; and a randomly selected group of other individuals. From this base population, all cases with a computer-recorded clinical diagnosis of dementia were identified. Each case was matched with up to four controls derived from the base population on age, sex, practice, and index date of case.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      The study encompassed 284 cases with dementia and 1080 controls. Among controls 13% had untreated hyperlipidaemia, 11% were prescribed statins, 7% other LLAs, and 69% had no hyperlipidaemia or LLA exposure. The relative risk estimates of dementia adjusted for age, sex, history of coronary-artery disease, hypertension, coronary-bypass surgery and cerebral ischaemia, smoking and body mass index for individuals with untreated hyperlipidaemia (odds ratio 0.72 [95% CI 0.45-1.14]), or treated with nonstatin LLAs (0.96 [0.47-1.97], was close to 1.0 and not significant compared with people who had no diagnosis of hyperlipidaemia or exposure to other lipid-lowering drugs. The adjusted relative risk for those prescribed statins was 0.29 (0.13-0.63; p=0.002).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to nonstatin LLAs. The available data do not distinguish between Alzheimer's disease and other forms of dementia.\n",
            "     </abstracttext>]\n",
            "18184294.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the efficacy of oral treatment with nebivolol and metoprolol in the prophylaxis of migraine attacks.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      Randomized, double-blind study in 30 patients with confirmed migraine diagnosis, a minimum 1-year history, onset prior to 50 years of age, written records of attacks for the previous 3 months, and minimum 2 attacks per month. Primary endpoint was frequency of attacks (prevention of migraine attacks) in the final 4 weeks of a 14-week treatment on full dose of metoprolol and nebivolol. Secondary endpoints were time to therapeutic effect, duration of attacks, intensity of headache, consumption of analgesics, evaluation of accompanying symptoms, migraine disability assessment, clinical global impression, quality of life, and responder rates. The statistical analysis was prospectively planned and conducted for all randomized patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Both metoprolol and nebivolol where similarly effective regarding the main endpoint (prevention of migraine attacks) as well as the secondary ones, and both had a fast onset of action, typically within 4 weeks from starting therapy, with responder rates increasing relatively little over time after the first 4 weeks. Use of acute pain medication decreased on both drugs, as well as accompanying symptoms. Both patients' and physicians' evaluations of disability and disease status were similarly favorable to the 2 treatments. Regarding safety, nebivolol was considerably better tolerated than metoprolol in terms of all reported events, treatment-related events, and event severity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our results suggest that nebivolol is as effective as metoprolol in the prophylaxis of migraine attacks, with the advantages of being better tolerated and not requiring up-titration to achieve therapeutic levels. Further and larger trials should be conducted on nebivolol in the prevention of migraine attacks as it may provide an improvement in current migraine prophylaxis with beta-blockers.\n",
            "     </abstracttext>]\n",
            "2193173.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "6529911.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12051216.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "4025675.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9371164.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Individual data from the studies were abstracted according to a predefined protocol. The summary odds ratios were calculated according to standard methods.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      There were eight post-MI and five CHF trials; nine trials were double-blind and placebo-controlled, and four compared amiodarone with usual care. 6553 patients were randomly assigned treatment, of which 78% were in post-MI trials and 22% in CHF trials. 89% had had previous MI. The mean left-ventricular ejection fraction was 31%, and median frequency of ventricular premature depolarisation 18 per h. Total mortality was reduced by 13% (odds ratio 0.87 [95% CI 0.78-0.99], p = 0.030) based on classic fixed-effects meta-analysis and by 15% (0.85 [0.71-1.02], p = 0.081) with the more conservative random-effects approach. Arrhythmic/sudden death was reduced by 29% (0.71 [0.59-0.85], p = 0.0003). There was no effect on non-arrhythmic deaths (1.02 [0.87-1.19], p = 0.84). There was no difference in treatment effect between post-MI and CHF studies. The risk of arrhythmic/sudden death in control-group patients was higher in CHF than in post-MI studies (10.7 vs 4.1%), and the best single predictor of risk of arrhythmic/sudden death among all patients was symptomatic CHF. The excess (amiodarone minus control) risk of pulmonary toxicity was 1% per year.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Prophylactic amiodarone reduces the rate of arrhythmic/sudden death in high-risk patients with recent MI or CHF and this effect results in an overall reduction of 13% in total mortality.\n",
            "     </abstracttext>]\n",
            "10739286.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "3821822.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9262493.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We studied 7046 pregnant women whom serologic tests showed to be at risk for herpes simplex virus (HSV) infection. Serum samples obtained at the first prenatal visit, at approximately 16 and 24 weeks, and during labor were tested for antibodies to HSV types 1 and 2 (HSV-1 and HSV-2) by the Western blot assay, and the results were correlated with the occurrence of antenatal genital infections.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Ninety-four of the women became seropositive for HSV; 34 of the 94 women (36 percent) had symptoms consistent with herpes infection. Women who were initially seronegative for both HSV-1 and HSV-2 had an estimated chance of seroconversion for either virus of 3.7 percent; those who were initially seropositive only for HSV-1 had an estimated chance of HSV-2 seroconversion of 1.7 percent; and those who were initially HSV-2-seropositive had an estimated chance of zero for acquiring HSV-1 infection. Among the 60 of the 94 pregnancies for which the time of acquisition of HSV infection was known, 30 percent of the infections occurred in the first trimester, 30 percent in the second, and 40 percent in the third. HSV seroconversion completed by the time of labor was not associated with an increase in neonatal morbidity or with any cases of congenital herpes infection. However, among the infants born to nine women who acquired genital HSV infection shortly before labor, neonatal HSV infection occurred in four infants, of whom one died.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Two percent or more of susceptible women acquire HSV infection during pregnancy. Acquisition of infection with seroconversion completed before labor does not appear to affect the outcome of pregnancy, but infection acquired near the time of labor is associated with neonatal herpes and perinatal morbidity.\n",
            "     </abstracttext>]\n",
            "8246082.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11849631.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To present efficacy and cycle control data pooled from three pivotal studies of the contraceptive patch (Ortho Evra/Evra).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Three multicenter, open-label, contraceptive studies that included up to 13 treatment cycles.Setting: 183 centers.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENT(S)\" nlmcategory=\"METHODS\">\n",
            "      3,319 women.Intervention(s): Three consecutive 7-day patches (21 days) with 1 patch-free week per cycle.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURE(S)\" nlmcategory=\"METHODS\">\n",
            "      Contraceptive efficacy and cycle control.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULT(S)\" nlmcategory=\"RESULTS\">\n",
            "      Overall and method failure life-table estimates of contraceptive failure through 13 cycles were 0.8% (95% CI, 0.3%-1.3%) and 0.6% (95% CI, 0.2%-0.9%), respectively. Corresponding Pearl indices were 0.88 (95% CI, 0.44-1.33) and 0.7 (95% CI, 0.31-1.10). Contraceptive failure among women with a body weight &lt; 90 kg (&lt;198 lb) was low and uniformly distributed across the weight range. A subgroup of women with body weight &gt; or = 90 kg (&gt; or = 198 lb) may have increased risk of pregnancy. The incidence of breakthrough bleeding was low and decreased over time.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION(S)\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In contraceptive patch users, the overall annual probability of pregnancy was 0.8% and the method failure probability was 0.6%. The efficacy of the patch was high and similar across age and racial groups. Among women &lt; 90 kg (&lt;198 lb), contraceptive failure was low and uniformly distributed across the range of body weights. In women &gt; or = 90 kg (&gt; or = 198 lb), contraceptive failures may be increased. Efficacy and cycle control have been shown to be comparable to an established oral contraceptive.\n",
            "     </abstracttext>]\n",
            "12683477.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      This study was conducted to test the effectiveness of an abbreviated cognitive-behavioral insomnia therapy (ACBT) with primary\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      A single-blind, randomized group design was used in which study patients were randomized to either a brief, 2-session ACBT or a similarly brief intervention (SHC) that included only generic sleep hygiene recommendations.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      A university-affiliated Department of Veterans Affairs medical center.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Twenty (2 women) veteran patients (M(age) = 51.0 yrs., SD = 13.7 years) who met criteria for chronic primary insomnia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MEASUREMENTS AND RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Participants completed sleep logs for 2 weeks and questionnaires to measures insomnia symptoms, sleep-related self-efficacy, and dysfunctional beliefs about sleep before treatment, during a 2-week posttreatment assessment, and again at a 3-month posttreatment follow-up. Statistical analyses showed that ACBT produced significantly larger improvements across a majority of outcome measures than did SHC. Case-by-case analyses showed that only the ACBT produced consistent positive effects across study patients, and a sizeable proportion of these patients receiving this treatment achieved clinically significant improvements by their study endpoints. Approximately 52% of those receiving the ACBT reported at least a 50% reduction in their wake time after sleep onset, and 55.6% of ACBT-treated patients who entered the study with pathologic scores on an Insomnia Symptom Questionnaire (ISQ), achieved normal ISQ scores by their final outcome assessment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      ACBT is effective for reducing subjective sleep disturbance and insomnia symptoms in primary care patients.\n",
            "     </abstracttext>]\n",
            "8875918.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We obtained clinical follow-up data through 1994-1995 in 229 patients with isolated mitral regurgitation due to flail leaflet; this condition was first diagnosed by echocardiography between 1980 and 1989.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The 86 patients who were treated medically had a mortality rate significantly higher than expected (6.3 percent yearly, P=0.016 for the comparison with the expected rate in the U.S. population according to the 1990 census). Independent determinants of mortality were an older age, the presence of symptoms, and a lower ejection fraction. Patients who were even transiently in New York Heart Association functional class III or IV had a high mortality rate (34 percent yearly), but the rate was also notable (4.1 percent yearly) among those in class I or II. At 10 years, the mean (+/- SE) rates of heart failure, atrial fibrillation, and death or surgery were 63 +/- 8, 30 +/- 12, and 90 +/- 3 percent, respectively. In a multivariate analysis, surgical correction of mitral regurgitation (performed in 143 patients) was associated with a reduced mortality rate (hazard ratio, 0.29; 95 percent confidence interval, 0.15 to 0.56; P&lt;0.001).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      When treated medically, mitral regurgitation due to flail leaflet is associated with excess mortality and high morbidity. Surgery is almost unavoidable within 10 years after the diagnosis and appears to be associated with an improved prognosis; this finding suggests that surgery should be considered early in the course of the disease.\n",
            "     </abstracttext>]\n",
            "12637923.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our goal was to evaluate the accuracy of preliminary biopsies performed by a group of predominantly experienced dermatologists (n = 46/72).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A total of 145 cases of cutaneous melanoma were examined retrospectively. We compared Breslow depth on preliminary biopsy with Breslow depth on subsequent excision. Was the initial diagnostic biopsy performed on the deepest part of the melanoma?\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of nonexcisional initial shave and punch biopsies, 88% were accurate, with Breslow depth greater than or equal to subsequent excision Breslow depth. Both superficial and deep shave biopsies were more accurate than punch biopsy for melanomas less than 1 mm. Excisional biopsy was found to be the most accurate method of biopsy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Deep shave biopsy is preferable to superficial shave or punch biopsy for thin and intermediate depth (&lt;2 mm) melanomas when an initial sample is taken for diagnosis instead of complete excision. We found that a group of predominantly experienced dermatologists accurately assessed the depth of invasive melanoma by use of a variety of initial biopsy types.\n",
            "     </abstracttext>]\n",
            "16336480.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To provide clinicians with a brief screening tool to predict accurately which individuals may develop aberrant behaviors when prescribed opioids for chronic pain.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      One hundred and eighty-five consecutive new patients treated in one pain clinic took the self-administered Opioid Risk Tool (ORT). The ORT measured the following risk factors associated in scientific literature with substance abuse: personal and family history of substance abuse; age; history of preadolescent sexual abuse; and certain psychological diseases. Patients received scores of 0-3 (low risk), 4-7 (moderate risk), or &gt;or= 8 (high risk), indicating the probability of their displaying opioid-related aberrant behaviors. All patients were monitored for aberrant behaviors for 12 months after their initial visits.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      For those patients with a risk category of low, 17 out of 18 (94.4%) did not display an aberrant behavior. For those patients with a risk category of high, 40 out of 44 (90.9%) did display an aberrant behavior. The authors used the c statistic to validate the ORT, because it simultaneously assesses sensitivity and specificity. The ORT displayed excellent discrimination for both the male (c = 0.82) and the female (c = 0.85) prognostic models.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In a preliminary study, among patients prescribed opioids for chronic pain, the ORT exhibited a high degree of sensitivity and specificity for determining which individuals are at risk for opioid-related, aberrant behaviors. Further studies in a variety of pain and nonpain settings are needed to determine the ORT's universal applicability.\n",
            "     </abstracttext>]\n",
            "10749962.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We randomly assigned 106 patients with hypertension who had atherosclerotic renal-artery stenosis (defined as a decrease in luminal diameter of 50 percent or more) and a serum creatinine concentration of 2.3 mg per deciliter (200 micromol per liter) or less to undergo percutaneous transluminal renal angioplasty or to receive drug therapy. To be included, patients also had to have a diastolic blood pressure of 95 mm Hg or higher despite treatment with two antihypertensive drugs or an increase of at least 0.2 mg per deciliter (20 micromol per liter) in the serum creatinine concentration during treatment with an angiotensin-converting-enzyme inhibitor. Blood pressure, doses of antihypertensive drugs, and renal function were assessed at 3 and 12 months, and patency of the renal artery was assessed at 12 months.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      At base line, the mean (+/-SD) systolic and diastolic blood pressures were 179+/-25 and 104+/-10 mm Hg, respectively, in the angioplasty group and 180+/-23 and 103+/-8 mm Hg, respectively, in the drug-therapy group. At three months, the blood pressures were similar in the two groups (169+/-28 and 99+/-12 mm Hg, respectively, in the 56 patients in the angioplasty group and 176+/-31 and 101+/-14 mm Hg, respectively, in the 50 patients in the drug-therapy group; P=0.25 for the comparison of systolic pressure and P=0.36 for the comparison of diastolic pressure between the two groups); at the time, patients in the angioplasty group were taking 2.1+/-1.3 defined daily doses of medication and those in the drug-therapy group were taking 3.2+/-1.5 daily doses (P&lt;0.001). In the drug-therapy group, 22 patients underwent balloon angioplasty after three months because of persistent hypertension despite treatment with three or more drugs or because of a deterioration in renal function. According to intention-to-treat analysis, at 12 months, there were no significant differences between the angioplasty and drug-therapy groups in systolic and diastolic blood pressures, daily drug doses, or renal function.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In the treatment of patients with hypertension and renal-artery stenosis, angioplasty has little advantage over antihypertensive-drug therapy.\n",
            "     </abstracttext>]\n",
            "2709545.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10678340.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our goal was to determine what drugs are most efficacious for controlling the ventricular rate in patients with atrial fibrillation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We conducted a systematic review of the literature published before May 1998, beginning with searches of The Cochrane Collaboration's CENTRAL database and MEDLINE.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      We included English-language articles describing randomized controlled trials of drugs used for heart rate control in adults with atrial fibrillation. DATA COLLECTION/ANALYSIS: Abstracts of trials were reviewed independently by 2 members of the study team. We reviewed English-language abstracts of non-English-language publications to assess qualitative consistency with our results.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Forty-five articles evaluating 17 drugs met our criteria for review. In the 5 trials of verapamil and 5 of diltiazem, heart rate was reduced significantly (P &lt;.05), both at rest and with exercise, compared with placebo, with equivalent or improved exercise tolerance in 6 of 7 comparisons. In 7 of 12 comparisons of a beta-blocker with placebo, the beta-blocker was efficacious for control of resting heart rate, with evidence that the effect is drug specific, as nadolol and atenolol proved to be most efficacious. All 9 comparisons demonstrated good heart rate control with beta-blockers during exercise, although exercise tolerance was compromised in 3 of 9 comparisons. In 7 of 8 trials, digoxin administered alone slowed the resting heart rate more than placebo, but it did not significantly slow the rate during exercise in 4 studies. The trials evaluating other drugs yielded insufficient evidence to support their use, but those drugs may yet be promising.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The calcium-channel blockers verapamil or diltiazem, or select beta-blockers are efficacious for heart rate control at rest and during exercise for patients with atrial fibrillation without a clinically important decrease in exercise tolerance. Digoxin is useful when rate control during exercise is less a concern.\n",
            "     </abstracttext>]\n",
            "15908441.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To identify risk factors in early life (up to 3 years of age) for obesity in children in the United Kingdom.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Prospective cohort study.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Avon longitudinal study of parents and children, United Kingdom.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      8234 children in cohort aged 7 years and a subsample of 909 children (children in focus) with data on additional early growth related risk factors for obesity.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Obesity at age 7 years, defined as a body mass index (3) 95th centile relative to reference data for the UK population in 1990.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Eight of 25 putative risk factors were associated with a risk of obesity in the final models: parental obesity (both parents: adjusted odds ratio, 10.44, 95% confidence interval 5.11 to 21.32), very early (by 43 months) body mass index or adiposity rebound (15.00, 5.32 to 42.30), more than eight hours spent watching television per week at age 3 years (1.55, 1.13 to 2.12), catch-up growth (2.60, 1.09 to 6.16), standard deviation score for weight at age 8 months (3.13, 1.43 to 6.85) and 18 months (2.65, 1.25 to 5.59); weight gain in first year (1.06, 1.02 to 1.10 per 100 g increase); birth weight, per 100 g (1.05, 1.03 to 1.07); and short (&lt; 10.5 hours) sleep duration at age 3 years (1.45, 1.10 to 1.89).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Eight factors in early life are associated with an increased risk of obesity in childhood.\n",
            "     </abstracttext>]\n",
            "11834677.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15285276.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether pulmonary function, asthma symptoms, quality of life, depression, anxiety, and power differ over time in adults with asthma who do and do not practice mental imagery (MI). (Power is the ability to make aware choices with the intention of freely involving oneself in creating desired change.)\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Randomized controlled study using univariate repeated measures analysis of variance (ANOVA) and replacement through block design.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Lenox Hill Hospital, an affiliate of New York University Medical School, New York, NY.\n",
            "     </abstracttext>, <abstracttext label=\"SUBJECTS\" nlmcategory=\"METHODS\">\n",
            "      Sixty-eight adults with symptomatic asthma, after 4 weeks of baseline data collection and analysis, met requirements for this randomized controlled study. Thirty-three completed pulmonary function as well as self-report tests at 4 time points over 17 weeks. The 16 experimental participants also completed the 4-session imagery protocol.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      Individual imagery instruction (week 1) and follow-up (weeks 4, 9, 15). Participants were given 7 imagery exercises to select from and practice 3 times a day for a total of 15 minutes.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      1) Spirometry (FEV1); 2) medication use; 3) Asthma Quality of Life Questionnaire; 4) Beck Depression Inventory; 5) Spielberger Anxiety Scales (A-State and A-Trait); 6) Barrett Power as Knowing Participation in Change Tool, Version II; 7) Epstein Balloon Test of Ability to Image.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There was little evidence of statistical change in this feasibility study; yet, valuable lessons were learned. Paired t-tests indicated there was a significant difference in the total power scores in the imagery group, and in the expected direction (two-tailed, t-statistic = -2.3, P = 0.035) and the choices sub-scale (two-tailed, tstatistic = -2.93, P = 0.01) of the power instrument from weeks one to 16 of the study. Eight of 17 (47%) participants in the MI group reduced or discontinued their medications. Three of 16 (19%) participants in the control group reduced their medications; none discontinued. Chi-square indicated differences between groups (X2 = 4.66, P = 0.05). Persons who reduced or discontinued their medications showed neither an increase in pulmonary function prior to medication discontinuation, nor a fall in these parameters following discontinuation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Findings related to major outcome measures must be viewed with caution due to the small sample size resulting from attrition related to labor intensiveness and, therefore, low statistical power. However, the study did provide significant data to plan a larger scale study of the use of mental imagery with adult asthmatics. The study also demonstrated that imagery is inexpensive, safe and, with training, can be used as an adjunct therapy by patients themselves. Its efficacy needs additional exploration. Further research for adults with asthma who practice imagery is important, as current treatments are not entirely efficacious. Lessons learned in this study may facilitate improvement in research designs.\n",
            "     </abstracttext>]\n",
            "11451298.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      We investigated the prognostic significance of exercise-induced silent myocardial ischemia in both high and low risk men with no prior coronary heart disease (CHD).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We investigated the association of silent ischemia, as defined by ST depression during and after maximal symptom-limited exercise test, with coronary risk in a population-based sample of men with no prior CHD followed for 10 years on average.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Silent ischemia during exercise was associated with a 5.9-fold (95% CI 2.3 to 11.8) CHD mortality in smokers, 3.8-fold (95% CI 1.9 to 7.9) in hypercholesterolemic men and 4.7-fold (95% CI 2.4 to 9.1) in hypertensive men adjusting for other risk factors. The respective relative risks (RRs) of any acute coronary event were 3.0 (95% CI 1.7 to 5.1), 1.9 (95% CI 1.2 to 3.1) and 2.2 (95% CI 1.4 to 3.5). These associations were weaker in men without these risk factors. Furthermore, silent ischemia after exercise was a stronger predictor for the risk of acute coronary events and CHD death in smokers and in hypercholesterolemic and hypertensive men than in men without risk factors.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Exercise-induced silent myocardial ischemia was a strong predictor of CHD in men with any conventional risk factor, emphasizing the importance of exercise testing to identify asymptomatic high risk men who could benefit from risk reduction and preventive measures.\n",
            "     </abstracttext>]\n",
            "11050261.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Four independent literature searches were performed on Medline, Pubmed, Cochrane Library, and Embase. Only randomised clinical trials were included. There were no restrictions on the language of publication. The data were extracted in a standardised, predefined manner and assessed critically.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Seventeen randomised clinical trials were found, six of which concerned the use of traditional Chinese herbal medicine and eight described traditional Indian medicine, of which five investigated Tylophora indica. Three other randomised trials tested a Japanese Kampo medicine, marihuana, and dried ivy leaf extract. Nine of the 17 trials reported a clinically relevant improvement in lung function and/or symptom scores.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      No definitive evidence for any of the herbal preparations emerged. Considering the popularity of herbal medicine with asthma patients, there is urgent need for stringently designed clinically relevant randomised clinical trials for herbal preparations in the treatment of asthma.\n",
            "     </abstracttext>]\n",
            "11211617.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10428520.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To test the hypothesis that prophylactic administration of clindamycin 2% vaginal cream can reduce the incidence of preterm birth in a high risk population.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      A multi-centre, randomised, double-blind, placebo-controlled trial.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Twelve city hospitals in The Netherlands.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      One hundred and sixty-eight women with a singleton pregnancy and a history of a spontaneous preterm delivery in the preceding pregnancy.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Clindamycin 2% vaginal cream, or placebo cream, administered daily for seven days at 26 and 32 weeks of gestation.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Spontaneous preterm birth at &lt; 37 weeks, admission for threatened preterm labour, neonatal infectious morbidity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      In the intention-to-treat analysis no difference was found in overall preterm birth between clindamycin and placebo (23% vs 18%, respectively). In the subgroup who completed the trial and administered all medication, more women delivered before 34 weeks in the clindamycin group (1.4% in the placebo vs 9.0% in the clindamycin group; P &lt; 0.05). The length of admissions for threatened preterm labour did not differ. More infectious neonatal morbidity was seen in the clindamycin group (5/83 vs 0/85; P &lt; 0.05).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Clindamycin 2% vaginal cream given prophylactically to women with a spontaneous preterm birth in the preceding pregnancy did not prevent preterm delivery or reduce the number of admissions for threatened preterm labour. The neonatal infectious morbidity in the group treated with clindamycin was significantly higher and a major concern.\n",
            "     </abstracttext>]\n",
            "16856114.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effects of donepezil in people with mild cognitive impairment but no diagnosis of dementia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 6 January 2006. This register contains records from major health care databases like CENTRAL, MEDLINE, EMBASE, CINAHL and PsycINFO and many ongoing trial databases and is updated regularly.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All double blind, randomized trials in which treatment with donepezil was compared with placebo for patients with mild cognitive impairment.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Data were extracted from the published reports of the included studies, pooled where appropriate and the treatment effects or the risks and benefits estimated.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The two included studies, with a total of 782 patients, all with a MMSE greater than 23 points, identified similar patients for inclusion, but were quite different with respect to design and objective. Pooling results in a meta-analysis was not possible. In the first study the 13-item ADAS-Cog showed benefit associated with 10 mg/day donepezil compared with placebo at 24 weeks (MD 1.90, 95% CI 0.51 to 3.29, p=0.007), but four other measures of cognitive function did not. The analysis of withdrawals before the end of treatment at 24 weeks, withdrawals due to an adverse event, and numbers experiencing an adverse event, showed a significant difference between the donepezil group and the placebo group in favour of placebo, (43/133 donepezil 23/137 placebo, OR 2.37, 95% CI 1.33 to 4.22, p=0.003), (29/133 donepezil 10/137 placebo, OR 3.54, 95% CI 1.65 to 7.60, p=0.001), (116/133 donepezil, 100/137 placebo, OR 2.52 95% CI 1.34 to 4.76, p=0.004). Various adverse effects were recorded, and several types of event, diarrhoea, nausea, vomiting, leg cramps and abnormal dreams, were reported more frequently in the donepezil group compared with the placebo. In the second study there was a significant difference between the number of patients diagnosed with AD or another dementia between the donepezil group and the placebo group in favour of donepezil after one year of treatment (16/253 donepezil 38/259 placebo) (OR 0.39, 95% CI 0.21 to 0.72, p=0.003), but no difference after 3 years of treatment (63/253 donepezil 73/259 placebo) (OR 0.84, 95% CI 0.57 to 1.25, p=0.4).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There are two included studies. One study demonstrated a modest treatment effect in cognitive function as assessed by ADAS-Cog13 but not for other outcomes assessing different domains of cognitive function. Donepezil was associated with significantly more adverse effects compared with placebo, mostly gastrointestinal. From the second study, there is no evidence that donepezil delays the onset of AD. There is no evidence to support the use of donepezil for patients with MCI. The putative benefits are minor, short lived and associated with significant side effects.\n",
            "     </abstracttext>]\n",
            "8280820.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9430243.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12394811.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare the presence of risk factors for methicillin resistance between patients with CA-MRSA and community-acquired methicillin-susceptible (CA-MSSA) infection and to compare the presence of risk factors among household contacts of the patients from both groups. To compare the demographic and clinical characteristics between children with CA-MRSA and CA-MSSA infection.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Prospective observational study conducted between February 2, 2000 and November 14, 2000, excluding the month of May and the period between September 2 and October 15.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING AND PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Texas Children's Hospital, Houston, TX; inpatients and outpatients with community-acquired infection.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Proportion of MRSA among all community-acquired infections. The presence of risk factors associated with methicillin resistance among patients, and their household contacts, with CA-MRSA and CA-MSSA.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The monthly rates of methicillin resistance of varied between 35 and 51%. CA-MSSA isolates were associated with deep-seated infections significantly more often (30%) than CA-MRSA isolates (11%; P= 0.01). CA-MRSA isolates were generally susceptible to clindamycin and trimethoprim-sulfamethoxazole and resistant to erythromycin. There were no significant differences in the exposure to risk factors between children with CA-MRSA and CA-MSSA infection. No significant risk factors for CA-MRSA were identified among household contacts.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      MRSA is an established, community-acquired pathogen in our area. This necessitates a change in empiric therapy of infections suspected to be caused by.\n",
            "     </abstracttext>]\n",
            "6700642.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8985189.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12421836.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "7264790.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8038475.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      The purpose of this article is to review the treatment options for bacterial vaginosis, including the newer topical antibiotics, metronidazole gel and clindamycin cream. The article also examines the controversies over whether bacterial vaginosis is a sexually transmitted disease and whether asymptomatic women should be treated.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCE\" nlmcategory=\"METHODS\">\n",
            "      A MEDLINE search was conducted to identify pertinent literature, including review articles.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Emphasis was placed on those clinical trials using metronidazole gel or clindamycin cream. Studies addressing the complications of bacterial vaginosis in pregnancy, the risk of treatment in pregnancy, and the method of transmission of the disease also were reviewed.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Clinical studies evaluating clindamycin cream and metronidazole gel were scarce; therefore, data from all available trials were reviewed. The objectives, methodology, and results from other studies were reviewed; those addressing complications of the disease and risks and benefits of treatment were included.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      There is evidence both for and against bacterial vaginosis being a sexually transmitted disease. Potential complications of the disease may warrant treatment of certain asymptomatic women, especially during pregnancy. Treatment options include oral or vaginal metronidazole or clindamycin, all of which provide high cure rates. Vaginal antibiotics result in minimal risk to the fetus in pregnant patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Complications of bacterial vaginosis may be associated with significant morbidity, especially among pregnant women. Treatment of asymptomatic women with the disease is controversial, but may be justified in certain high-risk populations. The topical agents, clindamycin vaginal cream 2% and metronidazole vaginal gel 0.75% provide a safe, effective, but expensive alternative to oral antibiotic regimens for the treatment of bacterial vaginosis.\n",
            "     </abstracttext>]\n",
            "9058342.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the efficacy of one-day, intermittent, monthly prophylaxis with 400 mg itraconazole in the management of recurrent vulvovaginal candidiasis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      In a randomized trial, 57 patients and 57 controls with recurrent vulvovaginal candidiasis were assigned either to receive one-day monthly itraconazole prophylaxis for six months or no treatment. Clinical and mycologic evaluations were carried out 3, 6 and 12 months after enrollment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      During the first six months of follow-up, the rate of symptomatic recurrences was 36.4% (20/55) among the treated women and 64.2% (34/53) in the controls. The mean time +/- SEM to symptomatic recurrence was 149 +/- 6 days among patients receiving prophylaxis and 120 +/- 6 days in the controls (P = .003 by log-rank test). These differences disappeared almost completely after the cessation of intermittent prophylaxis. In fact, the proportion of patients still asymptomatic after one year of follow-up was 38.9% (21/54) among treated women and 28.8% (15/53) in the controls (P = .83 by Fisher's exact test).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      One-day monthly, intermittent itraconazole prophylaxis reduced the rate of recurrence in patients with recurrent vulvovaginal candidiasis, but the beneficial effect of itraconazole was lost within a few months after cessation of prophylaxis.\n",
            "     </abstracttext>]\n",
            "3346773.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "20091541.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effectiveness and safety of interventions to reduce the severity of paroxysmal cough in whooping cough in children and adults.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 1), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register and the Database of Abstracts of Reviews of Effects (DARE); MEDLINE (1950 to March 2009); EMBASE (1980 to March 2009); AMED (1985 to March 2009); CINAHL (1982 to March 2009) and LILACS (March 2009).\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised controlled trials (RCTs) and quasi-RCTs of any intervention (excluding antibiotics and vaccines) to suppress the cough in whooping cough.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two review authors (SB, MT) independently selected trials, extracted data and assessed the quality of each trial. The primary outcome was frequency of paroxysms of coughing. Secondary outcomes were frequency of vomiting, frequency of whoop, frequency of cyanosis (turning blue), development of serious complications, mortality from any cause, side effects due to medication, admission to hospital and duration of hospital stay.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Ten trials were included of varying sample sizes (N = 9 to 135) from high-income countries. Study quality was generally poor. Included studies did not show a statistically significant benefit for any of the interventions. Diphenhydramine did not change coughing episodes; the mean difference of coughing spells per 24 hours was 1.9 (95% confidence interval (CI) - 4.7 to 8.5). One study on pertussis immunoglobulin reported a possible mean reduction of -3.1 whoops per 24 hours (95% CI -6.2 to 0.02) but no change in hospital stay (-0.7 days) (95% CI -3.8 to 2.4). Dexamethasone did not show a clear decrease in length of hospital stay (-3.5 days) (95% CI -15.3 to 8.4) and salbutamol showed no change in coughing paroxysms per 24 hours (-0.22) (95% CI -4.13 to 3.69).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Insufficient evidence exists to draw conclusions about the effects of interventions for the cough in whooping cough.\n",
            "     </abstracttext>]\n",
            "15111671.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To analyze the prevalence and demography of chronic daily headache (CDH) with analgesic overuse.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A population of 9,984 inhabitants aged 14 or older living in Santoa, Spain, was studied. The authors personally interviewed 4,855 subjects, using a quota sampling approach. Those with headache for &gt; or = 10 days/month and some analgesic use were asked to fill in a diary over the course of 1 month. Then, subjects were classified into CDH with or without analgesic overuse subtypes. Quality of life (Short Form-36 Health Survey [SF-36]) was also assessed in this second interview.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Headache for &gt; or = 10 days/month with analgesic consumption was reported by 332 subjects. Seven had secondary headache. Seventy-four (standardized prevalence 1.41%, 95% CI 1.1 to 1.8) fulfilled criteria for CDH with analgesic overuse. Prevalence in women (2.6%, 2.0 to 3.3) was much higher than in men (0.19%, 0.006 to 0.52). Mean age was 56 years (range 19 to 82 years). As recalled by the subjects, the mean age at onset of CDH was 38 years (range 9 to 82 years), whereas the mean age at onset of CDH with frequent analgesic consumption was 45 years (range 19 to 80 years) and that of primary headache was 22 years (range 5 to 60 years). CDH subjects showed a significant decrease in each SF-36 health-related score as compared with healthy control subjects. Transformed migraine was diagnosed in 49 (prevalence 0.9%), chronic tension-type headache in 20 (0.4%), and new daily persistent headache in 5 (0.1%). Thirty-five percent of patients overused simple analgesics, 22% ergotics, 12.5% opioids, and 2.7% triptans; the remaining 27.8% were overusing different combinations.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      CDH with analgesic overuse is a common disorder in the general population, mainly in women in their fifties, in whom 5% meet its diagnostic criteria.\n",
            "     </abstracttext>]\n",
            "2221647.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To derive and validate a clinical rule for predicting pneumonic infiltrates in adult patients with acute respiratory illness.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Prevalence studies in three settings.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Emergency departments of the University of Illinois Hospital at Chicago, the University of Nebraska Medical Center at Omaha, and the Medical College of Virginia at Richmond.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Symptoms, signs, comorbidity data, and chest roentgenogram results were recorded for 1134 patients from Illinois (the derivation set), 150 patients from Nebraska, and 152 patients from Virginia (the validation sets). All patients presented to the emergency department and had a chest roentgenogram to evaluate fever or respiratory complaints.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MEASUREMENTS AND MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Within the training set, temperature greater than 37.8 degrees C, pulse greater than 100 beats/min, rales, decreased breath sounds, and the absence of asthma were identified as significant predictors of radiographically proved pneumonia in a stepwise logistic regression model (P = 0.001). The logistic rule discriminated patients with and without pneumonia in the training set with a receiver operating characteristic (ROC) area of 0.82. In the validation sets, the rule discriminated pneumonia and nonpneumonia with ROC areas of 0.82 and 0.76 after adjusting for differences in disease prevalence (P greater than 0.2 compared with the training set). The predicted probability of having pneumonia for patients with different clinical findings corresponded closely with the incidence of pneumonia among patients with such findings in the three settings.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Among adults presenting with acute respiratory illness, a prediction rule based on clinical findings accurately discriminated patients with and without radiographic pneumonia, and was used in two other samples of patients without significant decrement in discriminatory ability. This rule can be used by physicians to develop more effective strategies for detecting pneumonia and for helping to determine the need for radiologic study among patients with acute respiratory disease.\n",
            "     </abstracttext>]\n",
            "10637680.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To obtain estimates of the relative efficacy of 3 main treatment strategies for attention-deficit hyperactivity disorder (ADHD) in children and youth (age &lt; 18 years).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Design: quantitative systematic review of randomized trials. Subjects: 999 patients with ADHD from 26 randomized trials. Interventions: medications alone, behavioural interventions alone, and a combination of these 2 modalities. Main outcome measure: differences in scores between treatment groups on commonly used teacher- and parent-completed behaviour rating scales.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Medication-only therapy was efficacious in ADHD. Behavioural therapies used alone appeared not to be efficacious in ADHD. Combination therapy was more efficacious than placebo or no treatment for parent but not teacher ratings, not more efficacious than drug therapy alone, and more efficacious than behavioural treatments alone based on parent but not teacher ratings.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Though stimulant medications were found to be an effective treatment strategy for ADHD in children and youth, it proved difficult to assess the relative benefits of behavioural interventions alone and combined medication and behavioural therapy because of the paucity of treatment studies other than medication-only treatment studies and heterogeneity of various kinds that exist in relation to ADHD studies and treatments.\n",
            "     </abstracttext>]\n",
            "10796833.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the effectiveness and acceptability of progestogens alone, and oestrogens and progestogens in combination in the management of irregular bleeding associated with anovulation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The search strategy of the Menstrual Disorders Group was used to identify all randomised trials of progestogens alone or in combination with oestrogens in the management of irregular menstrual bleeding associated with anovulation. In addition a search of the Cochrane Controlled Trials Register was undertaken.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All randomised controlled trials of progestogens (via any route) alone or in combination with oestrogens in the treatment of irregular bleeding associated with anovulation.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Study quality assessment and data extraction were carried out independently by two reviewers. Both reviewers were experts in the content matter.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      No randomised trials were identified which compared progestogens with oestrogens and progestogens in the management of irregular bleeding associated with anovulation. Only one small, non-randomised study compared two progestogen regimes in the management of heavy and irregular bleeding in subjects with confirmed anovulation. One randomised study compared the effects of two progestogens on endometrial histology in subjects with a variety of menstrual symptoms, half of whom had cystic glandular hyperplasia. No studies were found which compared progestogens with oestrogens and progestogens in combination or with placebo in the management of irregular bleeding associated with anovulation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is a paucity of randomised studies relating to the use of progestogens and of oestrogens and progestogens in combination in the treatment of irregular bleeding associated with anovulation. Further research is needed to establish the role of these treatments in the management of this common gynaecological problem.\n",
            "     </abstracttext>]\n",
            "15001941.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To test the hypothesis that desmopressin facilitates acquisition of continence, we aimed to establish whether, in children with nocturnal enuresis who are desmopressin nonresponders, adjunct desmopressin increases the rate of sustained continence after treatment with a conditioning alarm. Study design Patients with nocturnal enuresis (n=358; age range, 6-16 years) completed a 4-week \"run-in\" course of intranasal desmopressin (20-40 microg). Of these, 207 defined as nonresponders (&lt;50% reduction in wet nights) were randomly assigned to receive either desmopressin (n=101) or placebo (n=106) nasal spray, together with conditioning alarm therapy for 8 weeks. Principal outcome measures were remission (28 continuous dry nights) and relapse (&gt;2 wet nights in 2 weeks after having achieved remission).\n",
            "     </abstracttext>]\n",
            "[]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Remission rates were similar in both groups (51.5% desmopressin, 48.1% placebo; 95% CI on difference, -10%, 17%; P=.63), and relapse rates were not significantly different (13.5% vs 5.9%; 95% CI on difference, -3.7%, 19%; P=.19). Although remission rates were similar, children treated with desmopressin had significantly more dry nights during treatment than those in the placebo group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Desmopressin did not act synergistically with alarm treatment to achieve remission. Therefore, we infer that in partial or nonresponders, desmopressin does not enhance learning.\n",
            "     </abstracttext>]\n",
            "11006203.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12519615.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effect of anti-cholinergic agents on lung function and dyspnea in patients with acute exacerbations of COPD, compared with placebo or short-acting beta-2 agonists.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      A comprehensive search of the literature was carried out on MEDLINE, EMBASE, CINAHL and the Cochrane COPD Trials Register, using the terms: bronchodilator* OR ipratropium OR oxitropium. References listed in each included trial were searched for additional trial reports.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Studies were included if the participants were adult patients with a known diagnosis of COPD and had symptoms consistent with criteria for acute exacerbation of COPD. All randomized controlled trials that compared inhaled ipratropium bromide or oxitropium bromide to appropriate controls were considered. Appropriate control treatments included placebo, other bronchodilating agents, or combination therapies. Studies of acute asthma or ventilated patients were excluded.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      All trials that appeared to be relevant were assessed by two reviewers who independently selected trials for inclusion. Differences were resolved by consensus.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Four trials compared the short-term effects of ipratropium bromide vs. a beta2-agonist. Short-term changes in FEV1 (up to 90 minutes) showed no significant difference between beta2-agonist and ipratropium bromide treated patients. The differences were similar among the studies and when combined: Weighted Mean Difference (WMD) 0.0 liters (95% Confidence Interval (95% CI) -0.19, 0.19). There was no significant additional increase in change in FEV1 on adding ipratropium to beta2-agonist: WMD 0.02 liter (95% CI -0.08, 0.12). Long-term effects (24 hours) of the ipratropium bromide and beta2-agonist treatment combination were similar: WMD 0.05 liters (95%CI -0.14, 0.05). Neither of two studies found significant changes in PaO2, either short- or long-term, with ipratropium vs. beta-agonist, although one showed an increase in PaO2 in subjects receiving ipratropium bromide at 60 minutes. Adverse drug reactions included dry mouth and tremor.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There was no evidence that the degree of bronchodilation achieved with ipratropium bromide was greater than that using a short-acting beta2-agonist. The combination of a beta2-agonist and ipratropium did not appear to increase the effect on FEV1 more than either used alone.\n",
            "     </abstracttext>]\n",
            "16198776.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our purpose was to determine whether pulse-dose terbinafine is as effective as standard continuous-dose terbinafine for treatment of toenail onychomycosis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a double-blind, randomized, noninferiority, clinical intervention trial in the Minneapolis Veterans Affairs Medical Center. The main inclusion criteria for participants were a positive dermatophyte culture and at least 25% distal subungual clinical involvement. Six hundred eighteen volunteers were screened; 306 were randomized. Terbinafine, 250 mg daily for 3 months (continuous) or terbinafine, 500 mg daily for 1 week per month for 3 months (pulse) was administered. The primary outcome measure was mycological cure of the target toenail at 18 months. Secondary outcome measures included clinical cure and complete (clinical plus mycological) cure of the target toenail and complete cure of all 10 toenails.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Results of an intent-to-treat analysis did not meet the prespecified criterion for noninferiority but did demonstrate the superiority of continuous-dose terbinafine for: mycological cure of the target toenail (70.9% [105/148] vs 58.7% [84/143]; P =.03, relative risk [RR] of 1.21 [95% confidence interval (CI), 1.02-1.43]); clinical cure of the target toenail (44.6% [66/148] vs 29.3% [42/143]; P =.007, RR =1.52 [95% CI, 1.11-2.07); complete cure of the target toenail (40.5% [60/148] vs 28.0% [40/143]; P =.02, RR=1.45 [95% CI, 1.04-2.01); and complete cure of all 10 toenails (25.2% [36/143] vs 14.7% [21/143]; P =.03, RR =1.71 [95% CI, 1.05-2.79). Tolerability of the regimens did not differ significantly between the groups (chi2 =1.63; P =.65).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"LIMITATIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The study population primarily consisted of older men with severe onychomycosis.\n",
            "     </abstracttext>, <abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This study demonstrated the superiority of continuous- over pulse-dose terbinafine. We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.\n",
            "     </abstracttext>]\n",
            "15633203.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11289288.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      This study was performed according to a prospective, randomized, open design. The aim was to test the efficacy of local application of nifedipine ointment in healing acute thrombosed external hemorrhoids.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Ninety-eight patients who gave their informed consent were recruited; they received clinical examination and anoscopy. A questionnaire to evaluate symptoms, pain, and concurrent use of analgesics was administered. Patients treated with nifedipine (n = 50) used topical 0.3 percent nifedipine and 1.5 percent lidocaine ointment every 12 hours for two weeks. The control group, consisting of 48 patients, received topical 1.5 percent lidocaine ointment during therapy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Results obtained were as follows: complete relief of pain in 43 patients (86 percent) of the nifedipine-treated group as opposed to 24 patients (50 percent) of the control group after 7 days of therapy (P &lt; 0.01); oral analgesics were used by 4 patients (8 percent) in the nifedipine-treated group as opposed to 26 patients (54.1 percent) of the control group after 7 days of therapy (P &lt; 0.01); and resolution of acute thrombosed external hemorrhoids was achieved after 14 days of therapy in 46 patients (92 percent) of the nifedipine-treated group, as opposed to 22 patients (45.8 percent) of the control group (P &lt; 0.01). We did not observe any systemic side effect in patients treated with nifedipine.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our study clearly demonstrates that the use of topical nifedipine, which at present is for treatment of cardiovascular disorders, is a reliable new option in the conservative treatment of thrombosed external hemorrhoids.\n",
            "     </abstracttext>]\n",
            "7673531.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10085797.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9170464.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Macrosomia at term is associated with increased maternal and neonatal morbidity, including a higher rate of cesarean delivery and shoulder dystocia. Induction of labor has been suggested as a means to prevent further weight gain and improve outcome. The aim of this study was to determine whether or not induction of labor in these cases improves maternal and neonatal outcome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Patients at term with an ultrasonic fetal weight estimation of 4000-4500 g were prospectively randomized into two groups: induction of labor (group D and expectant management (group II). Patients with diabetes, a previous cesarean delivery, or nonvertex presentation were excluded. Outcome variables included mode of delivery, arterial cord pH, presence of shoulder dystocia, brachial plexus injury, clavicular fracture, cephalohematoma, and intraventricular hemorrhage.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of 273 patients who were eligible for the study, 134 were randomized to group I and 139 to group II. Parity, gestational age, and fetal weight estimation were similar in the two groups. The neonates of group II patients were significantly heavier (4132.8 +/- 347.4 versus 4062.8 +/- 306.9 g; P = .024). The rate of cesarean delivery was 19.4% in group I and 21.6% in group II patients (not significant [NS]). Cord pH was similar in both groups. Shoulder dystocia was diagnosed in five group I and six group II patients (NS). None developed brachial plexus injury. There were two cases of mild, transient brachial plexus injury in group II patients without documented shoulder dystocia. Mild intraventricular hemorrhage was diagnosed in three of 44 group I and two of 31 group II neonates evaluated (NS).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In this prospective, randomized study, induction of labor for suspected macrosomia at term did not decrease the rate of cesarean delivery or reduce neonatal morbidity. Ultrasonic estimation of fetal weight between 4000 and 4500 g should not be considered an indication for induction of labor.\n",
            "     </abstracttext>]\n",
            "9220205.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9879160.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8668411.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      This article reviews and synthesizes evidence in the published literature on the safety and efficacy of oral rehydration therapy (ORT) among young children with pediatric gastroenteritis in developed nations.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODOLOGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the literature for randomized, controlled trials comparing the safety and efficacy of ORT with intravenous (IV) rehydration treatment and/or oral rehydration solutions (ORSs) of different sodium content. We combined the failure rates of each set of studies in statistical meta-analyses and conducted tests of homogeneity of treatment effect over all the studies and for subgroups of children defined by the trial type, the sodium content of the ORS, and the setting of care. We also conducted a multivariate logistic regression on the probability of failure to determine the relative importance of these factors, controlling for other characteristics of the trials. Other outcomes were also tabulated and discussed. These include the relative incidence of hypernatremia and hyponatremia induced by treatment; weight gain; the volume, frequency, and duration of diarrhea; for inpatient trials, the length of stay; and for outpatient trials, rates of hospitalization.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The evidence suggests that among pediatric patients with gastroenteritis in developed countries, failure of ORT, defined as the need to rehydrate children intravenously, is infrequent. We found a combined overall ORT failure rate of 3.6%. We found no statistically significant difference in failure rates by trial type or the sodium content of the ORS. However, we did find some supporting evidence for a lower failure rate among children treated in outpatient settings. In addition, compared with patients rehydrated intravenously, pediatric patients treated with ORT were not found to be at higher risk of iatrogenic hypernatremia or hyponatremia. The evidence from the literature fails to show a consistent trend in favor of either high- or low-sodium solutions for rehydration of pediatric patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There seems to be a great potential for improving the medical treatment of children with acute gastroenteritis by the greater use of ORT.\n",
            "     </abstracttext>]\n",
            "8900550.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      This study evaluated different symptoms, signs, and blood tests in the diagnostic process of patients with a clinical diagnosis of acute sinusitis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A total of 201 primary care patients in southern Norway aged 15 years or older with a clinical diagnosis of acute sinusitis were evaluated. Computed tomography (CT) was used as a reference standard to divide the patients into two groups: one with and one without confirmed sinusitis. Fluid level or total opacification of any sinus on CT were used as hallmarks of confirmed sinusitis. Blood tests that included erythrocyte sedimentation rate (ESR), C-reactive protein, and white blood count were taken. The patients were evaluated in a standardized way for the medical history and the clinical investigation.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 127 (63%) patients had fluid level or total opacification in one or more sinus regions. \"Double sickening,\" purulent rhinorrhoea, purulent secretion in cavum nasi, and ESR &gt; 10 had the highest likelihood ratios and were independently associated with acute sinusitis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This study confirms the uncertainty of the clinical diagnosis of acute sinusitis in primary care, based on the clinical evaluation alone. Only four symptoms and signs had a high likelihood ratio and were independently associated with acute sinusitis. A combination of at least three of these four symptoms and signs gave a specificity of .81 and a sensitivity of .66.\n",
            "     </abstracttext>]\n",
            "2910090.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      High-dose (500 mg orally four times daily) vancomycin is considered by many investigators to be the most effective treatment for antibiotic-associated Clostridium difficile colitis. However, a lower dosage of 125 or 150 mg given three or four times a day has become popular, has been shown to be effective, and is less expensive than the high-dose regimen. We therefore decided to compare two vancomycin dosage regimens in a randomized trial.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PATIENTS AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      The study involved 46 hospitalized patients with serious underlying diseases complicated by C. difficile diarrhea or colitis. Patients were assigned (according to a table of random numbers) to treatment with either 125 or 500 mg of vancomycin orally four times daily for an average of 10 days.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      No significant differences in measurable responses to the two regimens were noted. There were no treatment failures. The mean duration of diarrhea after initiation of therapy was about four days, and almost all patients had no diarrhea after one week. The organism continued to be demonstrated in the stools of about 50 percent of patients for the first few weeks after completion of therapy, and nine (20 percent) patients developed a recurrence of their diarrheal illness. Vancomycin was well tolerated by all patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Since the dose of 125 mg appeared to be as effective as the 500-mg dose, which is more expensive, the 125-mg dose is preferred when vancomycin is used in treatment of this disease, unless the patient is critically ill.\n",
            "     </abstracttext>]\n",
            "17443559.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine the efficacy and safety of topical lidocaine in the treatment of postherpetic neuralgia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Pain, Palliative and Supportive Care Group Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS, SIGLE for conference proceedings, Citation Index, the reference lists of all eligible trials, key textbooks, and previous systematic reviews. We also wrote to authors of all identified trials.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised or quasi-randomised trials comparing all topical applications of lidocaine, including gels and patches in patients of all ages with postherpetic neuralgia (pain persisting at the site of shingles at least one month after the onset of the acute rash).\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two review authors extracted data, and a third checked them. We obtained some missing data from the US Food and Drugs Administration.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Three trials involving 182 topical lidocaine treated participants and 132 control participants were included. Two trials gave data on pain relief, and the remaining study provided data on secondary outcome measures. The largest trial published as an abstract compared topical lidocaine patch to a placebo patch and accounted for 150 of the 314 patients (48%).A meta-analysis combining two of the three studies identified a significant difference between the topical lidocaine and control groups for the primary outcome measure: a mean improvement in pain relief according to a pain relief scale. Topical lidocaine relieved pain better than placebo (P = 0.003). There was a statistical difference between the groups for the secondary outcome measure of mean VAS score reduction (P = 0.03), but this was only for a single small trial. There were a similar number of adverse skin reactions in both treatment and placebo groups. The highest recorded blood lidocaine concentration varied between 59 ng/ml and 431 ng/ml between trials. The latter figure is high and the authors of the study suggest that the sample had been contaminated during the assay procedure.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is insufficient evidence to recommend topical lidocaine as a first-line agent in the treatment of postherpetic neuralgia with allodynia. Further research should be undertaken on the efficacy of topical lidocaine for other chronic neuropathic pain disorders, and also to compare different classes of drugs (e.g. topical anaesthetics versus anti-epileptics).\n",
            "     </abstracttext>]\n",
            "15486746.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Few data exist on the actual recurrence rates of thrombosed external hemorrhoids. We wished to determine the incidence of recurrence, intervals to recurrence, and factors predicting recurrence of thrombosed external hemorrhoids after conservative or surgical management.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Two hundred and thirty-one consecutive patients with thrombosed external hemorrhoids treated from 1990 to 2002 were identified. Recurrence was defined as complete resolution of the index lesion with subsequent return of a thrombosed external hemorrhoid and did not include patients with chronic symptoms. Data were gathered retrospectively. Multiple potential risk factors were reviewed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The index thrombosed external hemorrhoid was managed conservatively in 51.5 percent of cases and surgically in 48.5 percent. There were no differences between groups in gender, age, or race, and 44.5 percent of all patients had a prior history of thrombosed external hemorrhoid. A prior history was less common in the conservative group than in the surgical group (38.1 percent vs. 51.3 percent; P &lt; 0.05). The frequency of pain or bleeding as the primary complaint was higher in the surgical group ( P &lt; 0.001 and P &lt; 0.002). In addition, the surgical group was more likely to report all three symptoms of pain, bleeding, and a lump ( P &lt; 0.005). Mean follow-up was 7.6 months, with the range extending to 7 years. Time to symptom resolution averaged 24 days in the conservative group vs. 3.9 days in the surgical group ( P &lt; 0.0001). The overall incidence to recurrence was 15.6 percent-80.6 percent in the conservative group vs. 19.4 percent in the surgical group. The rate of recurrence in the conservative group was 25.4 percent (4/29; 14 percent were excised) whereas only 6.3 percent of the surgical patients had recurrence ( P &lt; 0.0001). Mean time to recurrence was 7.1 months in the conservative group vs. 25 months in the surgical group ( P &lt; 0.0001). Survival analysis for time to recurrence of thrombosed external hemorrhoid indicated that time to recurrence was significantly longer for the surgical group ( P &lt; 0.0001). Logistic regression analysis of multiple factors (including diverticular disease, constipation, straining, benign prostatic hypertrophy, diarrhea, skin tags, history of travel, anoreceptive sex, anal fissures, internal hemorrhoids, and obesity) was performed to determine the outcome of each group. None of these variables were significant predictors of recurrence.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Patients whose initial presentation was pain or bleeding with or without a lump were more like to be treated surgically. Surgically treated patients had a lower frequency of recurrence and a longer time interval to recurrence than conservatively treated patients. None of the variables analyzed were significant predictors of a particular treatment, except for a prior history of thrombosed external hemorrhoids, which may represent patient choice. Although most patients treated conservatively will experience resolution of their symptoms, excision of thrombosed external hemorrhoids results in more rapid symptom resolution, lower incidence of recurrence, and longer remission intervals.\n",
            "     </abstracttext>]\n",
            "11343045.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      We tested the hypothesis that adding montelukast to budesonide would improve asthma control in children with inhaled glucocorticoid-dependent persistent asthma.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      In a multicenter, randomized, double-blind, crossover study, we compared the benefit of adding montelukast, 5 mg, or placebo once daily to budesonide, 200 microg, twice daily.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      After a 1-month run-in with budesonide, 200 microg, twice daily, 279 children were randomized to montelukast or placebo. The mean +/- SD age was 10.4 +/- 2.2 years, the mean forced expiratory volume in 1 second (FEV(1)) was 77.7% +/- 10.6% predicted, and reversibility was 18.1% +/- 12.9%. Compared with adding placebo to budesonide, adding montelukast produced significant improvements in mean percent change from baseline FEV(1) (P =.062 [P =.010 for per-protocol analysis]), mean absolute change from baseline FEV(1) (P =.040), mean increase from baseline in morning (P =.023) and evening (P =.012) peak expiratory flows, decrease in exacerbation days by approximately 23% (P &lt;.001), decreased beta2-agonist use (P =.013), and reduced blood eosinophil counts (P &lt;.001). The treatments did not differ significantly with regard to safety.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Montelukast, 5 mg, added to budesonide improved asthma control significantly, indicated by a small additive effect on lung function and a clinically relevant decrease in asthma exacerbation days.\n",
            "     </abstracttext>]\n",
            "12882847.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      We evaluated the renoprotective effects as reflected by short-term changes in albuminuria of dual blockade of the renin-angiotensin system (RAS) by adding an angiotensin II receptor blocker (ARB) to treatment with maximal recommended doses of an ACE inhibitor (ACEI) in patients with type 2 diabetes and nephropathy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESEARCH DESIGN AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      A total of 20 patients (17 men and 3 women) with type 2 diabetes along with hypertension and nephropathy were enrolled in this double-blind, randomized, two-period, crossover trial of 8 weeks of treatment with the ARB candesartan 16 mg daily and placebo added in random order to existing treatment with lisinopril/enalapril 40 mg daily or captopril 150 mg daily. At the end of each treatment period, we evaluated albuminuria in three 24-h urinary collections by turbidimetry, 24-h ambulatory blood pressure (ABP) using the Takeda-TM2420, and glomerular filtration rate (GFR) by the (51)Cr-EDTA plasma-clearance technique.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      During monoblockade of the RAS by ACEI treatment, albuminuria was 706 (349-1,219) mg/24 h [geometric mean (IQR)]; 24-h ABP was 138 +/- 3/72 +/- 2 mmHg (mean +/- SE); and GFR was 77 +/- 6 ml x min(-1) x 1.73 m(-2) (mean +/- SE). During dual blockade of the RAS by addition of candesartan 16 mg daily, there was a mean (95% CI) reduction in albuminuria of 28 (17-38) compared with ACEI alone (P &lt; 0.001). There was a modest reduction in systolic/diastolic 24-h ABP of 3/2 mmHg (-2 to 8 systolic, -2 to 5 diastolic; NS). Changes in albuminuria did not correlate to changes in ABP. Addition of candesartan 16 mg daily induced a small, insignificant decrease in GFR of 4 (-1 to 9) ml x min(-1) x 1.73 m(-2).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Dual blockade of the RAS provides superior short-term renoprotection independent of systemic blood pressure changes in comparison with maximally recommended doses of ACEI in patients with type 2 diabetes as well as nephropathy.\n",
            "     </abstracttext>]\n",
            "11560453.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To summarize and compare the validity of computed tomography angiography, magnetic resonance angiography, ultrasonography, captopril renal scintigraphy, and the captopril test for diagnosis of renal artery stenosis in patients suspected of having renovascular hypertension.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      For each diagnostic modality, published studies were identified by MEDLINE literature searches.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Original studies were selected if they met the following criteria: 1) suspicion of renovascular hypertension was the indication for the test; 2) intra-arterial x-ray angiography was used as the gold standard; 3) a cutoff point for a positive test result was explicitly defined; and 4) absolute numbers of true-positive, false-negative, true-negative, and false-positive results were available or could be derived from the presented data.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      A standard form was used to extract relevant data.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Data on the accuracy of the different diagnostic methods were analyzed and compared by constructing summary receiver-operating characteristic (ROC) curves and by computing areas under the summary ROC curves.\n",
            "     </abstracttext>, <abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Although accuracy varied greatly for all diagnostic modalities, summary ROC curves found that computed tomography angiography and gadolinium-enhanced, three-dimensional magnetic resonance angiography performed significantly better than the other diagnostic tests.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Computed tomography angiography and gadolinium-enhanced three-dimensional magnetic resonance angiography seem to be preferred in patients referred for evaluation of renovascular hypertension. However, because few studies of these tests have been published, further research is recommended.\n",
            "     </abstracttext>]\n",
            "17626140.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the efficacy and safety of polyethylene glycol 3350 plus electrolytes (PEG+E) for the treatment of chronic constipation in children.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Randomised, double blind, placebo controlled crossover trial, with two 2-week treatment periods separated by a 2-week placebo washout.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Six UK paediatric departments.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      51 children (29 girls, 22 boys) aged 24 months to 11 years with chronic constipation (lasting &gt; or =3 months), defined as &lt; or =2 complete bowel movements per week and one of the following: pain on defaecation on 25% of days; &gt; or =25% of bowel movements with straining; &gt; or =25% of bowel movements with hard/lumpy stools. 47 children completed the double blind treatment.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Number of complete defaecations per week (primary efficacy variable), total number of complete and incomplete defaecations per week, pain on defaecation, straining on defaecation, faecal incontinence, stool consistency, global assessment of treatment, adverse events and physical examination.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The mean number of complete defaecations per week was significantly higher for children on PEG+E than on placebo (3.12 (SD 2.05) v 1.45 (SD 1.20), respectively; p&lt;0.001). Further significant differences in favour of PEG+E were observed for total number of defaecations per week (p = 0.003), pain on defaecation (p = 0.041), straining on defaecation (p&lt;0.001), stool consistency (p&lt;0.001) and percentage of hard stools (p = 0.001). Treatment related adverse events (all mild or moderate) occurred in similar numbers of children on PEG+E (41%) and placebo during treatment (45%).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      PEG+E is significantly more effective than placebo, and appears to be safe and well tolerated in the treatment of chronic constipation in children.\n",
            "     </abstracttext>]\n",
            "12917703.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To conduct a descriptive systematic review into the nature and effectiveness of family involvement in weight control, weight maintenance and weight-loss interventions.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      We searched Medline and Psyclit for English language papers describing randomised trials with at least 1-y follow-up that evaluated interventions incorporating a family-based component. Studies involving people with eating disorders, learning disabilities and undernutrition or malnutrition were excluded. Data were extracted on characteristics of the participants, study design, target behaviours, nature of the intervention and study outcomes. A taxonomy was developed and used to classify family involvement in behaviour change interventions. Interventions were also classified according to an existing taxonomy that characterised the behaviour change techniques employed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 21 papers describing 16 intervention studies were identified. Studies were small (mean sample size: 52), heterogeneous, poorly described but with few losses to follow-up (median 15%). The majority were North American and aimed at weight loss. Few studies described a theoretical underpinning to the behaviour change techniques employed. There was a suggestion that spouse involvement increased effectiveness but that adolescents achieved greater weight loss when treated alone. In studies including children, beneficial effects were seen when greater numbers of behaviour change techniques were taught to both parents and children.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Relatively few intervention studies exist in this important area, particularly studies targeting adolescents, and they highlight continued uncertainty about how best to involve family members. The studies provide limited support for the involvement of spouses. They suggest that parental involvement is associated with weight loss in children, and that use of a greater range of behaviour change techniques improves weight outcomes for both parents and children. The development of future interventions and assessment of factors influencing effectiveness may be improved by paying careful attention to which family members are targeted and how they are involved in the intervention in terms of setting goals for behaviour change, providing support and training in behaviour change techniques.\n",
            "     </abstracttext>]\n",
            "7755059.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      The purpose of this study was to use transvaginal ultrasonographic measurements to find the thickness of the endometrium below which the risk of endometrial abnormality in women with postmenopausal bleeding is low.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      This multicenter study was carried out at eight clinics in four Nordic countries. The study included 1168 women with postmenopausal bleeding scheduled for curettage Before the curettage was performed, the thickness of the endometrium was measured with transvaginal ultrasonography. The measurement included both endometrial layers (double-layer technique). The transvaginal ultrasonographic measurement was compared with the histopathologic diagnosis of the curettage specimens.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      In women with atrophic endometrium the mean endometrial thickness (+/- SD) was 3.9 +/- 2.5 mm. The corresponding figures for women with endometrial cancer were 21.1 +/- 11.8 mm. No malignant endometrium was thinner than 5 mm. In 30 women (2.8%) it was not possible to measure the thickness of the endometrium; one of these women had endometrial cancer. The 95% confidence limit for the probability of excluding endometrial abnormality was 5.5% when the endometrial thickness was &lt; or = 4 mm as measured by transvaginal ultrasonography.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The risk of finding pathologic endometrium at curettage when the endometrium is &lt; or = 4 mm as measured by transvaginal ultrasonography is 5.5%. Thus in women with postmenopausal bleeding and an endometrium &lt; or = 4 mm it would seem justified to refrain from curettage.\n",
            "     </abstracttext>]\n",
            "10381965.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10613168.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "17943857.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the analgesic effectiveness and safety of antidepressant drugs in neuropathic pain.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      Randomised controlled trials (RCTs) of antidepressants in neuropathic pain were identified in MEDLINE (1966 to Oct 2005); EMBASE (1980 to Oct 2005); the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, Issue 3, 2005; and the Cochrane Pain, Palliative and Supportive Care Trials Register (May 2002). Additional reports were identified from the reference list of the retrieved papers, and by contacting investigators.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      RCTs reporting the analgesic effects of antidepressant drugs in adult patients, with subjective assessment of pain of neuropathic origin. Studies that included patients with chronic headache and migraine were excluded.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two review authors agreed the included studies, extracted data, and assessed methodological quality independently. Sixty one trials of 20 antidepressants were considered eligible (3293 participants) for inclusion. Relative Risk (RR) and Number-Needed-to-Treat (NNTs) were calculated from dichotomous data for effectiveness and adverse effects. This update includes 11 additional studies (778 participants).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Sixty one RCTs were included in total. Tricyclic antidepressants (TCAs) are effective and have an NNT of 3.6 (95% CI 3 to 4.5) RR 2.1 (95% CI 1.8 to 2.5) for the achievement of at least moderate pain relief. There is limited evidence for the effectiveness of the newer SSRIs but no studies of SNRIs were found. Venlafaxine (three studies) has an NNT of 3.1 (95% CI 2.2 to 5.1) RR 2.2 (95% CI 1.5 to 3.1). There were insufficient data to assess effectiveness for other antidepressants such as St Johns Wort and L-tryptophan. For diabetic neuropathy the NNT for effectiveness was 1.3 (95% CI 1.2 to 1.5) RR 12.4 (95% CI 5.2 to 29.2) (five studies); for postherpetic neuralgia 2.7 (95% CI 2 to 4.1), RR 2.2 (95% CI 1.6 to 3.1) (four studies). There was evidence that TCAs are not effective in HIV-related neuropathies. The number needed to harm (NNH) for major adverse effects defined as an event leading to withdrawal from a study was 28 (95% CI 17.6 to 68.9) for amitriptyline and 16.2 (95% CI 8 to 436) for venlafaxine. The NNH for minor adverse effects was 6 (95% CI 4.2 to 10.7) for amitriptyline and 9.6 (95% CI 3.5 to 13) for venlafaxine.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This update has provided additional confirmation on the effectiveness of antidepressants for neuropathic pain and has provided new information on another antidepressant - venlafaxine. There is still limited evidence for the role of SSRIs. Whether antidepressants prevent the development of neuropathic pain (pre-emptive use) is still unclear. Both TCAs and venlafaxine have NNTs of approximately three. This means that for approximately every three patients with neuropathic pain who are treated with either of these antidepressants, one will get at least moderate pain relief. There is evidence to suggest that other antidepressants may be effective but numbers of participants are insufficient to calculate robust NNTs. SSRIs are generally better tolerated by patients and more high quality studies are required.\n",
            "     </abstracttext>]\n",
            "9516745.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8449054.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11405989.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the effects of iron therapy on psychomotor development and cognitive function in iron deficient children less than 3 years of age.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The following databases were searched: COCHRANE LIBRARY (2000 ISSUE 4) MEDLINE (1966-August 2000) EMBASE (1980-August 2000) Latin American Database (LILACS) PsycLIT Journal articles (1974-August 2000) PsycLIT Chapters and Books (1987-August 2000) The references of identified trials and of important review articles were scrutinised. Citation searches on trials from the primary search were performed within the Science Citation Index. Key authors were contacted.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Studies were included if children less than 3 years of age with evidence of iron deficiency anaemia were randomly allocated to iron or iron and vitamin C versus a placebo or vitamin C alone and assessment of developmental status or cognitive function was carried out using standardised tests by observers blind to treatment allocation.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Abstracts and titles of studies identified on searches of electronic databases were read to determine whether they might meet the inclusion criteria. Full copies of those possibly meeting these criteria from electronic or other searches were assessed by two independent reviewers. Differences of opinion about suitability for inclusion were resolved by discussion. Data were analysed separately depending on whether participants had iron assessments were performed within one month of beginning iron therapy or later.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Five trials, including 180 children with IDA, examined the effects of iron therapy on measures of psychomotor development between 5 and 11 days of commencement of therapy. Data from four trials could be pooled. The pooled difference in pre to post treatment change in Bayley Scale PDI between iron treated and placebo groups was -3.2 (95%CI -7.24, 0.85) and in Bayley Scale MDI, 0.55 (95% CI -2.84, 1.75). Two studies, including 160 randomised children with IDA, examined the effects of iron therapy on measures of psychomotor development more than 30 days after commencement of therapy. Aukett et al reported the mean number of skills gained after two months of iron therapy, using the Denver test. The intervention group gained 0.8 (95% CI -0.18, 1.78) more skills on average than the control group. Idjrandinata et al reported that the difference in pre to post treatment change in Bayley Scale PDI between iron treated and placebo groups after 4 months was 18.40 (95%CI 10.16, 26.64) and in Bayley Scale MDI, 18.80 (95% CI 10.19, 27.41).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is no convincing evidence that iron treatment of young children with IDA has an effect on psychomotor development discernable within 5-11 days. The effect of longer term treatment remains unclear but the data would be compatible with clinically significant benefit. There is urgent need for further randomised controlled trials with long term follow up.\n",
            "     </abstracttext>]\n",
            "12121581.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine, from a societal perspective, the effectiveness and cost effectiveness of concentrated cranberry tablets, versus cranberry juice, versus placebo used as prophylaxis against lower urinary tract infection (UTI) in adult women.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MATERIALS AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      One hundred fifty sexually active women aged 21 through 72 years were randomized for one year to one of three groups of prophylaxis: placebo juice + placebo tablets versus placebo juice + cranberry tablets, versus cranberry juice + placebo tablets. Tablets were taken twice daily, juice 250 ml three times daily. Outcome measures were: (1) a &gt;50% decrease in symptomatic UTI's per year (symptoms + &gt;or= 100 000 single organisms/ml) and (2) a &gt;50% decrease in annual antibiotic consumption. Cost effectiveness was calculated as dollar cost per urinary tract infection prevented. Stochastic tree decision analytic modeling was used to identify specific clinical scenarios for cost savings.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Both cranberry juice and cranberry tablets statistically significantly decreased the number of patients experiencing at least 1 symptomatic UTI/year (to 20% and 18% respectively) compared with placebo (to 32%) (p&lt;0.05). The mean annual cost of prophylaxis was $624 and $1400 for cranberry tablets and juice respectively. Cost savings were greatest when patients experienced &gt;2 symptomatic UTI's per year (assuming 3 days antibiotic coverage) and had &gt;2 days of missed work or required protective undergarments for urgency incontinence. Total antibiotic consumption was less annually in both treatment groups compared with placebo. Cost effectiveness ratios demonstrated cranberry tablets were twice as cost effective as organic juice for prevention.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Cranberry tablets provided the most cost-effective prevention for UTI.\n",
            "     </abstracttext>]\n",
            "9918527.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[<abstracttext label=\"METHODS AND RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The long-term outcome of 478 patients with organic mitral regurgitation (199 in NYHA functional class I/II and 279 in class III/IV before surgery) operated on between 1984 and 1991 was analyzed. In patients in NYHA class I/II before surgery compared with those in class III/IV, postoperative long-term survival was higher (at 10 years, 76+/-5% versus 48+/-4%, P&lt;0.0001), with lower operative mortality (0.5% versus 5.4%, P=0.003) and better late survival (P&lt;0.0001). Comparison of observed and expected survival showed identical curves in patients in class I/II before surgery (P=0.18), whereas excess mortality was observed in patients in class III/IV before surgery (P&lt;0.0001). Excess mortality associated with severe symptoms was also confirmed in all subgroups (all P&lt;0.003) and in multivariate analysis (P=0.0036; adjusted hazard ratio [95% CI], 1.81 [1.21 to 2.70]).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In patients with organic mitral regurgitation, preoperative functional class III/IV symptoms are associated with excess short- and long-term postoperative mortality independently of all baseline characteristics. These data should lead to consideration of surgical correction of severe organic mitral regurgitation when no or minimal symptoms are present in patients at low operative risk, especially if repair is feasible.\n",
            "     </abstracttext>]\n",
            "17179478.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A total of 2437 women were randomly assigned between February 1994 and January 2001 in a ratio of 40:60 to dietary intervention (n = 975) or control (n = 1462) groups. An interim analysis was performed after a median follow-up of 60 months when funding for the intervention ceased. Mean differences between dietary intervention and control groups in nutrient intakes and anthropometric variables were compared with t tests. Relapse-free survival was examined using Kaplan-Meier analysis, stratified log-rank tests, and Cox proportional hazards models. Statistical tests were two-sided.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Dietary fat intake was lower in the intervention than in the control group (fat grams/day at 12 months, 33.3 [95% confidence interval {CI} = 32.2 to 34.5] versus 51.3 [95% CI = 50.0 to 52.7], respectively; P&lt;.001), corresponding to a statistically significant (P = .005), 6-pound lower mean body weight in the intervention group. A total of 277 relapse events (local, regional, distant, or ipsilateral breast cancer recurrence or new contralateral breast cancer) have been reported in 96 of 975 (9.8%) women in the dietary group and 181 of 1462 (12.4%) women in the control group. The hazard ratio of relapse events in the intervention group compared with the control group was 0.76 (95% CI = 0.60 to 0.98, P = .077 for stratified log rank and P = .034 for adjusted Cox model analysis). Exploratory analyses suggested a differential effect of the dietary intervention based on hormonal receptor status.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A lifestyle intervention reducing dietary fat intake, with modest influence on body weight, may improve relapse-free survival of breast cancer patients receiving conventional cancer management. Longer, ongoing nonintervention follow-up will address original protocol design plans, which called for 3 years of follow-up after completion of recruitment.\n",
            "     </abstracttext>]\n",
            "11326182.xml\n",
            "\n",
            "[<abstracttext label=\"STUDY OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      We sought to evaluate quantitatively the evidence on the diagnostic performance of out-of-hospital ECG for the diagnosis of acute cardiac ischemia (ACI) and acute myocardial infarction (AMI) and the clinical effect of out-of-hospital thrombolysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a systematic review and meta-analysis of the English-language literature published between 1966 and December 1998 on the diagnostic accuracy of out-of-hospital ECG and the clinical effect of out-of-hospital thrombolysis. Both prospective and retrospective studies qualified for the assessment of diagnostic performance. For clinical effect, data from prospective nonrandomized studies were synthesized separately from data from randomized trials. Diagnostic performance was assessed by using estimates of test sensitivity, specificity, and diagnostic odds ratios and was summarized by using summary receiver-operating characteristic curves. Measures of clinical effect included time savings, early ventricular function, early mortality, and long-term survival.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Diagnostic accuracy was evaluated in 11 studies with a total of 7,508 patients. Data were available for ACI in 5 studies and for AMI in 8 studies. For ACI, the random-effects pooled sensitivity was 76% (95% CI, 54% to 89%), the specificity was 88% (95% CI, 67% to 96%), and the diagnostic odds ratio was 23 (95% CI, 6.3 to 85). The respective figures for AMI were sensitivity of 68% (95% CI, 59% to 76%), specificity of 97% (95% CI, 89% to 92%), and diagnostic odds ratio of 104 (95% CI, 48 to 224). Both in nonrandomized (n=4, total 1,531 patients) and randomized (n=9, total 6,643 patients) studies, out-of-hospital thrombolysis shortened the time from onset of symptoms to thrombolytic treatment by 40 to 60 minutes. Data on short-term ejection fraction were sparse. Hospital mortality was reduced by 16% (95% CI, 2% to 27%) among randomized trials, and a similar estimate of effect was seen in nonrandomized studies. There was no clear effect on long-term mortality, but data were sparse.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Out-of-hospital ECG has excellent diagnostic performance for AMI and very good performance for ACI. Out-of-hospital thrombolysis achieves time savings and improves short-term mortality, but the effect on long-term mortality is unknown.\n",
            "     </abstracttext>]\n",
            "1734290.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9988787.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Our purpose was to compare the diagnostic ability and treatment efficacy of conization by the loop electrosurgical excision procedure with cold-knife conization.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      One hundred eighty women who required conization for diagnosis and treatment of cervical dysplasia or microinvasive cervical carcinoma were prospectively enrolled in a randomized clinical trial to receive either cold-knife conization or conization by the loop electrosurgical excision procedure. Conization complications, rate of lesion clearance, and therapeutic outcome were assessed for the 2 study groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There were no statistically significant differences in the complication rate (P = 1.00), the rate of lesion clearance (P =.18), or the rate of disease recurrence (P =.13) between the 2 study groups. The mean follow-up was 11.2 months in the cold-knife conization group and 10.4 months in the loop-excision conization group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Cold-knife conization and loop-excision conization yield similar diagnostic and therapeutic results.\n",
            "     </abstracttext>]\n",
            "8309029.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare escalating doses of immediate-release (IR) and sustained-release (SR) niacin for effectiveness in reducing levels of low-density lipoprotein cholesterol and triglycerides and increasing levels of high-density lipoprotein cholesterol, and for the occurrence of adverse reactions, especially hepatotoxicity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Randomized, double-blind, parallel comparison of IR and SR niacin administered sequentially at 500, 1000, 1500, 2000, and 3000 mg/d, each for 6 weeks.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Cholesterol research center.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Forty-six adults, 23 in each group, with low-density lipoprotein cholesterol levels greater than 4.14 mmol/L (160 mg/dL) after 1 month of a step 1 National Cholesterol Education Program diet.\n",
            "     </abstracttext>, <abstracttext label=\"OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Fourteen-hour fasting lipid and lipoprotein cholesterol levels, results of clinical laboratory tests, a symptom questionnaire, and withdrawal rates.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The SR niacin lowered low-density lipoprotein cholesterol levels significantly more than IR niacin did at the dosage of 1500 mg/d and above, while IR niacin increased high-density lipoprotein cholesterol levels significantly more than SR niacin did at all dosage levels. The reduction in triglyceride levels was similar with IR and SR niacin. Nine (39%) of the 23 patients assigned to the IR dosage form withdrew before completing the 3000-mg daily dose; the most common reasons for withdrawal were vasodilatory symptoms, fatigue, and acanthosis nigricans. Eighteen (78%) of the 23 patients assigned to the SR dosage form withdrew before completing the 3000-mg daily dose; the most common reasons for withdrawal were gastrointestinal tract symptoms, fatigue, and increases in levels of liver aminotransferases, often with symptoms of hepatic dysfunction. None of the patients taking IR niacin developed hepatotoxic effects, while 12 (52%) of the 23 patients taking SR niacin did.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The SR form of niacin is hepatotoxic and should be restricted from use. The IR niacin is preferred for the management of hypercholesterolemia but can also cause significant adverse effects and should be given only to patients who can be carefully monitored by experienced health professionals.\n",
            "     </abstracttext>]\n",
            "7224353.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "2473403.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8381089.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14557142.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the relationship between regional changes in antidepressant medication treatment and suicide in adolescents from 1990 to 2000.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Analysis of prescription data from the nation's largest pharmacy benefit management organization, national suicide mortality files, regional sociodemographic data from the 1990 and 2000 US Census, and regional data on physicians per capita.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Youth aged 10 to 19 years who filled a prescription for antidepressant medication and same-aged completed suicides from 588 three-digit ZIP code regions in the United States.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      The relationship between regional change in antidepressant medication treatment and suicide rate stratified by sex, age group, regional median income, and regional racial composition.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There was a significant adjusted negative relationship between regional change in antidepressant medication treatment and suicide during the study period. A 1% increase in adolescent use of antidepressants was associated with a decrease of 0.23 suicide per 100 000 adolescents per year (beta = -.023, t = -5.14, P&lt;.001). In stratified adjusted analyses, significant inverse relationships were present among males (beta = -.032, t = -3.81, P&lt;.001), youth aged 15 to 19 years (beta = -.029, t = -3.43, P&lt;.001), and regions with lower family median incomes (beta = -.023, t = -3.73, P&lt;.001).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      An inverse relationship between regional change in use of antidepressants and suicide raises the possibility of a role for using antidepressant treatment in youth suicide prevention efforts, especially for males, older adolescents, and adolescents who reside in lower-income regions.\n",
            "     </abstracttext>]\n",
            "15951574.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We randomly assigned women between 24 and 34 weeks' gestation who had gestational diabetes to receive dietary advice, blood glucose monitoring, and insulin therapy as needed (the intervention group) or routine care. Primary outcomes included serious perinatal complications (defined as death, shoulder dystocia, bone fracture, and nerve palsy), admission to the neonatal nursery, jaundice requiring phototherapy, induction of labor, cesarean birth, and maternal anxiety, depression, and health status.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The rate of serious perinatal complications was significantly lower among the infants of the 490 women in the intervention group than among the infants of the 510 women in the routine-care group (1 percent vs. 4 percent; relative risk adjusted for maternal age, race or ethnic group, and parity, 0.33; 95 percent confidence interval, 0.14 to 0.75; P=0.01). However, more infants of women in the intervention group were admitted to the neonatal nursery (71 percent vs. 61 percent; adjusted relative risk, 1.13; 95 percent confidence interval, 1.03 to 1.23; P=0.01). Women in the intervention group had a higher rate of induction of labor than the women in the routine-care group (39 percent vs. 29 percent; adjusted relative risk, 1.36; 95 percent confidence interval, 1.15 to 1.62; P&lt;0.001), although the rates of cesarean delivery were similar (31 percent and 32 percent, respectively; adjusted relative risk, 0.97; 95 percent confidence interval, 0.81 to 1.16; P=0.73). At three months post partum, data on the women's mood and quality of life, available for 573 women, revealed lower rates of depression and higher scores, consistent with improved health status, in the intervention group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Treatment of gestational diabetes reduces serious perinatal morbidity and may also improve the woman's health-related quality of life.\n",
            "     </abstracttext>]\n",
            "12565715.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      This study was a randomized, double-blind, placebo-controlled trial of 2 mg of warfarin in patients undergoing rehabilitation following completed stroke. The major efficacy endpoint was symptomatic, objectively proven VTE or asymptomatic VTE detected by monthly duplex ultrasonography (DU) of the proximal leg veins or mandatory bilateral contrast venography performed at the end of the study. The major safety endpoint was bleeding.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There were 475 patients screened for enrollment, 355 had one or more exclusion criterion, and 17 had previously undetected proximal DVT on admission. Of the 103 eligible and consenting patients, 56 received warfarin and 47 received placebo. Of the randomized patients, 88 had successful venography (47 warfarin and 41 placebo). In the warfarin group, three (8%) patients had DVT and one (2%) had proximal DVT whereas in the placebo group, seven (20%) had DVT and five (13%) had proximal DVT. The risk ratio for any DVT in warfarin-treated patients relative to placebo-treated patients was 0.39 (95% confidence interval (CI), 0.13-1.37). For proximal DVT, the risk ratio was 0.17 (95% CI, 0.01-1.4). No patients suffered major bleeding.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A fixed dose of 2 mg of warfarin per day in patients undergoing stroke rehabilitation is safe and associated with a relative risk reduction of about 80% in the incidence of proximal DVT and 60% in overall DVT.\n",
            "     </abstracttext>]\n",
            "8613604.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      This study evaluated the prognostic value of abnormal test results with pharmacologic stress with regard to perioperative and long-term outcomes in a large population of candidates for vascular surgery.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A systematic review of published reports on preoperative pharmacologic stress risk stratification from the MEDLINE data base (1985 to 1994) identified 10 reports on dipyridamole-thallium-201 myocardial perfusion (1,994 patients) and 5 on dobutamine stress echocardiography (446 patients). Random effects models were used to calculate summary odds ratios and 95% confidence intervals.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Summary odds ratios for death or myocardial infarction and secondary cardiac end points were greater for dobutamine echocardiographic dyssynergy (14- to 27-fold) than for dipyridamole-thallium-201 redistribution (4-fold); wider confidence intervals were noted with dobutamine echocardiography. Pretest coronary disease probability was correlated with the positive predictive value of a reversible thallium-201 defect (r=0.70), increasing sixfold from low to high risk patient subsets. Cardiac event rates were low in patients without a history of coronary artery disease (1% in 176 patients) compared with patients with coronary disease and a normal or fixed-defect pattern (4.8% in 83 patients) and one or more thallium-201 redistribution abnormality (18.6% in 97 patients, p=0.0001).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Meta-analysis of 15 studies demonstrated that the prognostic value of noninvasive stress imaging abnormalities for perioperative ischemic events is comparable between available techniques but that the accuracy varies with coronary artery disease prevalence.\n",
            "     </abstracttext>]\n",
            "15459412.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the feasibility of replacing virus culture with PCR for the diagnosis of genital herpes in settings serving large populations of genitourinary medicine (GUM) attendees.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Genital swabs collected from 233 consecutive GUM attendees with suspected genital herpes were tested in parallel by virus culture and automated real time PCR. Three specimen preparation methods were evaluated and the assay reliability was assessed by repeat testing, comparison with a commercially available assay, and herpes simplex virus (HSV) sequence analysis. Probe melting temperatures (Tm) were used to differentiate between HSV types without additional post-PCR steps.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      HSV was detected in 79/233 (34%) samples by virus culture and 132/233 (57%) samples by PCR. PCR significantly increased HSV detection in both early (&lt; 5 days) and late (&gt; or = 5 days) presentations and in both first and recurrent episodes. HSV detection and typing by PCR was achieved within less than 4 hours leading to a significant reduction in labour compared to virus culture. Most specimens (120/132, 91%) were typed as HSV-2. Results were highly reproducible.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Real time PCR is a highly reproducible, rapid, and labour efficient method for HSV detection in genital swabs. Its implementation is feasible in routine diagnostic settings.\n",
            "     </abstracttext>]\n",
            "17420682.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      The safety, efficacy, and tolerability of venlafaxine extended release (ER) in subjects ages 7 to 17 years with major depressive disorder were evaluated in two multicenter, randomized, double-blind, placebo-controlled trials conducted between October 1997 and August 2001.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Participants received venlafaxine ER (flexible dose, based on body weight; intent to treat, n = 169) or placebo (intent to treat, n = 165) for up to 8 weeks. The primary efficacy variable was the change from baseline in the Children's Depression Rating Scale-Revised score at week 8.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There were no statistically significant differences between venlafaxine ER and placebo on the Children's Depression Rating Scale-Revised in either study. A post hoc age subgroup analysis of the pooled data showed greater improvement on the Children's Depression Rating Scale-Revised with venlafaxine ER than with placebo (-24.4 versus -19.9; p = .022) among adolescents (ages 12-17), but not among children (ages 7-11). The most common adverse events were anorexia and abdominal pain. Hostility and suicide-related events were more common in venlafaxine ER-treated participants than in placebo-treated participants. There were no completed suicides.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Venlafaxine ER may be effective in depressed adolescents. However, its safety and efficacy in pediatric patients has not been established. Prescribers should monitor for signs of suicidal ideation and hostility in pediatric patients taking venlafaxine ER.\n",
            "     </abstracttext>]\n",
            "15111779.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9091013.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare two management policies: rupture of the fetal membranes when women are in normal labour or leave them intact as long as feasible.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      The labour ward of a city university hospital.\n",
            "     </abstracttext>, <abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Automated randomised clinical trial.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      1540 women in uncomplicated term labour. Data on labour duration, blood loss, oxytocin use and fetal condition were collected from 1132 women. Some data from nulliparous women has been presented earlier by the UK Amniotomy Group.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Duration of labour, Apgar score, fetal morbidity and maternal morbidity including perineal injury, mode of delivery, epidural rates and the total number of vaginal examinations in the first stage of labour after amniotomy.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Amniotomy at the next vaginal examination or amniotomy only if indicated. The median cervical dilatation at membrane rupture was 2 cm greater in the first group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A policy of routine amniotomy in labour had no measurable advantage over selective amniotomy for parous women (difference = 4 min) but shortened labour in nulliparous women by 1 h (Mann-Whitney U test: P &lt; 0.05). There was a suggestion of a higher caesarean section rate (OR 1.9; 95% CI 0.9-3.5), and there were more vaginal examinations after membrane rupture in the group allocated routine amniotomy. There were no measurable differences in oxytocin use, fetal condition at birth, retained placenta rates, blood loss, pain or analgesia requirements.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Routine amniotomy may shorten the first labour but not subsequent ones. There is a suggestion that routine surgical interference may be harmful by increasing the risk of caesarean section, and this agrees with data from other trials (common odds ratio 1.2; 95% CI 0.92-1.6).\n",
            "     </abstracttext>]\n",
            "10399422.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Experimental design: Data were collected from 2 days before until 4 days after the completion of the race. Participants: Twelve triathletes performed the triathlon and five did not. Measures: Maximal voluntary contraction (MVC), muscle soreness (DOMS) and total serum CK, CK-MB, LDH, AST and ALT activities were assessed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Significant changes after triathlon completion were found for all muscle damage indirect markers over time (p &lt; 0.0001). MVC of the knee extensor and flexor muscles decreased over time (p &lt; 0.05). There is disparity in the time point at which peak values where reached for DOMS, MVC and enzyme leakage. There is no correlation between serum enzyme leakage, DOMS and MVC impairment which occur after triathlon.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Long distance triathlon race caused muscle damage, but extent, as well as muscle recovery cannot be evaluated by the magnitude of changes in serum enzyme activities. Muscle enzyme release cannot be used to predict the magnitude of the muscle function impairment caused by muscle damage.\n",
            "     </abstracttext>]\n",
            "17682990.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A search of the Medline database (including articles published during 1966-2006) for studies of zinc and the common cold produced 105 published reports. Fourteen were randomized, placebo-controlled studies that examined the effect of zinc lozenges, nasal sprays, or nasal gels on naturally acquired common colds. Eleven features of experimental design affecting signal quality, chance, bias, and blinding were used to evaluate the 14 placebo-controlled studies. These criteria were validated case definition, quantifiable hypothesis, sample size calculation, randomized assignment, double blinding, proof of blinding, measurement of compliance, measurement of dropout rate, analysis by intent to treat, description of methods of analysis, and measurements of probability. Equal weight was given to each criterion, because failure to meet any one could potentially invalidate the findings of a clinical trial.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Four studies met all 11 criteria. Three of these studies reported no therapeutic effect from zinc lozenge or nasal spray. One study reported positive results from zinc nasal gel. Of the remaining 10 studies, 6 reported a positive effect and 4 reported no effect. Intent-to-treat analysis was the most common criterion not met.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This structured review suggests that the therapeutic effectiveness of zinc lozenges has yet to be established. One well-designed study did report a positive effect of zinc nasal gel.\n",
            "     </abstracttext>]\n",
            "8345037.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11207873.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10182646.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      This report describes ambulatory care visits made to physician offices within the United States. Statistics are presented on selected physician, patient, and visit characteristics of ambulatory care visits.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      The data presented in this report were collected from the 1996 National Ambulatory Medical Care Survey (NAMCS). The NAMCS is part of the ambulatory care component of the National Health Care Survey, which measures health care utilization across various types of providers. The NAMCS is a national probability sample survey of visits to office-based physicians in the United States. Sample data are weighted to produce annual estimates.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      During 1996, an estimated 734.5 million visits were made to physician offices in the United States, an overall rate of 2.8 visits per person. One quarter of the NAMCS visits were made to general and family physicians, which was significantly higher than the other 13 specialties. Persons 75 years and over had the highest rate of physician office visits, 6.3 visits per person. Females had a significantly higher rate of visits to physicians offices than males did overall, as did white persons compared with black persons. Of all visits made to these offices in 1996, 87 percent were covered by some form of insurance, and 8.7 percent were paid \"out-of-pocket.\" There were an estimated 87.6 million injury-related visits during 1996, or 33.1 visits per 100 persons. Three-quarters of these visits were for unintentional injuries.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "15265350.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine physicians' perceptions of hospice utilization and of their own hospice referral pattern; their perceived and actual knowledge of appropriate hospice referral diagnoses; and perceived barriers to hospice referral.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Surveys for anonymous response were distributed to 125 physicians in 2 internal medicine departments of a large not-for-profit health maintenance organization (HMO). Of these 125 physicians, 89% responded, including 91 staff physicians and 20 residents.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of the 111 physician-respondents, 78% reported their belief that hospice care was underutilized; 84% were unable to identify appropriate hospice diagnoses; and 12% were aware of the \"National Hospice Organization Medical Guidelines for Determining Prognosis in Selected Non-Cancer Diseases.\" Difficulty of predicting death to within 6 months was cited by 37% as the foremost barrier to hospice referral. In addition, 28% expressed concern that patients or families would interpret hospice referral as a cost saving measure; 11% of respondents had been accused of using hospice referral for this purpose.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our study-the first major survey of physician attitudes and practices regarding hospice utilization in an HMO setting-showed that barriers to hospice referral are similar to those in non-HMO settings; physicians have difficulty predicting life expectancy and lack knowledge of patient eligibility guidelines. Physician concern that patients or their family members would construe hospice referral as a cost-saving technique may be a barrier particularly troublesome in an HMO setting.\n",
            "     </abstracttext>]\n",
            "15788823.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      This study was undertaken to evaluate the discriminatory power of the peripheral white blood cell (WBC) count to identify bacterial infections in a cohort of febrile neonates (&lt;or=28 days of age) presenting to an emergency department.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Retrospective medical record review using descriptive statistics and a receiver operating characteristic (ROC) curve. Neonates who presented to a tertiary care paediatric emergency department between 1 January 1999 and 22 August 2002, had a temperature &gt;or=38 degrees C, underwent lumbar puncture, and had a WBC count obtained were included. They were divided according to microbiological and radiographic findings into four groups: bacterial infections, viral infections, pneumonia, and negative sepsis evaluations.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 69 febrile neonates met the inclusion criteria. The number of neonates in each group was as follows: 8 with bacterial infections, 10 with viral infections, 3 with pneumonias, and 48 with negative sepsis evaluations. There was substantial overlap in WBC counts among the groups. The area under the ROC curve was 0.7231 (95% CI 0.5665 to 0.8797).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In a cohort of febrile neonates evaluated in the emergency department, the WBC count had modest discriminatory power in identifying neonates with bacterial infections and demonstrated substantial overlap among groups. The present data suggest against the use of any WBC count threshold to identify bacterial infections in febrile neonates presenting to the emergency department.\n",
            "     </abstracttext>]\n",
            "11698781.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A systematic review of published, randomized, double-blind, placebo-controlled trials on probiotics in the treatment or prevention of acute diarrhea defined as &gt;3 loose or watery stools per 24 hours in infants and children.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The use of probiotics as compared with placebo was associated with a significantly reduced risk of diarrhea lasting &gt;3 days. The pooled estimate risk was 0.43 (95% CI, 0.34-0.53) with a fixed-effect model, and remained significant in a random-effect model (0.40; 95% CI, 0.28-0.57). Only Lactobacillus GG showed a consistent effect. Probiotics significantly reduced the duration of diarrhea when compared with placebo, particularly in rotaviral gastroenteritis-the pooled, weighted, mean difference (WMD) assuming the random-effect model was -20.1 hours (95% CI, -26.1 to -14.2) and -24.8 (95% CI, -31.8 to -17.9) respectively. A meta-analysis of the prevention studies was not feasible because of significant clinical and statistical heterogeneity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is evidence of a clinically significant benefit of probiotics in the treatment of acute infectious diarrhea in infants and children, particularly in rotaviral gastroenteritis. Lactobacillus GG showed the most consistent effect, although other probiotic strains may also be effective. Further research is needed. Clinical and statistical heterogeneity of the prophylactic interventions preclude drawing firm conclusions about the efficacy of probiotics in preventing acute gastroenteritis.\n",
            "     </abstracttext>]\n",
            "15329425.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      After inducing clinical remission with open-label fluconazole given in three 150-mg doses at 72-hour intervals, we randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluconazole (150 mg) or placebo weekly for six months, followed by six months of observation without therapy. The primary outcome measure was the proportion of women in clinical remission at the end of the first six-month period. Secondary efficacy measures were the clinical outcome at 12 months, vaginal mycologic status, and time to recurrence on the basis of Kaplan-Meier analysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Weekly treatment with fluconazole was effective in preventing symptomatic vulvovaginal candidiasis. The proportions of women who remained disease-free at 6, 9, and 12 months in the fluconazole group were 90.8 percent, 73.2 percent, and 42.9 percent, as compared with 35.9 percent, 27.8 percent, and 21.9 percent, respectively, in the placebo group (P&lt; 0.001). The median time to clinical recurrence in the fluconazole group was 10.2 months, as compared with 4.0 months in the placebo group (P&lt;0.001). There was no evidence of fluconazole resistance in isolates of Candida albicans or of superinfection with C. glabrata. Fluconazole was discontinued in one patient because of headache.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Long-term weekly treatment with fluconazole can reduce the rate of recurrence of symptomatic vulvovaginal candidiasis. However, a long-term cure remains difficult to achieve.\n",
            "     </abstracttext>]\n",
            "1565551.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "7391096.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8426621.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Men who were 45 to 84 years of age in 1977 and who had reported no life-threatening disease on questionnaires completed in 1962 or 1966 and again in 1977 were classified according to changes in lifestyle characteristics between the first and second questionnaires. We analyzed changes in their level of physical activity, cigarette smoking, blood pressure, and body weight, and the relation of these factors to mortality between 1977 and 1985.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of the 10,269 men, 476 died during this period (which totaled 90,650 man-years of observation). Beginning moderately vigorous sports activity (at an intensity of 4.5 or more metabolic equivalents) was associated with a 23 percent lower risk of death (95 percent confidence interval, 4 to 42 percent; P = 0.015) than not taking up moderately vigorous sports. Quitting cigarette smoking was associated with a 41 percent lower risk (95 percent confidence interval, 20 to 57 percent; P = 0.001) than continuing smoking, but with a 23 percent higher risk than constant nonsmoking. Men with recently diagnosed hypertension had a lower risk of death than those with long-term hypertension (relative risk, 0.75; 95 percent confidence interval, 0.55 to 1.02; P = 0.057), as did men with consistently normal blood pressure (relative risk, 0.52; 95 percent confidence interval, 0.40 to 0.68; P &lt; 0.001). Maintenance of lean body mass was associated with a lower mortality rate than long-term, recent, or previous obesity. The associations between changes in lifestyle and mortality were independent and were largely undiminished by age. Our findings on death from coronary heart disease mirrored those on death from all causes.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Beginning moderately vigorous sports activity, quitting cigarette smoking, maintaining normal blood pressure, and avoiding obesity were separately associated with lower rates of death from all causes and from coronary heart disease among middle-aged and older men.\n",
            "     </abstracttext>]\n",
            "15494989.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The aims of this review were to assess the effectiveness of advice from physicians in promoting smoking cessation; to compare minimal interventions by physicians with more intensive interventions; to assess the effectiveness of various aids to advice in promoting smoking cessation and to determine the effect of anti-smoking advice on disease-specific and all-cause mortality.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Tobacco Addiction Group trials register and the Cochrane Central Register of Controlled Trials (CENTRAL). Date of the most recent searches: March 2004.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomized trials of smoking cessation advice from a medical practitioner in which abstinence was assessed at least six months after advice was first provided.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      We extracted data in duplicate on the setting in which advice was given, type of advice given (minimal or intensive), and whether aids to advice were used, the outcome measures, method of randomization and completeness of follow up. The main outcome measures were abstinence from smoking after at least six months follow up and mortality. We used the most rigorous definition of abstinence in each trial, and biochemically validated rates where available. Subjects lost to follow up were counted as smokers. Where possible, meta-analysis was performed using a Mantel-Haenszel fixed effect model.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      We identified 39 trials, conducted between 1972 and 2003, including over 31,000 smokers. In some trials, subjects were at risk of specified diseases (chest disease, diabetes, ischaemic heart disease), but most were from unselected populations. The most common setting for delivery of advice was primary care. Other settings included hospital wards and outpatient clinics, and industrial clinics. Pooled data from 17 trials of brief advice versus no advice (or usual care) revealed a small but significant increase in the odds of quitting (odds ratio 1.74, 95% confidence interval 1.48 to 2.05). This equates to an absolute difference in the cessation rate of about 2.5%. There was insufficient evidence, from indirect comparisons, to establish a significant difference in the effectiveness of physician advice according to the intensity of the intervention, the amount of follow up provided, and whether or not various aids were used at the time of the consultation in addition to providing advice. Direct comparison of intensive versus minimal advice showed a small advantage of intensive advice (odds ratio 1.44, 95% confidence interval 1.24 to 1.67). Direct comparison also suggested a small benefit of follow-up visits. Only one study determined the effect of smoking advice on mortality. It found no statistically significant differences in death rates at 20 years follow up.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWERS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Simple advice has a small effect on cessation rates. Additional manoeuvres appear to have only a small effect, though more intensive interventions are marginally more effective than minimal interventions.\n",
            "     </abstracttext>]\n",
            "11735756.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To describe the occurrence of low bone mineral density (BMD) in postmenopausal women, its risk factors, and fracture incidence during short-term follow-up.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      The National Osteoporosis Risk Assessment, a longitudinal observational study initiated September 1997 to March 1999, with approximately 12 months of subsequent follow-up.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING AND PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      A total of 200 160 ambulatory postmenopausal women aged 50 years or older with no previous osteoporosis diagnosis, derived from 4236 primary care practices in 34 states.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Baseline BMD T scores, obtained from peripheral bone densitometry performed at the heel, finger, or forearm; risk factors for low BMD, derived from questionnaire responses; and clinical fracture rates at 12-month follow-up.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Using World Health Organization criteria, 39.6% had osteopenia (T score of -1 to -2.49) and 7.2% had osteoporosis (T score &lt;/=-2.5). Age, personal or family history of fracture, Asian or Hispanic heritage, smoking, and cortisone use were associated with significantly increased likelihood of osteoporosis; higher body mass index, African American heritage, estrogen or diuretic use, exercise, and alcohol consumption significantly decreased the likelihood. Among the 163 979 participants with follow-up information, osteoporosis was associated with a fracture rate approximately 4 times that of normal BMD (rate ratio, 4.03; 95% confidence interval [CI], 3.59-4.53) and osteopenia was associated with a 1.8-fold higher rate (95% CI, 1.49-2.18).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Almost half of this population had previously undetected low BMD, including 7% with osteoporosis. Peripheral BMD results were highly predictive of fracture risk. Given the economic and social costs of osteoporotic fractures, strategies to identify and manage osteoporosis in the primary care setting need to be established and implemented.\n",
            "     </abstracttext>]\n",
            "9596593.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the effectiveness of diets, drug treatment, and behavioural interventions on infantile colic in trials with crying or the presence of colic as the primary outcome measure.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      Controlled clinical trials identified by a highly sensitive search strategy in Medline (1966-96), Embase (1986-95), and the Cochrane Controlled Trials Register, in combination with reference checking for further relevant publications. Keywords were crying and colic.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Two independent assessors selected controlled trials with interventions lasting at least 3 days that included infants younger than 6 months who cried excessively.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Methodological quality was assessed by two assessors independently with a quality assessment scale (range 0-5). Effect sizes were calculated as percentage success. Effect sizes of trials using identical interventions were pooled using a random effects model.\n",
            "     </abstracttext>, <abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      27 controlled trials were identified. Elimination of cows' milk protein was effective when substituted by hypoallergenic formula milks (effect size 0.22 (95% confidence interval 0.09 to 0.34)). The effectiveness of substitution by soy formula milks was unclear when only trials of good methodological quality were considered. The benefit of eliminating cows' milk protein was not restricted to highly selected populations. Dicyclomine was effective (effect size 0.46 (0.33 to 0.60)), but serious side effects have been reported. The advice to reduce stimulation was beneficial (effect size 0.48 (0.23 to 0.74)), whereas the advice to increase carrying and holding seemed not to reduce crying. No benefit was shown for simethicone. Uncertainty remained about the effectiveness of low lactose formula milks.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Infantile colic should preferably be treated by advising carers to reduce stimulation and with a one week trial of a hypoallergenic formula milk.\n",
            "     </abstracttext>]\n",
            "11711507.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "16340941.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9643743.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      649 (156 HIV-1 infected 493 non-infected) women in Nairobi, Kenya, who requested and met local eligibility criteria for insertion of an IUD were enrolled. We gathered information on IUD-related complications, including pelvic inflammatory disease, removals due to infection, pain, or bleeding, expulsions, and pregnancies at 1 and 4 months after insertion. Patients' HIV-1 status was masked from physicians.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      Complications were identified in 48 of 615 women (11 [7.6%] HIV-1-infected women, 37 [7.9%] non-infected). Incident pelvic inflammatory disease (two [1.4%] HIV-1 infected, one [0.2%] non-infected) and infection-related complications (any tenderness, removal of IUD for infection or pain; ten [6.9%] HIV-1 infected, 27 [5.7%] non-infected) were also rare and similar in the two groups. Complication rates were similar by CD4 (immune) status. Multivariate analyses suggested no association between HIV-1 infection and increased risks for overall complications (odds ratio 0.8 [95% CI 0.4-1.7]) or infection-related complications (1.0 [0.5-2.3]), adjusted for marital status, study site, previous IUD use, ethnic origin, and frequency of sexual intercourse, but a slight increase cannot be ruled out.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our data suggest that IUDs may be a safe contraceptive method for appropriately selected HIV-1-infected women with continuing access to medical services.\n",
            "     </abstracttext>]\n",
            "15564985.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Baseline clinic and daytime ambulatory blood pressures were available from 5716 patients referred over a 22-year period. Individuals were considered to have WCH if they had an elevated clinic blood pressure measurement greater than 140/90 mmHg and normal daytime mean ambulatory blood pressure. Mean age was 53.6 years and 53.2% were female.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The overall prevalence of white-coat hypertension was 15.4%. A higher prevalence was seen amongst older adults, females, and non-smokers.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Multivariate logistic regression analysis confirmed these characteristics as independent predictors of WCH.\n",
            "     </abstracttext>]\n",
            "8747507.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Macrocytosis is considered to be an important sign of disease, although it often seems to be ignored. The aim of the present study was to assess the quality of the work done by general practitioners using macrocytosis as an indicator.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      All consecutive outpatients at Tampere City Health Center who had blood counts taken during 8 months in 1990 and were found to have macrocytosis (MCV &gt; or = 100 femtoliters) that had not earlier been examined, were included in this study. The further examinations undertaken were analyzed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of the 9,527 blood counts, previously unexamined macrocytosis was found in 3% (n = 287, 154 men and 133 women). Further examination because of macrocytosis was undertaken in 65 (42%) men and in 48 (36%) women. Alcohol abuse was the most common disease present in 52 (80%) men and in 22 (46%) women. No cause for macrocytosis was found in seven men and in 17 women. No difference between the examined and unexamined groups was found concerning medical history, medications, symptoms, or blood count values, including hemoglobin and MCV.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Evaluation of macrocytosis, when undertaken, was well done by general practitioners. However, it was performed too seldom and, thus, several diseases, especially alcohol abuse, may have been overlooked.\n",
            "     </abstracttext>]\n",
            "10190360.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12423708.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8345434.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "321002.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11061763.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To develop an improved model for the prediction of bacteremia in young febrile children.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A retrospective review was performed on patients 3 to 36 months of age seen in a children's hospital emergency department between December 1995 and September 1997 who had a complete blood count and blood culture ordered as part of their regular care. Exclusion criteria included current use of antibiotics or any immunodeficient state. Clinical and laboratory parameters reviewed included age, gender, race, weight, temperature, presence of focal bacterial infection, white blood cell count (WBC), polymorphonuclear cell count (PMN), band count, and absolute neutrophil count (ANC). Logistic regression analyses were used to identify factors associated with bacteremia, defined as growth of a pathogen in a blood culture. The model that was developed was then validated on a second dataset consisting of febrile patients 3 to 36 months of age collected from a second children's hospital (validation set).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There were 633 patients in the derivation set (46 bacteremic) and 9465 patients in the validation set (149 bacteremic). The mean age of patients in the derivation and validation sets were 15.8 months (95% confidence interval [CI]: 15.2-16.5) and 16.6 months (95% CI: 16.5-16.8), respectively; the mean temperatures were 39.1 degrees C (95% CI: 39. 0-39.2) and 39.8 degrees C (95% CI: 39.7-39.8); 56% were male in the derivation set and 55% male in the validation set. Predictors of bacteremia identified by logistic regression included ANC, WBC, PMN, temperature, and gender. Receiver operator characteristic (ROC) analysis showed similar performance of ANC and WBC as predictors of bacteremia. When placed into a multivariate logistic regression model, band count was not significantly associated with bacteremia. Information regarding focal infection was available for 572 patients in the derivation set. The percentage of patients diagnosed with bacteremia with a focal bacterial infection was not significantly different from the percentage who had bacteremia without a focal bacterial infection (16/200 vs 30/372). Based on this dataset, a logistic regression formula was developed that could be used to develop a unique risk value for each patient based on temperature, gender, and ANC. When the final model was applied to the validation set, the area under the ROC curve (AUC) constructed from these data indicated that the model retained good predictive value (AUC for the derivation vs validation data =.8348 vs 0.8221, respectively).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Use of the formulas derived here allows the clinician to estimate a child's risk for bacteremia based on temperature, ANC, and gender. This approach offers a useful alternative to predictions based on fever and WBC alone.bacteremia, detection, white blood cell.\n",
            "     </abstracttext>]\n",
            "15358010.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9036306.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In the main trial, patients with a left ventricular ejection fraction of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors (median dose of digoxin, 0.25 mg per day; average follow-up, 37 months). In an ancillary trial of patients with ejection fractions greater than 0.45, 492 patients were randomly assigned to digoxin and 496 to placebo.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      In the main trial, mortality was unaffected. There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was compared with placebo, 0.99; 95 percent confidence interval, 0.91 to 1.07; P=0.80). In the digoxin group, there was a trend toward a decrease in the risk of death attributed to worsening heart failure (risk ratio, 0.88; 95 percent confidence interval, 0.77 to 1.01; P=0.06). There were 6 percent fewer hospitalizations overall in that group than in the placebo group, and fewer patients were hospitalized for worsening heart failure (26.8 percent vs. 34.7 percent; risk ratio, 0.72; 95 percent confidence interval, 0.66 to 0.79; P&lt;0.001). In the ancillary trial, the findings regarding the primary combined outcome of death or hospitalization due to worsening heart failure were consistent with the results of the main trial.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure. These findings define more precisely the role of digoxin in the management of chronic heart failure.\n",
            "     </abstracttext>]\n",
            "7861574.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine the relationship between sudden infant death syndrome (SIDS) and smoking during pregnancy; postnatal tobacco smoke exposure from the mother, father, live-in-adults, and day care providers; and postnatal smoke exposure from breast-feeding.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Case-control study.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Five counties in Southern California.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      A total of 200 white, African-American, Hispanic, and Asian parents of infants who died of SIDS between 1989 and 1992 were compared with 200 control parents who delivered healthy infants. Case infants were matched to control infants on the basis of birth hospital, birth date, gender, and race. All information was obtained from a detailed telephone interview and validated with medical records.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Risk of SIDS associated with passive smoking by the mother, father, live-in adults, and day care providers; smoking in the same room as the infant; total number of cigarettes smoked by all adults; and maternal smoking during the time period of breast-feeding.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Conditional logistic regression resulted in overall adjusted odds ratios (ORs) for SIDS associated with passive smoke from the mother of 2.28, the father of 3.46, other live-in adults of 2.18, and all sources of 3.50 (95% confidence interval, 1.81 to 6.75), while simultaneously adjusting for birth weight, sleep position, prenatal care, medical conditions at birth, breast-feeding, and maternal smoking during pregnancy. A dose-response effect was noted for SIDS associated with increasing numbers of cigarettes, as well as total number of smokers. Breast-feeding was protective for SIDS among nonsmokers (OR = 0.37) but not smokers (OR = 1.38), when adjusting for potential confounders.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Passive smoking in the same room as the infant increases the risk for SIDS. Physicians should educate new and prospective parents about the risk of tobacco smoke exposure during pregnancy and the first year of the infant's life.\n",
            "     </abstracttext>]\n",
            "16098855.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11466188.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To develop an evidence and consensus based guideline for the management of the child who presents to hospital with diarrhoea (with or without vomiting), a common problem representing 16% of all paediatric medical attenders at an accident and emergency department. Clinical assessment, investigations (biochemistry and stool culture in particular), admission, and treatment are addressed. The guideline aims to aid junior doctors in recognising children who need admission for observation and treatment and those who may safely go home.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"EVIDENCE\" nlmcategory=\"METHODS\">\n",
            "      A systematic review of the literature was performed. Selected articles were appraised, graded, and synthesised qualitatively. Statements on recommendation were generated. CONSENSUS: An anonymous, postal Delphi consensus process was used. A panel of 39 selected medical and nursing staff were asked to grade their agreement with the generated statements. They were sent the papers, appraisals, and literature review. On the second and third rounds they were asked to re-grade their agreement in the light of other panelists' responses. Consensus was predefined as 83% of panelists agreeing with the statement.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"VALIDATION\" nlmcategory=\"RESULTS\">\n",
            "      The guideline has been successfully implemented and evaluated in a paediatric accident and emergency department.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RECOMMENDATIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Clinical signs useful in assessment of level of dehydration were agreed. Admission to a paediatric facility is advised for children who show signs of dehydration. For those with mild to moderate dehydration, estimated deficit is replaced over four hours with oral rehydration solution (glucose based, 200-250 mOsm/l) given \"little and often\". A nasogastric tube should be used if fluid is refused and normal feeds started following rehydration. Children at high risk of dehydration should be observed to ensure at least maintenance fluid is tolerated. Management of more severe dehydration is detailed. Antidiarrhoeal medication is not indicated.\n",
            "     </abstracttext>]\n",
            "15994719.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      There is a major unmet need for effective options in the treatment of bipolar depression.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Five hundred forty-two outpatients with bipolar I (N=360) or II (N=182) disorder experiencing a major depressive episode (DSM-IV) were randomly assigned to 8 weeks of quetiapine (600 or 300 mg/day) or placebo. The primary efficacy measure was mean change from baseline to week 8 in the Montgomery-Asberg Depression Rating Scale total score. Additional efficacy assessments included the Hamilton Depression Rating Scale, Clinical Global Impression of severity and improvement, Hamilton Anxiety Rating Scale, Pittsburgh Sleep Quality Index, and Quality of Life Enjoyment and Satisfaction Questionnaire.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Quetiapine at either dose demonstrated statistically significant improvement in Montgomery-Asberg Depression Rating Scale total scores compared with placebo from week 1 onward. The proportions of patients meeting response criteria (&gt; or =50% Montgomery-Asberg Depression Rating Scale score improvement) at the final assessment in the groups taking 600 and 300 mg/day of quetiapine were 58.2% and 57.6%, respectively, versus 36.1% for placebo. The proportions of patients meeting remission criteria (Montgomery-Asberg Depression Rating Scale &lt; or =12) were 52.9% in the groups taking 600 and 300 mg/day of quetiapine versus 28.4% for placebo. Quetiapine at 600 and 300 mg/day significantly improved 9 of 10 and 8 of 10 Montgomery-Asberg Depression Rating Scale items, respectively, compared to placebo, including the core symptoms of depression. Treatment-emergent mania rates were low and similar for the quetiapine and placebo groups (3.2% and 3.9%, respectively).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Quetiapine monotherapy is efficacious and well tolerated for the treatment of bipolar depression.\n",
            "     </abstracttext>]\n",
            "1337553.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "16286171.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      This study sought to determine whether statins reduce coronary heart disease (CHD) risk more than other interventions that also primarily lower low-density lipoprotein cholesterol (LDL-C).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Trials published in English language journals were retrieved by searching Medline (1966 to October 2004), bibliographies, and the author's reference files. Randomized, placebo-controlled trials of interventions to primarily lower LDL-C of three or more years' duration in which clinical disease or death were primary outcomes were used. Information on sample size, treatment type and duration, participant characteristics at baseline, reduction in lipids, and outcome was independently abstracted by two authors (J.R. and N.M.) using a standardized protocol. Data from 5 diet, 3 bile acid sequestrant, 1 surgery, and 10 statin trials, with 81,859 participants, were included in the CHD meta-regression analysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The regression lines for non-statin and statin trials were similar and consistent with a one-to-one relationship between LDL-C lowering and CHD and stroke reduction over five years of treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The pleiotropic effects of statins do not seem to contribute an additional cardiovascular risk reduction benefit beyond that expected from the degree of LDL-C lowering observed in other trials that primarily lowered LDL-C.\n",
            "     </abstracttext>]\n",
            "8535469.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12490470.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      A report in the orthopedics literature states that MR imaging for internal derangement of the knee has a lower accuracy in adolescents than in adults and may even provide spurious information that alters clinical management. This assertion has not been specifically addressed in the radiology literature. The purpose of our study was to determine the accuracy of MR imaging in adolescents with regard to injury of the cruciate ligaments and menisci.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MATERIALS AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      A database search of our institution's records from January 1998 to July 2000 yielded 2140 MR examinations of the knee, all of which had been performed with a standard knee protocol on a 1.5-T magnet. Of these 2140 examinations, 156 included patients younger than 18 years. Fifty-nine of these patients underwent surgery, and the orthopedic surgeons' operative reports were used as the gold standard with which the MR imaging results were compared. Thirty-four boys and 25 girls who ranged in age from 11 to 17 years (mean age, 15 years) were examined. The clinical notes for the remaining 97 patients were evaluated for information about management and clinical improvement.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The sensitivity and specificity values for MR imaging of the menisci and cruciate ligaments in adolescents were as follows: medial meniscus, 92% sensitivity and 87% specificity; lateral meniscus, 93% sensitivity and 95% specificity; anterior cruciate ligament, 100% sensitivity and 100% specificity; and posterior cruciate ligament, 0% sensitivity and 100% specificity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our data suggest that MR imaging of the knee in adolescents is sensitive, specific, and accurate.\n",
            "     </abstracttext>]\n",
            "12457784.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We did a randomised controlled trial in which we assigned 5804 men (n=2804) and women (n=3000) aged 70-82 years with a history of, or risk factors for, vascular disease to pravastatin (40 mg per day; n=2891) or placebo (n=2913). Baseline cholesterol concentrations ranged from 4.0 mmol/L to 9.0 mmol/L. Follow-up was 3.2 years on average and our primary endpoint was a composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Analysis was by intention-to-treat.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      Pravastatin lowered LDL cholesterol concentrations by 34% and reduced the incidence of the primary endpoint to 408 events compared with 473 on placebo (hazard ratio 0.85, 95% CI 0.74-0.97, p=0.014). Coronary heart disease death and non-fatal myocardial infarction risk was also reduced (0.81, 0.69-0.94, p=0.006). Stroke risk was unaffected (1.03, 0.81-1.31, p=0.8), but the hazard ratio for transient ischaemic attack was 0.75 (0.55-1.00, p=0.051). New cancer diagnoses were more frequent on pravastatin than on placebo (1.25, 1.04-1.51, p=0.020). However, incorporation of this finding in a meta-analysis of all pravastatin and all statin trials showed no overall increase in risk. Mortality from coronary disease fell by 24% (p=0.043) in the pravastatin group. Pravastatin had no significant effect on cognitive function or disability.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals. PROSPER therefore extends to elderly individuals the treatment strategy currently used in middle aged people.\n",
            "     </abstracttext>]\n",
            "2656959.xml\n",
            "\n",
            "[<abstracttext label=\"STUDY OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether acetaminophen affects the duration or severity of childhood varicella.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Randomized, double-blind, placebo-controlled trial.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Office- and hospital-based pediatric practices.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Seventy-two children between 1 and 12 years of age entered the study. One child was withdrawn because of high fever, and three children did not complete the study; 31 received placebo and 37 received acetaminophen.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Acetaminophen, 10 mg/kg/dose, was given at 8 AM, 12 PM, 4 PM, and 8 PM for 4 days. Placebo was given to the control group. Itching, appetite, activity, and overall condition were measured for 6 days. The time to last vesicle formation, time to total scabbing, and time to total healing were measured until complete resolution of the exanthem.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MEASUREMENTS AND MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The following results were better in the placebo group (p less than .05): time to total scabbing 5.6 days (SD 2.5) versus 6.7 days (SD 2.3) in the acetaminophen group, and itching on day 4 in the placebo group (symptom score 2.9 (SD 0.20) vs 2.2 (SD 0.26]. Activity was better in the acetaminophen group on day 2 (3.13 (SD 0.23) vs 2.82 (SD 0.24].\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      These results provide evidence that acetaminophen does not alleviate symptoms in children with varicella and may prolong illness.\n",
            "     </abstracttext>]\n",
            "7633770.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "16437473.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effectiveness and safety of herbal medicines in patients with irritable bowel syndrome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the following electronic databases till July 2004: The Cochrane Library (CENTRAL), MEDLINE, EMBASE, AMED, LILACS, the Chinese Biomedical Database, combined with hand searches of Chinese journals and conference proceedings till end of 2003. No language restriction was used.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised controlled trials of herbal medicines compared with no treatment, placebo, pharmacological interventions were included.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Data were extracted independently by two authors. The methodological quality of trials was evaluated using the components of randomisation, allocation concealment, double blinding, and inclusion of randomised participants.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Seventy-five randomised trials, involving 7957 participants with irritable bowel syndrome, met the inclusion criteria. The methodological quality of three double-blind, placebo-controlled trials was high, but the quality of remaining trials was generally low. Seventy-one different herbal medicines were tested in the included trials, in which herbal medicines were compared with placebo or conventional pharmacologic therapy. Herbal medicines were also combined with conventional therapy and compared to conventional therapy alone.Compared with placebo, a Standard Chinese herbal formula, individualised Chinese herbal medicine, STW 5 and STW 5-II, Tibetan herbal medicine Padma Lax, traditional Chinese formula Tongxie Yaofang, and Ayurvedic preparation showed significantly improvement of global symptoms. Compared with conventional therapy in 65 trials testing 51 different herbal medicines, 22 herbal medicines demonstrated a statistically significant benefit for symptom improvement, and 29 herbal medicines were not significantly different than conventional therapy. In nine trials that evaluated herbal medicine combined with conventional therapy, six tested herbal preparations showed additional benefit from the combination therapy compared with conventional monotherapy. No serious adverse events from the herbal medicines were reported.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Some herbal medicines may improve the symptoms of irritable bowel syndrome. However, positive findings from less rigorous trials should be interpreted with caution due to inadequate methodology, small sample sizes, and lack of confirming data. Some herbal medicines deserve further examination in high-quality trials.\n",
            "     </abstracttext>]\n",
            "15046273.xml\n",
            "\n",
            "[<abstracttext label=\"AIM\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the long-term results after conservative treatment (physiotherapy, casting, orthoses, or a combination of these) of idiopathic toe-walking (ITW).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Tiptoe-walking is diagnosed as idiopathic (habitual) if no signs of neurological, orthopaedic, or psychiatric disease are detected. The diagnosis is one of exclusion. Sixteen former patients with ITW, all now at least 13 y old, were asked to participate in a follow-up investigation 7-21 y after being first diagnosed. Two cases were excluded because heel-cord lengthening had been performed later on in other hospitals. The remaining 14 patients completed a questionnaire. Eleven patients consented to a clinical examination, during which they were videotaped and their active and passive ankle-joint dorsiflexion measured. These data were compared with the assessment at the initial evaluation. In one instance, the toe-walking ceased after conservative treatment (plaster cast). In all other cases the toe-walking pattern recurred.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      At follow-up three patients showed some toe-walking when they were unobtrusively observed. When videotaped, they did not toe-walk, although a distinct heel-strike was missing. The remaining eight patients all walked with a heel-strike. Two patients had slight symptoms possibly related to toe-walking. No fixed contracture was present at the first evaluation, and none was found at follow-up. There was no systematic change in ankle-joint dorsiflexion from initial assessment to follow-up examination.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Non-surgical treatment of ITW does not have a lasting effect and the long-term results in this study are considered to reflect the natural history, i.e. the toe-walking pattern eventually resolves spontaneously in the majority of children. Surgical treatment of ITW should be reserved for the few cases with a fixed ankle-joint contracture.\n",
            "     </abstracttext>]\n",
            "12873166.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10714731.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To test whether women who lose bone mineral density (BMD) during the first year of treatment for osteoporosis continue to lose BMD if the same treatment is continued beyond 1 year.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN AND SETTING\" nlmcategory=\"METHODS\">\n",
            "      Two randomized, double-blind, placebo-controlled trials in 11 US clinical research centers for the Fracture Intervention Trial and 180 centers in the United States and other countries for the Multiple Outcomes of Raloxifene Evaluation Trial.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS AND INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Postmenopausal women with low BMD assigned to treatment with 5 mg/d of alendronate sodium in the Fracture intervention Trial who completed 2 years of BMD monitoring and adhered to study medication (n = 2634), and postmenopausal women with osteoporosis assigned to treatment with 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial who similarly completed 2 years of monitoring while adhering to study medication (n = 3954).\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Baseline, 12-, and 24-month hip and spine BMD.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Women with the greatest loss of BMD during the first year of treatment were the most likely to gain BMD during continued treatment. Specifically, among women taking alendronate whose hip BMD decreased by more than 4% during the first year, 83% (95% confidence interval [CI], 82%-84%)had increases in hip BMD during the second year, with an overall mean increase of 4.7%. In contrast, those who seemed to gain at least 8% during the first year lost an average of 1% (95% CI, 0.1%-1.9%) during the next year. Similar results were observed among women taking raloxifene for 2 years.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our data suggest that most women who lose BMD during the first year of treatment with alendronate or raloxifene will gain BMD if the same treatment is continued for a second year. These results illustrate the principle of regression to the mean and suggest that effective treatments for osteoporosis should not be changed because of loss of BMD during the first year of use.\n",
            "     </abstracttext>]\n",
            "2194334.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11702618.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "3545282.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12180738.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether land based therapeutic exercise is beneficial for people with osteoarthritis (OA) of the hip or knee in terms of reduced joint pain, improved physical function, and/or the patient's global assessment of therapeutic effectiveness.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Five databases were searched for randomized clinical trials. Standardized mean differences (SMD) with their 95% confidence intervals (CI) were calculated for each study and then combined using a fixed effects model.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Only 2 studies, totaling about 100 participants, could potentially provide data on people with hip OA. Fourteen studies provided data on 1633 participants with knee OA. Nine of these studies were considered of high methodological quality. For pain, combining the results revealed a mean moderate beneficial effect (SMD 0.46, 95% Cl 0.35, 0.57), while for self-reported physical function a mean small beneficial effect (SMD 0.33, 95% CI 0.23, 0.43) was found. These results appeared to be sensitive to blinding of outcome assessor and choice of control group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Land based therapeutic exercise was shown to reduce pain and improve physical function for people with OA of the knee.\n",
            "     </abstracttext>]\n",
            "8445608.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12748199.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11443569.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10931404.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To analyze the characteristics of infants and children diagnosed with nutritional rickets at two medical centers in North Carolina in the 1990s.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      The physical and radiographic findings, calcium, phosphorus, alkaline phosphatase, and 25-hydroxyvitamin D levels of infants and children diagnosed with nutritional rickets at two medical centers were reviewed. Breast-feeding data were obtained from the North Carolina Women, Infants and Children Program (WIC).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Thirty patients with nutritional rickets were first seen between 1990 and June of 1999. Over half of the cases occurred in 1998 and the first half of 1999. All patients were African American children who were breast fed without receiving supplemental vitamin D. The average duration of breast-feeding was 12.5 months. The age at diagnosis was 5 to 25 months, with a median age of 15.5 months. Growth failure was common: length was &lt;5th percentile in 65% of cases, and weight was &lt;5th percentile in 43%.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Factors that may have contributed to the increase in referrals of children with nutritional rickets include more African American women breast-feeding, fewer infants receiving vitamin D supplements, and mothers and children exposed to less sunlight. We recommend that all dark-skinned breast-fed infants and children receive vitamin D supplementation.\n",
            "     </abstracttext>]\n",
            "17636776.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the efficacy and adverse outcomes, including definitive suicidal behaviour and suicidal ideation, of SSRIs compared to placebo in the treatment of depressive disorders in children and adolescents.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the CCDAN Trials Register, MEDLINE, PSYCHINFO and CENTRAL. Reference lists were checked, letters were sent to key researchers and internet databases searched.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      We included published and unpublished randomised controlled trials.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two or three review authors selected the trials, assessed the quality and extracted trial and outcome data. We used a fixed-effect meta-analysis. The relative risk was used to summarise dichotomous outcomes and the mean difference to summarise continuous measures.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Twelve trials were eligible for inclusion, with ten providing usable data. At 8-12 weeks, there was evidence that children and adolescents 'responded' to treatment with SSRIs (RR 1.28, 95% CI 1.17 to 1.41). There was also evidence of an increased risk of suicidal ideation and behaviour for those prescribed SSRIs (RR 1.80, 95% CI 1.19 to 2.72). Fluoxetine was the only SSRI where there was consistent evidence from three trials that it was effective in reducing depression symptoms in both children and adolescents (CDRS-R treatment effect -5.63, 95% CI -7.38 to -3.88), and 'response' to treatment (RR 1.86, 95% CI 1.49 to 2.32). Where rates of adverse events were reported, this was higher for those prescribed SSRIs.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Caution is required to interpret the results. First, there were methodological issues, including high attrition, issues regarding measurement instruments and clinical usefulness of outcomes, often variously defined across trials. Second, patients seen in clinical practice are likely to be more unwell, and at greater risk of suicide, compared to those in the trials, and it is unclear how this group would respond to SSRIs. This needs to be considered, along with the evidence of an increased risk of suicide related outcomes in those treated with SSRIs. It is unclear what the effect of SSRIs is on suicide completion. While untreated depression is associated with the risk of completed suicide and impacts on functioning, it is unclear whether SSRIs would modify this risk in a clinically meaningful way.\n",
            "     </abstracttext>]\n",
            "12707429.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      The authors conducted a multicenter, parallel-group, double-blind, placebo-controlled, 8-week, randomized clinical trial in PHN, defined as pain for 3 or more months following herpes zoster rash healing. Patients (n = 173) were randomized to treatment with pregabalin or placebo. Patients randomized to pregabalin received either 600 mg/day (creatinine clearance &gt; 60 mL/min) or 300 mg/day (creatinine clearance 30 to 60 mL/min). The primary efficacy measure was the mean of the last seven daily pain ratings. Secondary endpoints included additional pain ratings, sleep interference, quality of life, mood, and patient and clinician ratings of global improvement.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Pregabalin-treated patients had greater decreases in pain than patients treated with placebo (endpoint mean scores 3.60 vs 5.29, p = 0.0001). Pain was significantly reduced in the pregabalin-treated patients after the first full day of treatment and throughout the study, and significant improvement on the McGill Pain Questionnaire total, sensory, and affective pain scores was also found. The proportions of patients with &gt;or=30% and &gt;or=50% decreases in mean pain scores were greater in the pregabalin than in the placebo group (63% vs 25% and 50% vs 20%, p = 0.001). Sleep also improved in patients treated with pregabalin compared to placebo (p = 0.0001). Both patients and clinicians were more likely to report global improvement with pregabalin than placebo (p = 0.001). Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Treatment of PHN with pregabalin is safe, efficacious in relieving pain and sleep interference, and associated with greater global improvement than treatment with placebo.\n",
            "     </abstracttext>]\n",
            "12449547.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To review recent evidence on dietary factors associated with diverticular disease (DD) with special emphasis on dietary fibre.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"QUALITY OF EVIDENCE\" nlmcategory=\"METHODS\">\n",
            "      MEDLINE was searched from January 1966 to December 2001 for articles on the relationship between dietary and other lifestyle factors and DD. Most articles either focused on dietary intervention in treating symptomatic DD or were case-control studies with inherent limitations for studying diet-disease associations. Only one large prospective study of male health professionals in the United States assessed diet at baseline and before initial diagnosis of DD.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN MESSAGE\" nlmcategory=\"RESULTS\">\n",
            "      A diet high in fibre mainly from fruits and vegetables and low in total fat and red meat decreases risk of DD. Evidence indicates that the insoluble component of fibre is strongly associated with lower risk of DD; this association was particularly strong for cellulose. Caffeine and alcohol do not substantially increase risk of DD, nor does obesity, but higher levels of physical activity seem to reduce risk of DD.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A diet high in fibre and low in total fat and red meat and a lifestyle with more physical activity might help prevent DD.\n",
            "     </abstracttext>]\n",
            "15795718.xml\n",
            "\n",
            "[<abstracttext label=\"STUDY OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Many therapies are used in the treatment of acute migraine headache, with little agreement on effectiveness. This systematic review is designed to determine the effectiveness of parenteral dihydroergotamine in reducing pain, nausea, and relapse for episodes of acute migraine in adults.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Randomized controlled trials were identified using MEDLINE, EMBASE, other computerized databases, hand searching, bibliographies, and contacts with industry and authors. Studies in which dihydroergotamine (alone or in combination with an antiemetic) was compared with placebo or any other common migraine therapy were considered. Relevance, inclusion, and study quality were assessed independently by 2 reviewers.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      From 281 potentially relevant abstracts, 11 studies met the inclusion criteria. Solitary dihydroergotamine use was compared to sumatriptan and phenothiazines in 3 studies; results failed to demonstrate a significant benefit of dihydroergotamine over these therapies. In 8 combination treatment studies, heterogeneity in study methodology prevented statistical pooling. However, dihydroergotamine administered with an antiemetic was as effective as or more effective than meperidine, valproate, or ketorolac across all pain, nausea, and relapse outcomes reported in all studies.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This evidence suggests that dihydroergotamine is not as effective as sumatriptan or phenothiazines as a single agent for treatment of acute migraine headache; however, when administered with an antiemetic, dihydroergotamine appears to be as effective as opiates, ketorolac, or valproate. Given its nonnarcotic properties, parenteral dihydroergotamine combined with an antiemetic should be considered as effective initial therapy in clinical practice.\n",
            "     </abstracttext>]\n",
            "16048355.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14973951.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of this review was to assess the effects of antibiotics for children with acute otitis media.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE, Index Medicus (pre 1965), Current Contents and reference lists of articles from 1958 to January 2000. The search was updated in 2003.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised trials comparing antimicrobial drugs with placebo in children with acute otitis media.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Three reviewers independently assessed trial quality and extracted data.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Ten trials were eligible based on design, only eight of the trials, with a total of 2,287 children, included patient-relevant outcomes. The methodological quality of the included trials was generally high. All trials were from developed countries. The trials showed no reduction in pain at 24 hours, but a 30% relative reduction (95% confidence interval 19% to 40%) in pain at two to seven days. Since approximately 80% of patients will have settled spontaneously in this time, this means an absolute reduction of 7% or that about 15 children must be treated with antibiotics to prevent one child having some pain after two days. There was no effect of antibiotics on hearing problems of acute otitis media, as measured by subsequent tympanometry. However, audiometry was done in only two studies and incompletely reported. Nor did antibiotics influence other complications or recurrence. There were few serious complications seen in these trials: only one case of mastoiditis occurred in a penicillin treated group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Antibiotics provide a small benefit for acute otitis media in children. As most cases will resolve spontaneously, this benefit must be weighed against the possible adverse reactions. Antibiotic treatment may play an important role in reducing the risk of mastoiditis in populations where it is more common.\n",
            "     </abstracttext>]\n",
            "7657281.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12571845.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the safety and efficacy of long-term intraarticular (IA) steroid injections for knee pain related to osteoarthritis (OA).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In a randomized, double-blind trial, 68 patients with OA of the knee received IA injections of triamcinolone acetonide 40 mg (34 patients) or saline (34 patients) into the study knee every 3 months for up to 2 years. The primary outcome variable was radiologic progression of joint space narrowing of the injected knee after 2 years. Measurements of minimum joint space width were performed by an automated computerized method on standardized fluoroscopically guided radiographs taken with the patient standing and with the knee in a semiflexed position. The clinical efficacy measure of primary interest was the pain subscale from the Western Ontario and McMaster Universities OA Index (WOMAC). Efficacy measures of secondary interest were the total score on the WOMAC, physician's global assessment, patient's global assessment, patient's assessment of pain, range of motion (ROM) of the affected knee, and 50-foot walking time. Clinical symptoms were assessed just before each injection.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      At the 1-year and 2-year followup evaluations, no difference was noted between the two treatment groups with respect to loss of joint space over time. The steroid-injected knees showed a trend toward greater symptom improvement, especially at 1 year, for the WOMAC pain subscale, night pain, and ROM values (P = 0.05) compared with the saline-injected knees. Using area under the curve analyses, knee pain and stiffness were significantly improved throughout the 2-year study by repeated injections of triamcinolone acetonide, but not saline (P &lt; 0.05).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Our findings support the long-term safety of IA steroid injections for patients with symptomatic knee OA. No deleterious effects of the long-term administration of IA steroids on the anatomical structure of the knee were noted. Moreover, long-term treatment of knee OA with repeated steroid injections appears to be clinically effective for the relief of symptoms of the disease.\n",
            "     </abstracttext>]\n",
            "8235922.xml\n",
            "\n",
            "[<abstracttext label=\"BACKGROUND AND OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The epidemiology and etiology of bacterial vaginosis is poorly understood. Many antimicrobial agents have been studied and suggested as treatment alternatives for this infection. Fluoroquinolones have in vitro activity against some of the organisms associated with bacterial vaginosis and may provide another treatment option.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Women who presented with symptomatic bacterial vaginosis were randomly assigned to receive either oral ofloxacin 300 mg twice a day or oral metronidazole 500 mg twice a day for seven days. Twenty-seven of the 31 patients who were enrolled in this double-blinded study were evaluable.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Fourteen women received ofloxacin. At follow-up, four had no residual symptoms, seven noted a reduction in symptoms, and three had no change in symptoms. Eight (57%) of the 14 women who received ofloxacin had secretions at follow-up that satisfied the criteria for the diagnosis of bacterial vaginosis. Thirteen women received metronidazole. Nine had no residual symptoms and four noted a reduction in symptoms. Eleven (85%) of the 13 women had normal vaginal secretions and two (15%) had secretions that were improved. None of the women who received metronidazole had secretions at follow-up that met the criteria for the diagnosis of bacterial vaginosis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      We conclude that ofloxacin is less effective than metronidazole in the treatment of bacterial vaginosis.\n",
            "     </abstracttext>]\n",
            "16856045.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the efficacy and safety of steroid therapy for symptom control in glandular fever.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2005); MEDLINE (January 1966 to November 2005); EMBASE (January 1974 to November 2005); and the UK National Research Register (November 2005).\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised controlled trials (RCTs) that compared the effectiveness for symptom control of a steroid to placebo or to another intervention for people of any age with documented glandular fever were included.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Authors independently assessed trial inclusion according to predetermined criteria. Results are presented separately for each symptom and, where possible, it was intended to combine results in a meta-analysis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Seven trials were included. The diagnosis, steroid regime, outcomes and methodological quality varied between trials. The sample size ranged from 24 to 94. For sore throat the results of two studies suggest a benefit at 12 hours of steroid therapy over placebo; however this benefit was not maintained. The evidence from one trial suggests a longer benefit when the steroid is combined with an antiviral drug. There was evidence from one trial that steroids may improve resolution of fatigue around four weeks; however it is unclear if this is only in combination with an antiviral. Two trials reported severe complications in participants in the steroid group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is insufficient evidence - the trials were few, heterogeneous and some were of poor quality, to recommend steroid treatment for symptom control in glandular fever. There is also a lack of research on the side effects, potential adverse effects or complications, particularly in the long term.\n",
            "     </abstracttext>]\n",
            "11306234.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether screening and treating pregnant women for BV reduces adverse pregnancy outcomes, as part of an assessment for the U.S. Preventive Services Task Force.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      Randomized clinical trials of BV treatment in pregnancy that measured pregnancy outcomes were identified from multiple searches in MEDLINE from 1966 to 1999, the Cochrane Controlled Trials Register and Library, and national experts.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      All randomized controlled trials of BV treatment in pregnancy that specifically measured pregnancy outcomes.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      The following information was abstracted: study design and blinding, diagnostic methods, antibiotic interventions, timing of antibiotic treatment in pregnancy, criteria for treatment, comorbidities, demographic details, risk factors for preterm delivery such as previous preterm delivery, compliance, rates of spontaneous and total preterm delivery less than 37 weeks and less than 34 weeks, preterm premature rupture of membranes, low birth weight less than 2500 grams, spontaneous abortion, postpartum endometritis, and neonatal sepsis. For each study, we measured the effect of treatment by calculating the difference in the rate of a given pregnancy outcome in the control group minus the treatment group (the absolute risk reduction [ARR]). A stepwise procedure based on the profile likelihood was applied to assess heterogeneity, to pool studies when appropriate, and to calculate the mean and 90% confidence intervals (CIs) for the effect of treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Seven randomized controlled trials met inclusion criteria for the meta-analysis. We found no benefit to BV treatment in average-risk women for any pregnancy outcome. Results of studies of high-risk populations, women with previous preterm delivery, were statistically heterogeneous. They clustered into two groups; one showed no benefit (ARR=-0.08, 90% CI=-0.19 to 0.04), whereas the three homogeneous studies showed potential benefit of BV treatment (pooled ARR=0.22; 90% CI=0.13 to 0.31) for preterm delivery before 37 weeks. Four high-risk studies reported results for preterm delivery less than 34 weeks. The pooled estimate showed no benefit (ARR=0.04; 90% CI=-0.02 to 0.09), but variation was noted among individual studies. Two trials of high-risk women found an increase in preterm delivery less than 34 weeks in women who did not have BV but received BV treatment. Comparisons of patient populations, treatment regimens, and study designs did not explain the heterogeneity among studies.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      We found no benefit to routine BV screening and treatment. A subgroup of high-risk women may benefit from BV screening and treatment; however, there may be a subgroup for whom BV treatment could increase the occurrence of preterm delivery.\n",
            "     </abstracttext>]\n",
            "10496256.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the frequency and identify risk factors of unruptured aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage (SAH).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Magnetic resonance angiography (MRA) was performed in 626 first-degree relatives of a consecutive series of 193 index patients with \"sporadic\" SAH (participation rate, 78% of eligible relatives). The authors recorded demographic and medical data, and performed blood pressure measurements and blood tests (cholesterol, high-density lipid cholesterol, triglycerides, apoprotein A1, lipoprotein a, glucose).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Aneurysms were found in 25 of 626 relatives (4.0%; 95% CI, 2.6 to 5.8%), and 6 relatives had multiple aneurysms. Index patients with multiple aneurysms and a younger age had a higher risk of aneurysms in relatives. Siblings of index patients had a four times higher risk than children. In screened relatives female sex, increasing age, polycystic kidney disease, hypertension, and elevated levels of cholesterol and glucose tended to be associated with a higher risk of aneurysms. No increase in risk was conferred by smoking or alcohol use, or by a previous family history of SAH or of atherosclerosis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      First-degree relatives of index patients with sporadic subarachnoid hemorrhage have a 4.0% chance of intracranial aneurysms. Being a sibling of the index patient is the most important risk factor. Risk factors for general atherosclerosis (hypertension, smoking, hypercholesterolemia, high levels of blood triglycerides, lipoprotein a, and apoprotein A1) and use of alcohol do not increase the risk of intracranial aneurysms significantly in these relatives.\n",
            "     </abstracttext>]\n",
            "10732937.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate benefit of glucosamine and chondroitin preparations for OA symptoms using meta-analysis combined with systematic quality assessment of clinical trials of these preparations in knee and/or hip OA.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      We searched for human clinical trials in MEDLINE (1966 to June 1999) and the Cochrane Controlled Trials Register using the terms osteoarthritis, osteoarthrosis, degenerative arthritis, glucosamine, chondroitin, and glycosaminoglycans. We also manually searched review articles, manuscripts, and supplements from rheumatology and OA journals and sought unpublished data by contacting content experts, study authors, and manufacturers of glucosamine or chondroitin.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Studies were included if they were published or unpublished double-blind, randomized, placebo-controlled trials of 4 or more weeks' duration that tested glucosamine or chondroitin for knee or hip OA and reported extractable data on the effect of treatment on symptoms. Fifteen of 37 studies were included in the analysis.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Reviewers performed data extraction and scored each trial using a quality assessment instrument. We computed an effect size from the intergroup difference in mean outcome values at trial end, divided by the SD of the outcome value in the placebo group (0.2, small effect; 0.5, moderate; 0.8, large), and applied a correction factor to reduce bias. We tested for trial heterogeneity and publication bias and stratified for trial quality and size. We pooled effect sizes using a random effects model.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Quality scores ranged from 12.3% to 55.4% of the maximum, with a mean (SD) of 35.5% (12%). Only 1 study described adequate allocation concealment and 2 reported an intent-to-treat analysis. Most were supported or performed by a manufacturer. Funnel plots showed significant asymmetry (P&lt; or =.01) compatible with publication bias. Tests for heterogeneity were nonsignificant after removing 1 outlier trial. The aggregated effect sizes were 0.44 (95% confidence interval [CI], 0.24-0.64) for glucosamine and 0.78 (95% CI, 0.60-0.95) for chondroitin, but they were diminished when only high-quality or large trials were considered. The effect sizes were relatively consistent for pain and functional outcomes.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Trials of glucosamine and chondroitin preparations for OA symptoms demonstrate moderate to large effects, but quality issues and likely publication bias suggest that these effects are exaggerated. Nevertheless, some degree of efficacy appears probable for these preparations.\n",
            "     </abstracttext>]\n",
            "15016485.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      3280 adults with cerebrovascular disease, and an additional 17256 with other occlusive arterial disease or diabetes, were randomly allocated 40 mg simvastatin daily or matching placebo. Subgroup analyses were prespecified of first \"major vascular event\" (ie, non-fatal myocardial infarction or coronary death, stroke of any type, or any revascularisation procedure) in prior disease subcategories. Subsidiary outcomes included any stroke, and stroke sub-type. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie, \"intention-to-treat\"), which yielded an average difference in LDL cholesterol of 1.0 mmol/L (39 mg/dL) during the 5-year treatment period.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      Overall, there was a highly significant 25% (95% CI 15-34) proportional reduction in the first event rate for stroke (444 [4.3%] simvastatin vs 585 [5.7%] placebo; p&lt;0.0001), reflecting a definite 28% (19-37) reduction in presumed ischaemic strokes (p&lt;0.0001) and no apparent difference in strokes attributed to haemorrhage (51 [0.5%] vs 53 [0.5%]; rate ratio 0.95 [0.65-1.40]; p=0.8). In addition, simvastatin reduced the numbers having transient cerebral ischaemic attacks alone (2.0% vs 2.4%; p=0.02) or requiring carotid endarterectomy or angioplasty (0.4% vs 0.8%; p=0.0003). The reduction in stroke was not significant during the first year, but was already significant (p=0.0004) by the end of the second year. Among patients with pre-existing cerebrovascular disease there was no apparent reduction in the stroke rate, but there was a highly significant 20% (8-29) reduction in the rate of any major vascular event (406 [24.7%] vs 488 [29.8%]; p=0.001). The proportional reductions in stroke were about one-quarter in each of the other subcategories of participant studied, including: those with coronary disease or diabetes; those aged under or over 70 years at entry; and those presenting with different levels of blood pressure or lipids (even when the pretreatment LDL cholesterol was below 3.0 mmol/L [116 mg/dL]).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Much larger numbers of people in the present study suffered a stroke than in any previous cholesterol-lowering trial. The results demonstrate that statin therapy rapidly reduces the incidence not only of coronary events but also of ischaemic strokes, with no apparent effect on cerebral haemorrhage, even among individuals who do not have high cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rate of ischaemic strokes by about one-quarter and so, after making allowance for non-compliance in the trial, actual use of this regimen would probably reduce the stroke rate by about a third. HPS also provides definitive evidence that statin therapy is beneficial for people with pre-existing cerebrovascular disease, even if they do not already have manifest coronary disease.\n",
            "     </abstracttext>]\n",
            "15769914.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare the efficacy of aerobic walking and home based quadriceps strengthening exercises in patients with knee osteoarthritis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      The Medline, Pubmed, EMBASE, CINAHL, and PEDro databases and the Cochrane controlled trials register were searched for randomised controlled trials (RCTs) of subjects with knee osteoarthritis comparing aerobic walking or home based quadriceps strengthening exercise with a non-exercise control group. Methodological quality of retrieved RCTs was assessed. Outcome data were abstracted for pain and self reported disability and the effect size calculated for each outcome. RCTs were grouped according to exercise mode and the data pooled using both fixed and random effects models.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      35 RCTs were identified, 13 of which met inclusion criteria and provided data suitable for further analysis. Pooled effect sizes for pain were 0.52 for aerobic walking and 0.39 for quadriceps strengthening. For self reported disability, pooled effect sizes were 0.46 for aerobic walking and 0.32 for quadriceps strengthening.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Both aerobic walking and home based quadriceps strengthening exercise reduce pain and disability from knee osteoarthritis but no difference between them was found on indirect comparison.\n",
            "     </abstracttext>]\n",
            "16368032.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      First, to establish the efficacy of psychological interventions versus routine primary care for the management of postnatal depression (PND). Secondly, to provide a direct comparison of cognitive-behavioural therapy (CBT) versus counselling and, finally, to compare the relative value of group and individual delivery formats.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      The study involved 192 depressed women drawn from a large community screening programme in Melbourne, Australia and allocated to cognitive behaviour therapy, counselling, or routine primary care. Baseline and post-intervention measures of depression and anxiety were collected in the form of validated self-report inventories.\n",
            "     </abstracttext>, <abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Women were screened in the community and diagnosis of depression confirmed with a standardized psychiatric interview. Interventions were of 12 weeks duration, including three partner sessions, and adhered to a structured manual.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Psychological intervention per se was superior to routine care in terms of reductions in both depression and anxiety following intervention.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      For those women with PND, psychological intervention is a better option than routine care, leading to clinically significant reduction of symptoms. Counselling may be as effective as group cognitive behaviour therapy. The benefits of psychological intervention may be maximized by being delivered on a one-to-one basis.\n",
            "     </abstracttext>]\n",
            "11841361.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10723977.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "17054255.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare the use of circular stapling devices and conventional excisional techniques in patients with symptomatic hemorrhoids.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched all the major electronic databases (MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from 1998 to May 2006.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All randomized controlled trials comparing stapled hemorrhoidopexy to conventional excisional hemorrhoidal surgeries were included.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Data were collected on a data sheet. When appropriate, an Odds Ratio was generated using a random effects model.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Patients undergoing circular stapled hemorrhoidopexy (SH) were significantly more likely to have recurrent hemorrhoids in long term follow up at all time points than those receiving conventional hemorrhoidectomy (CH) (7 trials, 537 patients, OR 3.85, CI 1.47-10.07, p=0.006). There were 23 recurrences out of 269 patients in the stapled group versus only 4 out of 268 patients in the conventional group. Similarly, in trials where there was follow up of one year or more, SH was associated with a greater proportion of patients with hemorrhoid recurrence(5 trials, 417 patients, OR 3.60, CI 1.24-10.49, p=0.02). Furthermore, a significantly higher proportion of patients with SH complained of the symptom of prolapse at all time points (8 studies, 798 patients, OR 2.96, CI 1.33-6.58, p=0.008). In studies with follow up of greater than one year, the same significant outcome was found (6 studies, 628 patients, OR 2.68, CI 0.98-7.34, p=0.05). Non significant trends in favor of SH were seen in pain, pruritus ani, and fecal urgency. All other clinical parameters showed trends favoring CH AUTHORS' CONCLUSIONS: Stapled hemorrhoidopexy is associated with a higher long-term risk of hemorrhoid recurrence and the symptom of prolapse. It is also likely to be associated with a higher likelihood of long-term symptom recurrence and the need for additional operations compared to conventional excisional hemorrhoid surgeries. Patients should be informed of these risks when being offered the stapled hemorrhoidopexy as surgical therapy. If hemorrhoid recurrence and prolapse are the most important clinical outcomes, then conventional excisional surgery remains the \"gold standard\" in the surgical treatment of internal hemorrhoids.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "11006762.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a literature search of 3 electronic databases for the period 1966 to 1999. We also searched bibliographies from conference proceedings and contacted content experts to ensure completeness of our database. Each trial was evaluated on the basis of the following inclusion criteria: target population (children), intervention (antibiotic v. no antibiotic), outcome (number of urinary tract infections) and study design (randomized controlled trial). Quality was assessed for the studies that met these criteria.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Most of the studies identified were case series and cohort studies. Only 6 randomized trials fulfilled the inclusion criteria. All were of low quality (median 2, range 0 to 2 [maximum quality score 5]). Three trials dealt with children who had anatomically normal urinary tracts, and three included children with neurogenic bladder. The rate of infections for patients with normal urinary tracts ranged from 0 to 4.0 per 10 patient-years for the treatment groups and from 4.0 to 16.7 for the control groups. The recurrence rates for patients with neurogenic bladders in 2 trials were 2.9 and 17.1 per 10 patient-years for the treatment groups and 1.5 and 33.0 for the control groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The available evidence for using antimicrobial prophylaxis to prevent urinary tract infection in children with normal urinary tracts or neurogenic bladder is of low quality. This suggests that the magnitude of any benefit should at best be questioned. The surprising lack of data for children with reflux is of concern. Well-designed trials are needed to optimize the use of antimicrobials in children with recurrent urinary tract infection.\n",
            "     </abstracttext>]\n",
            "12821232.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      We sought to conduct a randomized trial with folic acid 0.5 mg/day in a patient population with stable coronary artery disease (CAD).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In this open-label study, 593 patients were included; 300 were randomized to folic acid and 293 served as controls. Mean follow-up time was 24 months. At baseline all patients had been on statin therapy for a mean of 3.2 years.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      In patients treated with folic acid, plasma homocysteine levels decreased by 18%, from 12.0 +/- 4.8 to 9.4 +/- 3.5 micromol/l, whereas these levels remained unaffected in the control group (p &lt; 0.001 between groups). The primary end point (all-cause mortality and a composite of vascular events) was encountered in 31 (10.3%) patients in the folic acid group and in 28 (9.6%) patients in the control group (relative risk 1.05; 95% confidence interval: 0.63 to 1.75). In a multifactorial survival model with adjustments for clinical factors, the most predictive laboratory parameters were, in order of significance, levels of creatinine clearance, plasma fibrinogen, and homocysteine.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Within two years, folic acid does not seem to reduce clinical end points in patients with stable coronary artery disease (CAD) while on statin treatment. Homocysteine might therefore merely be a modifiable marker of disease. Thus, low-dose folic acid supplementation should be treated with reservation, until more trial outcomes become available.\n",
            "     </abstracttext>]\n",
            "8517575.xml\n",
            "\n",
            "[<abstracttext label=\"STUDY OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To develop guidelines for the care of infants and children from birth to 36 months of age with fever without source.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PARTICIPANTS AND SETTING\" nlmcategory=\"METHODS\">\n",
            "      An expert panel of senior academic faculty with expertise in pediatrics and infectious diseases or emergency medicine.\n",
            "     </abstracttext>, <abstracttext label=\"DESIGN AND INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      A comprehensive literature search was used to identify all publications pertinent to the management of the febrile child. When appropriate, meta-analysis was used to combine the results of multiple studies. One or more specific management strategies were proposed for each of the decision nodes in draft management algorithms. The draft algorithms, selected publications, and the meta-analyses were provided to the panel, which determined the final guidelines using the modified Delphi technique.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      All toxic-appearing infants and children and all febrile infants less than 28 days of age should be hospitalized for parenteral antibiotic therapy. Febrile infants 28 to 90 days of age defined at low risk by specific clinical and laboratory criteria may be managed as outpatients if close follow-up is assured. Older children with fever less than 39.0 C without source need no laboratory tests or antibiotics. Children 3 to 36 months of age with fever of 39.0 C or more and whose WBC count is 15,000/mm3 or more should have a blood culture and be treated with antibiotics pending culture results. Urine cultures should be obtained from all boys 6 months of age or less and all girls 2 years of age or less who are treated with antibiotics.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      These guidelines do not eliminate all risk or strictly confine antibiotic treatment to children likely to have occult bacteremia. Physicians may individualize therapy based on clinical circumstances or adopt a variation of these guidelines based on a different interpretation of the evidence.\n",
            "     </abstracttext>]\n",
            "16428925.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8509358.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "14644896.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11869676.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the effect of inhaled corticosteroids use on biochemical markers of bone turnover, bone mineral density and the development of fractures.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Airways Group trials register, electronic reference databases, UK National Research Register, bibliographies of included studies, and contacted pharmaceutical companies.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised trials of the effect of inhaled steroid versus placebo on markers of bone function and metabolism, in adults with asthma or mild COPD.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Trial quality was assessed and data extracted from the papers included (2 reviewers per paper) and from additional data supplied by the authors.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of 438 references found, seven met the inclusion criteria. Three studies were in healthy subjects asthma or COPD. The patients were generally less than 60 years old and the male:female ratio was 2:1. There was no evidence of increased risk of loss of bone mineral density (BMD) or fractures. There was no significant change in osteocalcin at conventional doses of inhaled corticosteroids (Standardised Mean Difference [SMD] -0.34 (95% Confidence Interval [CI] -0.72, 0.04), although a statistically significant change was seen in those studies using experimental doses of inhaled steroid in excess of the doses recommended by the British Thoracic Society SMD 0.97 (95% CI -1.61, -0.34). A statistically significant change in parathyroid hormone seen in one small short trial (n=10, 6 weeks) may have been due to the trial design and outcome measurements used.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In patients with asthma or mild COPD, there is no evidence of an effect of inhaled corticosteroid at conventional doses given for two or three years on BMD or vertebral fracture. Higher doses were associated with biochemical markers of increased bone turnover, but data on BMD and fractures at these doses are not available. There is a need for further, even longer term prospective studies of conventional and high doses of inhaled corticosteroids.\n",
            "     </abstracttext>]\n",
            "11034729.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the effectiveness of exercise only rehabilitation and exercise in addition to other rehabilitation interventions (termed comprehensive cardiac rehabilitation) compared with usual care on the mortality, morbidity, health-related quality of life (HRQoL) and modifiable cardiac risk factors of patients with coronary heart disease.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      Electronic databases were searched for randomised controlled trials, using standardised trial filters, from the earliest date available to December 31st 1998.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Men and women of all ages, in both hospital-based and community-based settings, who have had myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, or who have angina pectoris or coronary artery disease defined by angiography have been included. Studies involving participants following heart transplant, heart valve surgery or heart failure have been excluded. Follow up periods of less than 6 months were excluded.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Studies were selected independently by two reviewers, and data extracted independently. Authors were contacted where possible to obtain missing information.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The current systematic review has allowed analysis of an increased number of patients from approximately 4500 in the earlier meta-analyses to 7683 (2582 in exercise only and 5101 in the comprehensive cardiac rehabilitation group). The quality of reporting overall was poor, with generally high losses to follow up. The pooled effect estimate for total mortality for the exercise only intervention shows a 27% reduction in all cause mortality (random effects model OR 0.73 (0.54, 0.98)). Similarly, comprehensive cardiac rehabilitation reduced all cause mortality compared to usual care, but to a lesser degree (OR 0.87 (0.71, 1.05)). Total cardiac mortality was reduced by 31% (random effects model OR 0.69 (0.51, 0.94)) and 26% (random effects model OR 0.74 (0.57, 0.96)) in the exercise only and comprehensive cardiac rehabilitation intervention groups respectively when compared to usual care. Neither intervention had any effect on the ocurrence of non-fatal myocardial infarction. There was a significant net reduction in total cholesterol in the comprehensive cardiac rehabilitation group (pooled WMD random effects model -0.57 mmol/l (-0.83, -0.31)), but not the exercise only rehabilitation group. Similarly, LDL was significantly reduced in the comprehensive cardiac rehabilitation group (pooled WMD random effects model -0.51 mmol/l (-0.82, -0.19). The effect of exercise only rehabilitation or comprehensive cardiac rehabilitation interventions on revascularisation rates, blood pressure or smoking behaviour could not be determined by this meta-analysis due to the small number of trials reporting these outcomes and heterogeneity between trials. It was not possible to combine the data from studies reporting HRQoL as an outcome. Eighteen different instruments were used to assess HRQoL in the 11 studies reporting it as an outcome. The data are presented qualitatively, only one trial reporting significant improvements with the intervention.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Exercise-based cardiac rehabilitation appears to be effective in reducing cardiac deaths but the evidence base is weakened by poor quality trials. It is not clear from this review whether exercise only or a comprehensive cardiac rehabilitation intervention is more beneficial. The population studied in this review is still predominately male, middle aged and low risk. Identification of the ethnic origin of the participants was seldom reported. (ABSTRACT TRUNCATED)\n",
            "     </abstracttext>]\n",
            "11687009.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      The objective of the review was to determine the effect of stimulant laxative treatment in children with chronic constipation who may also suffer from soiling / encopresis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The Cochrane database of randomised controlled trials was searched. Additional citations were sought by hand searching of paediatric journals and from contact with known professionals in the field.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All identified randomised controlled trials (RCTs) which compare the administering of stimulant laxatives to children with either placebo or alternative treatment.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      No trials were found that met the selection criteria.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      No trials were found that adequately met the selection criteria.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The need exists to establish a secure footing for treatment decisions and adequately sized trials are required to provide comparative data on commonly used drugs.\n",
            "     </abstracttext>]\n",
            "10606058.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To critically review the body of clinical trials that refute or support the efficacy of antihistamines in relieving pruritus in patients with atopic dermatitis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Review of MEDLINE from 1966 through March 1999, the Cochrane Database of Systematic Reviews, and Best Evidence to identify therapeutic trials of antihistamines in patients with atopic dermatitis.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      All randomized controlled trials or clinical trials of antihistamines used in the treatment of atopic dermatitis. We found 16 studies throughout the literature.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Large, randomized, double-blind, placebo-controlled clinical trials with definitive conclusions (grade A trials) have not been performed. Two grade B trials (small, rigorous, randomized trials with uncertain results due to moderate to high alpha or beta error) refuted the use of antihistamines in relieving pruritus. One grade B trial supported the efficacy of antihistamines in relieving pruritus. All remaining trials (grade C) lacked placebo controls or randomization, or contained fewer than 20 patients in each treatment group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Although antihistamines are often used in the treatment of atopic dermatitis, little objective evidence exists to demonstrate relief of pruritus. The majority of trials are flawed in terms of the sample size or study design. Based on the literature alone, the efficacy of antihistamines remains to be adequately investigated. Anecdotally, sedating antihistamines have sometimes been useful by virtue of their soporific effect and bedtime use may be warranted. There is no evidence to support the effectiveness of expensive nonsedating agents.\n",
            "     </abstracttext>]\n",
            "12913777.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      A serum sample was available from patients classified serologically as primary EBV infection (n = 28), EBV-seronegative (n = 25) and EBV-seropositive (n = 26). Patients were classified as having EBV infectious mononucleosis if they had specified clinical findings and &gt; or =10% atypical lymphocytes in peripheral blood or had a positive Monospot test result. DNA was purified by a spin column method and tested in PCR reactions with primers for EBV DNA polymerase gene and internal control targets. Amplification of the two PCR products was measured in real time with separate TaqMan DNA probes labeled with various fluorescent reporters.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The mean age of study patients was 9 years, 4 months. Twenty-one (75%) of the patients in the primary EBV infection group, one (4%) of the seronegatives and none of the seropositives had detectable EBV DNA. Within the primary infection group, those with detectable virus were more likely than those without detectable virus to have evidence of lymphadenopathy (14 of 16 vs.1 of 5; P = 0.011), higher mean atypical (11.7 vs.0.9%; P = 0.002) and absolute atypical (1.5 vs.0.1 x 109/l; P = 0.004) lymphocyte count, higher mean absolute lymphocyte count (4.7 vs.2.3 x 109/l; P = 0.026) and higher mean aspartate aminotransferase value (119.8 vs.37.3 IU/l; P = 0.036). Ten patients, all in the primary infection group, had EBV infectious mononucleosis, and all had positive PCR results. No sample contained PCR inhibitors.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A real time TaqMan PCR assay allows rapid identification of patients with primary EBV infection and those with EBV infectious mononucleosis.\n",
            "     </abstracttext>]\n",
            "12460095.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine prenatal and postnatal risk factors for SIDS among American Indians.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN, SETTING, AND PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Population-based case-control study of 33 SIDS infants and 66 matched living controls among American Indians in South Dakota, North Dakota, Nebraska, and Iowa enrolled from December 1992 to November 1996 and investigated using standardized parental interview, medical record abstraction, autopsy protocol, and infant death review.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Association of SIDS with maternal socioeconomic and behavioral factors, health care utilization, and infant care practices.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The proportions of case and control infants who were usually placed prone to sleep (15.2% and 13.6%, respectively), who shared a bed with parents (59.4% and 55.4%), or whose mothers smoked during pregnancy (69.7% and 54.6%) were similar. However, mothers of 72.7% of case infants and 45.5% of control infants engaged in binge drinking during pregnancy. Conditional logistic regression revealed significant associations between SIDS and 2 or more layers of clothing on the infant (adjusted odds ratio [aOR], 6.2; 95% confidence interval [CI], 1.4-26.5), any visits by a public health nurse (aOR, 0.2; 95% CI, 0.1-0.8), periconceptional maternal alcohol use (aOR, 6.2; 95% CI, 1.6-23.3), and maternal first-trimester binge drinking (aOR, 8.2; 95% CI, 1.9-35.3).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Public health nurse visits, maternal alcohol use during the periconceptional period and first trimester, and layers of clothing are important risk factors for SIDS among Northern Plains Indians. Strengthening public health nurse visiting programs and programs to reduce alcohol consumption among women of childbearing age could potentially reduce the high rate of SIDS.\n",
            "     </abstracttext>]\n",
            "11641669.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine if the timing of the administration of prophylactic oxytocin influences the incidence of postpartum hemorrhage caused by uterine atony, retained placenta, and third-stage duration.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Parturients who presented for vaginal delivery were randomized in a double-blinded fashion to receive oxytocin, 20 units in a 500-mL crystalloid intravenous bolus, beginning upon delivery of either the fetal anterior shoulder or placenta. For all patients, the third stage of labor was managed with controlled cord traction until placental expulsion, followed by at least 15 seconds of fundal massage. Patients were excluded if they had a previous cesarean section, multiple gestation, antepartum hemorrhage, or bleeding disorder.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 1486 patients were enrolled: 745 in the before-placenta group and 741 in the after-placenta group. The groups were similar with respect to gestational age, fetal weight, labor duration, maternal age, parity, and ethnicity. The incidence of postpartum hemorrhage did not differ significantly between the two groups (5.4% vs 5.8%; crude OR, 0.92; 95% CI, 0.59 to 1.43). There were no significant differences between the two groups with respect to incidence of retained placenta (2.4% vs 1.6%; OR, 1.49; 95% CI, 0.72 to 3.08), or third-stage duration (7.7 minutes vs 8.1 minutes; P =.23).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The administration of prophylactic oxytocin before placental delivery does not reduce the incidence of postpartum hemorrhage or third-stage duration, when compared with giving oxytocin after placental delivery. Early administration, however, does not increase the incidence of retained placenta.\n",
            "     </abstracttext>]\n",
            "7935681.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We studied 2007 persons (814 men and 1193 women) 60 years of age or older who did not have atrial fibrillation in order to determine the frequency of this arrhythmia during a 10-year follow-up period. The subjects were classified according to their serum thyrotropin concentrations: those with low values (&lt; or = 0.1 mU per liter; 61 subjects); those with slightly low values (&gt; 0.1 to 0.4 mU per liter; 187 subjects); those with normal values (&gt; 0.4 to 5.0 mU per liter; 1576 subjects); and those with high values (&gt; 5.0 mU per liter; 183 subjects).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      During the 10-year follow-up period, atrial fibrillation occurred in 13 persons with low initial values for serum thyrotropin, 23 with slightly low values, 133 with normal values, and 23 with high values. The cumulative incidence of atrial fibrillation at 10 years was 28 percent among the subjects with low serum thyrotropin values (&lt; or = 0.1 mU per liter), as compared with 11 percent among those with normal values; the age-adjusted incidence of atrial fibrillation was 28 per 1000 person-years among those with low values and 10 per 1000 person-years among those with normal values (P = 0.005). After adjustment for other known risk factors, the relative risk of atrial fibrillation in elderly subjects with low serum thyrotropin concentrations, as compared with those with normal concentrations, was 3.1 (95 percent confidence interval, 1.7 to 5.5; P &lt; 0.001). The 10-year incidence of atrial fibrillation in the groups with slightly low and high serum thyrotropin values was not significantly different from that in the group with normal values.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Among people 60 years of age or older, a low serum thyrotropin concentration is associated with a threefold higher risk that atrial fibrillation will develop in the subsequent decade.\n",
            "     </abstracttext>]\n",
            "9290622.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "18056558.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare the effects of a single nocturnal dose of buckwheat honey or honey-flavored dextromethorphan (DM) with no treatment on nocturnal cough and sleep difficulty associated with childhood upper respiratory tract infections.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      A survey was administered to parents on 2 consecutive days, first on the day of presentation when no medication had been given the prior evening and then the next day when honey, honey-flavored DM, or no treatment had been given prior to bedtime according to a partially double-blinded randomization scheme.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      A single, outpatient, general pediatric practice.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      One hundred five children aged 2 to 18 years with upper respiratory tract infections, nocturnal symptoms, and illness duration of 7 days or less.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      A single dose of buckwheat honey, honey-flavored DM, or no treatment administered 30 minutes prior to bedtime.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Cough frequency, cough severity, bothersome nature of cough, and child and parent sleep quality.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Significant differences in symptom improvement were detected between treatment groups, with honey consistently scoring the best and no treatment scoring the worst. In paired comparisons, honey was significantly superior to no treatment for cough frequency and the combined score, but DM was not better than no treatment for any outcome. Comparison of honey with DM revealed no significant differences.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In a comparison of honey, DM, and no treatment, parents rated honey most favorably for symptomatic relief of their child's nocturnal cough and sleep difficulty due to upper respiratory tract infection. Honey may be a preferable treatment for the cough and sleep difficulty associated with childhood upper respiratory tract infection.\n",
            "     </abstracttext>]\n",
            "14984373.xml\n",
            "\n",
            "[<abstracttext label=\"AIM\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the efficacy and safety of a commercially available herbal preparation (STW 5) (nine plant extracts), the research herbal preparation STW 5-II (six plant extracts) and the bitter candytuft mono-extract in patients with irritable bowel syndrome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Two hundred and eight patients with irritable bowel syndrome were recruited after standardized diagnostic work-up into a double-blind, placebo-controlled, multi-centre trial and were randomly assigned to receive one of four treatments: commercially available herbal preparation STW 5 (n = 51), research herbal preparation STW 5-II (n = 52), bitter candytuft mono-extract (n = 53) or placebo (n = 52). The main outcome variables were the changes in total abdominal pain and irritable bowel syndrome symptom scores.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Two hundred and three patients completed the trial. STW 5 and STW 5-II were significantly better than placebo in reducing the total abdominal pain score (intention-to-treat: STW 5, P = 0.0009; STW 5-II, P = 0.0005) and the irritable bowel syndrome symptom score (intention-to-treat: STW 5, P = 0.001; STW 5-II, P = 0.0003) at 4 weeks. There were no statistically significant differences between the bitter candytuft mono-extract group and the placebo group (P = 0.1473, P = 0.1207).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The commercially available herbal preparation STW 5 and its research preparation STW 5-II are both effective in alleviating irritable bowel syndrome symptoms.\n",
            "     </abstracttext>]\n",
            "10334745.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the efficacy of vitamin B-6 in the treatment of premenstrual syndrome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Systematic review of published and unpublished randomised placebo controlled trials of the effectiveness of vitamin B-6 in the management of premenstrual syndrome.\n",
            "     </abstracttext>, <abstracttext label=\"SUBJECTS\" nlmcategory=\"METHODS\">\n",
            "      Nine published trials representing 940 patients with premenstrual syndrome.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Proportion of women whose overall premenstrual symptoms showed an improvement over placebo. A secondary analysis was performed on the proportion of women whose premenstrual depressive symptoms showed an improvement over placebo.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Odds ratio relative to placebo for an improvement in overall premenstrual symptoms was 2.32 (95% confidence interval 1.95 to 2.54). Odds ratio relative to placebo for an improvement in depressive symptoms was 1.69 (1.39 to 2.06) from four trials representing 541 patients.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Conclusions are limited by the low quality of most of the trials included. Results suggest that doses of vitamin B-6 up to 100 mg/day are likely to be of benefit in treating premenstrual symptoms and premenstrual depression.\n",
            "     </abstracttext>]\n",
            "12409542.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a post hoc subgroup analysis to assess whether there were sex-based differences in the effect of digoxin therapy among the 6800 patients in the Digitalis Investigation Group study. The presence of an interaction between sex and digoxin therapy with respect to the primary end point of death from any cause was evaluated with the use of Mantel-Haenszel tests of heterogeneity and a multivariable Cox proportional-hazards model, adjusted for demographic and clinical variables.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There was an absolute difference of 5.8 percent (95 percent confidence interval, 0.5 to 11.1) between men and women in the effect of digoxin on the rate of death from any cause (P=0.034 for the interaction). Specifically, women who were randomly assigned to digoxin had a higher rate of death than women who were randomly assigned to placebo (33.1 percent vs. 28.9 percent; absolute difference, 4.2 percent, 95 percent confidence interval, -0.5 to 8.8). In contrast, the rate of death was similar among men randomly assigned to digoxin and men randomly assigned to placebo (35.2 percent vs. 36.9 percent; absolute difference, -1.6 percent; 95 percent confidence interval, -4.2 to 1.0). In the multivariable analysis, digoxin was associated with a significantly higher risk of death among women (adjusted hazard ratio for the comparison with placebo, 1.23; 95 percent confidence interval, 1.02 to 1.47), but it had no significant effect among men (adjusted hazard ratio, 0.93; 95 percent confidence interval, 0.85 to 1.02; P=0.014 for the interaction).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The effect of digoxin therapy differs between men and women. Digoxin therapy is associated with an increased risk of death from any cause among women, but not men, with heart failure and depressed left ventricular systolic function.\n",
            "     </abstracttext>]\n",
            "2929804.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8896541.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "7942584.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11687054.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To quantitatively assess the efficacy of a single dose of rizatriptan (Maxalt) for treating a single migraine attack using the outcomes of headache response and pain-free response at half-an-hour, one hour, two hours, and sustained relief over 24 hours. To express efficacy in terms of numbers-needed-to-treat (NNTs).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      Trials were identified by searching MEDLINE (1966-July 2000), EMBASE (1980-June 2000), the Cochrane Library (Issue 3, 2000) and the Oxford Pain Relief Database (1950-1994). Date of last search: July 2000.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      The inclusion criteria were randomised, placebo-controlled trials of rizatriptan for acute migraine; double-blind design; International Headache Society diagnostic criteria for migraine with or without aura; single migraine attack; single-dose treatment at standard doses; adult population; baseline pain of moderate or severe intensity using a four-point standardised rating scale; dichotomous or percentage data for at least one of the main efficacy outcomes; and full journal publication.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Main outcomes considered were i) headache response at two hours, ii) headache response at one hour, iii) pain-free response at two hours, iv) sustained relief over 24 hours, v) pain-free response at 24 hours and vi) adverse effects. Minor outcomes were headache response and pain-free response at half-an-hour and four hours, and pain-free response at one hour. Dichotomous or percentage data were extracted and used to calculate the relative benefit (RB) and number-needed-to-treat (NNT) for each outcome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Seven trials met our inclusion criteria, with 2626 patients given rizatriptan and 902 given placebo. Significant benefit of rizatriptan over placebo was shown for both doses of rizatriptan (5 mg and 10 mg) for all five main efficacy outcomes (ranging from one to 24 hours). A dose response was seen for the main outcomes. It was not possible to analyse adverse effects information in a meaningful way.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Rizatriptan 5 mg and 10 mg are effective in treating acute migraine, with a dose-related increase in efficacy.\n",
            "     </abstracttext>]\n",
            "1998638.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11567699.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We did a population-based study of mortality in a cohort of 1191 individuals not on thyroxine or antithyroid medication. All participants were aged 60 years or older. We measured concentration of thyrotropin in serum at baseline in 1988-89. We recorded vital status on June 1, 1999, and ascertained causes of death for those who had died. We compared data for causes of death with age-specific, sex-specific, and year-specific data for England and Wales. We also compared mortality within the cohort according to initial thyrotropin measurement.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      During 9733 person-years of follow-up, 509 of 1191 people died, the expected number of deaths being 496 (standardised mortality ratio [SMR] 1.0, 95% CI 0.9-1.1). Mortality from all causes was significantly increased at 2 (SMR 2.1), 3 (2.1), 4 (1.7), and 5 (1.8) years after first measurement in those with low serum thyrotropin (n471). These increases were largely accounted for by significant increases in mortality due to circulatory diseases (SMR 2.1, 2.2, 1.9, 2.0, at years 2, 3, 4, and 5 respectively). Increases in mortality from all causes in years 2-5 were higher in patients with low serum thyrotropin than in the rest of the cohort (hazard ratios for years 2, 3, 4, and 5 were 2.1, 2.2, 1.8, and 1.8, respectively). This result reflects an increase in mortality from circulatory diseases (hazard ratios at years 2, 3, 4, and 5 were 2.3, 2.6, 2.3, 2.3), and specifically from cardiovascular diseases (hazard ratios at years 2, 3, 4, and 5 were 3.3, 3.0, 2.3, 2.2).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A single measurement of low serum thyrotropin in individuals aged 60 years or older is associated with increased mortality from all causes, and in particular mortality due to circulatory and cardiovascular diseases.\n",
            "     </abstracttext>]\n",
            "9669977.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To review information on the benefits of screening with a sensitive thyroid-stimulating hormone (TSH) test for thyroid dysfunction in asymptomatic patients seeking primary care for other reasons. This paper focuses on whether screening should be aimed at detection of subclinical thyroid dysfunction and whether persons with mildly abnormal TSH levels can benefit.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      A MEDLINE search for studies of screening for thyroid dysfunction and of treatment for complications of subclinical thyroid dysfunction.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Studies of screening with thyroid function tests in the general adult population or in patients seen in the general office setting were selected (n=33). All controlled studies of treatment in patients with subclinical hypothyroidism or subclinical hyperthyroidism were also included (n=23).\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      The prevalence of overt and subclinical thyroid dysfunction, the evidence for the efficacy of treatment, and the incidence of complications in defined age and sex groups were extracted from each study.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      Screening can detect symptomatic but unsuspected overt thyroid dysfunction. The yield is highest for women older than 50 years of age: In this group, 1 in 71 women screened could benefit from relief of symptoms. Evidence of the efficacy of treatment for subclinical thyroid dysfunction is inconclusive.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Even though treatment for subclinical thyroid dysfunction is controversial, office-based screening to detect overt thyroid dysfunction may be indicated in women older than 50 years of age. Large randomized trials are needed to determine the likelihood that treatment will improve quality of life in otherwise healthy patients who have mildly elevated TSH levels.\n",
            "     </abstracttext>]\n",
            "8236597.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10796394.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effects of calcium and vitamin D compared to calcium alone or placebo in the prevention of bone loss in patients taking systemic corticosteroids.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Musculoskeletal trials register, Cochrane Controlled Trials Register, EMBASE and Medline up to 1996. We also conducted a hand search of abstracts from various scientific meetings and reference lists of selected trials.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      All randomized trials comparing calcium and vitamin D to calcium alone or placebo in patients taking systemic corticosteroids.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Data was abstracted from trials by two investigators. Methodological quality was assessed in a similar manner. Analysis was performed using fixed effects models.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Five trials were included, with 274 patients. The analysis was performed at two years after starting calcium and vitamin D. There was a significant weighted mean difference (WMD) between treatment and control groups in lumbar (WMD 2.6 (95% CI 0.7, 4.5), and radial bone mineral density (WMD 2.5 (95% CI 0.6, 4.4). The other outcome measures (femoral neck bone mass, fracture incidence, biochemical markers of bone resorption) were not significantly different.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This meta-analysis demonstrated a clinically and statistically significant prevention of bone loss at the lumbar spine and forearm with vitamin D and calcium in corticosteroid treated patients. Because of low toxicity and cost all patients being started on corticosteroids should receive prophylactic therapy with calcium and vitamin D.\n",
            "     </abstracttext>]\n",
            "6244871.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12114036.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      20,536 UK adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive 40 mg simvastatin daily (average compliance: 85%) or matching placebo (average non-study statin use: 17%). Analyses are of the first occurrence of particular events, and compare all simvastatin-allocated versus all placebo-allocated participants. These \"intention-to-treat\" comparisons assess the effects of about two-thirds (85% minus 17%) taking a statin during the scheduled 5-year treatment period, which yielded an average difference in LDL cholesterol of 1.0 mmol/L (about two-thirds of the effect of actual use of 40 mg simvastatin daily). Primary outcomes were mortality (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      All-cause mortality was significantly reduced (1328 [12.9%] deaths among 10,269 allocated simvastatin versus 1507 [14.7%] among 10,267 allocated placebo; p=0.0003), due to a highly significant 18% (SE 5) proportional reduction in the coronary death rate (587 [5.7%] vs 707 [6.9%]; p=0.0005), a marginally significant reduction in other vascular deaths (194 [1.9%] vs 230 [2.2%]; p=0.07), and a non-significant reduction in non-vascular deaths (547 [5.3%] vs 570 [5.6%]; p=0.4). There were highly significant reductions of about one-quarter in the first event rate for non-fatal myocardial infarction or coronary death (898 [8.7%] vs 1212 [11.8%]; p&lt;0.0001), for non-fatal or fatal stroke (444 [4.3%] vs 585 [5.7%]; p&lt;0.0001), and for coronary or non-coronary revascularisation (939 [9.1%] vs 1205 [11.7%]; p&lt;0.0001). For the first occurrence of any of these major vascular events, there was a definite 24% (SE 3; 95% CI 19-28) reduction in the event rate (2033 [19.8%] vs 2585 [25.2%] affected individuals; p&lt;0.0001). During the first year the reduction in major vascular events was not significant, but subsequently it was highly significant during each separate year. The proportional reduction in the event rate was similar (and significant) in each subcategory of participant studied, including: those without diagnosed coronary disease who had cerebrovascular disease, or had peripheral artery disease, or had diabetes; men and, separately, women; those aged either under or over 70 years at entry; and--most notably--even those who presented with LDL cholesterol below 3.0 mmol/L (116 mg/dL), or total cholesterol below 5.0 mmol/L (193 mg/dL). The benefits of simvastatin were additional to those of other cardioprotective treatments. The annual excess risk of myopathy with this regimen was about 0.01%. There were no significant adverse effects on cancer incidence or on hospitalisation for any other non-vascular cause.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Adding simvastatin to existing treatments safely produces substantial additional benefits for a wide range of high-risk patients, irrespective of their initial cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rates of myocardial infarction, of stroke, and of revascularisation by about one-quarter. After making allowance for non-compliance, actual use of this regimen would probably reduce these rates by about one-third. Hence, among the many types of high-risk individual studied, 5 years of simvastatin would prevent about 70-100 people per 1000 from suffering at least one of these major vascular events (and longer treatment should produce further benefit). The size of the 5-year benefit depends chiefly on such individuals' overall risk of major vascular events, rather than on their blood lipid concentrations alone.\n",
            "     </abstracttext>]\n",
            "16437528.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To review the evidence that omega 3 PUFA supplementation prevents cognitive impairment and dementia in cognitively intact elderly persons.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      The Cochrane Dementia and Cognitive Improvement Group's (CDCIG) Specialized register, MEDLINE, EMBASE,CINAHL PsycINFO, AMED AND CENTRAL and several ongoing trials databases were searched on 5 and 6 October 2005. The CDCIG Register is updated regularly and contains records from all major medical databases and many ongoing trials databases.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      In order to be selected, trials needed to be randomized, placebo-controlled, doubled blinded, of minimum study duration of 6 months, involved persons aged 60 years and above without pre-existing dementia at study onset, and employed cognitive endpoints.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Reviewers, working independently, were to select, quality assess and extract relevant data where appropriate and possible. In comparing intervention with placebo, the pooled odds ratios or weighted mean differences and standardized mean difference were to be estimated.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There were no randomized trials found in the search that met the selection criteria. Results of two clinical trials are expected in 2008.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      There is a growing body of evidence from biological, observational and epidemiological studies that suggests a protective effect of omega 3 PUFA against dementia. However, until data from randomized trials become available for analysis, there is no good evidence to support the use of dietary or supplemental omega 3 PUFA for the prevention of cognitive impairment or dementia.\n",
            "     </abstracttext>]\n",
            "7756486.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12114037.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      20,536 UK adults (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) or matching placebo. Intention-to-treat comparisons of outcome were conducted between all vitamin-allocated and all placebo-allocated participants. An average of 83% of participants in each treatment group remained compliant during the scheduled 5-year treatment period. Allocation to this vitamin regimen approximately doubled the plasma concentration of alpha-tocopherol, increased that of vitamin C by one-third, and quadrupled that of beta-carotene. Primary outcomes were major coronary events (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"FINDINGS\" nlmcategory=\"RESULTS\">\n",
            "      There were no significant differences in all-cause mortality (1446 [14.1%] vitamin-allocated vs 1389 [13.5%] placebo-allocated), or in deaths due to vascular (878 [8.6%] vs 840 [8.2%]) or non-vascular (568 [5.5%] vs 549 [5.3%]) causes. Nor were there any significant differences in the numbers of participants having non-fatal myocardial infarction or coronary death (1063 [10.4%] vs 1047 [10.2%]), non-fatal or fatal stroke (511 [5.0%] vs 518 [5.0%]), or coronary or non-coronary revascularisation (1058 [10.3%] vs 1086 [10.6%]). For the first occurrence of any of these \"major vascular events\", there were no material differences either overall (2306 [22.5%] vs 2312 [22.5%]; event rate ratio 1.00 [95% CI 0.94-1.06]) or in any of the various subcategories considered. There were no significant effects on cancer incidence or on hospitalisation for any other non-vascular cause.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"INTERPRETATION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Among the high-risk individuals that were studied, these antioxidant vitamins appeared to be safe. But, although this regimen increased blood vitamin concentrations substantially, it did not produce any significant reductions in the 5-year mortality from, or incidence of, any type of vascular disease, cancer, or other major outcome.\n",
            "     </abstracttext>]\n",
            "12427500.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12527571.xml\n",
            "\n",
            "[<abstracttext label=\"STUDY OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine the test performance characteristics of various modalities for the diagnosis of suspected lung cancer.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN, SETTING, AND PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      A systematic search of MEDLINE, HealthStar, and Cochrane Library databases to July 2001 and print bibliographies was performed to identify studies comparing the results of sputum cytology, bronchoscopy, transthoracic needle aspirate (TTNA), or biopsy with histologic reference standard diagnoses among at least 50 patients with suspected lung cancer.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MEASUREMENT AND RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      For sputum cytology, the pooled specificity was 0.99 and the pooled sensitivity was 0.66, but sensitivity was higher for central lesions than for peripheral lesions (0.71 vs 0.49, respectively). Studies on bronchoscopic procedures provided data only on diagnostic yield (sensitivity). The diagnosis of endobronchial disease by bronchoscopy in 30 studies showed the highest sensitivity for endobronchial biopsy (0.74), followed by cytobrushing (0.59) and washing (0.48). The sensitivity for all modalities combined was 0.88. Thirty studies reported on peripheral lesions. Cytobrushing demonstrated the highest sensitivity (0.52), followed by transbronchial biopsy (0.46) and BAL/washing (0.43). The overall sensitivity for all modalities was 0.69. Peripheral lesions &lt; 2 cm or &gt; 2 cm in diameter showed sensitivities of 0.33 and 0.62, respectively. Updating a previous meta-analysis with 19 studies revealed a pooled sensitivity of 0.90 for TTNA. A trend toward lower sensitivity was noted for lesions that were &lt; 2 cm in diameter. The accuracy in differentiating between small cell and non-small cell cytology for the various diagnostic modalities was 0.98, with individual studies ranging from 0.94 to 1.0. The average false-positive and false-negative rates were 0.09 and 0.02, respectively.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The sensitivity of bronchoscopy is high for endobronchial disease and poor for peripheral lesions that are &lt; 2 cm in diameter. The sensitivity of TTNA is excellent for malignant disease. The distinction between small cell lung cancer and non-small cell lung cancer by cytology appears to be accurate.\n",
            "     </abstracttext>]\n",
            "15935019.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To provide preliminary evidence on the effectiveness and optimal dosage of megestrol acetate for older persons with impaired appetite after hospitalization.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Randomized clinical trial.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Acute care hospital.\n",
            "     </abstracttext>, <abstracttext label=\"PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Forty-seven older persons (mean age 83) who were recently discharged from an acute care hospital and had fair or poor appetite.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      Participants were randomized to placebo or megestrol acetate suspension 200 mg, 400 mg, or 800 mg daily for 9 weeks.\n",
            "     </abstracttext>, <abstracttext label=\"MEASUREMENTS\" nlmcategory=\"METHODS\">\n",
            "      Appetite, health-related quality of life, and adverse effects were measured at baseline and 20, 42, and 63 days. Serum nutritional markers were measured at baseline and 20 and 63 days.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      During the course of the study, there were no significant differences between treatment groups on any of the appetite questions, although participants in the 400-mg and 800-mg groups demonstrated significant improvement from baseline on some questions. At 20 days, prealbumin increased in a dose-response relationship across the four groups (by 0.4, 5.1, 7.5, and 9.0 mg/dL, respectively). Participants in the 400-mg and 800-mg groups demonstrated greater improvement in prealbumin levels at 20 days than those receiving placebo (P=.009 and P=.004, respectively) and those in the 400-mg group also demonstrated improvement at 63 days (P=.02). At 20 days, no participant taking placebo had a morning serum cortisol level less than 8 ng/mL (the lower limit of normal). In contrast, 33%, 70%, and 78% of those taking 200 mg, 400 mg and 800 mg, respectively, had values below this level; by 63 days, these percentages were 11%, 30%, 56%, and 37%, respectively. No patient reported clinical symptoms of adrenal insufficiency. Diarrhea developed in three subjects, and thromboembolism occurred in two receiving active treatment.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Megestrol acetate at doses of 400 mg and 800 mg increases prealbumin in recently hospitalized older persons. Cortisol suppression is common at higher doses and may be persistent. In this small study, the drug did not confer benefit on other nutritional or clinical outcomes.\n",
            "     </abstracttext>]\n",
            "12220783.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the contraceptive efficacy, cycle control, tolerability, and user acceptability of a novel combined contraceptive vaginal ring for up to 13 cycles.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Healthy women requesting contraception were enrolled in this 1-year multicenter study. Each ring released 120 microg of etonogestrel and 15 microg of ethinylestradiol daily, and was used for 3 weeks followed by a 1-week ring-free period.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      A total of 2322 women started treatment and so formed the intent-to-treat population. Subjects were followed for 23,298 cycles, equivalent to 1786 woman-years. Compliance was good with 85.6% of cycles in full compliance with specified criteria. In the intent-to-treat population, 21 pregnancies occurred, giving a Pearl Index of 1.18 (95% confidence interval 0.73, 1.80). Eleven of the pregnancies were attributable to noncompliance; the Pearl Index for the per-protocol population was 0.77 (95% confidence interval 0.37, 1.40). The mean incidence of withdrawal bleeding was 98.5% in all cycles. Irregular bleeding occurred in 5.5% of all cycles, and in most women, early or late withdrawal bleeding was restricted to spotting. The ring was well tolerated with a low incidence of adverse events; only 2.5% of all discontinuations were device related. The ring was easy to insert and remove and did not interfere with intercourse. Eighty-five percent of women were satisfied with the ring, and 90% would recommend its use to others.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The ring is an effective contraceptive with excellent cycle control that is convenient, well tolerated, and highly acceptable to users.\n",
            "     </abstracttext>]\n",
            "4053146.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15126259.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine the evidence evaluating screening for lung cancer with chest radiography, sputum cytologic examination, and low-dose computed tomography (CT) to aid the USPSTF in updating its recommendation on lung cancer screening.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      MEDLINE, the Cochrane Library, reviews, editorials, and experts.\n",
            "     </abstracttext>, <abstracttext label=\"STUDY SELECTION\" nlmcategory=\"METHODS\">\n",
            "      Studies that evaluated mass screening programs for lung cancer involving the tests of interest were selected. All studies were reviewed, but only studies with control groups were rated in quality since these would most directly influence the USPSTF screening recommendation.\n",
            "     </abstracttext>, <abstracttext label=\"DATA EXTRACTION\" nlmcategory=\"METHODS\">\n",
            "      Data were abstracted to data collection forms. Studies were graded according to criteria developed by the USPSTF.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DATA SYNTHESIS\" nlmcategory=\"RESULTS\">\n",
            "      None of the 6 randomized trials of screening for lung cancer with chest radiography alone or in combination with sputum cytologic examination showed benefit among those screened. All studies were limited because some level of screening occurred in the control population. Five case-control studies from Japan suggested benefit to both high- and low-risk men and women. All studies were limited by potential healthy screenee bias. Six cohort studies showed that when CT was used to screen for lung cancer, lung cancer was diagnosed at an earlier stage than in usual clinical care. However, these studies did not have control groups, making mortality evaluation difficult. In addition, the studies demonstrated a high rate of false-positive findings.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Current data do not support screening for lung cancer with any method. These data, however, are also insufficient to conclude that screening does not work, particularly in women. Two randomized trials of screening with chest radiography or low-dose CT are currently under way and will better inform lung cancer screening decisions.\n",
            "     </abstracttext>]\n",
            "10356424.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15315995.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the effectiveness of 4 treatments among adolescents with major depressive disorder.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN, SETTING, AND PARTICIPANTS\" nlmcategory=\"METHODS\">\n",
            "      Randomized controlled trial of a volunteer sample of 439 patients between the ages of 12 to 17 years with a primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of major depressive disorder. The trial was conducted at 13 US academic and community clinics between spring 2000 and summer 2003.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTIONS\" nlmcategory=\"METHODS\">\n",
            "      Twelve weeks of (1) fluoxetine alone (10 to 40 mg/d), (2) CBT alone, (3) CBT with fluoxetine (10 to 40 mg/d), or (4) placebo (equivalent to 10 to 40 mg/d). Placebo and fluoxetine alone were administered double-blind; CBT alone and CBT with fluoxetine were administered unblinded.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Children's Depression Rating Scale-Revised total score and, for responder analysis, a (dichotomized) Clinical Global Impressions improvement score.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Compared with placebo, the combination of fluoxetine with CBT was statistically significant (P =.001) on the Children's Depression Rating Scale-Revised. Compared with fluoxetine alone (P =.02) and CBT alone (P =.01), treatment of fluoxetine with CBT was superior. Fluoxetine alone is a superior treatment to CBT alone (P =.01). Rates of response for fluoxetine with CBT were 71.0% (95% confidence interval [CI], 62%-80%); fluoxetine alone, 60.6% (95% CI, 51%-70%); CBT alone, 43.2% (95% CI, 34%-52%); and placebo, 34.8% (95% CI, 26%-44%). On the Clinical Global Impressions improvement responder analysis, the 2 fluoxetine-containing conditions were statistically superior to CBT and to placebo. Clinically significant suicidal thinking, which was present in 29% of the sample at baseline, improved significantly in all 4 treatment groups. Fluoxetine with CBT showed the greatest reduction (P =.02). Seven (1.6%) of 439 patients attempted suicide; there were no completed suicides.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The combination of fluoxetine with CBT offered the most favorable tradeoff between benefit and risk for adolescents with major depressive disorder.\n",
            "     </abstracttext>]\n",
            "11529209.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a case-control study of 1895 women recruited between 1997 and 1999. We enrolled 358 women with primary infertility who had tubal occlusion documented by hysterosalpingography, as well as 953 women with primary infertility who did not have tubal occlusion (infertile controls) and 584 primigravid women (pregnant controls). We collected information on the women's past use of contraceptives, including copper IUDs, previous sexual relationships, and history of genital tract infections. Each woman's blood was tested for antibodies to Chlamydia trachomatis. We used stratified analyses and logistic regression to assess the association between the previous use of a copper IUD and tubal occlusion.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      In analyses involving the women with tubal occlusion and the infertile controls, the odds ratio for tubal occlusion associated with the previous use of a copper IUD was 1.0 (95 percent confidence interval, 0.6 to 1.7). When the primigravid women served as the controls, the corresponding odds ratio was 0.9 (95 percent confidence interval, 0.5 to 1.6). Tubal infertility was not associated with the duration of IUD use, the reason for the removal of the IUD, or the presence or absence of gynecologic problems related to its use. The presence of antibodies to chlamydia was associated with infertility.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The previous use of a copper IUD is not associated with an increased risk of tubal occlusion among nulligravid women whereas infection with C. trachomatis is.\n",
            "     </abstracttext>]\n",
            "14659983.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10609710.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10696941.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      The records of 200 patients presenting to the Accident and Emergency Department (A&amp;E) with acute flank pain during two periods were retrospectively reviewed. The first period was before the spiral CT protocol was instituted and the second was after. Cost analyses between the two periods were performed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      After the spiral CT protocol, 72 versus 31 patients had a definitive diagnosis prior to discharge from hospital. The time taken to diagnosis was also significantly shorter after the protocol implementation (6.3 vs. 16.8 h). This resulted in a shorter time spent in the A&amp;E, and hence bed cost savings. Radiological costs were reduced by 22%, but the major cost saving was made by a reduction in time spent in A&amp;E (44%).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The implementation of a protocol of early spiral CT for patients with suspected renal colic has led to earlier definitive diagnosis and shorter hospital stays. This is associated with a significant reduction in costs associated with managing this condition.\n",
            "     </abstracttext>]\n",
            "1952493.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10659912.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Examine the benefits/risks of beta-blockers for pregnancy hypertension.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"STUDY DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Meta-analysis of relevant trials identified by comprehensive literature review (1966-97).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Included were 30 trials for pregnancy hypertension, and four others for perinatal outcomes only. For mild chronic hypertension treated throughout pregnancy (n=2 trials), oral beta-blockers (compared with no therapy) were associated with an inconsistent increase in small for gestational age (SGA) infants (OR 2.46 [1.02, 5.92]). For mild-moderate 'late-onset' pregnancy hypertension (i.e. either chronic treated only late in pregnancy, or pregnancy-induced) (n=8 trials), oral beta-blockers (compared with no therapy) were associated with a decrease in severe hypertension (OR 0.27 [0.16, 0.451), borderline decrease in development of proteinuria (OR 0.69 [0.48, 1.02]), decrease in RDS (OR 0.33 [0.13, 0.85]), but a borderline increase in SGA infants (OR 1.47 [0.96, 2.26]). Beta-blockers were equivalent to other agents (n=15 trials). For severe 'late-onset' pregnancy hypertension (n=5 trials), i.v. labetalol produced less maternal hypotension (OR 0.13 [0.03, 0.71]) and fewer cesareans (OR 0.23 [0.13, 0.63]) than i.v. hydralazine/diazoxide.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      It is not clear that the benefits outweigh the risks when beta-blockers are used to treat mild to moderate chronic or pregnancy-induced hypertension, given the unknown overall effect on perinatal outcomes. For severe 'late-onset' pregnancy hypertension, i.v. labetalol is safer than i.v. hydralazine or diazoxide.\n",
            "     </abstracttext>]\n",
            "11933571.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "12729427.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the cost-effectiveness of strategies for pulmonary nodule diagnosis and to specifically compare strategies that did and did not include FDG-PET.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Decision model.\n",
            "     </abstracttext>, <abstracttext label=\"DATA SOURCES\" nlmcategory=\"METHODS\">\n",
            "      Accuracy and complications of diagnostic tests were estimated by using meta-analysis and literature review. Modeled survival was based on data from a large tumor registry. Cost estimates were derived from Medicare reimbursement and other sources.\n",
            "     </abstracttext>, <abstracttext label=\"TARGET POPULATION\" nlmcategory=\"METHODS\">\n",
            "      All adult patients with a new, noncalcified pulmonary nodule seen on chest radiograph.\n",
            "     </abstracttext>, <abstracttext label=\"TIME HORIZON\" nlmcategory=\"METHODS\">\n",
            "      Patient lifetime.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      40 clinically plausible combinations of 5 diagnostic interventions, including computed tomography, FDG-PET, transthoracic needle biopsy, surgery, and watchful waiting.\n",
            "     </abstracttext>, <abstracttext label=\"OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS OF BASE-CASE ANALYSIS\" nlmcategory=\"RESULTS\">\n",
            "      The cost-effectiveness of strategies depended critically on the pretest probability of malignancy. For patients with low pretest probability (26%), strategies that used FDG-PET selectively when computed tomography results were possibly malignant cost as little as 20 000 dollars per QALY gained. For patients with high pretest probability (79%), strategies that used FDG-PET selectively when computed tomography results were benign cost as little as 16 000 dollars per QALY gained. For patients with intermediate pretest probability (55%), FDG-PET strategies cost more than 220 000 dollars per QALY gained because they were more costly but only marginally more effective than computed tomography-based strategies.\n",
            "     </abstracttext>, <abstracttext label=\"RESULTS OF SENSITIVITY ANALYSIS\" nlmcategory=\"RESULTS\">\n",
            "      The choice of strategy also depended on the risk for surgical complications, the probability of nondiagnostic needle biopsy, the sensitivity of computed tomography, and patient preferences for time spent in watchful waiting. In probabilistic sensitivity analysis, FDG-PET strategies were cost saving or cost less than 100 000 dollars per QALY gained in 76.7%, 24.4%, and 99.9% of computer simulations for patients with low, intermediate, and high pretest probability, respectively.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PERSPECTIVE\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Societal.\n",
            "     </abstracttext>, <abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      FDG-PET should be used selectively when pretest probability and computed tomography findings are discordant or in patients with intermediate pretest probability who are at high risk for surgical complications. In most other circumstances, computed tomography-based strategies result in similar quality-adjusted life-years and lower costs.\n",
            "     </abstracttext>]\n",
            "12076448.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To assess the effects of oral tricyclic antidepressants compared to placebo in the treatment of child and adolescent depression.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched MEDLINE (1966-1997), EMBASE, Excerpta Medica (June 1974-1997), the Cochrane Collaboration Depression, Anxiety and Neurosis Group trials register (most recent search 25/1/2000) and bibliographies of previously published reviews and papers describing original research were cross-checked. Current Contents was screened for recent publications. We contacted authors of relevant abstracts in conference proceedings of the American Academy of Child and Adolescent Psychiatry, and we hand searched the Journal of the American Academy of Child and Adolescent Psychiatry (1978-1999).\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised controlled trials comparing the efficacy of orally administered tricyclic medication with placebo in depressed people aged 6-18 years.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Most studies reported multiple outcome measures including depression scales and clinical global impression scales. For each study the best available depression measure was taken as the index measure of depression outcome. Predetermined criteria were established to assist in the ranking of measures. Where authors reported categorical outcomes we calculated individual and pooled odds ratios for the odds of improvement in treated compared with control subjects. For continuous outcomes pooled effect sizes were calculated as the number of standard deviations by which the change in depression scores for the treatment group exceeded those for the control groups.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Thirteen trials (involving 506 participants) were included. No overall improvement with treatment compared to placebo was seen for children or adolescents (odds ratio = 0.84, 95% confidence interval 0.56 to 1.25). A statistically significant but small benefit of treatment over placebo was seen in reducing symptoms (effect size (standardised mean difference) = -0.31, 95% confidence interval -0.62 to -0.01). Subgroup analyses suggest a larger benefit among adolescents (effect size = -0.47, 95% confidence interval -0.92 to -0.02), and no benefit among children (effect size = 0.15, 95% confidence interval -0.34 to 0.64). Treatment with a tricyclic antidepressant caused more vertigo (odds ratio = 4.38, 95% confidence interval 2.33 to 8.25), orthostatic hypotension (odds ratio = 6.78, 95% confidence interval 2.06 to 22.26), tremor (odds ratio 6.29, 95% confidence interval 1.78 to 22.17) and dry mouth (odds ratio = 5.17, 95% confidence interval 2.68 to 29.99) than did placebo, but no statistically significant difference was found for other possible adverse effects.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Data suggest tricyclic antidepressants are not useful in treating depression in pre pubertal children. There is marginal evidence to support the use of tricyclic antidepressants in the treatment of depression in adolescents, although the magnitude of effect is likely to be moderate at best.\n",
            "     </abstracttext>]\n",
            "7771913.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a randomized, 7-week, placebo-controlled, crossover study of methylphenidate in 23 adult patients with DSM-III-R ADHD using standardized instruments for diagnosis, separate assessments of ADHD and depressive and anxiety symptoms, and a robust daily dose of methylphenidate hydrochloride, 1.0 mg/kg per day.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      We found a marked therapeutic response for methylphenidate treatment of ADHD symptoms that exceeded the placebo response (78% vs 4%, P &lt; .0001). Response to methylphenidate was independent of gender, psychiatric comorbidity with anxiety or moderate depression, or family history of psychiatric disorders.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Robust doses of methylphenidate are effective in the treatment of adult ADHD.\n",
            "     </abstracttext>]\n",
            "16319919.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9416884.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[<abstracttext label=\"METHODS AND RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The 4S cohort of 4444 CHD patients included 827 women and 1021 patients &gt; or = 65 years of age. Total cholesterol at baseline was 5.5 to 8.0 mmol/L with triglycerides &lt; or = 2.5 mmol/L. Patients were randomized to therapy with simvastatin 20 to 40 mg daily or placebo for a median follow-up period of 5.4 years. End points consisted of all-cause and CHD mortality, major coronary events (primarily CHD death and nonfatal myocardial infarction), other acute CHD and atherosclerotic events, hospitalizations for CHD and cardiovascular events, and coronary revascularization procedures. Mean changes in serum lipids were similar in the different subgroups. In patients &gt; or = 65 years of age in the simvastatin group, relative risks (95% confidence intervals) for clinical events were as follows: all-cause mortality, 0.66 (0.48 to 0.90); CHD mortality, 0.57 (0.39 to 0.83); major coronary events, 0.66 (0.52 to 0.84); any atherosclerosis-related event, 0.67 (0.56 to 0.81); and revascularization procedures, 0.59 (0.41 to 0.84). In women, the corresponding figures were 1.16 (0.68 to 1.99); 0.86 (0.42 to 1.74), 0.66 (0.48 to 0.91), 0.71 (0.56 to 0.91), and 0.51 (0.30 to 0.86), respectively.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Cholesterol lowering with simvastatin produced similar reductions in relative risk for major coronary events in women compared with men and in elderly (&gt; or = 65 years of age) compared with younger patients. There were too few female deaths to assess the effects on mortality in women. Because mortality rates increased substantially with age, the absolute risk reduction for both all-cause and CHD mortality in simvastatin-treated subjects was approximately twice as great in the older patients.\n",
            "     </abstracttext>]\n",
            "12529459.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In a prospective trial involving 309 children (1 to 24 months old), an ultrasonogram and an initial renal scan were obtained within 72 hours after diagnosis, contrast voiding cystourethrography was performed one month later, and renal scanning was repeated six months later.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The ultrasonographic results were normal in 88 percent of the children (272 of 309); the identified abnormalities did not modify management. Acute pyelonephritis was diagnosed in 61 percent of the children (190 of 309). Thirty-nine percent of the children who underwent cystourethrography (117 of 302) had vesicoureteral reflux; 96 percent of these children (112 of 117) had grade I, II, or III vesicoureteral reflux. Repeated scans were obtained for 89 percent of the children (275 of 309); renal scarring was noted in 9.5 percent of these children (26 of 275).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      An ultrasonogram performed at the time of acute illness is of limited value. A voiding cystourethrogram for the identification of reflux is useful only if antimicrobial prophylaxis is effective in reducing reinfections and renal scarring. Renal scans obtained at presentation identify children with acute pyelonephritis, and scans obtained six months later identify those with renal scarring. The routine performance of urinalysis, urine culture, or both during subsequent febrile illnesses in all children with a previous febrile urinary tract infection will probably obviate the need to obtain either early or late scans.\n",
            "     </abstracttext>]\n",
            "12696781.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10780124.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "8065869.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Prospective studies were conducted to test the hypothesis that infants unlikely to have serious bacterial infections (SBI) can be accurately identified by low risk criteria.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Febrile infants (rectal T &gt; or = 38 degrees C) &lt; or = 60 days of age were considered at low risk for SBI if they met the following criteria: 1) appear well; 2) were previously healthy; 3) have no focal infection; 4) have WBC count 5.0-15.0 x 10(9) cells/L (5000-15,000/mm3), band form count &lt; or = 1.5 x 10(9) cells/L (&lt; or = 1500/mm3), &lt; or = 10 WBC per high power field on microscopic examination of spun urine sediment, and &lt; or = 5 WBC per high power field on microscopic examination of a stool smear (if diarrhea). The recommended evaluation included the culture of specimens of blood, cerebrospinal fluid, and urine for bacteria. Outcomes were determined. The negative predictive values of the low risk criteria for SBI and bacteremia were calculated.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Of 1057 eligible infants, 931 were well appearing, and, of these, 437 met the remaining low risk criteria. Five low risk infants had SBI including two infants with bacteremia. The negative predictive value of the low risk criteria was 98.9% (95% confidence interval, 97.2% to 99.6%) for SBI, and 99.5% (95% confidence interval, 98.2% to 99.9%) for bacteremia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      These data confirm the ability of the low risk criteria to identify infants unlikely to have SBI. Infants who meet the low risk criteria can be carefully observed without administering antimicrobial agents.\n",
            "     </abstracttext>]\n",
            "16816220.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      Few controlled studies have addressed the issue of which antidepressant medications should be recommended for outpatients who have not responded to multiple treatment trials. This study compared the efficacy of switching to mirtazapine to that of switching to a tricyclic antidepressant (nortriptyline) following two prospective, consecutive, unsuccessful medication treatments for nonpsychotic major depressive disorder.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHOD\" nlmcategory=\"METHODS\">\n",
            "      Following lack of remission or an inability to tolerate an initial trial of citalopram for up to 12 weeks (first step) and a second trial with either monotherapy involving another antidepressant or augmentation of citalopram with bupropion or buspirone (second step), adult outpatients (N=235) with nonpsychotic major depressive disorder were randomly assigned to 14 weeks of treatment with mirtazapine (up to 60 mg/day) (N=114) or nortriptyline (up to 200 mg/day) (N=121). The primary outcome, symptom remission, was defined a priori as a total exit score of &lt;/=7 on the 17-item Hamilton Rating Scale for Depression. The 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR(16)), obtained at treatment visits, provided secondary outcomes of remission (score &lt;/=5 at exit) and response (&gt;/=50% reduction in score from baseline).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      For mirtazapine, remission rates were 12.3% and 8.0% per the Hamilton and QIDS-SR(16) scores, respectively. For nortriptyline, remission rates were 19.8% and 12.4%, respectively. QIDS-SR(16) response rates were 13.4% for mirtazapine and 16.5% for nortriptyline. Neither response nor remission rates statistically differed by treatment, nor did these two treatments differ in tolerability or adverse events.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Switching to a third antidepressant monotherapy regimen after two consecutive unsuccessful antidepressant trials resulted in low remission rates (&lt;20%) among patients with major depressive disorder.\n",
            "     </abstracttext>]\n",
            "12865262.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We constructed a register of all patients diagnosed with columnar mucosa (including specialised intestinal metaplasia) of the oesophagus within Northern Ireland between 1993 and 1999. Deaths occurring within this cohort until 31 December 2000 were identified and mortality rates were compared with the general population.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Overall mortality was not raised in Barrett's patients. During 7413 person years of follow up in 2373 patients there were 253 deaths (standardised mortality ratio (SMR) 96 (95% confidence interval (CI) 84-107)). Mortality from oesophageal cancer was raised in patients with specialised intestinal metaplasia (SMR 774 (95% CI 317-1231)) but only 4.7% of patients died from this cancer. Mortality from stroke (SMR 65 (95% CI 37-93)) was significantly lower than the general population while mortality from non-cancerous digestive system diseases was significantly higher (SMR 211 (95% CI 111-311)). Mortality rates from all other causes were similar to those of the general population.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      This study demonstrates that the overall mortality rate in patients with Barrett's oesophagus is closely similar to that of the general population. Oesophageal cancer mortality was raised but is an uncommon cause of death in these patients who also appear to have a reduced risk of death from stroke.\n",
            "     </abstracttext>]\n",
            "12972967.xml\n",
            "\n",
            "[<abstracttext label=\"PURPOSE\" nlmcategory=\"OBJECTIVE\">\n",
            "      This study was a retrospective analysis of complication rates, symptom recurrence, long-term results, and patient satisfaction after outpatient excision (local anesthesia) of thrombosed external hemorrhoids.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      From 1995 to 2000, 340 patients (166 males) underwent office-based excision of thrombosed external hemorrhoids under local anesthesia. Data regarding complications, operations because of recurrence, residual symptoms, patient's satisfaction with anesthesia, and wound treatment were obtained by questionnaire. Response was solicited at a minimum of 9 months postprocedure.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Complete follow-up data was available in 88 percent of patients (mean follow-up, 17.3 months). Recurrent thrombosed external hemorrhoid requiring a procedure developed in 22 (6.5 percent) patients. Other complications that required operative intervention were one (0.3 percent) incidence of postoperative bleeding and seven (2.1 percent) perianal abscess/fistula. The majority of patients (66 percent) had no anal complaints at follow-up. Local anesthesia would be preferred if a repeat excision was required in 79 percent, whereas 11 percent would prefer another form of anesthesia and 10 percent were unsure.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Outpatient excision under local anesthesia of a thrombosed external hemorrhoid can be safely performed with a low recurrence and complication rate while offering a high level of patient of acceptance and satisfaction.\n",
            "     </abstracttext>]\n",
            "11083738.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine baseline predictors of tolerance to the alpha/beta blocker carvedilol in everyday clinical practice.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Retrospective analysis of tolerance to carvedilol in patients with chronic heart failure. Tolerance was defined as currently on carvedilol or on it at the time of death or heart transplantation. To meet the criteria for tolerance, carvedilol had to be prescribed at a stable dose for &gt;/= 3 months.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Everyday clinical practice, comprising both hospital specialist practice and private practice. Tolerance was assessed in all patients prescribed carvedilol for chronic heart failure in those practices.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      808 consecutive patients in both hospital specialist (611 patients) and private practice (197 patients).\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Baseline predictors of tolerance assessed by proportional hazards analysis. Both univariate and multivariate analyses were performed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Within the entire cohort of 808 patients, 95 had stopped carvedilol, 606 were currently receiving the drug, 50 had died, and 44 had received a heart transplant. Overall, 88% of patients tolerated carvedilol (87% in the hospital specialist group, 92% in the private practitioner group). Factors that indicated impaired tolerance by univariate analysis were increased age in years (hazard ratio 1.01, 95% confidence interval (CI) 1.0 to 1.3), low diastolic blood pressure (hazard ratio 1.04, 95% CI 1.02 to 1.08), and raised plasma urea concentration (hazard ratio 1.04, 95% CI 1.02 to 1.05). New York Heart Association (NYHA) class was also a marker of tolerance (proportion not tolerated: 3% class I; 9% class II; 13% class III, 22% class IV). By multivariate analysis, no single baseline variable was an independent marker of inability to tolerate carvedilol. Tolerance was also assessed in relation to traditional precautions or relative contraindications to beta blockade. Tolerance in these subgroups was: chronic obstructive airways disease/asthma 85% (89 patients), diabetes 86% (127 patients), peripheral vascular disease 84% (58 patients), concomitant amiodarone treatment 83% (230 patients), and heart rate &lt; 70 beats/min 84% (184 patients).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      beta Blocker treatment was well tolerated in everyday clinical practice, including non-hospital-based private practice. There was no single predictor of poor tolerance on multivariate analysis, although there was a clear association with NYHA class as well as age, diastolic blood pressure, and plasma urea on univariate analysis. Carvedilol was tolerated well among selected patients with traditional contraindications to beta blockade in this situation.\n",
            "     </abstracttext>]\n",
            "15135147.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To test the hypothesis that glucose intolerance does not occur when healthy adults consume normal, recommended dosages of glucosamine sulfate.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Healthy adults (N=19) ingested 1500 mg of glucosamine sulfate or placebo (double blind) each day for 12 weeks. Three-hour oral glucose tolerance tests (OGTT) were performed using 75 g of dextrose. These occurred before the start of supplementation, at 6 weeks, and at the completion of supplementation (12 weeks).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      There were no significant differences between fasted levels of serum insulin or blood glucose. Glucosamine sulfate supplementation did not alter serum insulin or plasma glucose during the OGTT. There were no significant differences within or between treatments, ages or gender. Glycated hemoglobin measurements at the three time points showed no significant change over time, within or between treatments, ages or gender. The lack of significant changes may have been due to large standard deviations in the data.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The data suggests that glucosamine supplementation, with normal recommended dosages, does not cause glucose intolerance in healthy adults. This cannot be determined conclusively, however, until further studies are conducted using alternative types of testing.\n",
            "     </abstracttext>]\n",
            "17943896.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine evidence for the effectiveness of vena caval filters in preventing pulmonary embolism (PE). Secondary outcomes were mortality, distal (to filter) thrombosis, and filter-related complications.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (last searched August 2007), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2007, Issue 3, MEDLINE (1966 to August 2007), and EMBASE (1966 to August 2007). Filter manufacturers and clinicians interested in filters were contacted for information.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Controlled clinical trials (CCTs) and randomised controlled trials (RCTs) that examined the efficacy of filters in preventing PE were selected.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Three authors extracted information independently. Incidence figures were extracted from survival tables. Dichotomous outcomes were analysed as hazard ratio estimates.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      One RCT was included. The PREPIC (Prvention du Risque d'Embolie Pulmonaire par Interruption Cave) trial was an open RCT of 400 participants with documented proximal deep vein thrombosis (DVT) or PE and who received concurrent anticoagulation. Permanent caval filters prevented PE at eight years (HR 0.37, 95% CI 0.17 to 0.79, in favour of the filter). No reduction in mortality was seen, but this reflected an older study population (mean age 73 years); the majority of deaths were due to cancer or cardiovascular causes. There was an increased incidence of DVT in the filter group (HR 1.52, 95% CI 1.02 to 2.27). No details were recorded of adverse events of filters.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"AUTHORS' CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Limited generalisability prevents any conclusions to be drawn from the PREPIC trial in that permanent filters were used and the study lacked statistical power to detect a reduction in PE over shorter and more clinically significant time periods. However, the PREPIC trial demonstrated that permanent caval filters were associated with an increased risk of long term lower limb DVT. There is a marked paucity of caval filter outcomes evidence when used within their currently approved indications. There is also a lack of retrievable filter trials. Further trials are needed to assess vena caval filter safety and effectiveness.\n",
            "     </abstracttext>]\n",
            "17846141.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "10649820.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "15765388.xml\n",
            "\n",
            "[<abstracttext label=\"BACKGROUND &amp; AIMS\" nlmcategory=\"OBJECTIVE\">\n",
            "      The aim of this study was to compare the response of symptoms and cytokine ratios in irritable bowel syndrome (IBS) with ingestion of probiotic preparations containing a lactobacillus or bifidobacterium strain.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Seventy-seven subjects with IBS were randomized to receive either Lactobacillus salivarius UCC4331 or Bifidobacterium infantis 35624, each in a dose of 1 x 10 10 live bacterial cells in a malted milk drink, or the malted milk drink alone as placebo for 8 weeks. The cardinal symptoms of IBS were recorded on a daily basis and assessed each week. Quality of life assessment, stool microbiologic studies, and blood sampling for estimation of peripheral blood mononuclear cell release of the cytokines interleukin (IL)-10 and IL-12 were performed at the beginning and at the end of the treatment phase.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      For all symptoms, with the exception of bowel movement frequency and consistency, those randomized to B infantis 35624 experienced a greater reduction in symptom scores; composite and individual scores for abdominal pain/discomfort, bloating/distention, and bowel movement difficulty were significantly lower than for placebo for those randomized to B infantis 35624 for most weeks of the treatment phase. At baseline, patients with IBS demonstrated an abnormal IL-10/IL-12 ratio, indicative of a proinflammatory, Th-1 state. This ratio was normalized by B infantis 35624 feeding alone.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      B infantis 35624 alleviates symptoms in IBS; this symptomatic response was associated with normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for this organism, in this disorder.\n",
            "     </abstracttext>]\n",
            "1474406.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "9574657.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE AND IMPORTANCE\" nlmcategory=\"OBJECTIVE\">\n",
            "      We present a case of a giant prolactinoma with a falsely low serum prolactin concentration determined by a two-site chemiluminometric assay. Awareness of the possibility of the \"high-dose hook effect\" in such cases will prevent preoperative misdiagnosis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CLINICAL PRESENTATION\" nlmcategory=\"METHODS\">\n",
            "      A patient with a giant invasive pituitary tumor was found preoperatively to have serum prolactin of 31 ng/ml. Pathological examination of the excised tissue, however, demonstrated strong staining for prolactin.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      Serial dilutions of the serum disclosed hyperprolactinemia of 280,000 ng/ml, establishing the presence of the \"high-dose hook effect.\" Treatment with pergolide (Permax; Athena Neurosciences, S. San Francisco, CA) decreased tumor size and lowered serum prolactin by more than 99%.\n",
            "     </abstracttext>]\n",
            "[]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      A \"high-dose hook effect\" needs to be suspected in every patient with a giant pituitary adenoma (&gt;3 cm) and normal serum prolactin. Subsequently assaying the diluted serum will reliably disclose this phenomenon and allow correct diagnosis and therapy.\n",
            "     </abstracttext>]\n",
            "12519540.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVES\" nlmcategory=\"OBJECTIVE\">\n",
            "      To examine the effects of heparin (unfractionated (U), and low molecular weight (LMW) heparins), and physical methods (compression stockings, calf or foot pumps) for prevention of deep venous thrombosis (DVT) and pulmonary embolism after surgery for hip fracture in the elderly.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"SEARCH STRATEGY\" nlmcategory=\"METHODS\">\n",
            "      We searched the Cochrane Musculoskeletal Injuries Group specialised register (up to March 2002), MEDLINE (1966 to March 2002), EMBASE (1980 to March 2002), CINAHL (1982 to February week 4 2002), Current Contents (1993 week 26 to 2002 week 12), reference lists of published articles and contacted trialists and other workers in the field. Date of most recent search: March 2002.\n",
            "     </abstracttext>, <abstracttext label=\"SELECTION CRITERIA\" nlmcategory=\"METHODS\">\n",
            "      Randomised and quasi-randomised trials evaluating the use of heparins and physical agents for prevention of DVT and pulmonary embolism in patients undergoing surgery for hip fracture.\n",
            "     </abstracttext>, <abstracttext label=\"DATA COLLECTION AND ANALYSIS\" nlmcategory=\"METHODS\">\n",
            "      Two reviewers independently assessed methodological quality and extracted data. Trials were grouped into five categories (heparin versus control, mechanical versus control, LMW heparin versus U heparin, heparin versus mechanical, and miscellaneous) and results pooled where possible.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"MAIN RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The 31 included trials involved at least 2958 predominantly female and elderly patients. Overall, trial quality was disappointing. Ten trials involving 826 patients which compared U heparin with control, and five trials of 373 patients which compared LMW heparin with control, showed a reduction in the incidence of lower limb DVT (124/474 (26%) versus 219/519 (42%); relative risk (RR) 0.60; 95% confidence interval (CI) 0.50 to 0.71). There were insufficient data to confirm the efficacy of either agent in the prevention of pulmonary embolism. There was no statistically significant difference in overall mortality (42/356 (12%) versus 38/374 (10%); RR 1.16; 95%CI 0.77 to 1.74). Data were inadequate for all other outcomes including wound complications. There is insufficient evidence from five trials, involving 644 patients, to establish if LMW heparin was superior to U heparin. Most trials evaluating heparins had methodological defects. Five trials, involving 487 patients, testing mechanical pumping devices were also methodologically flawed, and so pooled results need to be viewed cautiously. Mechanical pumping devices may protect against DVT (16/221 (7%) versus 52/229 (22%); RR 0.31; 95%CI 0.19 to 0.51) and pulmonary embolism. Data were insufficient to establish any effect on the incidence of fatal pulmonary embolism and overall mortality. Problems with skin abrasion and compliance were reported.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"REVIEWER'S CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      U and LMW heparins protect against lower limb DVT. There is insufficient evidence to confirm either protection against pulmonary embolism or an overall benefit, or to distinguish between various applications of heparin. Foot and calf pumping devices appear to prevent DVT, may protect against pulmonary embolism, and reduce mortality, but compliance remains a problem. Good quality trials of mechanical methods as well as direct comparisons with heparin and low dose aspirin should be considered.\n",
            "     </abstracttext>]\n",
            "17065637.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      In a large collaborative study, we screened 31,567 asymptomatic persons at risk for lung cancer using low-dose CT from 1993 through 2005, and from 1994 through 2005, 27,456 repeated screenings were performed 7 to 18 months after the previous screening. We estimated the 10-year lung-cancer-specific survival rate among participants with clinical stage I lung cancer that was detected on CT screening and diagnosed by biopsy, regardless of the type of treatment received, and among those who underwent surgical resection of clinical stage I cancer within 1 month. A pathology panel reviewed the surgical specimens obtained from participants who underwent resection.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Screening resulted in a diagnosis of lung cancer in 484 participants. Of these participants, 412 (85%) had clinical stage I lung cancer, and the estimated 10-year survival rate was 88% in this subgroup (95% confidence interval [CI], 84 to 91). Among the 302 participants with clinical stage I cancer who underwent surgical resection within 1 month after diagnosis, the survival rate was 92% (95% CI, 88 to 95). The 8 participants with clinical stage I cancer who did not receive treatment died within 5 years after diagnosis.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Annual spiral CT screening can detect lung cancer that is curable.\n",
            "     </abstracttext>]\n",
            "2642673.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11036118.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We studied 404 women with singleton pregnancies and gestational diabetes that required treatment. The women were randomly assigned between 11 and 33 weeks of gestation to receive glyburide or insulin according to an intensified treatment protocol. The primary end point was achievement of the desired level of glycemic control. Secondary end points included maternal and neonatal complications.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The mean (+/-SD) pretreatment blood glucose concentration as measured at home for one week was 114+/-19 mg per deciliter (6.4+/-1.1 mmol per liter) in the glyburide group and 116+/-22 mg per deciliter (6.5+/-1.2 mmol per liter) in the insulin group (P=0.33). The mean concentrations during treatment were 105+/-16 mg per deciliter (5.9+/-0.9 mmol per liter) in the glyburide group and 105+/-18 mg per deciliter (5.9+/-1.0 mmol per liter) in the insulin group (P=0.99). Eight women in the glyburide group (4 percent) required insulin therapy. There were no significant differences between the glyburide and insulin groups in the percentage of infants who were large for gestational age (12 percent and 13 percent, respectively); who had macrosomia, defined as a birth weight of 4000 g or more (7 percent and 4 percent); who had lung complications (8 percent and 6 percent); who had hypoglycemia (9 percent and 6 percent); who were admitted to a neonatal intensive care unit (6 percent and 7 percent); or who had fetal anomalies (2 percent and 2 percent). The cord-serum insulin concentrations were similar in the two groups, and glyburide was not detected in the cord serum of any infant in the glyburide group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In women with gestational diabetes, glyburide is a clinically effective alternative to insulin therapy.\n",
            "     </abstracttext>]\n",
            "12879992.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "16423126.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate Breslau's 7-item screen for posttraumatic stress disorder (PTSD) for use in primary care.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      One hundred and thirty-four patients were recruited from primary care clinics at a large medical center. Participants completed the self-administered 7-item PTSD screen. Later, psychologists blinded to the results of the screen-interviewed patients using the Clinician Administered PTSD Scale (CAPS). Sensitivity, specificity, and likelihood ratios (LR) were calculated using the CAPS as the criterion for PTSD.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The screen appears to have test-retest reliability (r=.84), and LRs range from 0.04 to 13.4.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Screening for PTSD in primary care is time efficient and has the potential to increase the detection of previously unrecognized PTSD.\n",
            "     </abstracttext>]\n",
            "10727588.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      We conducted a prospective study to investigate genital shedding of HSV among 53 subjects who had antibodies to HSV-2 but who reported having no history of genital herpes, and we compared their patterns of viral shedding with those in a similar cohort of 90 subjects with symptomatic HSV-2 infection. Genital secretions of the subjects in both groups were sampled daily and cultured for HSV for a median of 94 days.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      HSV was isolated from the genital mucosa in 38 of the 53 HSV-2-seropositive subjects (72 percent) who reported no history of genital herpes, and HSV DNA was detected by the polymerase-chain-reaction assay in cultures prepared from genital mucosal swabs in 6 additional subjects. The rate of subclinical shedding of HSV in the subjects with no reported history of genital herpes was similar to that in the subjects with such a history (3.0 percent vs. 2.7 percent). Of the 53 subjects who had no reported history of genital herpes, 33 (62 percent) subsequently reported having typical herpetic lesions; the duration of their recurrences in these subjects was shorter (median, three days vs. five days; P&lt;0.001) and the frequency lower (median, 3.0 per year vs. 8.2 per year; P&lt;0.001) than in the 90 subjects with previously diagnosed symptomatic infection. Only 1 of these 53 subjects had no clinical or virologic evidence of HSV infection.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects with no reported history of genital herpes.\n",
            "     </abstracttext>]\n",
            "10074011.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To compare the effect of unmodified cows' milk and iron supplemented formula milk on psychomotor development in infants from inner city areas when used as the main milk source.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Double blind, randomised intervention trial.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Birmingham health centre.\n",
            "     </abstracttext>, <abstracttext label=\"SUBJECTS\" nlmcategory=\"METHODS\">\n",
            "      100 infants, mean age 7.8 months (range 5.7 to 8.6 months), whose mothers had already elected to use unmodified cows' milk as their infant's milk source.\n",
            "     </abstracttext>, <abstracttext label=\"INTERVENTION\" nlmcategory=\"METHODS\">\n",
            "      Changing to an iron supplemented formula milk from enrolment to 18 months of age, or continuing with unmodified cows' milk.\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Developmental assessments using Griffiths scales at enrolment and at 18 and 24 months.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      85 participants completed the trial. There were no significant differences in haemoglobin concentration between the two groups at enrolment, but by 18 months of age 33% of the unmodified cows' milk group, but only 2% of the iron supplemented group, were anaemic (P&lt;0.001). The experimental groups had Griffiths general quotient scores that were not significantly different at enrolment, but the scores in both groups declined during the study. By 24 months the decrease in the mean scores in the unmodified cows' milk group was 14.7 whereas the decrease in the mean scores in the iron supplemented group was 9.3 (P&lt;0.02, 95% confidence interval 0.4 to 10.4). Mean subquotient scores were considerably lower in the unmodified cows' milk group at 24 months; significantly so for personal and social scores (P&lt;0.02, 1.2 to 16.8 [corrected]).\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Replacing unmodified cows' milk with an iron supplemented formula milk up to 18 months of age in infants from inner city areas prevents iron deficiency anaemia and reduces the decline in psychomotor development seen in such infants from the second half of the first year.\n",
            "     </abstracttext>]\n",
            "11588078.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the efficacy of progesterone and progestogens in the management of premenstrual syndrome.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      Systematic review of published randomised, placebo controlled trials. Studies reviewed: 10 trials of progesterone therapy (531 women) and four trials of progestogen therapy (378 women).\n",
            "     </abstracttext>, <abstracttext label=\"MAIN OUTCOME MEASURES\" nlmcategory=\"METHODS\">\n",
            "      Proportion of women whose symptoms showed improvement with progesterone preparations (suppositories and oral micronised). Proportion of women whose symptoms showed improvement with progestogens. Secondary analysis of efficacy of progesterone and progestogens in managing physical and behavioural symptoms.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Overall standardised mean difference for all trials that assessed efficacy of progesterone (by both routes of administration) was -0.028 (95% confidence interval -0.017 to -0.040). The odds ratio was 1.05 (1.03 to 1.08) in favour of progesterone, indicating no clinically important difference between progesterone and placebo. For progestogens the overall standardised mean was -0.036 (-0.014 to -0.060), which corresponds to an odds ratio of 1.07 (1.03 to 1.11) showing a statistically, but not clinically, significant improvement for women taking progestogens.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The evidence from these meta-analyses does not support the use of progesterone or progestogens in the management of premenstrual syndrome.\n",
            "     </abstracttext>]\n",
            "10218753.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the effectiveness of a training program for physician-delivered nutrition counseling, alone and in combination with an office-support program, on dietary fat intake, weight, and blood low-density lipoprotein cholesterol levels in patients with hyperlipidemia.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PARTICIPANTS AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      Forty-five primary care internists at the Fallon Community Health Plan, a central Massachusetts health maintenance organization, were randomized by site into 3 groups: (1) usual care; (2) physician nutrition counseling training; and (3) physician nutrition counseling training plus an office-support program. Eleven hundred sixty-two of their patients with blood total cholesterol levels in the highest 25th percentile, having previously scheduled physician visits, were recruited. Physicians in groups 2 and 3 attended a 3-hour training program on the use of brief patient-centered interactive counseling and the use of an office-support program that included in-office prompts, algorithms, and simple dietary assessment tools. Primary outcome measures included change at 1-year of follow-up in percentage of energy intake from saturated fat; weight; and blood low-density lipoprotein cholesterol levels.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      Improvement was seen in all 3 primary outcome measures, but was limited to patients in group 3. Compared with group 1, patients in group 3 had average reductions of 1.1 percentage points in percent of energy from saturated fat (a 10.3% decrease) (P = .01); a reduction in weight of 2.3 kg (P&lt;.001); and a decrease of 0.10 mmol/L (3.8 mg/dL) in low-density lipoprotein cholesterol level (P = .10). Average time for the initial counseling intervention in group 3 was 8.2 minutes, 5.5 minutes more than in the control group.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Brief supported physician nutrition counseling can produce beneficial changes in diet, weight, and blood lipids.\n",
            "     </abstracttext>]\n",
            "12120909.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "11847935.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To evaluate the effects of tablet splitting on low-density lipoprotein (LDL) cholesterol and total cholesterol values in patients taking simvastatin and atorvastatin.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"DESIGN\" nlmcategory=\"METHODS\">\n",
            "      A retrospective chart review of total cholesterol and LDL cholesterol values of patients instructed to split simvastatin or atorvastatin between January 1999 and November 2000.\n",
            "     </abstracttext>, <abstracttext label=\"SETTING\" nlmcategory=\"METHODS\">\n",
            "      Veterans Affairs Medical Center in Huntington, WV.\n",
            "     </abstracttext>, <abstracttext label=\"PATIENTS\" nlmcategory=\"METHODS\">\n",
            "      Patients were included if they were taking simvastatin or atorvastatin with regular lipid management and follow-up laboratory results. Patients were required to remain on the same milligram-per-day dose at least 6-8 weeks before and after tablet-splitting initiation and have cholesterol values drawn at least 6 weeks after initiation of both whole-tablet and half-tablet dosing. Patients were excluded if they had a triglyceride level &gt; 400 mg/dL or were noncompliant on the basis of pharmacy records and provider notes. MEASUREMENT OUTCOMES: The primary end points were changes in total cholesterol and LDL cholesterol values before and after the patient was switched to half-tablet therapy.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The overall results for this review demonstrated no statistically significant increase in total cholesterol and LDL cholesterol concentrations. Total cholesterol and LDL cholesterol values actually decreased from presplitting to postsplitting, p = 0.017 and p = 0.003, respectively.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      The investigation showed that half-tablet dosing was as effective as whole-tablet dosing. The program will be continued as a part of quality patient care at the Huntington Veterans Affairs Medical Center.\n",
            "     </abstracttext>]\n",
            "9356004.xml\n",
            "\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "[]\n",
            "17051752.xml\n",
            "\n",
            "[]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Patients admitted between 1996 and 2005 to Taipei Veterans General Hospital under the diagnosis of preseptal or orbital cellulitis were retrospectively reviewed. The demographics, administrative history, past history, clinical presentations, treatments, and complications were analyzed.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      In total, 94 patients fulfilling the diagnostic criteria for preseptal or orbital cellulitis were identified (67 had preseptal cellulitis, 27 had orbital cellulitis). While paranasal sinus disease was the most common predisposing cause in orbital cases, skin lesions in children and dacryocystitis in adults were the most common in preseptal cases. Microbiologic investigations showed variable results, but the most common pathogen isolated was Staphylococcus aureus. Cultures from eye swabs and local abscesses gave the highest positive yield. Blood cultures were taken in some patients, but the positive rate was extremely low. Treatments included intravenous antibiotics alone, or intravenous antibiotics combined with surgical drainage. Only one case had permanent ocular motility impairment after removal of the orbital foreign body.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Despite the past history of potential morbidity and even mortality from orbital cellulitis, early diagnosis and prompt treatment with proper antibiotics and/or surgical intervention can achieve a good prognosis.\n",
            "     </abstracttext>]\n",
            "8944521.xml\n",
            "\n",
            "[<abstracttext label=\"OBJECTIVE\" nlmcategory=\"OBJECTIVE\">\n",
            "      To determine whether there is justification for a policy of conservative management of acute scrotal emergencies, based on the ability to exclude a twisted testicle or the assumption that there is a \"missed torsion' when the duration of symptoms is prolonged.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"PATIENTS AND METHODS\" nlmcategory=\"METHODS\">\n",
            "      The case notes of 209 consecutive emergency scrotal explorations, carried out in one district general hospital over a 7-year period, were reviewed. The decision to operate was based solely on a clinical diagnosis, with no information from additional radiological investigations.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The commonest finding was testicular torsion (39.5%) with an orchidectomy rate of 22%. Only 5% of scrotal torsions occurred in patients &lt; 12 years of age, whereas 26% occurred in those &gt; 20 years of age. In five of 82 cases (6%) of confirmed testicular torsion, the surgeon did not consider this the most likely diagnosis. With a pain duration of &lt; 16 h, 89% of testes were salvaged, but with pain for &gt; 16 h this decreased to 25%. In three cases the testis was viable after pain had been present for &gt; 24 h.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSION\" nlmcategory=\"CONCLUSIONS\">\n",
            "      In the absence of supportive radiological investigations, a small but significant number of twisted testes will be missed if conservative management is adopted.\n",
            "     </abstracttext>]\n",
            "9834257.xml\n",
            "\n",
            "[<abstracttext label=\"BACKGROUND &amp; AIMS\" nlmcategory=\"OBJECTIVE\">\n",
            "      Tissue transglutaminase has been reported to be the target for endomysial antibodies in celiac disease. We sought to establish whether immunoglobulin (Ig) A class tissue transglutaminase autoantibodies can be considered specific for celiac disease.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"METHODS\" nlmcategory=\"METHODS\">\n",
            "      Serum samples from 136 patients with untreated celiac disease (diagnosed according to the criteria of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition) and 207 disease controls were studied. Enzyme-linked immunosorbent assay (ELISA) and Western blots were performed using calcium-treated and untreated tissue transglutaminase as antigen. Reticulin, endomysial, and mouse monoclonal tissue transglutaminase antibodies were studied by an indirect immunofluorescence method and gliadin antibodies with ELISA.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"RESULTS\" nlmcategory=\"RESULTS\">\n",
            "      The calcium-activated tissue transglutaminase autoantibody ELISA was highly sensitive (129 of 136) and specific (194 of 207) in detecting celiac disease. The new autoantibody ELISA test correlated well with the endomysial antibody test. Tissue transglutaminase autoantibody ELISA showed a clearly better predictive potential than the IgA class gliadin antibody ELISA. Immunoblots and ELISA blocking studies showed that calcium is needed for the specific antigen-antibody reaction to occur. Double immunofluorescence staining in human umbilical cord with sera from patients with celiac disease and with monoclonal tissue transglutaminase antibodies showed complete overlap.\n",
            "     </abstracttext>]\n",
            "[<abstracttext label=\"CONCLUSIONS\" nlmcategory=\"CONCLUSIONS\">\n",
            "      Calcium-activated tissue transglutaminase autoantibody ELISA is highly accurate in detecting untreated celiac disease. Tissue transglutaminase seems to be the target self-antigen for endomysial antibodies.\n",
            "     </abstracttext>]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "9xRmp_P96Pzd"
      },
      "source": [
        ""
      ],
      "execution_count": null,
      "outputs": []
    }
  ]
}